benzoate ester - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	benzoate ester	go back to main search page
Accession:	CHEBI:36054	browse the term
Definition:	Esters of benzoic acid or substituted benzoic acids.
Synonyms:	related_synonym:	benzoate esters; benzoic acid esters
	cyclic_relationship:	has_functional_parent CHEBI:22723

show annotations for term's descendants Sort by:
Rat (5458 ) Mouse (5371 ) Human (5700 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (13 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (5458)

(+)-epicatechin-3-O-gallate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases expression

ISO

epicatechin gallate results in increased expression of ABCB11 mRNA

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

actin, beta

multiple interactions

EXP

epicatechin gallate inhibits the reaction [3,4-Dihydroxyphenylacetic Acid analog binds to ACTB protein]

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

ISO

epicatechin gallate results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]

PMID:21945981 PMID:29061316

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BCL2-associated agonist of cell death

increases expression

ISO

epicatechin gallate results in increased expression of BAD protein

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2, apoptosis regulator

multiple interactions

ISO

epicatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of BCL2 mRNA]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

increases expression

ISO

epicatechin gallate results in increased expression of BCL2L1 protein alternative form

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

brain-derived neurotrophic factor

multiple interactions

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]]

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

basic helix-loop-helix ARNT like 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of BMAL1 mRNA]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of BMAL1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the localization of NFE2L2 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BNIP3 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX4 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX6C mRNA]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of FIS1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of MFN1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of NDUFS1 mRNA]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of UQCRC2 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of HMOX1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of NQO1 protein]

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

BCL2 interacting protein 3

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BNIP3 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BNIP3 protein]]

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

caspase 3

increases activity

ISO

epicatechin gallate results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

clock circadian regulator

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CLOCK mRNA]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CLOCK protein]

NCBI chr14:32,262,747...32,346,872
Ensembl chr14:32,262,750...32,346,872

G

cytochrome c oxidase subunit 6C

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX6C mRNA]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX6C mRNA]]

NCBI chr 7:69,014,410...69,027,145
Ensembl chr 7:69,014,417...69,027,166

G

cAMP responsive element binding protein 1

multiple interactions

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

cryptochrome circadian regulator 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CRY1 mRNA]

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

cryptochrome circadian regulator 2

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CRY2 mRNA]

NCBI chr 3:98,830,479...98,860,437
Ensembl chr 3:98,830,483...98,860,447

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity

EXP

epicatechin gallate results in increased activity of CYP1A1 protein

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2D22 mRNA

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2E1 mRNA

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

dihydrofolate reductase

multiple interactions

ISO

epicatechin gallate binds to and results in decreased activity of DHFR protein

NCBI chr 2:25,320,895...25,346,004

G

dynamin 1

multiple interactions

ISO

BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1 protein]]

NCBI chr 3:36,002,535...36,055,220
Ensembl chr 3:36,002,064...36,046,289

G

dynamin 1-like

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1L protein]

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420

G

fission, mitochondrial 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of FIS1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of FIS1 protein]]

NCBI chr12:25,345,239...25,360,135
Ensembl chr12:25,345,239...25,349,335

G

glucose-6-phosphate dehydrogenase

increases activity

ISO

epicatechin gallate results in increased activity of G6PD protein

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

heme oxygenase 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of HMOX1 protein; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of HMOX1 protein]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

HRas proto-oncogene, GTPase

multiple interactions

ISO

epicatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of HRAS mRNA]; epicatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of HRAS protein]

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590

G

interleukin 1 alpha

multiple interactions

ISO

epicatechin gallate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1A mRNA]

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; epicatechin gallate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of INS1 protein

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

leptin

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of LEP protein

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

epicatechin gallate results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

epicatechin gallate results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitofusin 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of MFN1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of MFN1 protein]]

NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190

G

myeloperoxidase

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MPO protein]; epicatechin gallate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

mitochondrially encoded cytochrome c oxidase II

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]

NCBI chr MT:7,006...7,689
Ensembl chr MT:6,991...7,674

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND1 protein]]

NCBI chr MT:2,740...3,694
Ensembl chr MT:2,729...3,685

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

ISO

epicatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of MYC mRNA]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

NADH:ubiquinone oxidoreductase core subunit S1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of NDUFS1 mRNA]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of NDUFS1 mRNA]]

NCBI chr 9:72,040,286...72,073,605
Ensembl chr 9:72,040,090...72,073,605

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the localization of NFE2L2 protein; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the localization of NFE2L2 protein]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nitric oxide synthase 2

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of NQO1 protein; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of NQO1 protein]

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 0, group B, member 2

increases expression

ISO

epicatechin gallate results in increased expression of NR0B2 mRNA

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 1, group H, member 4

increases activity
multiple interactions

ISO

epicatechin gallate results in increased activity of NR1H4 protein
[epicatechin gallate co-treated with gallocatechol] results in increased activity of NR1H4 protein

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

period circadian regulator 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of PER1 mRNA]

NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211

G

period circadian regulator 2

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of PER2 mRNA]

NCBI chr 9:99,454,828...99,497,069
Ensembl chr 9:99,454,830...99,496,993

G

prostaglandin-endoperoxide synthase 1

decreases activity

ISO

epicatechin gallate results in decreased activity of PTGS1 protein

NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; epicatechin gallate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

sirtuin 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of SIRT1 protein]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

superoxide dismutase 2

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] results in increased activity of SOD2 protein

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

toll-like receptor 4

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TLR4 protein]

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; epicatechin gallate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

DNA topoisomerase II alpha

decreases activity

ISO

epicatechin gallate results in decreased activity of TOP2A protein

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

tumor protein p53

multiple interactions

ISO

epicatechin gallate promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 mRNA]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

ubiquinol cytochrome c reductase core protein 2

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of UQCRC2 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of UQCRC2 protein]]

NCBI chr 1:184,599,240...184,629,804
Ensembl chr 1:184,599,212...184,630,946

(-)-epigallocatechin 3-gallate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adipogenesis associated, Mth938 domain containing

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AAMDC mRNA

NCBI chr 1:161,273,205...161,303,253
Ensembl chr 1:161,262,347...161,299,340

G

AAR2 splicing factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AAR2 mRNA

NCBI chr 3:165,517,467...165,540,260
Ensembl chr 3:165,517,556...165,548,519

G

aminoadipate-semialdehyde dehydrogenase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AASDH mRNA

NCBI chr14:31,609,488...31,636,066
Ensembl chr14:31,609,528...31,636,500

G

ATP binding cassette subfamily A member 1

increases expression
increases expression

ISO

epigallocatechin gallate results in increased expression of ABCA1 mRNA; epigallocatechin gallate results in increased expression of ABCA1 protein
(-)-epigallocatechin 3-gallate increases expression of Abca1 mRNA in liver

CTD
RGD

PMID:24165878 PMID:29593532

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily B member 10

increases expression

ISO

epigallocatechin gallate results in increased expression of ABCB10 mRNA

NCBI chr19:68,850,108...68,881,689
Ensembl chr19:68,850,134...68,880,203

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases expression
increases expression

ISO
EXP

epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of ABCB11 mRNA]
epigallocatechin gallate results in decreased expression of ABCB11 mRNA
epigallocatechin gallate results in increased expression of ABCB11 mRNA

PMID:22178739 PMID:23146761

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ABCB1 mRNA; epigallocatechin gallate results in decreased expression of ABCB1 protein

PMID:18851785 PMID:20149610

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 1

multiple interactions
decreases expression

ISO

[Docetaxel co-treated with epigallocatechin gallate co-treated with Quercetin] results in decreased expression of ABCC1 protein; [Docetaxel co-treated with epigallocatechin gallate] results in decreased expression of ABCC1 protein; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of ABCC1 protein]
epigallocatechin gallate results in decreased expression of ABCC1 protein

PMID:25655047 PMID:35218280

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCC10 mRNA

NCBI chr 9:22,154,811...22,174,743
Ensembl chr 9:22,154,804...22,174,743

G

ATP binding cassette subfamily C member 2

decreases expression

EXP

epigallocatechin gallate results in decreased expression of ABCC2 protein

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 4

increases expression

EXP

epigallocatechin gallate results in increased expression of ABCC4 protein

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily C member 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

ATP binding cassette subfamily D member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCD3 mRNA

NCBI chr 2:212,536,791...212,590,379
Ensembl chr 2:212,536,791...212,590,504

G

ATP binding cassette subfamily E member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCE1 mRNA

NCBI chr19:45,109,880...45,134,819
Ensembl chr19:45,109,906...45,134,819

G

ATP binding cassette subfamily G member 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ABCG1 mRNA

PMID:16084531 PMID:32512070

NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563

G

ATP binding cassette subfamily G member 2

decreases activity
increases expression

ISO

epigallocatechin gallate results in decreased activity of ABCG2 protein
epigallocatechin gallate results in increased expression of ABCG2 mRNA

PMID:18851785 PMID:20149610

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

ATP binding cassette subfamily G member 5

increases expression

ISO

(-)-epigallocatechin 3-gallate increases expression of Abcg5 mRNA in liver

RGD

NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376

G

ATP binding cassette subfamily G member 8

increases expression

ISO

(-)-epigallocatechin 3-gallate increases expression of Abcg8 mRNA in liver

RGD

NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:15,698,448...15,717,730

G

abhydrolase domain containing 6, acylglycerol lipase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABHD6 mRNA

NCBI chr15:19,289,967...19,337,500
Ensembl chr15:19,289,969...19,337,193

G

ABL proto-oncogene 2, non-receptor tyrosine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ABL2 mRNA

NCBI chr13:71,223,902...71,319,770
Ensembl chr13:71,224,019...71,389,775

G

ABR activator of RhoGEF and GTPase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABR mRNA

NCBI chr10:61,760,743...61,959,526
Ensembl chr10:61,760,743...61,959,467

G

acetyl-CoA carboxylase alpha

multiple interactions

ISO
EXP

epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in decreased phosphorylation of ACACA protein]
epigallocatechin gallate analog inhibits the reaction [Dietary Fats results in decreased phosphorylation of ACACA protein]

PMID:30092300 PMID:39577827

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acyl-CoA dehydrogenase medium chain

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACADM mRNA

NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:245,518,693...245,542,864

G

acyl-CoA dehydrogenase, short/branched chain

decreases expression

EXP

epigallocatechin gallate results in decreased expression of ACADSB mRNA

NCBI chr 1:195,619,088...195,660,564
Ensembl chr 1:195,619,038...195,660,561

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACAP2 mRNA

NCBI chr11:83,043,442...83,159,105
Ensembl chr11:83,043,511...83,159,107

G

acetyl-CoA acetyltransferase 2

increases expression

ISO

epigallocatechin gallate results in increased expression of ACAT2 mRNA

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095

G

angiotensin I converting enzyme

multiple interactions

ISO

Ascorbic Acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein]; boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein]; epigallocatechin gallate binds to and results in decreased activity of ACE protein

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942

G

ATP citrate lyase

increases expression

ISO

epigallocatechin gallate results in increased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

acyl-CoA thioesterase 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACOT13 mRNA

NCBI chr17:40,668,404...40,680,876
Ensembl chr17:40,668,316...40,680,876

G

acyl-CoA synthetase long-chain family member 1

decreases expression

EXP

epigallocatechin gallate results in decreased expression of ACSL1 mRNA

NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023

G

acyl-CoA synthetase short-chain family member 2

increases expression

ISO

epigallocatechin gallate results in increased expression of ACSS2 mRNA

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

acyl-CoA synthetase short-chain family member 3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ACSS3 mRNA

NCBI chr 7:44,127,725...44,336,707
Ensembl chr 7:44,127,122...44,336,684

G

actin alpha 2, smooth muscle

multiple interactions
affects expression

EXP
ISO

epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]
epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of ACTA2 mRNA]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of ACTA2 protein]
epigallocatechin gallate affects the expression of ACTA2
epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of ACTA2 protein]

PMID:19646978 PMID:20438794 PMID:22101032 PMID:25955525 PMID:38146662

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actin, beta

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ACTB protein

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

actin, beta-like 2

increases expression

ISO

epigallocatechin gallate results in increased expression of ACTBL2 protein

NCBI chr 2:44,591,391...44,594,138
Ensembl chr 2:44,591,391...44,594,138

G

actin related protein 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACTR10 mRNA

NCBI chr 6:95,182,082...95,208,325
Ensembl chr 6:95,182,111...95,209,021

G

ADAM metallopeptidase domain 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAM19 mRNA

NCBI chr10:30,992,713...31,084,455
Ensembl chr10:30,992,754...31,084,455

G

ADAM metallopeptidase with thrombospondin type 1 motif, 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS12 mRNA

NCBI chr 2:61,759,975...62,054,716
Ensembl chr 2:61,759,987...62,054,716

G

ADAM metallopeptidase with thrombospondin type 1 motif, 15

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS15 mRNA
epigallocatechin gallate results in increased expression of ADAMTS15 mRNA

NCBI chr 8:37,566,064...37,589,446
Ensembl chr 8:37,566,065...37,589,446

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of ADAMTS5 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS5 mRNA

NCBI chr11:38,486,945...38,533,516
Ensembl chr11:38,486,955...38,533,516

G

adenosine deaminase, RNA-specific, B1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADARB1 mRNA

NCBI chr20:11,222,171...11,350,416
Ensembl chr20:11,222,164...11,350,415

G

adenosine deaminase, tRNA-specific 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAT1 mRNA

NCBI chr19:56,825,153...56,866,136
Ensembl chr19:56,826,849...56,866,117

G

adhesion G protein-coupled receptor E1

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of ADGRE1 protein]

NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,329,438...2,484,959

G

adrenomedullin

decreases secretion

ISO

epigallocatechin gallate results in decreased secretion of ADM protein

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

adrenoceptor alpha 1B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADRA1B mRNA

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor beta 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADRB2 mRNA

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

adenylosuccinate synthase 2

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADSS2 mRNA
epigallocatechin gallate results in increased expression of ADSS2 protein

PMID:22079256 PMID:31195006

NCBI chr13:92,301,302...92,331,638
Ensembl chr13:92,301,302...92,331,638

G

ALF transcription elongation factor 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AFF1 mRNA
epigallocatechin gallate results in increased expression of AFF1 mRNA

NCBI chr14:6,165,864...6,328,848
Ensembl chr14:6,169,562...6,328,879

G

AFG1 like ATPase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AFG1L mRNA

NCBI chr20:47,380,582...47,550,307
Ensembl chr20:47,380,583...47,550,126

G

alpha-fetoprotein

multiple interactions

ISO

epigallocatechin gallate affects the reaction [sodium arsenate affects the expression of AFP protein]

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGAP1 mRNA

NCBI chr 9:97,487,382...97,922,870
Ensembl chr 9:97,487,406...97,922,870

G

advanced glycosylation end product-specific receptor

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of AGER protein]

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGL mRNA

NCBI chr 2:207,389,949...207,445,959
Ensembl chr 2:207,389,949...207,445,724

G

alkylglycerone phosphate synthase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGPS mRNA

NCBI chr 3:81,154,599...81,253,099
Ensembl chr 3:81,154,604...81,258,277

G

angiotensin II receptor, type 1a

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGTR1 mRNA; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 protein]]

PMID:22079256 PMID:36162953

NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660

G

adenosylhomocysteinase

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AHCY mRNA
epigallocatechin gallate results in decreased expression of AHCY protein

PMID:22079256 PMID:31195006

NCBI chr 3:164,029,338...164,044,562
Ensembl chr 3:164,029,338...164,044,587

G

aryl hydrocarbon receptor

multiple interactions
increases expression
decreases methylation
decreases activity

ISO

epigallocatechin gallate binds to and results in decreased activity of AHR protein; epigallocatechin gallate inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein]; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AHR protein]
epigallocatechin gallate results in increased expression of AHR mRNA; epigallocatechin gallate results in increased expression of AHR protein
epigallocatechin gallate results in decreased methylation of AHR promoter
epigallocatechin gallate binds to and results in decreased activity of AHR protein; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein]; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]]
epigallocatechin gallate results in decreased activity of AHR protein

PMID:11064004 PMID:11853182 PMID:12870889 PMID:15794642 PMID:20450880 More...

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

axin interactor, dorsalization associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AIDA mRNA

NCBI chr13:97,471,931...97,499,531
Ensembl chr13:97,471,604...97,499,535

G

apoptosis inducing factor, mitochondria associated 1

affects localization

ISO

epigallocatechin gallate analog affects the localization of AIFM1 protein

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237

G

aminoacyl tRNA synthetase complex-interacting multifunctional protein 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of AIMP1 mRNA

NCBI chr 2:223,825,930...223,849,477
Ensembl chr 2:223,825,931...223,849,994

G

ajuba LIM protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AJUBA mRNA

NCBI chr15:31,989,796...32,000,042
Ensembl chr15:31,989,799...32,000,042

G

A-kinase anchoring protein 13

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of AKAP13 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKAP13 mRNA

NCBI chr 1:138,722,445...139,029,401
Ensembl chr 1:138,724,150...139,029,401

G

A-kinase anchoring protein 9

decreases expression

ISO

epigallocatechin gallate results in decreased expression of AKAP9 protein

NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:31,011,475...31,147,338

G

A-kinase interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKIP1 mRNA

NCBI chr 1:173,169,520...173,178,445
Ensembl chr 1:173,169,458...173,178,445

G

akirin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AKIRIN2 mRNA

NCBI chr 5:53,897,792...53,918,873
Ensembl chr 5:53,904,285...53,918,934

G

aldo-keto reductase family 1, member C1

increases expression

ISO

epigallocatechin gallate results in increased expression of AKR1C1 mRNA

NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247

G

aldo-keto reductase family 1, member C2

increases expression

ISO

epigallocatechin gallate results in increased expression of AKR1C2 mRNA

NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686

G

aldo-keto reductase family 1, member C3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKR1C3 mRNA

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

AKT serine/threonine kinase 1

multiple interactions
decreases expression
decreases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; [epigallocatechin gallate co-treated with Quercetin] promotes the reaction [Docetaxel results in decreased phosphorylation of AKT1 protein]; [epigallocatechin gallate co-treated with Quercetin] results in decreased phosphorylation of AKT1 protein; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; CYFIP2 protein inhibits the reaction [epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; Docetaxel promotes the reaction [[epigallocatechin gallate co-treated with Quercetin] results in decreased phosphorylation of AKT1 protein]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of AKT1 protein]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]
epigallocatechin gallate results in decreased expression of AKT1 protein
epigallocatechin gallate inhibits the reaction [Imiquimod results in increased phosphorylation of AKT1 protein]; epigallocatechin gallate results in decreased expression of and results in decreased phosphorylation of AKT1 protein
epigallocatechin gallate results in decreased phosphorylation of AKT1 protein

PMID:12931129 PMID:19244381 PMID:23954321 PMID:25655047 PMID:29061316 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

AKT serine/threonine kinase 2

multiple interactions

ISO

CYFIP2 protein inhibits the reaction [epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT2 protein]]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT2 protein]

NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:92,014,859...92,061,420

G

AKT serine/threonine kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKT3 mRNA; CYFIP2 protein inhibits the reaction [epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT3 protein]]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT3 protein]

PMID:22079256 PMID:39667565

NCBI chr13:91,475,839...91,758,060
Ensembl chr13:91,475,839...91,748,020

G

AKT interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKTIP mRNA

NCBI chr19:32,039,507...32,059,634
Ensembl chr19:32,039,466...32,067,178

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALDH3A2 mRNA

NCBI chr10:46,427,789...46,448,449
Ensembl chr10:46,407,993...46,448,648

G

aldolase, fructose-bisphosphate A

increases expression

ISO

epigallocatechin gallate results in increased expression of ALDOA protein

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

aldolase, fructose-bisphosphate C

increases expression

ISO

epigallocatechin gallate results in increased expression of ALDOC protein

NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,715,489...63,719,133

G

ALG14, UDP-N-acetylglucosaminyltransferase subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG14 mRNA

NCBI chr 2:212,053,008...212,130,136
Ensembl chr 2:212,044,969...212,130,140

G

ALG6, alpha-1,3-glucosyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG6 mRNA

NCBI chr 5:119,520,415...119,606,365
Ensembl chr 5:119,520,430...119,606,659

G

ALG8, alpha-1,3-glucosyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG8 mRNA

NCBI chr 1:161,095,570...161,115,533
Ensembl chr 1:161,095,412...161,115,527

G

alpha-kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALPK2 mRNA

NCBI chr18:61,045,717...61,161,703
Ensembl chr18:61,045,380...61,175,985

G

anti-Mullerian hormone

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AMH mRNA

NCBI chr 7:9,557,451...9,559,867
Ensembl chr 7:9,557,451...9,559,867

G

AMMECR nuclear protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AMMECR1 mRNA

NCBI chr X:111,262,792...111,368,099
Ensembl chr X:111,262,792...111,368,099

G

adenosine monophosphate deaminase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AMPD1 mRNA

NCBI chr 2:193,287,219...193,308,446
Ensembl chr 2:193,287,265...193,308,443

G

anaphase promoting complex subunit 10

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of ANAPC10 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC10 mRNA

NCBI chr19:45,057,278...45,109,882
Ensembl chr19:45,029,546...45,109,882

G

anaphase promoting complex subunit 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC4 mRNA

NCBI chr14:62,338,798...62,370,572
Ensembl chr14:62,338,798...62,370,572

G

anaphase promoting complex subunit 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC7 mRNA

NCBI chr12:39,793,518...39,821,614
Ensembl chr12:39,794,349...39,821,066

G

ankyrin repeat and IBR domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKIB1 mRNA

NCBI chr 4:31,288,393...31,412,500
Ensembl chr 4:31,288,142...31,412,504

G

ankyrin repeat and MYND domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKMY2 mRNA

NCBI chr 6:58,616,251...58,657,634
Ensembl chr 6:58,615,243...58,657,685

G

ankyrin repeat domain 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ANKRD10 mRNA

NCBI chr16:84,566,021...84,591,849
Ensembl chr16:84,568,506...84,591,846

G

ankyrin repeat domain containing 26

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD26 mRNA

NCBI chr 4:153,342,901...153,412,321
Ensembl chr 4:153,343,578...153,412,256

G

ankyrin repeat domain 44

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD44 mRNA

NCBI chr 9:63,621,193...63,921,999
Ensembl chr 9:63,555,869...63,921,940

G

anoctamin 1

decreases activity

ISO

epigallocatechin gallate results in decreased activity of ANO1 protein

NCBI chr 1:209,180,755...209,329,413
Ensembl chr 1:209,180,755...209,329,550

G

anoctamin 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANO4 mRNA

NCBI chr 7:25,216,389...25,625,811
Ensembl chr 7:25,216,389...25,625,746

G

anoctamin 6

decreases activity

ISO

epigallocatechin gallate results in decreased activity of ANO6 protein

NCBI chr 7:128,812,842...128,992,805
Ensembl chr 7:128,813,068...128,992,799

G

annexin A11

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ANXA11 protein

NCBI chr16:1,419,627...1,464,590
Ensembl chr16:1,418,351...1,464,839

G

annexin A4

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ANXA4 protein

NCBI chr 4:120,741,750...120,798,534
Ensembl chr 4:120,741,750...120,798,513

G

aminopeptidase O

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AOPEP mRNA

NCBI chr17:1,817,001...2,133,008
Ensembl chr17:1,817,001...2,133,104

G

adaptor related protein complex 1 subunit sigma 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP1S3 mRNA

NCBI chr 9:88,399,109...88,458,396
Ensembl chr 9:88,399,109...88,488,089

G

adaptor related protein complex 2 subunit alpha 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP2A2 mRNA

NCBI chr 1:206,081,856...206,155,146
Ensembl chr 1:206,081,878...206,155,150

G

adaptor related protein complex 5 subunit sigma 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP5S1 mRNA

NCBI chr 3:138,882,634...138,885,940
Ensembl chr 3:138,882,634...138,888,899

G

apoptotic peptidase activating factor 1

increases expression
decreases expression

ISO

epigallocatechin gallate results in increased expression of APAF1 protein
epigallocatechin gallate results in decreased expression of APAF1 mRNA

PMID:15657356 PMID:39667565

NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772

G

amyloid beta precursor protein binding family B member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APBB2 mRNA

NCBI chr14:41,849,638...42,232,930
Ensembl chr14:41,911,785...42,232,280

G

APC regulator of WNT signaling pathway

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in decreased expression of APC mRNA]; epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in decreased expression of APC protein]

NCBI chr18:26,138,382...26,196,021
Ensembl chr18:26,102,679...26,197,022

G

aph-1 homolog B, gamma secretase subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APH1B mRNA

NCBI chr 8:76,310,380...76,334,146
Ensembl chr 8:76,310,380...76,331,428

G

apolipoprotein B

decreases secretion
multiple interactions

ISO
EXP

epigallocatechin gallate results in decreased secretion of APOB protein
epigallocatechin gallate results in increased ubiquitination of and results in increased degradation of and results in decreased secretion of APOB protein; lactacystin inhibits the reaction [epigallocatechin gallate results in increased ubiquitination of and results in increased degradation of and results in decreased secretion of APOB protein]; lactacystin inhibits the reaction [epigallocatechin gallate results in increased ubiquitination of and results in increased degradation of APOB protein]

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

apolipoprotein L2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APOL2 mRNA

NCBI chr 7:111,211,944...111,219,209
Ensembl chr 7:111,211,893...111,217,223

G

amyloid beta precursor protein

affects folding

ISO

epigallocatechin gallate affects the folding of APP protein modified form

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APPL2 mRNA

NCBI chr 7:22,019,480...22,072,386
Ensembl chr 7:22,022,963...22,072,385

G

aquaporin 1

decreases expression
increases expression

ISO

epigallocatechin gallate results in decreased expression of AQP1 mRNA
epigallocatechin gallate results in increased expression of AQP1 mRNA

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504

G

aquaporin 3 (Gill blood group)

increases expression

ISO

epigallocatechin gallate results in increased expression of AQP3 mRNA

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685

G

aquarius intron-binding spliceosomal factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AQR mRNA

NCBI chr 3:121,329,287...121,399,375
Ensembl chr 3:121,329,289...121,399,321

G

androgen receptor

decreases expression
increases expression
affects expression

ISO

epigallocatechin gallate results in decreased expression of AR mRNA
epigallocatechin gallate results in increased expression of AR protein
epigallocatechin gallate affects the expression of AR protein

PMID:20706672 PMID:34600025 PMID:35863485

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARAP3 mRNA

NCBI chr18:30,058,739...30,085,415
Ensembl chr18:30,058,275...30,084,865

G

archain 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ARCN1 protein

NCBI chr 8:53,954,401...53,979,005
Ensembl chr 8:53,954,404...53,979,005

G

ARF guanine nucleotide exchange factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARFGEF1 mRNA

NCBI chr 5:13,764,507...13,859,237
Ensembl chr 5:13,764,975...13,859,237

G

Rho GTPase activating protein 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP10 mRNA

NCBI chr19:47,352,783...47,614,532
Ensembl chr19:47,352,276...47,614,531

G

Rho GTPase activating protein 11A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP11A mRNA

NCBI chr 3:121,045,187...121,071,985
Ensembl chr 3:121,045,187...121,061,468

G

Rho GTPase activating protein 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP12 mRNA

NCBI chr17:56,284,282...56,397,630
Ensembl chr17:56,284,286...56,397,563

G

Rho GTPase activating protein 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP18 mRNA

NCBI chr 1:20,222,948...20,456,827
Ensembl chr 1:20,222,954...20,456,670

G

Rho GTPase activating protein 20

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP20 mRNA

NCBI chr 8:60,970,480...61,055,199
Ensembl chr 8:60,970,475...61,055,198

G

Rho GTPase activating protein 21

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP21 mRNA

NCBI chr17:88,256,961...88,380,478
Ensembl chr17:88,256,961...88,380,797

G

Rho GTPase activating protein 24

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP24 mRNA

NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950

G

Rho GTPase activating protein 28

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP28 mRNA

NCBI chr 9:115,277,849...115,444,789
Ensembl chr 9:115,279,734...115,445,008

G

Rho GTPase activating protein 29

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP29 mRNA

NCBI chr 2:212,744,626...212,816,710
Ensembl chr 2:212,755,803...212,986,729

G

Rho GTPase activating protein 42

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP42 mRNA

NCBI chr 8:14,436,478...14,666,588
Ensembl chr 8:14,419,256...14,666,385

G

Rho guanine nucleotide exchange factor 26

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF26 mRNA

NCBI chr 2:148,889,405...149,000,538
Ensembl chr 2:148,889,423...149,000,538

G

Rho guanine nucleotide exchange factor 28

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF28 mRNA

NCBI chr 2:30,998,292...31,294,757
Ensembl chr 2:30,998,295...31,294,853

G

Rho guanine nucleotide exchange factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF3 mRNA

NCBI chr16:2,308,311...2,588,634
Ensembl chr16:2,308,400...2,588,819

G

ARF like GTPase 15

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARL15 mRNA

NCBI chr 2:47,171,377...47,555,666
Ensembl chr 2:47,094,900...47,555,666

G

armadillo repeat containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC1 mRNA

NCBI chr 2:103,524,333...103,568,355
Ensembl chr 2:103,524,333...103,568,355

G

armadillo repeat containing 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC9 mRNA

NCBI chr 9:94,250,492...94,376,589
Ensembl chr 9:94,250,859...94,376,589

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARNT mRNA; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ARNT protein]
epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]]

PMID:20450880 PMID:22079256

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546

G

actin related protein 2/3 complex, subunit 5-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARPC5L mRNA

NCBI chr 3:43,169,518...43,177,224
Ensembl chr 3:43,169,462...43,177,240
Ensembl chr 9:43,169,462...43,177,240

G

arrestin, beta 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARRB1 mRNA

NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859

G

arrestin domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARRDC3 mRNA

NCBI chr 2:12,873,202...12,885,716
Ensembl chr 2:12,873,202...12,885,875

G

arylsulfatase family, member I

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARSI mRNA

NCBI chr18:56,634,556...56,642,168
Ensembl chr18:56,625,487...56,642,168

G

arylsulfatase family, member J

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARSJ mRNA

NCBI chr 2:217,449,147...217,529,142
Ensembl chr 2:217,449,147...217,529,142

G

ADP-ribosyltransferase 4

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ART4 mRNA

NCBI chr 4:171,468,415...171,482,435
Ensembl chr 4:171,471,534...171,481,868

G

ARV1 homolog, fatty acid homeostasis modulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARV1 mRNA

NCBI chr19:69,589,728...69,601,547
Ensembl chr19:69,589,328...69,601,537

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASAP1 mRNA

NCBI chr 7:97,675,354...97,982,523
Ensembl chr 7:97,675,354...97,982,024

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASAP2 mRNA

NCBI chr 6:46,386,605...46,549,669
Ensembl chr 6:46,386,605...46,549,669

G

ankyrin repeat and SOCS box-containing 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ASB6 mRNA

NCBI chr 3:34,508,390...34,513,033
Ensembl chr 3:34,508,140...34,513,033

G

activating signal cointegrator 1 complex subunit 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASCC3 mRNA

NCBI chr20:55,089,430...55,372,374
Ensembl chr20:55,255,503...55,372,374

G

anti-silencing function 1A histone chaperone

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASF1A mRNA

NCBI chr20:33,436,632...33,451,478
Ensembl chr20:33,436,707...33,449,639

G

ASH2 like histone lysine methyltransferase complex subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASH2L mRNA

NCBI chr16:72,943,527...72,966,791
Ensembl chr16:72,944,949...72,967,839

G

assembly factor for spindle microtubules

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASPM mRNA

NCBI chr13:53,625,584...53,674,489
Ensembl chr13:53,625,584...53,674,489

G

ATPase family, AAA domain containing 2B

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATAD2B mRNA
epigallocatechin gallate results in increased expression of ATAD2B mRNA

PMID:22079256 PMID:35701726

NCBI chr 6:33,646,075...33,789,532
Ensembl chr 6:33,646,075...33,789,532

G

arginyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATE1 mRNA

NCBI chr 1:194,391,843...194,514,284
Ensembl chr 1:194,391,843...194,511,348

G

activating transcription factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATF4 mRNA

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

autophagy related 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG10 mRNA

NCBI chr 2:23,843,695...24,133,459
Ensembl chr 2:23,844,482...24,133,368

G

autophagy related 12

multiple interactions
increases expression

ISO

TFEB protein affects the reaction [epigallocatechin gallate results in increased expression of ATG12 protein]

NCBI chr18:41,638,841...41,649,311
Ensembl chr18:41,635,835...41,649,261

G

autophagy related 4A, cysteine peptidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG4A mRNA

NCBI chr X:109,453,712...109,553,758
Ensembl chr X:109,453,689...109,553,760

G

autophagy related 4C, cysteine peptidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG4C mRNA

NCBI chr 5:118,977,594...119,050,894
Ensembl chr 5:118,982,918...119,052,695

G

autophagy related 4D, cysteine peptidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATG4D mRNA

NCBI chr 8:28,083,902...28,093,491
Ensembl chr 8:28,083,936...28,093,491

G

autophagy related 5

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG5 mRNA; TFEB protein affects the reaction [epigallocatechin gallate results in increased expression of ATG5 protein]

PMID:22079256 PMID:39313106

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

atlastin GTPase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATL1 mRNA

NCBI chr 6:94,113,149...94,210,955
Ensembl chr 6:94,112,877...94,211,219

G

atrophin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATN1 mRNA

NCBI chr 4:159,240,573...159,254,378
Ensembl chr 4:159,237,562...159,254,418

G

ATPase phospholipid transporting 10D (putative)

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP10D mRNA

NCBI chr14:36,265,696...36,366,460
Ensembl chr14:36,265,696...36,366,460

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP1B1 mRNA

NCBI chr13:79,319,708...79,340,226
Ensembl chr13:79,319,706...79,340,549

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

ISO

epigallocatechin gallate results in increased expression of ATP2A2 mRNA

NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B1 mRNA

NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904

G

ATPase plasma membrane Ca2+ transporting 4

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of ATP2B4 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B4 mRNA

NCBI chr13:47,708,157...47,807,389
Ensembl chr13:47,711,121...47,758,876

G

ATPase H+ transporting V0 subunit C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATP6V0C mRNA

NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,700,764...13,706,245

G

ATPase copper transporting beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP7B mRNA

NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801

G

ATPase phospholipid transporting 8B1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP8B1 mRNA

NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027

G

ATR serine/threonine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATR mRNA

NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:105,306,305...105,403,718

G

ataxin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN2 mRNA

NCBI chr12:40,413,657...40,509,895
Ensembl chr12:40,414,904...40,510,473

G

ataxin 2-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATXN2L mRNA

NCBI chr 1:190,508,878...190,526,263
Ensembl chr 1:190,508,878...190,520,579

G

ataxin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN3 mRNA

NCBI chr 6:126,837,107...126,872,919
Ensembl chr 6:126,839,327...126,872,781

G

ataxin 7-like 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of ATXN7L1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN7L1 mRNA

NCBI chr 6:55,487,309...55,709,751
Ensembl chr 6:55,649,362...55,701,996

G

aurora kinase A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

antizyme inhibitor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AZIN1 mRNA

NCBI chr 7:71,539,711...71,566,515
Ensembl chr 7:71,539,711...71,566,515

G

beta 3-glucosyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of B3GLCT mRNA

NCBI chr12:10,291,910...10,383,190
Ensembl chr12:10,291,910...10,426,357

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of QTGAL mRNA

NCBI chr10:107,363,036...107,431,988
Ensembl chr10:107,371,442...107,431,908

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAAT mRNA

NCBI chr 5:68,647,166...68,656,137
Ensembl chr 5:68,646,203...68,656,181

G

beta-secretase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BACE1 mRNA

NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:55,038,823...55,064,918

G

BAG cochaperone 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG1 mRNA

NCBI chr 5:60,864,476...60,877,059
Ensembl chr 5:60,864,476...60,878,161

G

BAG cochaperone 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAG2 mRNA

NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752

G

BAG cochaperone 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG3 mRNA

NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280

G

BAG cochaperone 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG4 mRNA

NCBI chr16:72,991,407...73,008,620
Ensembl chr16:72,991,362...73,013,273

G

BAG cochaperone 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG6 mRNA

NCBI chr20:3,680,607...3,693,329
Ensembl chr20:3,680,607...3,693,329

G

BCL2-antagonist/killer 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of BAK1 mRNA

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression
affects localization
increases activity
decreases expression
affects expression
increases response to substance

ISO
EXP

[decitabine co-treated with epigallocatechin gallate] affects the expression of BAX mRNA; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; epigallocatechin gallate promotes the reaction [BAX protein binds to BAX protein]
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of BAX protein]
epigallocatechin gallate results in increased expression of BAX protein
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; [Tea results in increased abundance of epigallocatechin gallate] inhibits the reaction [Histamine results in increased expression of BAX mRNA]; epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of BAX mRNA]; epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of BAX protein]; epigallocatechin gallate inhibits the reaction [Morphine results in increased expression of BAX protein]
epigallocatechin gallate analog affects the localization of BAX protein
epigallocatechin gallate results in increased activity of BAX protein
epigallocatechin gallate results in decreased expression of BAX mRNA
epigallocatechin gallate affects the expression of BAX protein
BAX protein results in increased susceptibility to epigallocatechin gallate

PMID:12672908 PMID:15657356 PMID:15705601 PMID:15764647 PMID:15975156 More...

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

bromodomain adjacent to zinc finger domain, 1A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAZ1A mRNA

NCBI chr 6:78,124,872...78,247,672
Ensembl chr 6:78,124,872...78,247,648

G

bromodomain adjacent to zinc finger domain, 2B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAZ2B mRNA

NCBI chr 3:64,792,984...65,034,547
Ensembl chr 3:64,794,001...65,001,781

G

Bardet-Biedl syndrome 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS10 mRNA

NCBI chr 7:48,637,324...48,640,395
Ensembl chr 7:48,637,356...48,640,391

G

Bardet-Biedl syndrome 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS2 mRNA

NCBI chr19:10,915,566...10,950,911
Ensembl chr19:10,915,476...10,950,921

G

Bardet-Biedl syndrome 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS4 mRNA

NCBI chr 8:68,627,739...68,661,232
Ensembl chr 8:68,627,656...68,661,358

G

BBX high mobility group box domain containing

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBX mRNA

NCBI chr11:63,850,034...64,097,700
Ensembl chr11:63,850,018...64,093,265

G

butyrylcholinesterase

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased activity of BCHE protein]

NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
affects expression

ISO
EXP

[arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2 protein; [decitabine co-treated with epigallocatechin gallate] affects the expression of BCL2 mRNA; CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of BCL2 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]
epigallocatechin gallate results in decreased expression of BCL2 protein
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; [Tea results in increased abundance of epigallocatechin gallate] inhibits the reaction [Histamine results in decreased expression of BCL2 mRNA]; epigallocatechin gallate inhibits the reaction [Acrylamide results in decreased expression of BCL2 protein]; epigallocatechin gallate inhibits the reaction [Morphine results in decreased expression of BCL2 protein]
epigallocatechin gallate affects the expression of BCL2 protein
epigallocatechin gallate affects the reaction [mono-(2-ethylhexyl)phthalate affects the expression of BCL2 protein]; epigallocatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of BCL2 mRNA]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
epigallocatechin gallate analog results in decreased expression of BCL2 protein; epigallocatechin gallate results in decreased expression of BCL2 protein

PMID:12672908 PMID:15657356 PMID:15975156 PMID:16115949 PMID:18250043 More...

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

multiple interactions

ISO

[arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 protein; [Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form; [Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form; calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form]; calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form]; tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form]; tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form]

PMID:18348186 PMID:20950636

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

BCL3, transcription coactivator

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BCL3 mRNA
epigallocatechin gallate results in increased expression of BCL3 mRNA

NCBI chr 1:88,599,321...88,613,555
Ensembl chr 1:88,599,321...88,614,368

G

BCL6, transcription repressor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BCL6 mRNA

NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047

G

BAF chromatin remodeling complex subunit BCL7A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BCL7A mRNA

NCBI chr12:38,872,851...38,904,770
Ensembl chr12:38,872,851...38,904,770

G

bradykinin receptor B1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BDKRB1 mRNA

NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973

G

brain-derived neurotrophic factor

decreases expression
multiple interactions

EXP
ISO

epigallocatechin gallate results in decreased expression of BDNF protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]]

PMID:22886603 PMID:29061316

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

beclin 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of BECN1 protein
epigallocatechin gallate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of BECN1 protein]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of BECN1 protein]

PMID:32512070 PMID:34740634

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

BICD cargo adaptor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BICD2 mRNA

NCBI chr17:15,449,011...15,511,423
Ensembl chr17:15,435,894...15,511,305

G

bridging integrator 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BIN3 mRNA

NCBI chr15:51,583,474...51,622,329
Ensembl chr15:51,583,481...51,622,329

G

baculoviral IAP repeat-containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BIRC3 mRNA

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

baculoviral IAP repeat-containing 5

multiple interactions

ISO

[epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in decreased expression of BIRC5 protein

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

bridge-like lipid transfer protein family member 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BLTP1 mRNA
epigallocatechin gallate results in increased expression of BLTP1 mRNA

NCBI chr 2:121,636,181...121,852,802
Ensembl chr 2:121,636,323...121,852,802

G

biliverdin reductase A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BLVRA mRNA

NCBI chr 3:134,793,397...134,819,367
Ensembl chr 3:134,794,203...134,819,785

G

basic helix-loop-helix ARNT like 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of BMAL1 mRNA]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of BMAL1 protein]; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMAL1 mRNA; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the localization of NFE2L2 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BDNF protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BNIP3 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX4 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX6C mRNA]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of FIS1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of MFN1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of NDUFS1 mRNA]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of UQCRC2 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of HMOX1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of NQO1 protein]

PMID:22079256 PMID:29061316

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

BMP-2 inducible kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMP2K mRNA

NCBI chr14:12,785,169...12,882,676
Ensembl chr14:12,785,169...12,882,657

G

bone morphogenetic protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMP4 mRNA

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

BMP-binding endothelial regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMPER mRNA

NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359

G

bone morphogenetic protein receptor type 1A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMPR1A mRNA

NCBI chr16:9,740,751...9,786,861
Ensembl chr16:9,742,875...9,786,861

G

BMX non-receptor tyrosine kinase

increases expression

ISO

epigallocatechin gallate results in increased expression of BMX protein

NCBI chr X:33,859,128...33,921,876
Ensembl chr X:33,859,129...33,921,874

G

BCL2 interacting protein 3

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BNIP3 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of BNIP3 protein]]

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

bolA family member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BOLA1 mRNA

NCBI chr 2:186,447,386...186,448,402
Ensembl chr 2:186,443,583...186,501,358

G

bora, aurora kinase A activator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BORA mRNA

NCBI chr15:82,205,467...82,243,499
Ensembl chr15:82,205,697...82,244,052

G

bisphosphoglycerate mutase

decreases expression

ISO

epigallocatechin gallate results in decreased expression of BPGM mRNA

NCBI chr 4:64,106,809...64,135,749
Ensembl chr 4:64,106,804...64,135,627

G

3'(2'), 5'-bisphosphate nucleotidase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BPNT2 mRNA

NCBI chr 5:22,573,241...22,600,126
Ensembl chr 5:22,570,165...22,600,126

G

BRCA1, DNA repair associated

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA1 mRNA
epigallocatechin gallate results in increased expression of BRCA1 mRNA

PMID:22079256 PMID:25839702

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

BRCA2, DNA repair associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA2 mRNA

NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194

G

bromodomain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BRD1 mRNA

NCBI chr 7:121,653,859...121,701,700
Ensembl chr 7:121,653,859...121,701,700

G

bromodomain containing 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRD10 mRNA

NCBI chr 1:236,904,520...236,984,414
Ensembl chr 1:236,904,520...236,983,923

G

BRCA1 interacting DNA helicase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRIP1 mRNA

NCBI chr10:71,402,035...71,528,083
Ensembl chr10:71,401,151...71,575,206

G

bromodomain and PHD finger containing, 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BRPF3 mRNA

NCBI chr20:6,866,378...6,904,456
Ensembl chr20:6,867,635...6,904,456

G

bromodomain and WD repeat domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRWD3 mRNA

NCBI chr X:77,843,766...77,937,240
Ensembl chr X:77,848,982...77,937,745

G

BTB domain containing 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTBD8 mRNA

NCBI chr14:2,410,093...2,483,114
Ensembl chr14:2,410,093...2,479,202

G

basic transcription factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BTF3 mRNA

NCBI chr 2:31,394,010...31,401,138
Ensembl chr 2:31,394,011...31,401,125
Ensembl chr13:31,394,011...31,401,125

G

basic transcription factor 3-like 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTF3L4 mRNA

NCBI chr 5:128,796,594...128,816,219
Ensembl chr 5:128,796,594...128,816,602

G

BTG anti-proliferation factor 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of BTG1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BTG1 mRNA

PMID:16084531 PMID:22079256

NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:33,227,833...33,230,406

G

beta-transducin repeat containing E3 ubiquitin protein ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTRC mRNA

NCBI chr 1:254,159,085...254,324,819
Ensembl chr 1:254,159,124...254,328,357

G

BUB1 mitotic checkpoint serine/threonine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BUB1 mRNA

NCBI chr 3:135,473,525...135,504,921
Ensembl chr 3:135,472,582...135,504,921

G

BUD31 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BUD31 mRNA

NCBI chr12:14,576,602...14,584,132
Ensembl chr12:14,576,605...14,584,039

G

similar to human chromosome 1 open reading frame 21

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1ORF21 mRNA

NCBI chr13:66,540,245...66,749,631
Ensembl chr13:66,540,245...66,659,684

G

similar to human chromosome 14 open reading frame 119

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C14ORF119 mRNA

NCBI chr15:32,116,220...32,121,425
Ensembl chr15:32,116,021...32,122,416

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1GALT1 mRNA

NCBI chr 4:36,894,440...36,932,434
Ensembl chr 4:36,894,488...36,932,441

G

C2CD2-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C2CD2L mRNA

NCBI chr 8:53,544,887...53,557,127
Ensembl chr 8:53,544,892...53,555,153

G

C2 domain containing 3 centriole elongation regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2CD3 mRNA

NCBI chr 1:164,127,304...164,225,088
Ensembl chr 1:164,127,281...164,225,086

G

C2 calcium-dependent domain containing 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2CD5 mRNA

NCBI chr 4:177,700,515...177,790,576
Ensembl chr 4:177,700,516...177,786,717

G

similar to human chromosome 1 open reading frame 162

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF162 mRNA

NCBI chr 2:196,101,669...196,107,404
Ensembl chr 2:196,100,702...196,106,832

G

similar to human chromosome 1 open reading frame 52

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF52 mRNA

NCBI chr 2:237,510,974...237,520,346
Ensembl chr 2:237,513,711...237,520,346

G

similar to human chromosome 15 open reading frame 48

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COXFA4L3 mRNA

NCBI chr 3:130,173,535...130,177,088
Ensembl chr 3:130,173,416...130,177,089

G

similar to human chromosome 15 open reading frame 39

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C15ORF39 mRNA

NCBI chr 8:66,542,269...66,551,835
Ensembl chr 8:66,542,269...66,554,782

G

calcium voltage-gated channel auxiliary subunit beta 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CACNB1 mRNA

NCBI chr10:83,494,509...83,515,164
Ensembl chr10:83,494,509...83,515,146

G

calcium/calmodulin-dependent protein kinase II delta

multiple interactions
decreases expression

ISO
EXP

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAMK2D mRNA
EGCG decreases expression of camk2d protein after myocardial infarction in rat heart left ventricle

CTD
RGD

PMID:22079256 PMID:26067684

NCBI chr 2:217,698,324...217,961,898
Ensembl chr 2:217,698,551...217,960,276

G

calmodulin-lysine N-methyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAMKMT mRNA

NCBI chr 6:14,951,838...15,332,966
Ensembl chr 6:14,951,840...15,333,106

G

calcium modulating ligand

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CAMLG mRNA

NCBI chr17:8,997,868...9,009,140
Ensembl chr17:8,997,272...9,009,012

G

cullin-associated and neddylation-dissociated 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CAND1 protein

NCBI chr 7:56,566,765...56,604,653
Ensembl chr 7:56,551,394...56,604,655

G

calpain 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CAPN2 protein

NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625

G

caprin family member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAPRIN2 mRNA

NCBI chr 4:183,537,935...183,592,162
Ensembl chr 4:183,537,430...183,592,809

G

capping protein regulator and myosin 1 linker 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CARMIL1 mRNA

NCBI chr17:41,235,819...41,516,204
Ensembl chr17:41,236,229...41,516,221

G

carnosine N-methyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CARNMT1 mRNA

NCBI chr 1:225,520,345...225,549,971
Ensembl chr 1:225,520,151...225,550,232

G

CASC3 exon junction complex subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CASC3 mRNA

NCBI chr10:84,264,157...84,286,639
Ensembl chr10:84,265,033...84,286,637

G

CAS1 domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASD1 mRNA

NCBI chr 4:33,613,805...33,705,821
Ensembl chr 4:33,613,450...33,705,821

G

caspase 1

multiple interactions

ISO
EXP

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP1 mRNA; epigallocatechin gallate inhibits the reaction [bisphenol A affects the expression of CASP1 mRNA]; epigallocatechin gallate inhibits the reaction [bisphenol A results in increased expression of CASP1 protein]
epigallocatechin gallate inhibits the reaction [ochratoxin A results in increased expression of CASP1 mRNA]
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in decreased expression of CASP1 mRNA]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 mRNA]; epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CASP1 protein]

PMID:22079256 PMID:35439536 PMID:36056792 PMID:37286014 PMID:39299375

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

affects cleavage
increases expression
multiple interactions
increases cleavage
increases activity

ISO
EXP

epigallocatechin gallate affects the cleavage of CASP3 protein
epigallocatechin gallate results in increased expression of CASP3 protein
epigallocatechin gallate inhibits the reaction [Formaldehyde results in increased expression of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; epigallocatechin gallate results in increased expression of and results in increased cleavage of CASP3 protein
epigallocatechin gallate analog results in increased cleavage of CASP3 protein; epigallocatechin gallate results in increased cleavage of CASP3 protein
epigallocatechin gallate results in increased activity of CASP3 protein
[Arsenic Trioxide co-treated with epigallocatechin gallate] results in increased activity of CASP3 protein; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased cleavage of and results in increased activity of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Nitroprusside binds to and results in increased activity of CASP3 protein]; epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased cleavage of and results in increased activity of CASP3 protein]
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]; [epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; [Tea results in increased abundance of epigallocatechin gallate] inhibits the reaction [Histamine results in increased expression of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Acrylamide results in increased activity of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; epigallocatechin gallate promotes the reaction [Sulindac inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP3 protein]]

PMID:12672908 PMID:15657356 PMID:15705601 PMID:15764647 PMID:15795422 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP6 mRNA

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

caspase 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP8 mRNA
epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CASP8 protein]

PMID:22079256 PMID:37286014

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases activity
increases cleavage
increases expression
affects activity
multiple interactions

ISO

epigallocatechin gallate results in increased activity of CASP9 protein
epigallocatechin gallate results in increased cleavage of CASP9 protein
epigallocatechin gallate results in increased expression of CASP9 protein
epigallocatechin gallate affects the activity of CASP9 protein
epigallocatechin gallate inhibits the reaction [Nitroprusside binds to and results in increased activity of CASP9 protein]
epigallocatechin gallate analog results in increased cleavage of CASP9 protein

PMID:15764647 PMID:16115949 PMID:23665936 PMID:23954321 PMID:32512070 More...

Ensembl chr 5:159,391,188...159,409,648

G

catalase

multiple interactions
increases expression
increases activity
decreases expression
decreases activity

ISO
EXP

CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of BCL2 protein]; CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of MCL1 protein]; CAT protein inhibits the reaction [epigallocatechin gallate analog results in increased abundance of Reactive Oxygen Species]; epigallocatechin gallate inhibits the reaction [sodium arsenite affects the expression of CAT mRNA]
epigallocatechin gallate results in increased expression of CAT mRNA
epigallocatechin gallate results in increased activity of CAT protein
[[sodium arsenite results in increased abundance of Arsenic] which co-treated with epigallocatechin gallate] results in decreased activity of CAT protein; epigallocatechin gallate inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased activity of CAT protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in decreased expression of CAT mRNA]; epigallocatechin gallate inhibits the reaction [sodium arsenate results in decreased activity of CAT protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of and affects the activity of CAT protein]; epigallocatechin gallate inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of CAT protein]; epigallocatechin gallate inhibits the reaction [Acrylamide results in decreased activity of CAT protein]; epigallocatechin gallate inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; epigallocatechin gallate inhibits the reaction [Ethanol results in decreased activity of CAT protein]; epigallocatechin gallate inhibits the reaction [lead acetate results in decreased activity of CAT protein]
epigallocatechin gallate results in decreased expression of CAT mRNA
epigallocatechin gallate results in decreased activity of CAT protein

PMID:16115949 PMID:20020850 PMID:20666448 PMID:25382014 PMID:25585349 More...

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

caveolin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAV2 mRNA

NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:46,582,096...46,591,425

G

caveolae associated protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAVIN2 mRNA

NCBI chr 9:57,794,007...57,806,024
Ensembl chr 9:57,794,019...57,806,024

G

caveolae associated protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CAVIN4 mRNA

NCBI chr 5:67,792,171...67,893,094
Ensembl chr 5:67,792,392...67,803,254

G

Cbl proto-oncogene B

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CBLB mRNA
epigallocatechin gallate results in increased expression of CBLB mRNA

NCBI chr11:62,058,829...62,225,904
Ensembl chr11:62,061,653...62,225,778

G

Cbl proto-oncogene like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CBLL1 mRNA

NCBI chr 6:53,798,712...53,812,890
Ensembl chr 6:53,798,712...53,813,880

G

chromobox 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CBX4 mRNA

NCBI chr10:104,835,685...104,841,727
Ensembl chr10:104,835,685...104,841,727

G

chibby 1, beta catenin antagonist

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CBY1 mRNA

NCBI chr 7:113,097,220...113,103,831

G

coiled-coil and C2 domain containing 1B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CC2D1B mRNA

NCBI chr 5:128,581,962...128,596,045
Ensembl chr 5:128,581,994...128,596,022

G

coiled-coil and C2 domain containing 2A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CC2D2A mRNA

NCBI chr14:71,563,835...71,648,352
Ensembl chr14:71,563,835...71,648,331

G

coiled-coil domain containing 125

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC125 mRNA

NCBI chr 2:33,542,916...33,568,501
Ensembl chr 2:33,543,300...33,568,288

G

coiled-coil domain containing 126

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC126 mRNA

NCBI chr 4:79,628,483...79,649,513
Ensembl chr 4:79,628,412...79,649,508

G

coiled-coil domain containing 138

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC138 mRNA

NCBI chr20:27,037,256...27,115,454
Ensembl chr20:27,038,349...27,115,452

G

coiled-coil domain containing 167

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of CCDC167 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC167 mRNA

NCBI chr20:7,768,425...7,783,181
Ensembl chr20:7,753,072...7,783,181

G

coiled-coil domain containing 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC18 mRNA

NCBI chr14:1,646,725...1,752,581
Ensembl chr14:1,646,809...1,750,470

G

coiled-coil domain containing 62

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCDC62 mRNA

NCBI chr12:38,284,089...38,320,828
Ensembl chr12:38,284,089...38,320,965

G

coiled-coil domain containing 71

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC71 mRNA

NCBI chr 8:118,025,192...118,040,143
Ensembl chr 8:118,003,244...118,046,209

G

coiled-coil domain containing 77

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC77 mRNA

NCBI chr 4:155,206,402...155,238,235
Ensembl chr 4:155,193,275...155,239,207

G

coiled-coil domain containing 86

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCDC86 mRNA

NCBI chr 1:217,015,059...217,021,439
Ensembl chr 1:217,014,848...217,021,468

G

coiled-coil domain containing 91

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of CCDC91 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC91 mRNA

NCBI chr 4:182,132,931...182,304,948
Ensembl chr 4:182,132,942...182,304,948

G

coiled-coil alpha-helical rod protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCHCR1 mRNA

NCBI chr20:3,210,383...3,223,187
Ensembl chr20:3,210,384...3,222,765

G

C-C motif chemokine ligand 2

multiple interactions
decreases secretion

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCL2 mRNA
epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of CCL2 protein]
epigallocatechin gallate results in decreased secretion of CCL2 protein

PMID:20816778 PMID:22079256 PMID:22101032

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

affects expression

ISO

epigallocatechin gallate affects the expression of CCL3

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

cellular communication network factor 2

affects expression

ISO

epigallocatechin gallate affects the expression of CCN2

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cyclin B1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin B1 interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNB1IP1 mRNA

NCBI chr15:26,488,462...26,504,167
Ensembl chr15:26,488,465...26,502,028

G

cyclin D1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of CCND1 protein
epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]
epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of CCND1 protein]

PMID:15142168 PMID:24508477 PMID:27058323 PMID:32512070

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin F

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNF mRNA

NCBI chr10:13,757,884...13,783,669
Ensembl chr10:13,758,421...13,783,837

G

cyclin G1

increases expression

ISO

epigallocatechin gallate results in increased expression of CCNG1 mRNA; epigallocatechin gallate results in increased expression of CCNG1 protein

NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766

G

cyclin G2

increases expression

ISO

epigallocatechin gallate results in increased expression of CCNG2 mRNA

NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206

G

cyclin L1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNL1 mRNA

NCBI chr 2:152,495,169...152,508,855
Ensembl chr 2:152,495,172...152,507,468

G

cyclin T2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNT2 mRNA

NCBI chr13:41,804,007...41,845,641
Ensembl chr13:41,804,046...41,844,488

G

cyclin Y

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNY mRNA

NCBI chr17:62,079,925...62,207,780
Ensembl chr17:62,079,925...62,207,979

G

coiled-coil serine-rich protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCSER2 mRNA

NCBI chr16:12,633,374...12,746,045
Ensembl chr16:12,637,083...12,746,003

G

chaperonin containing TCP1 subunit 6A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CCT6A protein

NCBI chr12:32,508,842...32,519,072
Ensembl chr12:32,508,675...32,519,119

G

chaperonin containing TCP1 subunit 8

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CCT8 protein

NCBI chr11:40,196,619...40,208,328
Ensembl chr11:40,196,619...40,208,328

G

CD14 molecule

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD14 mRNA

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

CD2-associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD2AP mRNA

NCBI chr 9:25,580,071...25,679,968
Ensembl chr 9:25,583,975...25,679,968

G

CD44 molecule

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of CD44 protein]

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

CD9 molecule

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CD9 protein

NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444

G

cell division cycle 25A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDC25A mRNA

NCBI chr 8:118,742,824...118,761,190
Ensembl chr 8:118,742,426...118,761,188

G

cell division cycle 25C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC25C mRNA

NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292

G

cell division cycle 27

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC27 mRNA

NCBI chr10:89,900,676...89,949,770
Ensembl chr10:89,900,684...89,949,770

G

cell division cycle 42

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CDC42 protein

NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:154,839,631...154,876,627

G

CDC42 effector protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC42EP3 mRNA

NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:21,461,762...21,508,540

G

CDC42 small effector 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC42SE2 mRNA

NCBI chr10:39,337,269...39,405,772
Ensembl chr 1:100,424,547...100,424,801
Ensembl chr10:100,424,547...100,424,801

G

cell division cycle 73

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC73 mRNA

NCBI chr13:57,897,924...58,000,031
Ensembl chr13:57,883,983...57,999,978

G

cell division cycle associated 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDCA3 mRNA

NCBI chr 4:159,321,203...159,325,072
Ensembl chr 4:159,321,014...159,325,068

G

cadherin 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of CDH1 mRNA; epigallocatechin gallate results in increased expression of CDH1 protein
3-methyladenine inhibits the reaction [epigallocatechin gallate results in increased expression of CDH1 protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; TFEB protein affects the reaction [epigallocatechin gallate results in increased expression of CDH1 protein]
epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in decreased expression of CDH1 mRNA]

PMID:25839702 PMID:27058323 PMID:38146662 PMID:39313106

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 13

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CDH13 mRNA

NCBI chr19:63,258,251...64,296,122
Ensembl chr19:63,258,122...64,296,119

G

cadherin 2

multiple interactions
decreases expression

ISO

3-methyladenine inhibits the reaction [epigallocatechin gallate results in decreased expression of CDH2 protein]; TFEB protein affects the reaction [epigallocatechin gallate results in decreased expression of CDH2 protein]

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

CDAN1 interacting nuclease 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDIN1 mRNA

NCBI chr 3:122,895,754...123,101,099
Ensembl chr 3:122,895,824...123,101,099

G

cyclin-dependent kinase 17

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDK17 mRNA

NCBI chr 7:29,570,982...29,677,613
Ensembl chr 7:29,570,816...29,652,008

G

cyclin-dependent kinase 19

increases expression

ISO

epigallocatechin gallate results in increased expression of CDK19 mRNA

NCBI chr20:45,324,911...45,465,121
Ensembl chr20:45,324,862...45,465,121

G

cyclin-dependent kinase 4

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CDK4 protein

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

cyclin-dependent kinase 5 regulatory subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDK5R1 mRNA

NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272

G

CDK5 regulatory subunit associated protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDK5RAP2 mRNA

NCBI chr 5:88,807,402...88,976,005
Ensembl chr 5:88,807,402...88,976,069

G

cyclin-dependent kinase 6

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of CDK6 protein
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDK6 mRNA

PMID:15142168 PMID:22079256

NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701

G

cyclin-dependent kinase-like 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDKL5 mRNA

NCBI chr X:37,566,320...37,796,766
Ensembl chr X:37,566,378...37,796,760

G

cyclin-dependent kinase inhibitor 1A

increases response to substance
multiple interactions
increases expression
decreases expression

ISO

CDKN1A protein results in increased susceptibility to epigallocatechin gallate
[epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A mRNA; [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A protein; [Sulindac co-treated with epigallocatechin gallate] results in increased expression of CDKN1A mRNA
[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA]
epigallocatechin gallate results in increased expression of CDKN1A protein
epigallocatechin gallate results in decreased expression of CDKN1A mRNA

PMID:12628509 PMID:15764647 PMID:18851785 PMID:23717041 PMID:25922640 More...

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDKN1B mRNA

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cyclin-dependent kinase inhibitor 2A

decreases metabolic processing
increases expression
decreases methylation

ISO

epigallocatechin gallate results in decreased metabolism of CDKN2A promoter
epigallocatechin gallate results in increased expression of CDKN2A mRNA; epigallocatechin gallate results in increased expression of CDKN2A protein
epigallocatechin gallate results in decreased methylation of CDKN2A gene; epigallocatechin gallate results in decreased methylation of CDKN2A promoter

PMID:14633667 PMID:16037419 PMID:17683969

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

CDKN2A interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDKN2AIP mRNA

NCBI chr16:51,266,613...51,274,051
Ensembl chr16:51,268,896...51,274,049

G

cell adhesion associated, oncogene regulated

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDON mRNA
epigallocatechin gallate results in increased expression of CDON mRNA

PMID:22079256 PMID:35701726

NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345

G

CEA cell adhesion molecule 20

multiple interactions

ISO

epigallocatechin gallate affects the reaction [sodium arsenate affects the expression of CEACAM20 protein]

NCBI chr 1:88,750,010...88,771,679
Ensembl chr 1:88,750,000...88,772,779

G

CCAAT/enhancer binding protein alpha

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CEBPA protein]

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein delta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEBPD mRNA

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

cell migration inducing hyaluronidase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEMIP2 mRNA

NCBI chr 1:228,756,826...228,834,313
Ensembl chr 1:228,757,466...228,832,906

G

centromere protein A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein E

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPE mRNA

NCBI chr 2:226,310,970...226,369,636
Ensembl chr 2:226,300,798...226,369,636

G

centromere protein I

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPI mRNA

NCBI chr X:101,809,192...101,860,935
Ensembl chr X:101,809,659...101,860,934

G

centromere protein P

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPP mRNA

NCBI chr17:15,220,521...15,395,741
Ensembl chr17:15,220,291...15,395,739

G

centrosomal protein 112

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP112 mRNA

NCBI chr10:93,865,630...94,332,679
Ensembl chr10:93,865,699...94,332,680

G

centrosomal protein 128

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP128 mRNA

NCBI chr 6:115,681,753...116,059,758
Ensembl chr 6:115,681,712...116,057,167

G

centrosomal protein 15

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of CEP15 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP15 mRNA

NCBI chr15:15,247,627...15,265,560
Ensembl chr15:15,247,932...15,265,475

G

centrosomal protein 170

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP170 mRNA

NCBI chr13:91,201,808...91,285,990
Ensembl chr13:91,201,808...91,285,990

G

centrosomal protein 290

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP290 mRNA

NCBI chr 7:37,196,765...37,285,955
Ensembl chr 7:37,196,783...37,285,955

G

centrosomal protein 41

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP41 mRNA

NCBI chr 4:60,238,602...60,279,670
Ensembl chr 4:60,239,539...60,254,419

G

centrosomal protein 70

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP70 mRNA

NCBI chr 8:108,689,562...108,742,620
Ensembl chr 8:108,689,671...108,742,617

G

centrosomal protein 83

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP83 mRNA

NCBI chr 7:31,167,198...31,276,513
Ensembl chr 7:31,167,216...31,276,716

G

choline/ethanolamine phosphotransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEPT1 mRNA

NCBI chr 2:196,682,455...196,724,430
Ensembl chr 2:196,681,681...196,723,812

G

carboxylesterase 1D

multiple interactions
affects activity

ISO
EXP

epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]
epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased activity of CES1 protein]
epigallocatechin gallate affects the activity of CES1 protein

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

centrin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CETN3 mRNA

NCBI chr 2:13,817,760...13,837,502
Ensembl chr 2:13,824,803...13,837,502

G

complement factor B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CFB mRNA

NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,955,776...3,981,740

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CFLAR mRNA

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHAC1 mRNA

NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361

G

ChaC glutathione specific gamma-glutamylcyclotransferase 2

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHAC2 mRNA
epigallocatechin gallate results in decreased expression of CHAC2 mRNA

NCBI chr14:108,921,669...108,929,215
Ensembl chr14:108,921,341...108,929,469

G

coiled-coil-helix-coiled-coil-helix domain containing 1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHCHD1 mRNA
epigallocatechin gallate results in decreased expression of CHCHD1 mRNA

NCBI chr15:3,641,973...3,643,155
Ensembl chr15:3,641,981...3,643,155

G

chromodomain helicase DNA binding protein 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD6 mRNA

NCBI chr 3:170,016,204...170,177,480
Ensembl chr 3:170,016,204...170,177,558

G

chromodomain helicase DNA binding protein 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD7 mRNA

NCBI chr 5:26,609,245...26,792,736
Ensembl chr 5:26,609,407...26,792,734

G

chromodomain helicase DNA binding protein 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD9 mRNA

NCBI chr19:32,114,379...32,337,488
Ensembl chr19:32,115,920...32,319,042

G

charged multivesicular body protein 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHMP6 mRNA

NCBI chr10:105,690,400...105,696,070
Ensembl chr10:105,690,398...105,696,333

G

carbohydrate sulfotransferase 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHST11 mRNA

NCBI chr 7:22,412,121...22,630,577
Ensembl chr 7:22,415,686...22,630,441

G

carbohydrate sulfotransferase 15

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHST15 mRNA

NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444

G

circadian associated repressor of transcription

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CIART mRNA

NCBI chr 2:186,108,744...186,113,778
Ensembl chr 2:186,108,752...186,112,246

G

CDGSH iron sulfur domain 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CISD1 mRNA

NCBI chr20:17,254,462...17,267,843
Ensembl chr20:17,254,187...17,271,042

G

CDKN1A interacting zinc finger protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CIZ1 mRNA

NCBI chr 3:36,055,753...36,071,510
Ensembl chr 3:36,056,370...36,075,192

G

cytoskeleton-associated protein 4

increases expression

ISO

epigallocatechin gallate results in increased expression of CKAP4 protein

NCBI chr 7:21,118,527...21,126,624
Ensembl chr 7:21,118,085...21,126,624

G

cytoskeleton associated protein 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CKAP5 mRNA

NCBI chr 3:97,946,966...98,049,050
Ensembl chr 3:97,947,031...98,049,049

G

CDC28 protein kinase regulatory subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CKS2 mRNA

NCBI chr17:13,722,360...13,727,519
Ensembl chr17:13,722,361...13,727,519

G

cytoplasmic linker associated protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLASP1 mRNA

NCBI chr13:32,046,362...32,267,954
Ensembl chr13:32,046,444...32,267,924

G

CLK4-associating serine/arginine rich protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SFRS16 mRNA

NCBI chr 1:88,360,235...88,384,343
Ensembl chr 1:88,360,235...88,384,343

G

chloride voltage-gated channel 7

increases expression

ISO

epigallocatechin gallate results in increased expression of CLCN7 mRNA

NCBI chr10:14,656,261...14,681,632
Ensembl chr10:14,656,245...14,681,631

G

claudin 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLDN7 mRNA

NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905

G

CDC-like kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLK1 mRNA

NCBI chr 9:67,441,962...67,453,180
Ensembl chr 9:67,441,952...67,451,187

G

CDC-like kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLK3 mRNA

NCBI chr 8:67,048,121...67,063,192
Ensembl chr 8:67,048,123...67,062,881

G

calmin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLMN mRNA

NCBI chr 6:129,470,613...129,572,079
Ensembl chr 6:129,478,149...129,572,027

G

CXADR-like membrane protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLMP mRNA

NCBI chr 8:49,957,639...50,065,959
Ensembl chr 8:49,957,720...50,065,959

G

clock circadian regulator

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CLOCK mRNA]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CLOCK protein]; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLOCK mRNA

PMID:22079256 PMID:29061316

NCBI chr14:32,262,747...32,346,872
Ensembl chr14:32,262,750...32,346,872

G

cleavage factor polyribonucleotide kinase subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLP1 mRNA

NCBI chr 3:90,213,461...90,217,165
Ensembl chr 3:90,213,465...90,217,538

G

ClpB family mitochondrial disaggregase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLPB mRNA

NCBI chr 1:165,440,705...165,563,514
Ensembl chr 1:165,440,861...165,583,815

G

cytidine monophosphate N-acetylneuraminic acid synthetase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CMAS mRNA

NCBI chr 4:177,449,801...177,468,117
Ensembl chr 4:177,449,732...177,476,291

G

c-Maf-inducing protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CMIP mRNA

NCBI chr19:62,213,402...62,419,443
Ensembl chr19:62,213,365...62,417,500

G

cytidine/uridine monophosphate kinase 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CMPK2 mRNA

NCBI chr 6:48,802,150...48,813,652
Ensembl chr 6:48,802,321...48,813,652

G

connector enhancer of kinase suppressor of Ras 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNKSR2 mRNA

NCBI chr X:40,722,843...40,971,730
Ensembl chr X:40,722,996...40,965,604

G

Cnksr family member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNKSR3 mRNA

NCBI chr 1:45,904,581...45,996,921
Ensembl chr 1:45,904,581...45,996,921

G

cyclin and CBS domain divalent metal cation transport mediator 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNNM1 mRNA

NCBI chr 1:252,245,377...252,304,205
Ensembl chr 1:252,245,623...252,304,205

G

CCR4-NOT transcription complex, subunit 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT11 mRNA

NCBI chr 9:49,310,624...49,320,325
Ensembl chr 9:49,309,518...49,321,771

G

CCR4-NOT transcription complex, subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT2 mRNA
epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of CNOT2 protein]

PMID:22079256 PMID:30092300

NCBI chr 7:54,016,447...54,117,511
Ensembl chr 7:54,016,447...54,107,960

G

CCR4-NOT transcription complex, subunit 6-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT6L mRNA

NCBI chr14:13,714,475...13,806,481
Ensembl chr14:13,714,475...13,806,481

G

centlein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNTLN mRNA

NCBI chr 5:104,340,801...104,622,491
Ensembl chr 5:104,342,173...104,630,976

G

centriolin

increases expression

ISO

epigallocatechin gallate results in increased expression of CNTRL protein

NCBI chr 3:38,825,575...38,897,835
Ensembl chr 3:38,825,624...38,897,833

G

cytochrome C oxidase assembly factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COA3 mRNA

NCBI chr10:86,720,454...86,721,435
Ensembl chr10:86,720,456...86,721,440

G

cytochrome c oxidase assembly factor 6

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of COA6 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COA6 mRNA

NCBI chr19:71,293,066...71,295,668
Ensembl chr19:71,278,765...71,296,015

G

component of oligomeric golgi complex 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG2 mRNA

NCBI chr19:69,391,305...69,430,072
Ensembl chr19:69,391,326...69,426,620

G

component of oligomeric golgi complex 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG6 mRNA

NCBI chr 2:139,212,459...139,249,505
Ensembl chr 2:139,211,678...139,249,737

G

component of oligomeric golgi complex 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG7 mRNA

NCBI chr 1:185,921,053...185,980,711
Ensembl chr 1:185,889,348...185,983,421

G

collagen type I alpha 1 chain

multiple interactions
increases expression

ISO

epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]
epigallocatechin gallate results in increased expression of COL1A1 mRNA

PMID:20438794 PMID:20706672

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type III alpha 1 chain

multiple interactions

ISO
EXP

epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of COL3A1 protein]
[Oxygen deficiency results in increased susceptibility to epigallocatechin gallate] which results in decreased expression of COL3A1 mRNA; epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in increased expression of COL3A1 mRNA]

PMID:22101032 PMID:28478070

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type IV alpha 1 chain

decreases expression

ISO

epigallocatechin gallate results in decreased expression of COL4A1 mRNA

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

collagen type VI alpha 1 chain

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of COL6A1 mRNA

NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107

G

catechol-O-methyltransferase

affects binding

EXP

epigallocatechin gallate binds to COMT protein

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

COP1, E3 ubiquitin ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COP1 mRNA

NCBI chr13:73,954,058...74,095,283
Ensembl chr13:73,963,145...74,095,269

G

coenzyme Q2, polyprenyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ2 mRNA

NCBI chr14:9,245,777...9,265,784
Ensembl chr14:9,245,803...9,265,783

G

coenzyme Q5, methyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ5 mRNA

NCBI chr12:46,977,632...46,994,575
Ensembl chr12:46,977,632...46,994,712

G

coenzyme Q6 monooxygenase

increases expression

ISO

epigallocatechin gallate results in increased expression of COQ6 protein

NCBI chr 6:109,738,934...109,750,315
Ensembl chr 6:109,738,951...109,750,310

G

coenzyme Q9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ9 mRNA

NCBI chr19:10,172,943...10,185,960
Ensembl chr19:10,172,949...10,185,937

G

coactosin-like F-actin binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of COTL1 mRNA

NCBI chr19:64,780,309...64,814,629
Ensembl chr19:64,780,322...64,814,840

G

cytochrome c oxidase copper chaperone COX17

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of COX17 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COX17 mRNA

NCBI chr11:75,906,245...75,912,036
Ensembl chr11:75,906,248...75,912,019

G

cytochrome c oxidase subunit 6C

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX6C mRNA]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX6C mRNA]]

NCBI chr 7:69,014,410...69,027,145
Ensembl chr 7:69,014,417...69,027,166

G

carboxypeptidase A3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPA3 mRNA

NCBI chr 2:104,641,619...104,673,253
Ensembl chr 2:104,641,621...104,673,237

G

carboxypeptidase E

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CPE mRNA

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524

G

cytoplasmic polyadenylation element binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPEB2 mRNA

NCBI chr14:71,999,958...72,056,012
Ensembl chr14:72,002,072...72,052,263

G

ciliogenesis and planar polarity effector complex subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPLANE1 mRNA

NCBI chr 2:58,996,119...59,096,817
Ensembl chr 2:58,996,130...59,096,817

G

copine 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPNE8 mRNA

NCBI chr 7:123,494,864...123,669,060
Ensembl chr 7:123,494,865...123,669,060

G

cleavage and polyadenylation specific factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPSF3 mRNA

NCBI chr 6:46,564,855...46,592,776
Ensembl chr 6:46,564,735...46,594,136

G

carnitine palmitoyltransferase 1A

multiple interactions

EXP

epigallocatechin gallate analog inhibits the reaction [Dietary Fats results in decreased expression of CPT1A protein]

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

ceramide-1-phosphate transfer protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPTP mRNA

NCBI chr 5:171,757,181...171,761,271
Ensembl chr 5:171,757,181...171,761,266

G

CASP2 and RIPK1 domain containing adaptor with death domain

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of CRADD mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRADD mRNA

PMID:16084531 PMID:22079256

NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:31,685,622...31,874,512

G

cAMP responsive element binding protein 1

multiple interactions

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]]; [Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CREB1 mRNA; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of CREB1 protein]]
epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in decreased phosphorylation of CREB1 protein]

PMID:22079256 PMID:29061316 PMID:30092300

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

cAMP responsive element binding protein 3-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CREB3L1 mRNA

NCBI chr 3:98,408,240...98,449,104
Ensembl chr 3:98,408,058...98,449,104

G

CREB binding protein

increases expression

ISO

epigallocatechin gallate results in increased expression of CREBBP protein

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

CREB3 regulatory factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CREBRF mRNA

NCBI chr10:16,903,607...16,967,450
Ensembl chr10:16,903,547...16,966,430

G

CREB/ATF bZIP transcription factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CREBZF mRNA

NCBI chr 1:153,829,544...153,836,073
Ensembl chr 1:153,829,448...153,845,122

G

carnitine O-octanoyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CROT mRNA

NCBI chr 4:26,031,729...26,088,057
Ensembl chr 4:26,052,516...26,088,064

G

C-reactive protein

decreases expression

EXP

epigallocatechin gallate results in decreased expression of CRP mRNA; epigallocatechin gallate results in decreased expression of CRP protein

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

CREB regulated transcription coactivator 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CRTC2 protein

NCBI chr 2:178,007,233...178,017,397
Ensembl chr 2:178,007,240...178,017,389

G

cryptochrome circadian regulator 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CRY1 mRNA]

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

cryptochrome circadian regulator 2

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of CRY2 mRNA]

NCBI chr 3:98,830,479...98,860,437
Ensembl chr 3:98,830,483...98,860,447

G

crystallin, alpha B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRYAB mRNA

NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528

G

crystallin, beta B2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CRYBB2 mRNA

NCBI chr12:49,230,192...49,240,116
Ensembl chr12:49,230,192...49,240,116

G

crystallin zeta like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRYZL1 mRNA

NCBI chr11:44,419,099...44,464,366
Ensembl chr11:44,419,103...44,463,793

G

chromosome segregation 1 like

increases expression

ISO

epigallocatechin gallate results in increased expression of CSE1L protein

NCBI chr 3:176,060,183...176,097,909
Ensembl chr 3:176,060,215...176,108,734

G

casein kinase 2 alpha 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CSNK2A2 mRNA

NCBI chr19:9,562,340...9,602,136
Ensembl chr19:9,562,321...9,602,136

G

chondroitin sulfate proteoglycan 4

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of CSPG4 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CSPG4 mRNA

NCBI chr 8:66,160,942...66,195,987
Ensembl chr 8:66,160,942...66,200,806

G

cysteine and serine rich nuclear protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AXUD1 mRNA

NCBI chr 8:128,582,364...128,594,163
Ensembl chr 8:128,582,365...128,588,469

G

cap binding complex dependent translation initiation factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTIF mRNA

NCBI chr18:71,331,222...71,602,493
Ensembl chr18:71,307,314...71,602,492

G

catenin beta 1

decreases expression
multiple interactions
increases methylation
decreases localization
decreases phosphorylation

ISO
EXP

epigallocatechin gallate results in decreased expression of CTNNB1 mRNA; epigallocatechin gallate results in decreased expression of CTNNB1 protein
epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of CTNNB1 protein]
epigallocatechin gallate results in increased methylation of CTNNB1 promoter
epigallocatechin gallate promotes the reaction [Sulindac inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CTNNB1 protein]]
epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of CTNNB1 mRNA]; epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of CTNNB1 protein]
epigallocatechin gallate results in decreased localization of CTNNB1 protein
epigallocatechin gallate results in decreased phosphorylation of CTNNB1 protein

PMID:12351151 PMID:16968065 PMID:27058323 PMID:29999212 PMID:35863485 More...

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cystinosin, lysosomal cystine transporter

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTNS mRNA

NCBI chr10:58,300,069...58,315,725
Ensembl chr10:58,299,967...58,321,661

G

CTP synthase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTPS1 mRNA

NCBI chr 5:139,372,349...139,440,441
Ensembl chr 5:139,410,249...139,440,465

G

CTP synthase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTPS2 mRNA

NCBI chr X:35,277,658...35,418,505
Ensembl chr X:35,277,658...35,418,505

G

cathepsin B

multiple interactions

EXP

epigallocatechin gallate inhibits the reaction [Isoproterenol results in increased activity of CTSB protein]

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

cathepsin D

multiple interactions
increases expression

EXP
ISO

epigallocatechin gallate inhibits the reaction [Isoproterenol affects the activity of CTSD protein]
epigallocatechin gallate results in increased expression of CTSD mRNA; epigallocatechin gallate results in increased expression of CTSD protein

PMID:18294627 PMID:31195006 PMID:39313106

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

CWC25 spliceosome-associated protein homolog

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CWC25 protein

NCBI chr10:83,232,052...83,256,722
Ensembl chr10:83,232,052...83,256,722

G

C-X-C motif chemokine ligand 1

multiple interactions

ISO
EXP

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXCL1 mRNA
epigallocatechin gallate inhibits the reaction [CXCL1 protein results in increased abundance of Calcium]; epigallocatechin gallate inhibits the reaction [IL1B protein results in increased expression of CXCL1 protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein]

PMID:15237969 PMID:22079256

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXCL10 mRNA

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

C-X-C motif chemokine ligand 2

affects expression

ISO

epigallocatechin gallate affects the expression of CXCL2

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXCL1 mRNA

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

CXXC finger protein 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXXC5 mRNA

NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635

G

cytochrome b561 family, member D2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYB561D2 mRNA

NCBI chr 8:117,091,844...117,094,434
Ensembl chr 8:117,091,845...117,094,366

G

cytochrome b5 domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CYB5D1 mRNA

NCBI chr10:54,612,230...54,616,375
Ensembl chr10:54,612,230...54,616,713

G

cytochrome b-245 beta chain

decreases expression

EXP

epigallocatechin gallate results in decreased expression of CYBB mRNA; epigallocatechin gallate results in decreased expression of CYBB protein

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome c, somatic

affects localization
multiple interactions

ISO
EXP

epigallocatechin gallate affects the localization of CYCS protein
epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of CYCS protein]

PMID:15657356 PMID:28056603

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytoplasmic FMR1 interacting protein 2

multiple interactions
decreases expression

ISO

CYFIP2 protein inhibits the reaction [epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; CYFIP2 protein inhibits the reaction [epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT2 protein]]; CYFIP2 protein inhibits the reaction [epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT3 protein]]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of CYFIP2 mRNA]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of CYFIP2 protein]
epigallocatechin gallate results in decreased expression of CYFIP2 mRNA

NCBI chr10:31,122,653...31,242,440
Ensembl chr10:31,122,653...31,242,440

G

cytoglobin

decreases expression

ISO

epigallocatechin gallate results in decreased expression of CYGB mRNA

NCBI chr10:102,376,506...102,386,272
Ensembl chr10:102,376,507...102,386,272

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity
multiple interactions
increases expression

ISO
EXP

epigallocatechin gallate results in decreased activity of CYP19A1 protein
epigallocatechin gallate inhibits the reaction [lead acetate results in decreased expression of CYP19A1 mRNA]
epigallocatechin gallate results in increased expression of CYP19A1 mRNA

PMID:14600287 PMID:31054310

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
affects binding
decreases expression
increases activity

ISO
EXP

epigallocatechin gallate inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
epigallocatechin gallate binds to CYP1A1 protein
epigallocatechin gallate results in decreased expression of CYP1A1 mRNA
epigallocatechin gallate results in increased activity of CYP1A1 protein

PMID:11064004 PMID:14558788 PMID:15895106 PMID:20816778 PMID:23010222

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects binding
multiple interactions

EXP
ISO

epigallocatechin gallate binds to CYP1A2 protein
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP1A2 mRNA

PMID:23010222 PMID:25663641

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYP1B1 mRNA

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CYP27B1 mRNA

NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:64,756,626...64,761,570

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2D22 mRNA

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
affects binding

ISO
EXP

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2E1 mRNA; epigallocatechin gallate results in increased expression of and results in increased activity of CYP2E1 protein
epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of CYP2E1 protein]
epigallocatechin gallate binds to CYP2E1 protein

PMID:14600287 PMID:23010222 PMID:24508477 PMID:25663641

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO

[epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CYP3A4 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 51

increases expression

ISO

epigallocatechin gallate results in increased expression of CYP51A1 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

cytochrome P450 family 7 subfamily A member 1

increases expression

EXP

epigallocatechin gallate results in increased expression of CYP7A1 mRNA; epigallocatechin gallate results in increased expression of CYP7A1 protein

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cell cycle regulator of NHEJ

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYREN mRNA

NCBI chr 4:64,514,477...64,519,896
Ensembl chr 4:64,514,477...64,518,742

G

CYFIP related Rac1 interactor B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYRIB mRNA

NCBI chr 7:97,524,941...97,649,846
Ensembl chr 7:97,523,121...97,649,853

G

cytohesin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYTH3 mRNA

NCBI chr12:15,953,781...16,076,584
Ensembl chr12:15,953,791...16,047,506

G

dishevelled associated activator of morphogenesis 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAAM1 mRNA

NCBI chr 6:96,125,521...96,286,049
Ensembl chr 6:96,125,621...96,286,049

G

DAB adaptor protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAB2 mRNA

NCBI chr 2:57,241,947...57,294,893
Ensembl chr 2:57,242,064...57,294,888

G

death associated protein kinase 1

decreases expression
multiple interactions
increases expression

ISO

epigallocatechin gallate results in decreased expression of DAPK1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAPK1 mRNA
epigallocatechin gallate results in increased expression of DAPK1 mRNA

PMID:12628509 PMID:22079256

NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,935,625...4,096,581

G

death-associated protein kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAPK3 mRNA

NCBI chr 7:9,174,903...9,183,272
Ensembl chr 7:9,174,904...9,183,272

G

aspartyl-tRNA synthetase 2 (mitochondrial)

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DARS2 mRNA

NCBI chr13:75,842,078...75,870,319
Ensembl chr13:75,836,565...75,869,904

G

discoidin, CUB and LCCL domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCBLD1 mRNA

NCBI chr20:32,161,241...32,254,391
Ensembl chr20:32,161,254...32,281,176

G

doublecortin-like kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCLK2 mRNA

NCBI chr 2:174,506,660...174,636,353
Ensembl chr 2:174,506,660...174,636,192

G

DNA cross-link repair 1A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCLRE1A mRNA

NCBI chr 1:265,575,087...265,594,987
Ensembl chr 1:265,575,087...265,593,899

G

defective in cullin neddylation 1 domain containing 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCUN1D4 mRNA

NCBI chr14:35,006,792...35,087,285
Ensembl chr14:35,006,792...35,088,520

G

DDHD domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDHD1 mRNA

NCBI chr15:21,304,053...21,370,608
Ensembl chr15:21,303,826...21,370,608

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[epigallocatechin gallate co-treated with Celecoxib] results in increased expression of DDIT3 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[epigallocatechin gallate co-treated with Celecoxib] results in increased expression of DDIT3 protein]; [epigallocatechin gallate co-treated with Celecoxib] results in increased expression of DDIT3 mRNA; [epigallocatechin gallate co-treated with Celecoxib] results in increased expression of DDIT3 protein; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DDIT3 mRNA; [Sulindac co-treated with epigallocatechin gallate] results in increased expression of DDIT3 mRNA; U 0126 inhibits the reaction [[epigallocatechin gallate co-treated with Celecoxib] results in increased expression of DDIT3 mRNA]; U 0126 inhibits the reaction [[epigallocatechin gallate co-treated with Celecoxib] results in increased expression of DDIT3 protein]
epigallocatechin gallate results in increased expression of DDIT3 mRNA

PMID:12628509 PMID:16084531 PMID:16463383 PMID:22079256

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DEAD-box helicase 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX10 mRNA

NCBI chr 8:62,384,876...62,539,585
Ensembl chr 8:62,384,876...62,539,585

G

DExD-box helicase 39A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of DDX39A protein

NCBI chr19:41,323,465...41,331,413
Ensembl chr19:41,322,836...41,332,306

G

DEXD/H-box helicase 60

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX60 mRNA
epigallocatechin gallate results in decreased expression of DDX60 mRNA

PMID:22079256 PMID:32512070

NCBI chr16:33,087,940...33,208,843
Ensembl chr16:33,087,988...33,208,839

G

DENN domain containing 2B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND2B mRNA

NCBI chr 1:172,978,895...173,129,623
Ensembl chr 1:172,978,895...173,129,810

G

DENN domain containing 2C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DENND2C mRNA

NCBI chr 2:193,310,822...193,378,986
Ensembl chr 2:193,335,230...193,378,978

G

DENN domain containing 2D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND2D mRNA

NCBI chr 2:196,661,465...196,680,505
Ensembl chr 2:196,661,345...196,682,397

G

DENN domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND3 mRNA

NCBI chr 7:107,304,860...107,362,573
Ensembl chr 7:107,220,192...107,362,573

G

DENN domain containing 4A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND4A mRNA

NCBI chr 8:74,218,131...74,331,543
Ensembl chr 8:74,218,191...74,331,542

G

DENN domain containing 4C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND4C mRNA

NCBI chr 5:106,316,942...106,421,484
Ensembl chr 5:106,318,281...106,415,489

G

DENN domain containing 6A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND6A mRNA

NCBI chr16:1,843,803...1,892,165
Ensembl chr16:1,843,752...1,892,163

G

density regulated reinitiation and release factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENR mRNA

NCBI chr12:38,323,433...38,346,207
Ensembl chr12:38,323,445...38,344,797

G

DEP domain containing 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DEPDC7 mRNA

NCBI chr 3:111,554,701...111,575,979
Ensembl chr 3:111,554,706...111,575,979

G

DET1 partner of COP1 E3 ubiquitin ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DET1 mRNA

NCBI chr 1:142,159,120...142,175,366
Ensembl chr 1:142,127,876...142,175,336

G

diacylglycerol kinase, delta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DGKD mRNA

NCBI chr 9:95,964,507...96,055,160
Ensembl chr 9:95,964,148...96,055,160

G

diacylglycerol kinase, eta

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DGKH mRNA
epigallocatechin gallate results in increased expression of DGKH mRNA

NCBI chr15:60,390,279...60,559,777
Ensembl chr15:60,402,004...60,560,218

G

7-dehydrocholesterol reductase

increases expression

ISO

epigallocatechin gallate results in increased expression of DHCR7 mRNA

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382

G

dihydrofolate reductase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DHFR mRNA; epigallocatechin gallate binds to and results in decreased activity of DHFR protein

PMID:20054477 PMID:22079256

NCBI chr 2:25,320,895...25,346,004

G

DEAH-box helicase 32 (putative)

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX32 mRNA

NCBI chr 1:197,954,503...198,013,779
Ensembl chr 1:197,954,503...198,007,489

G

DEAH-box helicase 35

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX35 mRNA

NCBI chr 3:167,869,971...167,927,300
Ensembl chr 3:167,870,055...167,927,300

G

DExH-box helicase 57

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX57 mRNA

NCBI chr 6:20,474,889...20,528,556
Ensembl chr 6:20,477,191...20,528,556

G

diablo, IAP-binding mitochondrial protein

multiple interactions
affects localization

EXP
ISO

epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of DIABLO protein]
epigallocatechin gallate analog affects the localization of DIABLO protein

PMID:16115949 PMID:17936647

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

diaphanous-related formin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIAPH3 mRNA

NCBI chr15:68,951,992...69,421,623
Ensembl chr15:68,951,989...69,421,552

G

DIM1 rRNA methyltransferase and ribosome maturation factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIMT1L mRNA

NCBI chr 2:40,076,622...40,101,792
Ensembl chr 2:40,076,570...40,101,787

G

iodothyronine deiodinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIO2 mRNA

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

disco-interacting protein 2 homolog A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIP2A mRNA

NCBI chr20:12,284,037...12,373,519
Ensembl chr20:12,284,038...12,370,532

G

disco-interacting protein 2 homolog B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIP2B mRNA

NCBI chr 7:133,053,393...133,231,430
Ensembl chr 7:133,053,401...133,228,874

G

DIS3-like exosome 3'-5' exoribonuclease

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIS3L mRNA

NCBI chr 8:73,699,185...73,735,581
Ensembl chr 8:73,699,185...73,735,527

G

dispatched RND transporter family member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DISP1 mRNA

NCBI chr13:97,252,574...97,398,329
Ensembl chr13:97,252,574...97,398,460

G

DIX domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIXDC1 mRNA

NCBI chr 8:59,904,218...59,977,595
Ensembl chr 8:59,904,218...59,978,447

G

dickkopf WNT signaling pathway inhibitor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DKK1 mRNA

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650

G

dihydrolipoamide dehydrogenase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLD mRNA

NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:53,619,631...53,652,354

G

discs large MAGUK scaffold protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLG1 mRNA

NCBI chr11:82,416,853...82,607,797
Ensembl chr11:82,416,853...82,607,797

G

DLG associated protein 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLGAP5 mRNA

NCBI chr15:23,113,678...23,144,281
Ensembl chr15:23,113,678...23,144,176

G

delta like non-canonical Notch ligand 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLK2 mRNA

NCBI chr 9:22,174,667...22,179,149
Ensembl chr 9:22,173,158...22,179,149

G

delta like canonical Notch ligand 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DLL4 mRNA

NCBI chr 3:126,770,945...126,780,769
Ensembl chr 3:126,770,794...126,780,763

G

DNA methyltransferase 1-associated protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMAP1 mRNA

NCBI chr 5:136,380,211...136,388,229
Ensembl chr 5:136,380,216...136,388,219

G

Dmx-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMXL1 mRNA

NCBI chr18:45,179,505...45,349,999
Ensembl chr18:45,179,551...45,356,406

G

Dmx-like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMXL2 mRNA

NCBI chr 8:63,637,314...63,803,911
Ensembl chr 8:63,637,314...63,781,116

G

dynein axonemal assembly factor 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAAF19 mRNA

NCBI chr10:88,346,453...88,349,853
Ensembl chr10:88,346,453...88,349,853

G

dynein, axonemal, assembly factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAAF2 mRNA

NCBI chr 6:93,397,157...93,406,323
Ensembl chr 6:93,397,164...93,406,323

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJB4 mRNA

NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042

G

DnaJ heat shock protein family (Hsp40) member B5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJB5 mRNA

NCBI chr 5:61,972,637...61,981,887
Ensembl chr 5:61,972,706...61,981,860

G

DnaJ heat shock protein family (Hsp40) member B9

increases expression

ISO

epigallocatechin gallate results in increased expression of DNAJB9 mRNA

NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344

G

DnaJ heat shock protein family (Hsp40) member C13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC13 mRNA

NCBI chr 8:113,646,573...113,756,104
Ensembl chr 8:113,646,573...113,756,104

G

DnaJ heat shock protein family (Hsp40) member C14

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC14 mRNA

NCBI chr 7:1,818,360...1,831,642
Ensembl chr 7:1,820,247...1,831,658

G

DnaJ heat shock protein family (Hsp40) member C19

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of DNAJC19 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC19 mRNA

NCBI chr 2:118,851,497...118,875,813
Ensembl chr 2:118,869,413...118,873,781

G

DnaJ heat shock protein family (Hsp40) member C28

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC28 mRNA

NCBI chr11:44,341,528...44,344,348
Ensembl chr11:44,338,646...44,344,482

G

dynein heavy chain domain 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DNHD1 mRNA

NCBI chr 1:169,402,615...169,486,684
Ensembl chr 1:169,394,884...169,487,646

G

dynamin 1

multiple interactions

ISO

BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1 protein]]

NCBI chr 3:36,002,535...36,055,220
Ensembl chr 3:36,002,064...36,046,289

G

dynamin 1-like

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of DNM1L protein]

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420

G

dynamin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNM3 mRNA

NCBI chr13:76,892,381...77,371,346
Ensembl chr13:76,892,171...77,371,350

G

DNA methyltransferase 1

multiple interactions
increases expression
decreases activity

ISO

epigallocatechin gallate binds to and results in decreased activity of DNMT1 protein; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of DNMT1 mRNA]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of DNMT1 protein]; Magnesium promotes the reaction [epigallocatechin gallate results in decreased activity of DNMT1 protein]
epigallocatechin gallate results in increased expression of DNMT1 mRNA

PMID:14633667 PMID:16037419 PMID:25839702 PMID:38146662

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

DNA methyltransferase 3 alpha

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of DNMT3A mRNA
epigallocatechin gallate inhibits the reaction [sodium arsenite affects the expression of DNMT3A mRNA]
epigallocatechin gallate results in increased expression of DNMT3A protein

PMID:25839702 PMID:35863485 PMID:38146662

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

DNA methyltransferase 3 beta

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNMT3B mRNA
epigallocatechin gallate results in increased expression of DNMT3B mRNA

PMID:22079256 PMID:25839702

NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313

G

aspartyl aminopeptidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNPEP mRNA

NCBI chr 9:84,248,581...84,257,484
Ensembl chr 9:84,233,486...84,256,977

G

deoxynucleotidyltransferase, terminal, interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNTTIP1 mRNA

NCBI chr 3:173,901,070...173,924,742
Ensembl chr 3:173,900,945...173,925,098

G

deoxynucleotidyltransferase, terminal, interacting protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DNTTIP2 mRNA

NCBI chr 2:213,058,975...213,071,020
Ensembl chr 2:213,058,962...213,071,016

G

dedicator of cytokinesis 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK10 mRNA

NCBI chr 9:89,291,936...89,549,871
Ensembl chr 9:89,291,800...89,549,973

G

dedicator of cytokinesis 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK11 mRNA

NCBI chr X:119,997,523...120,180,643
Ensembl chr X:119,997,552...120,180,634

G

dedicator of cytokinesis 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK7 mRNA

NCBI chr 5:118,714,863...118,898,362
Ensembl chr 5:118,714,863...118,898,335

G

dedicator of cytokinesis 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK9 mRNA

NCBI chr15:105,018,341...105,289,799
Ensembl chr15:105,024,912...105,289,799

G

docking protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOK1 mRNA

NCBI chr 4:117,095,171...117,098,251
Ensembl chr 4:117,095,175...117,097,825

G

DOP1 leucine zipper like protein B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOP1B mRNA

NCBI chr11:46,494,058...46,595,601
Ensembl chr11:46,494,058...46,595,601

G

diphthamine biosynthesis 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DPH6 mRNA

NCBI chr 3:121,761,495...121,891,727
Ensembl chr 3:121,676,141...121,891,658

G

dipeptidylpeptidase 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DPP4 mRNA

NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422

G

DNA-damage regulated autophagy modulator 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DRAM1 mRNA

NCBI chr 7:24,630,233...24,665,270
Ensembl chr 7:24,630,238...24,664,354

G

dopamine receptor D2

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339

G

drosha ribonuclease III

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DROSHA mRNA

NCBI chr 2:63,591,885...63,703,688
Ensembl chr 2:63,591,968...63,703,687

G

DNA replication and sister chromatid cohesion 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DSCC1 mRNA

NCBI chr 7:88,372,349...88,390,815
Ensembl chr 7:88,372,146...88,387,973

G

dermatan sulfate epimerase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DSE mRNA

NCBI chr20:26,661,326...26,740,011
Ensembl chr20:26,661,326...26,740,114

G

desmoglein 3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of DSG3 mRNA

NCBI chr18:12,074,321...12,105,954
Ensembl chr18:12,074,321...12,111,766

G

dystonin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DST mRNA

NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533

G

D-aminoacyl-tRNA deacylase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTD2 mRNA

NCBI chr 6:75,185,496...75,191,774
Ensembl chr 6:75,156,201...75,191,774

G

dystrobrevin binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTNBP1 mRNA

NCBI chr17:19,891,313...19,982,770
Ensembl chr17:19,891,337...19,984,418

G

DTW domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTWD2 mRNA

NCBI chr18:45,003,242...45,088,595
Ensembl chr18:45,003,644...45,088,419

G

deoxythymidylate kinase

decreases expression

ISO

epigallocatechin gallate results in decreased expression of DTYMK mRNA

NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504

G

dihydrouridine synthase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DUS2 mRNA

NCBI chr19:50,816,306...50,864,559
Ensembl chr19:50,816,310...50,864,559

G

dual specificity phosphatase 4

increases expression

ISO

epigallocatechin gallate results in increased expression of DUSP4 mRNA

NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700

G

dual specificity phosphatase 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP5 mRNA
epigallocatechin gallate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of DUSP5 protein]

PMID:22079256 PMID:34740634

NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417

G

dual specificity phosphatase 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dual specificity phosphatase 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP7 mRNA

NCBI chr 8:115,888,091...115,895,126
Ensembl chr 8:115,887,892...115,895,126

G

dual specificity phosphatase 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP8 mRNA

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

dynein 2 intermediate chain 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DYNC2I1 mRNA

NCBI chr 6:143,276,441...143,333,006
Ensembl chr 6:143,276,441...143,331,773

G

dynein light chain Tctex-type 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of DYNLT1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DYNLT1 mRNA

NCBI chr 1:49,292,093...49,299,051
Ensembl chr 1:49,282,243...49,298,951

G

dual specificity tyrosine phosphorylation regulated kinase 1A

decreases activity
decreases expression

ISO
EXP

epigallocatechin gallate results in decreased activity of DYRK1A protein
EGCG decreases expression of dyrk1a protein after myocardial infarction in rat heart left ventricle

CTD
RGD

PMID:12534346 PMID:26067684

NCBI chr11:47,360,824...47,479,033
Ensembl chr11:47,360,850...47,479,033

G

DAZ interacting zinc finger protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DZIP3 mRNA

NCBI chr11:65,286,190...65,356,314
Ensembl chr11:65,286,190...65,356,314

G

E2F transcription factor 1

affects methylation

EXP

epigallocatechin gallate affects the methylation of E2F1 gene

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563

G

ELL associated factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EAF1 mRNA

NCBI chr16:6,704,727...6,719,476
Ensembl chr16:6,704,727...6,719,476

G

estrogen receptor binding site associated antigen 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EBAG9 mRNA

NCBI chr 7:77,695,213...77,713,565
Ensembl chr 7:77,695,072...77,713,557

G

endothelin converting enzyme 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ECE1 mRNA

NCBI chr 5:155,361,031...155,462,723
Ensembl chr 5:155,360,639...155,462,719

G

enoyl-CoA delta isomerase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ECI2 mRNA

NCBI chr17:30,056,274...30,092,169
Ensembl chr17:30,076,524...30,092,161

G

extracellular matrix protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ECM1 mRNA

NCBI chr 2:185,976,439...185,981,656
Ensembl chr 2:185,976,440...185,981,606

G

epithelial cell transforming 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ECT2 mRNA

NCBI chr 2:111,904,522...111,966,786
Ensembl chr 2:111,904,522...111,966,626

G

ER degradation enhancing alpha-mannosidase like protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDEM3 mRNA

NCBI chr13:66,403,022...66,470,496
Ensembl chr13:66,408,590...66,472,270

G

endothelin 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of EDN1 mRNA
epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of EDN1 mRNA]

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDNRB mRNA

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

early endosome antigen 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EEA1 mRNA

NCBI chr 7:32,441,281...32,608,808
Ensembl chr 7:32,441,272...32,608,476

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EEF1A1 mRNA

NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072

G

eukaryotic elongation factor-2 kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EEF2K mRNA

NCBI chr 1:184,824,420...184,888,048
Ensembl chr 1:184,824,420...184,888,048

G

EEIG family member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EEIG2 mRNA

NCBI chr 2:199,296,582...199,351,449
Ensembl chr 2:199,296,582...199,351,449

G

EF-hand domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFHC1 mRNA

NCBI chr 9:30,872,238...30,910,703
Ensembl chr 9:30,871,565...30,910,703

G

elongation factor like GTPase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFL1 mRNA

NCBI chr 1:146,047,734...146,172,719
Ensembl chr 1:146,048,592...146,173,532

G

ephrin A1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA1 mRNA

NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726

G

ephrin A4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA4 mRNA

NCBI chr 2:177,046,463...177,050,713
Ensembl chr 2:177,046,463...177,050,713

G

ephrin A5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA5 mRNA

NCBI chr 9:109,763,786...110,042,396
Ensembl chr 9:109,767,252...110,042,348

G

ephrin B2

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of EFNB2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EFNB2 mRNA

PMID:16084531 PMID:22079256

NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208

G

EFR3 homolog A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3A mRNA

NCBI chr 7:99,441,764...99,522,454
Ensembl chr 7:99,441,767...99,522,454

G

EFR3 homolog B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3B mRNA

NCBI chr 6:32,664,593...32,740,417
Ensembl chr 6:32,666,945...32,740,417

G

epidermal growth factor

multiple interactions
decreases expression

ISO

epigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein]; epigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased activity of SP1 protein]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased expression of FAS mRNA]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased expression of FAS protein]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
epigallocatechin gallate results in decreased expression of EGF mRNA

PMID:12931129 PMID:17616711 PMID:20346928 PMID:20706672

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EGFR mRNA; [Raloxifene Hydrochloride co-treated with epigallocatechin gallate] results in decreased phosphorylation of EGFR protein; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of EGFR protein]; epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of EGFR protein]; epigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein]; epigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of EGFR mRNA]
epigallocatechin gallate results in increased expression of EGFR mRNA

PMID:17616711 PMID:18371987 PMID:22079256 PMID:24508477 PMID:27058323 More...

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 1

multiple interactions
decreases expression
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EGR1 mRNA; epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased expression of EGR1 mRNA]
epigallocatechin gallate results in decreased expression of EGR1 mRNA
epigallocatechin gallate results in increased expression of EGR1 mRNA

PMID:22079256 PMID:32512070

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

EH domain binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHBP1 mRNA

NCBI chr14:100,294,585...100,581,764
Ensembl chr14:100,294,585...100,546,579

G

EH-domain containing 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of EHD2 protein

NCBI chr 1:85,767,757...85,786,974
Ensembl chr 1:85,768,667...85,786,943

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHHADH mRNA
epigallocatechin gallate results in increased expression of EHHADH protein

PMID:22079256 PMID:31195006

NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662

G

euchromatic histone lysine methyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHMT1 mRNA; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of EHMT1 mRNA]

PMID:22079256 PMID:38146662

NCBI chr 3:27,978,888...28,127,178
Ensembl chr 3:27,978,888...28,127,349

G

eukaryotic translation initiation factor 2 alpha kinase 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EIF2AK4 mRNA

NCBI chr 3:125,810,207...125,895,574
Ensembl chr 3:125,810,060...125,895,574

G

eukaryotic translation initiation factor 2 subunit gamma

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF2S3 mRNA

NCBI chr X:62,910,292...62,933,936
Ensembl chr X:62,910,293...62,934,489

G

eukaryotic translation initiation factor 3, subunit B

decreases expression

ISO

epigallocatechin gallate results in decreased expression of EIF3B protein

NCBI chr12:19,310,308...19,334,768
Ensembl chr12:19,310,311...19,334,939

G

eukaryotic translation initiation factor 3, subunit F

decreases expression

ISO

epigallocatechin gallate results in decreased expression of EIF3F protein

NCBI chr 1:172,369,062...172,378,043
Ensembl chr 1:172,369,062...172,378,041

G

eukaryotic translation initiation factor 4A2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF4A2 mRNA

NCBI chr11:91,268,730...91,276,738
Ensembl chr11:91,268,731...91,275,323

G

eukaryotic translation initiation factor 4B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF4B mRNA

NCBI chr 7:135,085,259...135,107,054
Ensembl chr 7:135,085,066...135,107,064

G

eukaryotic translation initiation factor 5A

increases expression

ISO

epigallocatechin gallate results in increased expression of EIF5A protein

NCBI chr10:55,138,821...55,143,272
Ensembl chr10:55,138,823...55,143,330

G

EARP complex and GARP complex interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EIPR1 mRNA

NCBI chr 6:51,116,827...51,230,453
Ensembl chr 6:51,116,747...51,230,452

G

elaC ribonuclease Z 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELAC1 mRNA

NCBI chr18:69,596,475...69,617,206
Ensembl chr18:69,598,827...69,616,175

G

ELAV like RNA binding protein 1

increases expression

ISO

epigallocatechin gallate results in increased expression of ELAVL1 protein

NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631

G

ELAV like RNA binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELAVL2 mRNA

NCBI chr 5:111,076,705...111,202,341
Ensembl chr 5:111,076,705...111,224,918

G

E74 like ETS transcription factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELF1 mRNA

NCBI chr15:61,354,026...61,395,762
Ensembl chr15:61,330,877...61,395,758

G

ETS transcription factor ELK1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ELK1 mRNA

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

elongation factor for RNA polymerase II 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELL2 mRNA

NCBI chr 2:6,910,446...6,990,654
Ensembl chr 2:6,921,771...7,016,199

G

elongation factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ELOF1 mRNA

NCBI chr 8:28,921,338...28,926,612
Ensembl chr 8:28,921,339...28,926,228

G

ELOVL fatty acid elongase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELOVL1 mRNA

NCBI chr 5:137,246,781...137,251,351
Ensembl chr 5:137,246,849...137,251,352

G

ELOVL fatty acid elongase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELOVL2 mRNA

NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,750,350...23,790,601

G

elongator acetyltransferase complex subunit 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELP4 mRNA

NCBI chr 3:112,617,020...112,839,963
Ensembl chr 3:112,617,035...112,839,963

G

ER membrane protein complex subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EMC2 mRNA

NCBI chr 7:76,471,899...76,508,866
Ensembl chr 7:76,471,899...76,510,178

G

emerin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EMD mRNA

NCBI chr X:157,190,438...157,193,479
Ensembl chr X:157,189,819...157,197,095

G

EMG1 N1-specific pseudouridine methyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EMG1 mRNA

NCBI chr 4:159,195,545...159,203,826
Ensembl chr 4:159,195,564...159,203,826

G

EMAP like 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EML4 mRNA

NCBI chr 6:16,972,054...17,087,365
Ensembl chr 6:16,972,075...17,087,439

G

ecto-NOX disulfide-thiol exchanger 2

decreases activity
increases response to substance
multiple interactions

ISO

epigallocatechin gallate results in decreased activity of ENOX2 protein
ENOX2 results in increased susceptibility to epigallocatechin gallate
[epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD

PMID:15706060 PMID:20518072

NCBI chr X:133,148,813...133,470,914
Ensembl chr X:133,148,813...133,470,891

G

erythrocyte membrane protein band 4.1 like 4B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPB41L4B mRNA

NCBI chr 5:76,486,886...76,647,752
Ensembl chr 5:76,486,902...76,647,752

G

ectopic P-granules 5 autophagy tethering factor

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPG5 mRNA
epigallocatechin gallate results in increased expression of EPG5 mRNA

NCBI chr18:73,679,106...73,776,694
Ensembl chr18:73,679,116...73,776,677

G

Eph receptor A4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPHA4 mRNA

NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:86,263,982...86,406,755

G

EPM2A interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EPM2AIP1 mRNA

NCBI chr 8:120,112,265...120,119,613
Ensembl chr 8:120,112,084...120,121,458

G

epsin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPN2 mRNA

NCBI chr10:46,697,238...46,759,128
Ensembl chr10:46,697,238...46,759,092

G

epiplakin 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of EPPK1 protein

NCBI chr 7:109,697,607...109,718,468
Ensembl chr 7:109,697,607...109,718,468

G

EGFR pathway substrate 8, signaling adaptor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPS8 mRNA

NCBI chr 4:172,119,497...172,291,670
Ensembl chr 4:172,119,497...172,218,160

G

epithelial stromal interaction 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPSTI1 mRNA

NCBI chr15:59,692,712...59,791,376
Ensembl chr15:59,693,142...59,791,380

G

erb-b2 receptor tyrosine kinase 2

decreases phosphorylation

ISO

epigallocatechin gallate results in decreased phosphorylation of ERBB2 protein

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

ELKS/RAB6-interacting/CAST family member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERC1 mRNA

NCBI chr 4:154,435,936...154,727,987
Ensembl chr 4:154,435,944...154,727,987

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions

ISO

[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]; epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of ERCC1 mRNA]

NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120

G

ERCC excision repair 4, endonuclease catalytic subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC4 mRNA; epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of ERCC4 mRNA]

NCBI chr10:2,926,085...2,958,176
Ensembl chr10:2,920,455...2,955,539

G

ERCC excision repair 6 like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC6L2 mRNA

NCBI chr17:1,055,881...1,323,207
Ensembl chr17:1,222,139...1,316,056

G

ERGIC and golgi 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERGIC2 mRNA

NCBI chr 4:182,822,225...182,858,392
Ensembl chr 4:182,822,225...182,854,490

G

glutamate-rich 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERICH1 mRNA

NCBI chr16:82,203,536...82,271,361
Ensembl chr16:82,203,610...82,272,989

G

endoplasmic reticulum lectin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERLEC1 mRNA

NCBI chr14:108,856,661...108,894,511
Ensembl chr14:108,856,661...108,894,297

G

ER membrane-associated RNA degradation

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERMARD mRNA

NCBI chr 1:64,656,414...64,675,803
Ensembl chr 1:64,656,529...64,675,806

G

endoplasmic reticulum protein 29

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ERP29 mRNA

NCBI chr12:40,750,177...40,756,607
Ensembl chr12:40,750,314...40,757,010

G

ERBB receptor feedback inhibitor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ERRFI1 mRNA

NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432

G

esterase D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ESD mRNA

NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508

G

estrogen receptor 1

increases expression

ISO

epigallocatechin gallate results in increased expression of ESR1 protein

PMID:34600025 PMID:35863485

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

decreases expression
increases methylation
increases expression

ISO

epigallocatechin gallate results in decreased expression of ESR2 mRNA
epigallocatechin gallate results in increased methylation of ESR2 promoter
epigallocatechin gallate results in decreased expression of ESR2 protein
epigallocatechin gallate results in increased expression of ESR2 protein

PMID:20706672 PMID:34600025 PMID:35863485

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

ETAA1 activator of ATR kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ETAA1 mRNA

NCBI chr14:96,500,899...96,515,617
Ensembl chr14:96,500,899...96,517,796

G

electron transfer flavoprotein regulatory factor 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of ETFRF1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ETFRF1 mRNA

NCBI chr 4:179,910,651...179,916,095
Ensembl chr 4:179,910,914...179,916,095

G

ETS variant transcription factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ETV3 mRNA

NCBI chr 2:175,263,389...175,278,217
Ensembl chr 2:175,263,459...175,278,208

G

ETS variant transcription factor 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ETV5 mRNA

NCBI chr11:92,113,171...92,170,758
Ensembl chr11:92,113,224...92,170,767

G

ETS variant transcription factor 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ETV6 mRNA

NCBI chr 4:168,580,405...168,819,817
Ensembl chr 4:168,580,138...168,819,802

G

exocyst complex component 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC1 mRNA

NCBI chr14:31,965,782...32,014,156
Ensembl chr14:31,965,782...32,014,127

G

exocyst complex component 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC2 mRNA

NCBI chr17:33,714,949...33,906,901
Ensembl chr17:33,715,008...33,901,944

G

exocyst complex component 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC4 mRNA

NCBI chr 4:62,774,896...63,551,541
Ensembl chr 4:62,774,935...63,552,943

G

exocyst complex component 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC6 mRNA

NCBI chr 1:244,727,084...244,870,263
Ensembl chr 1:244,711,981...244,870,396

G

exophilin 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXPH5 mRNA

NCBI chr 8:62,595,116...62,671,575
Ensembl chr 8:62,595,116...62,671,575

G

EYA transcriptional coactivator and phosphatase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EYA2 mRNA

NCBI chr 3:174,754,772...174,938,035
Ensembl chr 3:174,818,554...174,938,034

G

coagulation factor II, thrombin

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein]; epigallocatechin gallate inhibits the reaction [F2 protein results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 protein]

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

coagulation factor III, tissue factor

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; epigallocatechin gallate inhibits the reaction [F2 protein results in increased activity of F3 protein]; epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 mRNA]; epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 protein]

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

Fas associated via death domain

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FADD mRNA

NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:209,169,318...209,174,976

G

fatty acid desaturase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FADS3 mRNA

NCBI chr 1:216,110,547...216,127,431
Ensembl chr 1:216,110,201...216,141,758

G

Fas apoptotic inhibitory molecule

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAIM mRNA

NCBI chr 8:108,423,259...108,445,365
Ensembl chr 8:108,423,221...108,440,151

G

family with sequence similarity 110, member B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM110B mRNA

NCBI chr 5:23,587,093...23,727,188
Ensembl chr 5:23,586,867...23,799,583

G

family with sequence similarity 114, member A1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM114A1 mRNA

NCBI chr14:43,629,349...43,699,800
Ensembl chr14:43,629,375...43,699,800

G

family with sequence similarity 118, member B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM118B mRNA

NCBI chr 8:41,824,522...41,875,190
Ensembl chr 8:41,824,158...41,846,256

G

family with sequence similarity 162, member A

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of FAM162A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM162A mRNA

NCBI chr11:78,186,260...78,215,186
Ensembl chr11:78,185,852...78,216,560

G

family with sequence similarity 177 member B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM177B mRNA

NCBI chr13:97,435,189...97,441,261

G

FAM3 metabolism regulating signaling molecule C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM3C mRNA

NCBI chr 4:51,805,686...51,853,030
Ensembl chr 4:51,805,703...51,853,030

G

family with sequence similarity 50, member B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM50B mRNA

NCBI chr17:30,379,796...30,399,399
Ensembl chr17:30,379,171...30,399,651

G

family with sequence similarity 76, member A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM76A mRNA

NCBI chr 5:150,391,460...150,419,526
Ensembl chr 5:150,391,463...150,419,807

G

family with sequence similarity 83, member G

increases expression

ISO

epigallocatechin gallate results in increased expression of FAM83G protein

NCBI chr10:46,862,983...46,887,499
Ensembl chr10:46,862,369...46,886,277

G

FANCD2 and FANCI associated nuclease 1

multiple interactions
affects methylation

ISO
EXP

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAN1 mRNA
epigallocatechin gallate affects the methylation of FAN1 gene

PMID:22079256 PMID:29381301

NCBI chr 1:127,327,098...127,356,807
Ensembl chr 1:127,330,016...127,356,400

G

FA complementation group C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FANCC mRNA

NCBI chr17:1,686,374...1,818,672
Ensembl chr17:1,687,017...1,835,096

G

FA complementation group M

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FANCM mRNA

NCBI chr 6:88,862,898...88,916,701
Ensembl chr 6:88,863,306...88,921,652

G

fatty acyl CoA reductase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAR2 mRNA

NCBI chr 4:182,705,499...182,819,290
Ensembl chr 4:182,705,381...182,825,279

G

phenylalanyl-tRNA synthetase 2, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FARS2 mRNA

NCBI chr17:28,524,737...28,951,818
Ensembl chr17:28,524,738...28,951,591

G

Fas cell surface death receptor

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [EGF protein results in increased expression of FAS mRNA]; epigallocatechin gallate inhibits the reaction [EGF protein results in increased expression of FAS protein]

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

fatty acid synthase

decreases expression

EXP
ISO

epigallocatechin gallate results in decreased expression of FASN mRNA

PMID:16988119 PMID:20816778

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

FAST kinase domains 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FASTKD1 mRNA

NCBI chr 3:74,857,539...74,883,483
Ensembl chr 3:74,845,261...74,883,367

G

FAST kinase domains 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FASTKD2 mRNA

NCBI chr 9:72,659,961...72,681,986
Ensembl chr 9:72,661,764...72,721,338

G

FAT atypical cadherin 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of FAT1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAT1 mRNA

NCBI chr16:53,909,759...54,029,175
Ensembl chr16:53,909,556...54,028,609

G

FAT atypical cadherin 4

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of FAT4 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAT4 mRNA

NCBI chr 2:123,855,289...123,984,716
Ensembl chr 2:123,855,289...123,984,716

G

FAU ubiquitin like and ribosomal protein S30 fusion

increases expression

ISO

epigallocatechin gallate results in increased expression of FAU protein

NCBI chr 1:212,779,429...212,781,028
Ensembl chr 1:212,779,473...212,781,026
Ensembl chr 1:212,779,473...212,781,026

G

fatty acid hydroxylase domain containing 2

increases expression

ISO

epigallocatechin gallate results in increased expression of FAXDC2 mRNA

NCBI chr10:42,747,323...42,772,156
Ensembl chr10:42,747,524...42,781,458

G

F-box DNA helicase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBH1 mRNA

NCBI chr17:71,659,351...71,697,431
Ensembl chr17:71,659,249...71,697,432

G

fibrillin 1

increases expression
decreases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of FBN1 mRNA
epigallocatechin gallate results in decreased expression of FBN1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBN1 mRNA

PMID:20706672 PMID:22079256

NCBI chr 3:133,007,693...133,204,277
Ensembl chr 3:133,008,361...133,204,283

G

fibrillin 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of FBN2 mRNA

NCBI chr18:53,696,197...53,901,992
Ensembl chr18:53,697,708...53,902,191

G

fructose-bisphosphatase 1

decreases expression

EXP

epigallocatechin gallate results in decreased expression of FBP1 mRNA

NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746

G

F-box and leucine-rich repeat protein 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FBXL12 mRNA

NCBI chr 8:27,453,042...27,459,136
Ensembl chr 8:27,445,823...27,457,772

G

F-box and leucine-rich repeat protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL2 mRNA

NCBI chr 8:122,794,870...122,843,265
Ensembl chr 8:122,794,870...122,854,798

G

F-box and leucine-rich repeat protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL4 mRNA

NCBI chr 5:40,752,513...40,826,154
Ensembl chr 5:40,752,521...40,850,826

G

F-box and leucine-rich repeat protein 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL5 mRNA

NCBI chr14:71,517,452...71,559,850
Ensembl chr14:71,480,270...71,560,652

G

F-box and leucine-rich repeat protein 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL7 mRNA

NCBI chr 2:78,870,236...79,239,697
Ensembl chr 2:78,871,287...79,239,697

G

F-box protein 48

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXO48 mRNA

NCBI chr14:95,582,493...95,583,950
Ensembl chr14:95,581,279...95,587,616

G

FCH and mu domain containing endocytic adaptor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FCHO2 mRNA

NCBI chr 2:31,813,356...31,916,471
Ensembl chr 2:31,814,950...31,915,445

G

FCH and double SH3 domains 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FCHSD2 mRNA

NCBI chr 1:164,775,916...165,097,391
Ensembl chr 1:164,775,926...165,097,391

G

fem-1 homolog A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FEM1A mRNA

NCBI chr 9:1,178,857...1,181,063
Ensembl chr 9:1,177,543...1,188,006

G

fem-1 homolog C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FEM1C mRNA

NCBI chr18:41,419,511...41,445,300
Ensembl chr18:41,419,511...41,445,300

G

FER tyrosine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FER mRNA

NCBI chr 9:110,967,317...111,274,315
Ensembl chr 9:110,967,390...111,274,315

G

FERM domain containing kindlin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FERMT2 mRNA

NCBI chr15:21,162,603...21,257,995
Ensembl chr15:21,162,605...21,258,115

G

FYVE, RhoGEF and PH domain containing 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGD6 mRNA

NCBI chr 7:30,484,600...30,599,898
Ensembl chr 7:30,484,600...30,595,806

G

fibroblast growth factor 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of FGF1 mRNA

NCBI chr18:30,937,670...31,023,786
Ensembl chr18:30,939,870...30,961,393

G

fibroblast growth factor 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF12 mRNA

NCBI chr11:85,501,947...86,069,543
Ensembl chr11:85,501,936...86,069,543

G

fibroblast growth factor 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FGF18 mRNA

NCBI chr10:18,210,240...18,241,929
Ensembl chr10:18,210,512...18,240,933

G

fibroblast growth factor 19

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of FGF15 mRNA
NR1H4 protein affects the reaction [epigallocatechin gallate results in increased expression of FGF15 mRNA]

NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267

G

fibroblast growth factor 2

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of FGF2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF2 mRNA

PMID:16084531 PMID:22079256

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

fibroblast growth factor binding protein 1

increases expression

ISO

epigallocatechin gallate results in increased expression of FGFBP1 mRNA

NCBI chr14:71,316,171...71,319,965
Ensembl chr14:71,317,065...71,320,309

G

filamin A interacting protein 1-like

decreases expression

ISO

epigallocatechin gallate results in decreased expression of FILIP1L mRNA

PMID:16084531 PMID:39667565

NCBI chr11:56,403,467...56,646,422
Ensembl chr11:56,410,582...56,646,402

G

FIGNL1 interacting regulator of recombination and mitosis

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FIRRM mRNA

NCBI chr13:78,835,081...78,879,022
Ensembl chr13:78,834,216...78,879,213

G

fission, mitochondrial 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of FIS1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of FIS1 protein]]

NCBI chr12:25,345,239...25,360,135
Ensembl chr12:25,345,239...25,349,335

G

FKBP prolyl isomerase 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FKBP10 mRNA

NCBI chr10:85,845,801...85,858,361
Ensembl chr10:85,844,703...85,858,355

G

FKBP prolyl isomerase 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FKBP9 mRNA

NCBI chr 4:87,436,439...87,486,909
Ensembl chr 4:87,436,478...87,508,940

G

filamin A

increases expression

ISO

epigallocatechin gallate results in increased expression of FLNA protein

NCBI chr X:157,159,051...157,185,559
Ensembl chr X:157,159,051...157,182,343

G

fibronectin leucine rich transmembrane protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FLRT2 mRNA

NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004

G

formin-like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FMNL2 mRNA

NCBI chr 3:57,758,236...58,033,832
Ensembl chr 3:57,758,191...58,033,831

G

fibronectin 1

affects expression
multiple interactions

ISO

epigallocatechin gallate affects the expression of FN1
epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of FN1 mRNA]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of FN1 protein]

PMID:25955525 PMID:38146662

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

formin binding protein 1-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNBP1L mRNA

NCBI chr 2:213,331,871...213,432,821
Ensembl chr 2:213,318,662...213,423,051

G

fibronectin type III domain containing 3a

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNDC3A mRNA

NCBI chr15:54,099,510...54,276,963
Ensembl chr15:54,099,510...54,276,407

G

fibronectin type III domain containing 3B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNDC3B mRNA

NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:112,243,202...112,546,306

G

fibronectin type III domain containing 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FNDC7 mRNA

NCBI chr 2:199,189,029...199,226,425
Ensembl chr 2:199,190,549...199,225,783

G

focadhesin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FOCAD mRNA

NCBI chr 5:107,610,489...107,932,485
Ensembl chr 5:107,610,416...107,933,109

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases activity

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FOS mRNA
epigallocatechin gallate results in decreased activity of FOS protein

PMID:12663506 PMID:22079256

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FOSB mRNA

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

forkhead box O3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of FOXO3 protein

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

forkhead box P1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FOXP1 mRNA

NCBI chr 4:133,117,346...133,808,647
Ensembl chr 4:133,122,055...133,500,272

G

FERM domain containing 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRMD6 mRNA

NCBI chr 6:95,081,958...95,155,561
Ensembl chr 6:95,081,985...95,155,560

G

fibroblast growth factor receptor substrate 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FRS2 mRNA

NCBI chr 7:54,597,182...54,678,656
Ensembl chr 7:54,597,182...54,678,774

G

FRY microtubule binding protein

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of FRY mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRY mRNA

NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603

G

FRY like transcription coactivator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRYL mRNA

NCBI chr14:35,307,225...35,545,199
Ensembl chr14:35,310,656...35,545,147

G

alpha-L-fucosidase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FUCA2 mRNA

NCBI chr 1:9,706,121...9,720,910
Ensembl chr 1:9,706,094...9,721,706

G

fucosyltransferase 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FUT8 mRNA

NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:101,683,007...101,909,775

G

frataxin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FXN mRNA

NCBI chr 1:231,300,457...231,323,989
Ensembl chr 1:231,300,150...231,323,989

G

FXYD domain-containing ion transport regulator 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FXYD5 mRNA

NCBI chr 1:95,395,327...95,404,722
Ensembl chr 1:95,395,146...95,405,364

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FYN mRNA

NCBI chr20:44,322,635...44,514,498
Ensembl chr20:44,322,361...44,515,479

G

frizzled class receptor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FZD1 mRNA

NCBI chr 4:30,265,074...30,269,472
Ensembl chr 4:30,247,228...30,833,176

G

frizzled class receptor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FZD2 mRNA

NCBI chr10:88,061,988...88,063,898
Ensembl chr10:88,061,667...88,065,396

G

G2/M-phase specific E3 ubiquitin protein ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of G2E3 mRNA

NCBI chr 6:74,498,801...74,530,703
Ensembl chr 6:74,503,109...74,528,198

G

G4 protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C6ORF47 mRNA

NCBI chr20:3,698,359...3,701,036
Ensembl chr20:3,697,669...3,701,044

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

EXP
ISO

epigallocatechin gallate results in decreased expression of G6PC1 mRNA

PMID:15549673 PMID:16988119

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033

G

alpha glucosidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GAA mRNA

NCBI chr10:105,028,106...105,045,365
Ensembl chr10:105,028,307...105,045,366

G

GRB2-associated binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GAB1 mRNA

NCBI chr19:44,035,693...44,143,617
Ensembl chr19:44,035,063...44,143,617

G

GRB2-associated binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GAB2 mRNA

NCBI chr 1:160,841,066...161,036,940
Ensembl chr 1:160,841,066...161,036,940

G

gamma-aminobutyric acid type A receptor subunit epsilon

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GABRE mRNA

NCBI chr X:155,102,078...155,120,821
Ensembl chr X:155,102,083...155,120,735

G

glutamate decarboxylase 1

increases expression

EXP

epigallocatechin gallate results in increased expression of GAD1 protein

NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GADD45A mRNA; epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased expression of GADD45A mRNA]
[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of GADD45A mRNA]; epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of GADD45A mRNA]

PMID:22079256 PMID:23717041

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

galanin and GMAP prepropeptide

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GAL mRNA

NCBI chr 1:210,079,709...210,084,572
Ensembl chr 1:210,079,702...210,084,229

G

galactose mutarotase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GALM mRNA

NCBI chr 6:20,589,775...20,641,516
Ensembl chr 6:20,589,776...20,644,417

G

polypeptide N-acetylgalactosaminyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GALNT1 mRNA

NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588

G

glucosidase II alpha subunit

decreases expression

ISO

epigallocatechin gallate results in decreased expression of GANAB protein

NCBI chr 1:215,222,918...215,242,808
Ensembl chr 1:215,222,995...215,243,036

G

golgi associated kinase 1B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GASK1B mRNA

NCBI chr 2:167,345,738...167,410,606
Ensembl chr 2:167,345,809...167,410,603

G

glutamyl-tRNA amidotransferase subunit B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GATB mRNA

NCBI chr 2:173,228,562...173,315,144
Ensembl chr 2:173,228,568...173,314,661

G

1,4-alpha-glucan branching enzyme 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBE1 mRNA

NCBI chr11:22,181,194...22,446,640
Ensembl chr11:22,181,103...22,446,638

G

guanylate binding protein 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of GBP1 mRNA

NCBI chr 2:234,071,366...234,106,012
Ensembl chr 2:234,190,708...234,206,802
Ensembl chr 2:234,190,708...234,206,802

G

guanylate binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBP2 mRNA

NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810

G

guanylate binding protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBP3 mRNA

NCBI chr 2:234,144,042...234,173,527
Ensembl chr 2:234,146,519...234,180,055

G

guanylate binding protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBP4 mRNA

NCBI chr 2:233,978,163...233,992,124
Ensembl chr 2:233,978,486...233,992,120

G

grancalcin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GCA mRNA

NCBI chr 3:67,705,874...67,738,475
Ensembl chr 3:67,705,890...67,737,387

G

GRIP and coiled-coil domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GCC1 mRNA

NCBI chr 4:57,996,261...58,008,126
Ensembl chr 4:57,996,267...58,002,185

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of GCLC mRNA
[arsenite co-treated with epigallocatechin gallate] results in increased expression of GCLC protein

PMID:25585349 PMID:29572906

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

epigallocatechin gallate results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

glucosaminyl (N-acetyl) transferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GCNT1 mRNA

NCBI chr 1:224,145,104...224,182,496
Ensembl chr 1:224,141,108...224,185,741

G

glucosaminyl (N-acetyl) transferase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GCNT2 mRNA

NCBI chr17:24,002,592...24,107,339
Ensembl chr17:24,002,597...24,106,989

G

growth differentiation factor 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GDF9 mRNA

NCBI chr10:38,090,021...38,100,801
Ensembl chr10:38,089,878...38,100,797

G

glycerophosphodiester phosphodiesterase domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GDPD1 mRNA

NCBI chr10:72,318,716...72,381,143
Ensembl chr10:72,337,778...72,381,120

G

gem (nuclear organelle) associated protein 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GEMIN6 mRNA

NCBI chr 6:20,538,325...20,542,867
Ensembl chr 6:20,538,325...20,542,852

G

glial fibrillary acidic protein

multiple interactions

EXP

[Tea results in increased abundance of epigallocatechin gallate] inhibits the reaction [Histamine results in increased expression of GFAP protein]

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685

G

glutamine-fructose-6-phosphate transaminase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GFPT2 mRNA

NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419

G

GRB10 interacting GYF protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GIGYF2 mRNA

NCBI chr 9:95,449,143...95,574,927
Ensembl chr 9:95,449,167...95,574,927

G

gypsy retrotransposon integrase 1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GIN1 mRNA
epigallocatechin gallate results in decreased expression of GIN1 mRNA

NCBI chr 9:105,740,914...105,762,357
Ensembl chr 9:105,742,094...105,762,357

G

GINS complex subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GINS1 mRNA

NCBI chr 3:160,184,920...160,206,334
Ensembl chr 3:160,180,151...160,206,332

G

GIT ArfGAP 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GIT2 mRNA

NCBI chr12:47,490,350...47,531,232
Ensembl chr12:47,490,369...47,533,250

G

gap junction protein, alpha 4

decreases expression

ISO

epigallocatechin gallate results in decreased expression of GJA4 mRNA

NCBI chr 5:144,917,791...144,920,324
Ensembl chr 5:144,914,147...144,921,216

G

glucocorticoid induced 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLCCI1 mRNA
epigallocatechin gallate results in increased expression of GLCCI1 mRNA

PMID:22079256 PMID:35701726

NCBI chr 4:37,274,271...37,601,898
Ensembl chr 4:37,529,364...37,599,802
Ensembl chr 4:37,529,364...37,599,802

G

GLI family zinc finger 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of GLI1 mRNA; epigallocatechin gallate results in decreased expression of GLI1 protein
epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of GLI1 mRNA]; epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of GLI1 protein]

PMID:20395211 PMID:27058323

NCBI chr 7:65,042,237...65,054,888
Ensembl chr 7:65,042,237...65,054,540

G

GLI family zinc finger 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLI2 mRNA

NCBI chr13:32,499,678...32,716,418
Ensembl chr13:32,499,678...32,716,418

G

GLI family zinc finger 3

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of GLI3 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLI3 mRNA

NCBI chr17:54,134,064...54,405,198
Ensembl chr17:54,134,064...54,405,198

G

GLIS family zinc finger 3

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLIS3 mRNA
epigallocatechin gallate results in increased expression of GLIS3 mRNA

NCBI chr 1:235,389,567...235,809,416
Ensembl chr 1:235,392,651...235,809,221

G

glomulin, FKBP associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLMN mRNA

NCBI chr14:2,332,052...2,375,366
Ensembl chr14:2,332,497...2,375,695

G

glutaredoxin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLRX2 mRNA

NCBI chr13:58,032,199...58,055,061
Ensembl chr13:58,032,401...58,043,150

G

glutaminase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLS mRNA

NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:56,836,584...56,908,861

G

glycosyltransferase 8 domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLT8D1 mRNA

NCBI chr16:6,198,152...6,213,671
Ensembl chr16:6,204,740...6,213,668

G

glutamate dehydrogenase 1

multiple interactions
decreases expression

ISO

[epigallocatechin gallate results in decreased expression of GLUD1 protein] which results in decreased abundance of alpha-hydroxyglutarate; Acetylcysteine inhibits the reaction [epigallocatechin gallate results in decreased expression of GLUD1 mRNA]
epigallocatechin gallate results in decreased expression of GLUD1 mRNA; epigallocatechin gallate results in decreased expression of GLUD1 protein

NCBI chr16:9,646,569...9,680,215
Ensembl chr16:9,646,509...9,680,210

G

guanosine monophosphate reductase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GMPR mRNA

NCBI chr17:19,357,992...19,395,807
Ensembl chr17:19,357,992...19,431,655

G

G protein subunit alpha i1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNAI1 mRNA

NCBI chr 4:17,706,061...17,790,176
Ensembl chr 4:17,706,025...17,789,198

G

G protein subunit alpha q

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNAQ mRNA

NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:222,852,097...223,126,742

G

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNE mRNA

NCBI chr 5:63,062,953...63,103,320
Ensembl chr 5:63,062,850...63,103,251

G

G protein nucleolar 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GNL3 mRNA

NCBI chr16:6,213,844...6,220,029
Ensembl chr16:6,213,871...6,219,845

G

N-acetylglucosamine-1-phosphate transferase subunits alpha and beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNPTAB mRNA

NCBI chr 7:24,687,923...24,754,821
Ensembl chr 7:24,687,969...24,754,821

G

gonadotropin releasing hormone 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GNRH1 mRNA

NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977
Ensembl chr15:46,148,301...46,148,977

G

golgin A1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GOLGA1 mRNA

NCBI chr 3:43,175,400...43,222,319
Ensembl chr 3:43,175,400...43,222,319

G

golgi integral membrane protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GOLIM4 mRNA

NCBI chr 2:162,939,429...163,031,901
Ensembl chr 2:162,939,429...163,031,901

G

glutamic-oxaloacetic transaminase 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of GOT2 protein

NCBI chr19:9,180,428...9,206,113
Ensembl chr19:9,180,431...9,206,111

G

glycerol-3-phosphate acyltransferase, mitochondrial

decreases expression

EXP

epigallocatechin gallate results in decreased expression of GPAM mRNA

NCBI chr 1:264,111,599...264,176,112
Ensembl chr 1:264,113,813...264,175,911

G

G patch domain containing 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GPATCH4 mRNA

NCBI chr 2:175,797,503...175,816,547
Ensembl chr 2:175,807,682...175,817,358

G

gephyrin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPHN mRNA

NCBI chr 6:102,687,405...103,216,679
Ensembl chr 6:102,687,423...103,216,674

G

G protein-coupled receptor 107

increases expression

ISO

epigallocatechin gallate results in increased expression of GPR107 protein

NCBI chr 3:34,832,462...34,893,692
Ensembl chr 3:34,832,480...34,893,654

G

G protein-coupled receptor 160

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR160 mRNA

NCBI chr 2:114,414,084...114,491,590
Ensembl chr 2:114,410,261...114,474,790

G

G protein-coupled receptor 180

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR180 mRNA

NCBI chr15:101,602,870...101,635,556
Ensembl chr15:101,603,259...101,635,556

G

G protein-coupled receptor 21

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of GPR21 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GPR21 mRNA

NCBI chr 3:41,685,072...41,688,791
Ensembl chr 3:41,685,492...41,698,995

G

G protein-coupled receptor 39

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR39 mRNA

NCBI chr13:39,667,908...39,879,944
Ensembl chr13:39,667,909...39,880,902

G

G protein-coupled receptor 87

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR87 mRNA

NCBI chr 2:145,589,630...145,608,094
Ensembl chr 2:145,589,569...145,604,442

G

G protein-coupled receptor, class C, group 5, member B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPRC5B mRNA

NCBI chr 1:182,748,247...182,772,711
Ensembl chr 1:182,748,247...182,772,757

G

G-protein signaling modulator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPSM2 mRNA

NCBI chr 2:199,015,250...199,063,788
Ensembl chr 2:199,015,250...199,063,056

G

glutamic--pyruvic transaminase

increases activity
multiple interactions
increases expression

ISO
EXP

epigallocatechin gallate results in increased activity of GPT protein
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased activity of GPT protein]
epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of GPT protein]
epigallocatechin gallate results in increased expression of GPT protein

PMID:25585349 PMID:29175576 PMID:30092300 PMID:33393703

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

decreases expression
multiple interactions

ISO
EXP

epigallocatechin gallate results in decreased expression of GPX1 mRNA
[epigallocatechin gallate co-treated with leptomycin B] results in increased expression of GPX1 mRNA
epigallocatechin gallate results in decreased expression of GPX1 mRNA; epigallocatechin gallate results in decreased expression of GPX1 protein
[1-Methyl-4-phenylpyridinium co-treated with epigallocatechin gallate] results in increased expression of GPX1 mRNA; epigallocatechin gallate inhibits the reaction [Acrylamide results in decreased activity of GPX1 protein]

PMID:18851785 PMID:22742579 PMID:25585349 PMID:25922640 PMID:28056603 More...

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

GRAM domain containing 1B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GRAMD1B mRNA

NCBI chr 8:49,551,642...49,790,965
Ensembl chr 8:49,556,332...49,791,052

G

GRAM domain containing 2B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GRAMD2B mRNA

NCBI chr18:52,082,128...52,180,056
Ensembl chr18:52,082,029...52,180,054

G

GREB1 like retinoic acid receptor coactivator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GREB1L mRNA

NCBI chr18:1,665,468...1,902,291
Ensembl chr18:1,766,214...1,900,178

G

G protein-coupled receptor kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GRK3 mRNA

NCBI chr12:49,285,228...49,395,803
Ensembl chr12:49,285,263...49,395,802

G

granulin precursor

increases expression

ISO

epigallocatechin gallate results in increased expression of GRN mRNA

NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,886,122...87,893,936

G

gamma-secretase activating protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GSAP mRNA

NCBI chr 4:14,705,237...14,800,057
Ensembl chr 4:14,705,237...14,800,005

G

gasdermin D

multiple interactions

ISO
EXP

epigallocatechin gallate inhibits the reaction [bisphenol A results in increased expression of GSDMD mRNA]; epigallocatechin gallate inhibits the reaction [bisphenol A results in increased expression of GSDMD protein]
epigallocatechin gallate inhibits the reaction [ochratoxin A results in increased expression of GSDMD mRNA]

PMID:35439536 PMID:39299375

NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722

G

gasdermin E

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GSDME mRNA

NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525

G

glycogen synthase kinase 3 alpha

increases phosphorylation

ISO

epigallocatechin gallate results in increased phosphorylation of GSK3A protein

NCBI chr 1:89,943,669...89,953,514
Ensembl chr 1:89,943,669...89,953,593

G

glycogen synthase kinase 3 beta

increases phosphorylation
decreases phosphorylation
multiple interactions

ISO

epigallocatechin gallate results in increased phosphorylation of GSK3B protein
epigallocatechin gallate results in decreased phosphorylation of GSK3B protein
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GSK3B mRNA

PMID:16968065 PMID:22079256 PMID:34600025

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

glutathione-disulfide reductase

multiple interactions
increases activity
decreases expression

ISO
EXP

epigallocatechin gallate inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased activity of GSR protein]; epigallocatechin gallate inhibits the reaction [epigallocatechin gallate results in decreased expression of GSR mRNA]
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in decreased activity of GSR protein]; epigallocatechin gallate inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of GSR protein]; epigallocatechin gallate inhibits the reaction [Ethanol results in decreased activity of GSR protein]
epigallocatechin gallate results in increased activity of GSR protein

PMID:20020850 PMID:25528115 PMID:26187476 PMID:31350662 PMID:33393703 More...

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione synthetase

decreases expression
increases expression

ISO

epigallocatechin gallate results in decreased expression of GSS mRNA
epigallocatechin gallate results in increased expression of GSS mRNA

PMID:18851785 PMID:25585349

NCBI chr 3:164,508,005...164,538,343
Ensembl chr 3:164,508,005...164,538,306

G

glutathione S-transferase alpha 2

increases expression

ISO

epigallocatechin gallate results in increased expression of GSTA1 mRNA

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092

G

glutathione S-transferase alpha 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GSTA4 mRNA

NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:87,930,566...87,964,488

G

glutathione S-transferase mu 1

increases expression

ISO

epigallocatechin gallate results in increased expression of GSTM1 mRNA

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569

G

glutathione S-transferase mu 2

increases expression

EXP

epigallocatechin gallate results in increased expression of GSTM2 mRNA; epigallocatechin gallate results in increased expression of GSTM2 protein

NCBI chr 2:198,312,179...198,316,962

G

glutathione S-transferase pi 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

general transcription factor IIH subunit 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTF2H5 mRNA

NCBI chr 1:49,061,904...49,068,612
Ensembl chr 1:49,061,959...49,070,039

G

GTF2I repeat domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTF2IRD1 mRNA

NCBI chr12:27,890,594...27,997,506
Ensembl chr12:27,890,675...27,997,494

G

general transcription factor IIIC subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTF3C2 mRNA

NCBI chr 6:30,913,263...30,941,305
Ensembl chr 6:30,923,106...30,940,465

G

general transcription factor IIIC subunit 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GTF3C4 mRNA

NCBI chr 3:32,552,773...32,570,705
Ensembl chr 3:32,555,628...32,570,689

G

GTP binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTPBP2 mRNA

NCBI chr 9:22,311,532...22,321,405
Ensembl chr 9:22,311,158...22,321,441

G

GULP PTB domain containing engulfment adaptor 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of GULP1 mRNA

NCBI chr 9:54,114,823...54,391,058
Ensembl chr 9:54,114,731...54,397,452

G

glucuronidase, beta

multiple interactions

EXP
ISO

epigallocatechin gallate inhibits the reaction [Isoproterenol results in increased activity of GUSB protein]
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GUSB mRNA; epigallocatechin gallate inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein]

PMID:11944907 PMID:18294627 PMID:22079256

NCBI chr12:32,337,281...32,350,838
Ensembl chr12:32,334,075...32,363,024

G

H1.0 linker histone

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H1-0 mRNA

NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006

G

H1.1 linker histone, cluster member

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H1-1 mRNA

NCBI chr17:41,762,278...41,794,876

G

H1.2 linker histone, cluster member

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H1-2 mRNA

NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317

G

H1.4 linker histone, cluster member

increases expression

ISO

epigallocatechin gallate results in increased expression of H1-4 protein

NCBI chr17:41,914,425...41,915,206
Ensembl chr17:41,914,431...41,916,129

G

H1.5 linker histone, cluster member

decreases expression
increases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of H1-5 mRNA
epigallocatechin gallate results in increased expression of H1-5 protein
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H1-5 mRNA

PMID:22079256 PMID:31195006

NCBI chr17:47,421,875...47,422,905
Ensembl chr17:47,421,843...47,477,387

G

H1.6 linker histone, cluster member

increases expression

ISO

epigallocatechin gallate results in increased expression of H1-6 protein

NCBI chr17:41,855,216...41,855,960

G

H2A clustered histone 21

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H2AC21 mRNA

NCBI chr 2:186,468,224...186,468,657

G

H2A clustered histone 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H2AC6 mRNA

NCBI chr17:47,403,701...47,404,167

G

H2A.X variant histone

increases phosphorylation
increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased phosphorylation of H2AX protein
epigallocatechin gallate results in increased expression of H2AX protein
epigallocatechin gallate inhibits the reaction [epigallocatechin gallate results in increased phosphorylation of H2AX protein]

PMID:25528115 PMID:25585349 PMID:29175576

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

H2B clustered histone 1

increases expression

ISO

epigallocatechin gallate results in increased expression of H2BC1 protein

NCBI chr17:41,599,912...41,600,381
Ensembl chr17:41,599,211...41,608,681

G

H2B clustered histone 27

decreases expression

ISO

epigallocatechin gallate results in decreased expression of H2BC26 mRNA

NCBI chr10:44,232,318...44,233,065
Ensembl chr10:44,232,318...44,233,065

G

H2B clustered histone 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H2BC9 mRNA

NCBI chr17:47,166,372...47,174,369

G

H4 clustered histone 8

increases expression

ISO

epigallocatechin gallate results in increased expression of H4C9 protein

NCBI chr17:47,176,246...47,180,690
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr17:41,797,152...41,806,539
Ensembl chr 4:41,797,152...41,806,539

G

H1.3 linker histone, cluster member

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H1-3 mRNA

NCBI chr17:41,979,562...41,980,341
Ensembl chr17:41,796,116...41,980,485

G

3-hydroxyacyl-CoA dehydratase 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HACD4 mRNA

NCBI chr 5:107,935,514...107,961,271
Ensembl chr 5:107,934,937...107,962,836

G

hyaluronan and proteoglycan link protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HAPLN3 mRNA

NCBI chr 1:142,455,828...142,473,877
Ensembl chr 1:142,454,629...142,471,832

G

HUWE1 associated protein modifying stress responses

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HAPSTR1 mRNA

NCBI chr10:7,252,737...7,281,678
Ensembl chr10:7,252,737...7,281,678

G

hyaluronan synthase 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HAS1 mRNA

NCBI chr 1:67,366,460...67,378,686
Ensembl chr 1:67,366,460...67,378,444

G

histone acetyltransferase 1

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of HAT1 mRNA]

NCBI chr 3:76,624,442...76,672,701
Ensembl chr 3:76,624,869...76,672,696

G

HAUS augmin-like complex, subunit 1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HAUS1 mRNA
epigallocatechin gallate results in decreased expression of HAUS1 mRNA

NCBI chr18:73,550,549...73,561,757
Ensembl chr18:73,548,669...73,565,761

G

hemoglobin alpha, adult chain 2

increases expression

ISO

epigallocatechin gallate results in increased expression of HBA1 protein

NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,828,377...15,829,141

G

heparin-binding EGF-like growth factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HBEGF mRNA; epigallocatechin gallate affects the reaction [Sodium Chloride results in increased expression of HBEGF mRNA]

PMID:22079256 PMID:26800359

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

histone deacetylase 1

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [sodium arsenite affects the expression of HDAC1 protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of HDAC1 mRNA]

NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387

G

histone deacetylase 5

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HDAC5 mRNA

NCBI chr10:87,653,139...87,688,078
Ensembl chr10:87,652,656...87,694,244

G

histone deacetylase 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HDAC8 mRNA

NCBI chr X:71,425,240...71,632,865
Ensembl chr X:71,394,928...71,632,865

G

HEAT repeat containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR3 mRNA

NCBI chr19:35,065,915...35,103,779
Ensembl chr19:35,067,060...35,103,978

G

HEAT repeat containing 5A

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR5A mRNA
epigallocatechin gallate results in decreased expression of HEATR5A protein

PMID:22079256 PMID:31195006

NCBI chr 6:75,057,226...75,155,207
Ensembl chr 6:75,057,226...75,155,120

G

HEAT repeat containing 5B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR5B mRNA

NCBI chr 6:21,995,558...22,075,582
Ensembl chr 6:21,995,602...22,075,582

G

HEAT repeat containing 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR6 mRNA

NCBI chr10:69,132,532...69,161,334
Ensembl chr10:69,132,181...69,162,945

G

hdc homolog, cell cycle regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HECA mRNA

NCBI chr 1:14,345,306...14,395,226
Ensembl chr 1:14,345,306...14,395,191

G

heart development protein with EGF-like domains 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEG1 mRNA

NCBI chr11:80,512,096...80,600,150
Ensembl chr11:80,512,096...80,600,092

G

HemK methyltransferase family member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEMK1 mRNA

NCBI chr 8:116,878,317...116,889,342
Ensembl chr 8:116,878,318...116,888,873

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of HERC1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERC1 mRNA

NCBI chr 8:75,796,347...75,965,347
Ensembl chr 8:75,796,357...75,965,347

G

HECT and RLD domain containing E3 ubiquitin protein ligase 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERC4 mRNA

NCBI chr20:25,329,005...25,403,443
Ensembl chr20:25,328,822...25,403,372

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERC6 mRNA

NCBI chr 4:88,854,612...88,897,043
Ensembl chr 4:88,854,640...88,896,993

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

ISO

epigallocatechin gallate results in increased expression of HERPUD1 mRNA

NCBI chr19:10,604,360...10,624,168
Ensembl chr19:10,604,362...10,624,081

G

HERPUD family member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERPUD2 mRNA

NCBI chr 8:31,849,216...31,894,219
Ensembl chr 8:31,849,216...31,894,219

G

hes family bHLH transcription factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HES1 mRNA

NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061

G

HEXIM P-TEFb complex subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HEXIM1 mRNA

NCBI chr10:88,562,889...88,565,001
Ensembl chr10:88,560,519...88,580,000

G

hepatocyte growth factor

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of AKT1 protein]; epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

heparan-alpha-glucosaminide N-acetyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HGSNAT mRNA

NCBI chr16:72,807,967...72,840,180
Ensembl chr16:72,807,849...72,840,176

G

hematopoietically expressed homeobox

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HHEX mRNA

NCBI chr 1:244,602,945...244,608,532
Ensembl chr 1:244,602,825...244,608,604

G

HHIP like 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HHIPL2 protein

NCBI chr13:97,586,296...97,606,223
Ensembl chr13:97,586,341...97,606,223

G

3-hydroxyisobutyryl-CoA hydrolase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIBCH mRNA

NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
decreases expression

ISO

epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein]]; epigallocatechin gallate results in decreased hydroxylation of and results in decreased degradation of HIF1A protein; epigallocatechin gallate results in increased expression of and results in increased activity of HIF1A protein
epigallocatechin gallate results in decreased expression of HIF1A mRNA; epigallocatechin gallate results in decreased expression of HIF1A protein

PMID:16005427 PMID:20346928 PMID:36162953

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

hypoxia inducible factor 1 subunit alpha inhibitor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIF1AN mRNA

NCBI chr 1:253,368,400...253,385,495
Ensembl chr 1:253,367,683...253,385,491

G

heat shock protein nuclear import factor hikeshi

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIKESHI mRNA

NCBI chr 1:153,237,948...153,261,856
Ensembl chr 1:153,237,948...153,261,911

G

huntingtin interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIP1 mRNA

NCBI chr12:26,769,868...26,904,367
Ensembl chr12:26,769,961...26,904,296

G

HIVEP zinc finger 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of HIVEP1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIVEP1 mRNA

NCBI chr17:22,790,855...22,920,359
Ensembl chr17:22,790,855...22,917,196

G

HIVEP zinc finger 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of HIVEP2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIVEP2 mRNA

NCBI chr 1:10,176,880...10,376,089
Ensembl chr 1:10,179,402...10,376,089

G

hexokinase 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of HK2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HK2 mRNA

PMID:16084531 PMID:22079256

NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275

G

holocarboxylase synthetase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HLCS mRNA

NCBI chr11:46,925,491...47,123,111
Ensembl chr11:46,925,491...47,105,082

G

helicase-like transcription factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HLTF mRNA

NCBI chr 2:104,478,725...104,538,531
Ensembl chr 2:104,478,772...104,538,818

G

high mobility group AT-hook 1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HMGA1 mRNA
epigallocatechin gallate results in decreased expression of HMGA1 protein

PMID:22079256 PMID:31195006

NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,613,471...5,620,593

G

high mobility group AT-hook 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HMGA2 protein

NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341

G

high mobility group box 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HMGB1 mRNA

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of HMGCR mRNA
epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of HMGCR mRNA]; epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of HMGCR protein]

PMID:30092300 PMID:32512070

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

decreases expression
increases expression
multiple interactions

EXP
ISO

epigallocatechin gallate results in decreased expression of HMGCS1 mRNA
epigallocatechin gallate results in increased expression of HMGCS1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMGCS1 mRNA

PMID:16988119 PMID:22079256 PMID:32512070

NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802

G

high mobility group nucleosomal binding domain 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMGN3 mRNA

NCBI chr 8:92,902,555...92,939,980

G

hyaluronan-mediated motility receptor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMMR mRNA

NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,635,915...25,665,390

G

heme oxygenase 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of HMOX1 protein
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of HMOX1 protein; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of HMOX1 protein]; epigallocatechin gallate promotes the reaction [arsenite results in increased expression of HMOX1 protein]
epigallocatechin gallate results in increased expression of HMOX1 mRNA
[Formaldehyde co-treated with epigallocatechin gallate] results in increased expression of HMOX1 protein; epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of HMOX1 protein]; epigallocatechin gallate results in increased expression of and results in increased activity of HMOX1 protein

PMID:16799064 PMID:25585349 PMID:29061316 PMID:29572906 PMID:30395894 More...

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heme oxygenase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMOX2 mRNA

NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800

G

H6 family homeobox 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HMX3 mRNA

NCBI chr 1:195,743,411...195,745,375
Ensembl chr 1:195,743,271...195,746,444

G

heterogeneous nuclear ribonucleoprotein A1

increases expression

ISO

epigallocatechin gallate results in increased expression of HNRNPA1 protein

NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085

G

heterogeneous nuclear ribonucleoprotein F

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HNRNPF protein

NCBI chr 4:152,755,668...152,776,867
Ensembl chr 4:152,722,617...152,815,769

G

heterogeneous nuclear ribonucleoprotein H1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HNRNPH1 mRNA

NCBI chr10:35,187,412...35,203,909
Ensembl chr10:35,193,890...35,203,906

G

homer scaffold protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HOMER1 mRNA

NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657

G

homeo box B9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HOXB9 mRNA

NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872

G

histone PARylation factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HPF1 mRNA

NCBI chr16:34,211,971...34,230,551
Ensembl chr16:34,193,421...34,253,210

G

HPS3, biogenesis of lysosomal organelles complex 2 subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HPS3 mRNA

NCBI chr 2:104,413,618...104,455,091
Ensembl chr 2:104,413,417...104,455,091

G

HPS5, biogenesis of lysosomal organelles complex 2 subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HPS5 mRNA

NCBI chr 1:106,417,902...106,457,220
Ensembl chr 1:106,417,902...106,452,859

G

HRas proto-oncogene, GTPase

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of HRAS mRNA]; epigallocatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of HRAS protein]

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590

G

hydroxysteroid dehydrogenase like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSDL2 mRNA

NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798

G

heat shock protein family A (Hsp70) member 1B

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HSPA1B mRNA

NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979

G

heat shock protein family A (Hsp70) member 1 like

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HSPA1L mRNA

NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877

G

heat shock protein family A (Hsp70) member 4

increases expression

ISO

epigallocatechin gallate results in increased expression of HSPA4 protein

NCBI chr10:37,908,866...37,951,994
Ensembl chr10:37,908,866...37,949,835

G

heat shock protein family A (Hsp70) member 4 like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSPA4L mRNA

NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:125,668,236...125,720,986

G

heat shock protein family B (small) member 7

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HSPB7 mRNA

NCBI chr 5:159,010,759...159,014,245
Ensembl chr 5:159,010,629...159,014,243

G

heat shock protein family E (Hsp10) member 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of HSPE1 protein

NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502

G

HIV-1 Tat interactive protein 2

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of HTATIP2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HTATIP2 mRNA

PMID:16084531 PMID:22079256

NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815

G

5-hydroxytryptamine receptor 1D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HTR1D mRNA

NCBI chr 5:153,939,735...153,960,012
Ensembl chr 5:153,939,516...153,960,012

G

HtrA serine peptidase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HTRA2 mRNA

NCBI chr 4:117,114,631...117,117,793
Ensembl chr 4:117,114,633...117,117,793

G

HYLS1, centriolar and ciliogenesis associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HYLS1 mRNA

NCBI chr 8:42,170,505...42,179,573
Ensembl chr 8:42,168,546...42,179,725

G

inhibitor of Bruton tyrosine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IBTK mRNA

NCBI chr 8:95,505,630...95,579,435
Ensembl chr 8:95,505,630...95,578,301

G

interactor of little elongation complex ELL subunit 2

increases expression

ISO

epigallocatechin gallate results in increased expression of ICE2 mRNA

NCBI chr 8:78,921,962...78,965,983
Ensembl chr 8:78,924,421...78,966,200

G

inducible T-cell co-stimulator ligand

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ICOSLG mRNA

NCBI chr20:10,600,078...10,610,385
Ensembl chr20:10,600,078...10,610,365

G

inhibitor of DNA binding 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ID2 mRNA

NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:47,457,554...47,472,961

G

insulin degrading enzyme

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IDE mRNA

NCBI chr 1:244,415,495...244,516,925
Ensembl chr 1:244,416,343...244,514,526

G

isopentenyl-diphosphate delta isomerase 1

increases expression

ISO

epigallocatechin gallate results in increased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524

G

immediate early response 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IER2 mRNA

NCBI chr19:40,399,373...40,400,897
Ensembl chr19:40,398,160...40,402,708

G

interferon, alpha-inducible protein 27

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IFI27 mRNA

NCBI chr 6:128,355,312...128,361,783
Ensembl chr 6:128,355,079...128,361,781

G

interferon-induced protein 44

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IFI44 mRNA

NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:243,286,052...243,306,877

G

interferon induced with helicase C domain 1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFIH1 mRNA
epigallocatechin gallate results in decreased expression of IFIH1 mRNA

PMID:22079256 PMID:32512070

NCBI chr 3:67,635,924...67,683,968
Ensembl chr 3:67,637,545...67,683,968

G

interferon-induced protein with tetratricopeptide repeats 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFIT3 mRNA

NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521

G

interferon induced transmembrane protein 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IFITM1 mRNA

NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776

G

interferon induced transmembrane protein 3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IFITM3 mRNA

PMID:32512070 PMID:35701726

NCBI chr 1:205,540,649...205,541,758
Ensembl chr 1:205,481,168...205,547,920

G

interferon gamma

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; epigallocatechin gallate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interferon, lambda receptor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IFNLR1 mRNA

NCBI chr 5:153,203,597...153,225,911
Ensembl chr 5:153,203,597...153,225,911

G

intraflagellar transport 46

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT46 mRNA

NCBI chr 8:53,975,085...54,000,837
Ensembl chr 8:53,984,242...54,000,836

G

intraflagellar transport 70B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT70B mRNA

NCBI chr 3:81,263,074...81,265,645

G

intraflagellar transport 74

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT74 mRNA

NCBI chr 5:114,576,106...114,679,581
Ensembl chr 5:114,593,397...114,679,581

G

intraflagellar transport 80

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT80 mRNA

NCBI chr 2:155,455,773...155,550,082
Ensembl chr 2:155,455,774...155,550,275

G

intraflagellar transport 81

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT81 mRNA

NCBI chr12:39,618,559...39,697,971
Ensembl chr12:39,618,651...39,697,962

G

intraflagellar transport 88

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT88 mRNA

NCBI chr15:35,685,678...35,786,875
Ensembl chr15:35,688,927...35,781,634

G

insulin-like growth factor 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IGF1 mRNA

PMID:20346928 PMID:20706672

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 1 receptor

multiple interactions
increases expression
decreases expression

EXP
ISO

[Carbon Tetrachloride co-treated with epigallocatechin gallate] results in decreased expression of IGF1R mRNA
epigallocatechin gallate results in increased expression of IGF1R mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IGF1R mRNA
epigallocatechin gallate results in decreased expression of IGF1R protein modified form

PMID:19646978 PMID:20346928 PMID:22079256

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

insulin-like growth factor 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IGF2 mRNA

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

insulin-like growth factor 2 mRNA binding protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IGF2BP3 mRNA

NCBI chr 4:79,391,367...79,525,923
Ensembl chr 4:79,393,067...79,525,730

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions
decreases expression

ISO
EXP

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IKBKB mRNA
epigallocatechin gallate results in decreased expression of IKBKB protein modified form

PMID:22079256 PMID:27659729

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

inhibitor of nuclear factor kappa B kinase regulatory subunit gamma

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IKBKG mRNA

NCBI chr X:157,358,279...157,397,563
Ensembl chr X:157,367,639...157,392,757

G

IKAROS family zinc finger 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IKZF2 mRNA

NCBI chr 9:78,495,670...78,640,896
Ensembl chr 9:78,492,275...78,640,463

G

interleukin 10

increases expression
multiple interactions

EXP
ISO

epigallocatechin gallate results in increased expression of IL10 protein
epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IL10 protein]

PMID:27659729 PMID:37286014

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 10 receptor subunit beta

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of IL10RB mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL10RB mRNA

PMID:16084531 PMID:22079256

NCBI chr11:44,132,471...44,154,062
Ensembl chr11:44,132,189...44,154,053

G

interleukin 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IL11 mRNA

NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:78,096,930...78,104,915

G

interleukin 18

multiple interactions

EXP

epigallocatechin gallate inhibits the reaction [ochratoxin A results in increased expression of IL18 mRNA]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 alpha

multiple interactions
decreases expression

ISO

epigallocatechin gallate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1A mRNA]
epigallocatechin gallate results in decreased expression of IL1A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL1A mRNA

PMID:7665919 PMID:20706672 PMID:22079256

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions
decreases expression
affects expression

ISO
EXP

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; [Sulindac co-treated with epigallocatechin gallate] results in decreased expression of IL1B mRNA; epigallocatechin gallate inhibits the reaction [bisphenol A affects the expression of IL1B mRNA]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of IL1B protein]
epigallocatechin gallate inhibits the reaction [Formaldehyde results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of IL1B mRNA]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]
epigallocatechin gallate results in decreased expression of IL1B mRNA
epigallocatechin gallate affects the expression of IL1B
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [Gentamicins results in increased expression of IL1B protein]; epigallocatechin gallate inhibits the reaction [IL1B protein results in increased expression of CXCL1 protein]; epigallocatechin gallate inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]; epigallocatechin gallate results in decreased expression of and results in decreased secretion of IL1B protein

PMID:12628509 PMID:15237969 PMID:18377686 PMID:19557821 PMID:20816778 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 2

multiple interactions

ISO

epigallocatechin gallate results in decreased expression of and results in decreased secretion of IL2 protein

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 23 subunit alpha

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IL23A mRNA

NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434

G

interleukin 27 receptor subunit alpha

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of IL27RA mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IL27RA mRNA

PMID:16084531 PMID:22079256

NCBI chr19:41,014,730...41,026,740
Ensembl chr19:41,014,730...41,026,760

G

interleukin 5

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of IL5 protein]

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

increases expression
multiple interactions
decreases expression
decreases secretion

ISO
EXP

epigallocatechin gallate results in increased expression of IL6 mRNA
epigallocatechin gallate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of IL6 protein]
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of IL6 protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of IL6 protein]
epigallocatechin gallate results in decreased expression of IL6 mRNA; epigallocatechin gallate results in decreased expression of IL6 protein
epigallocatechin gallate results in increased expression of IL6 protein
[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL6 mRNA; epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of MT1X mRNA]; epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of MT2A mRNA]; epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of SLC39A14 mRNA]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of IL6 protein]
epigallocatechin gallate results in decreased secretion of IL6 protein

PMID:18025290 PMID:18209571 PMID:20471814 PMID:20816778 PMID:22079256 More...

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL7 mRNA

NCBI chr 2:96,142,523...96,186,282
Ensembl chr 2:96,142,092...96,187,389

G

interleukin 7 receptor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL7R mRNA

NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027

G

interleukin enhancer binding factor 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ILF2 protein

NCBI chr 2:178,256,927...178,268,773
Ensembl chr 2:178,248,585...178,268,920

G

interleukin enhancer binding factor 3

increases expression

ISO

epigallocatechin gallate results in increased expression of ILF3 protein

NCBI chr 8:28,198,454...28,236,634
Ensembl chr 8:28,198,543...28,236,612

G

inner mitochondrial membrane peptidase subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IMMP1L mRNA

NCBI chr 3:112,840,015...112,904,297
Ensembl chr 3:112,840,113...112,904,296

G

interphotoreceptor matrix proteoglycan 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IMPG2 mRNA

NCBI chr11:57,787,914...57,887,450
Ensembl chr11:57,787,914...58,033,766

G

inositol polyphosphate-5-phosphatase A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INPP5A mRNA

NCBI chr 1:203,619,676...203,810,035
Ensembl chr 1:203,619,637...203,810,028

G

insulin 1

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of INS1 protein; epigallocatechin gallate inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein]; epigallocatechin gallate inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]

PMID:18591783 PMID:25663641

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin induced gene 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INSIG1 mRNA

NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778

G

integrator complex subunit 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTS10 mRNA

NCBI chr16:25,682,818...25,735,840
Ensembl chr16:25,682,050...25,734,528

G

integrator complex subunit 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTS8 mRNA

NCBI chr 5:29,094,475...29,141,874
Ensembl chr 5:29,094,475...29,142,099

G

integrator complex subunit 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTS9 mRNA

NCBI chr15:43,376,235...43,460,549
Ensembl chr15:43,375,850...43,478,936

G

inturned planar cell polarity protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTU mRNA

NCBI chr 2:125,528,965...125,613,295
Ensembl chr 2:125,529,208...125,613,295

G

inversin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INVS mRNA

NCBI chr 5:67,406,511...67,559,355
Ensembl chr 5:67,406,485...67,559,350

G

inositol hexakisphosphate kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IP6K2 mRNA

NCBI chr 8:118,362,154...118,388,668
Ensembl chr 8:118,362,795...118,388,667

G

interleukin-1 receptor-associated kinase 1 binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IRAK1BP1 mRNA

NCBI chr 8:92,608,468...92,628,377
Ensembl chr 8:92,611,843...92,628,377

G

interleukin-1 receptor-associated kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IRAK3 mRNA

NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706

G

iron responsive element binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IREB2 mRNA

NCBI chr 8:64,124,152...64,207,702
Ensembl chr 8:64,154,945...64,205,520

G

interferon regulatory factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IRF2 mRNA

NCBI chr16:52,171,855...52,283,620
Ensembl chr16:52,164,442...52,282,627

G

interferon regulatory factor 9

decreases expression

ISO

epigallocatechin gallate results in decreased expression of IRF9 mRNA

NCBI chr15:33,065,422...33,071,881
Ensembl chr15:33,065,659...33,071,879

G

insulin receptor substrate 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IRS2 mRNA

NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543

G

iron-sulfur cluster assembly 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ISCA2 mRNA

NCBI chr 6:110,149,593...110,151,103
Ensembl chr14:71,931,399...71,934,660
Ensembl chr 6:71,931,399...71,934,660

G

ISL LIM homeobox 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ISL2 mRNA

NCBI chr 8:64,819,879...64,824,864
Ensembl chr 8:64,819,879...64,824,864

G

itchy E3 ubiquitin protein ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITCH mRNA

NCBI chr 3:164,102,490...164,193,932
Ensembl chr 3:164,105,812...164,193,932

G

integrin subunit alpha 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITGA4 mRNA

NCBI chr 3:84,569,487...84,646,276
Ensembl chr 3:84,560,369...84,641,039

G

integrin subunit alpha 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITGA6 mRNA

NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076

G

integrin subunit alpha V

decreases expression

ISO

epigallocatechin gallate results in decreased expression of ITGAV mRNA

NCBI chr 3:89,245,382...89,333,512
Ensembl chr 3:89,245,095...89,333,511

G

integrin subunit beta 1 binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ITGB1BP2 mRNA

NCBI chr X:70,612,118...70,617,158
Ensembl chr X:70,612,521...70,617,158

G

integrin subunit beta 3 binding protein

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of ITGB3BP mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITGB3BP mRNA

NCBI chr 5:119,575,657...119,640,974
Ensembl chr 5:119,575,248...119,640,997

G

integrin subunit beta 4

multiple interactions
decreases expression

ISO

[Sulindac co-treated with epigallocatechin gallate] results in decreased expression of ITGB4 mRNA
epigallocatechin gallate results in decreased expression of ITGB4 protein

PMID:12628509 PMID:31195006

NCBI chr10:101,705,592...101,741,933
Ensembl chr10:101,705,587...101,741,932

G

inositol 1,4,5-trisphosphate receptor, type 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of ITPR2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITPR2 mRNA

NCBI chr 4:180,759,325...181,165,361
Ensembl chr 4:180,760,442...181,164,763

G

inositol 1,4,5-trisphosphate receptor interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ITPRIP mRNA

NCBI chr 1:256,704,087...256,727,661
Ensembl chr 1:256,699,832...256,727,644

G

intersectin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITSN1 mRNA

NCBI chr11:44,464,515...44,646,598
Ensembl chr11:44,513,186...44,646,598

G

interacts with SUPT6H, CTD assembly factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IWS1 mRNA

NCBI chr18:23,969,352...24,011,560
Ensembl chr18:23,969,733...24,010,415

G

jagged canonical Notch ligand 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of JAG1 mRNA

NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872

G

Janus kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of JAK2 mRNA

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

Janus kinase 3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of JAK3 protein; epigallocatechin gallate results in decreased expression of JAK3 protein modified form

NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222

G

jumonji and AT-rich interaction domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of JARID2 mRNA

NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,983,217...20,161,970

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of JUN protein
epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased phosphorylation of JUN protein]

PMID:12663506 PMID:31252129

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

KN motif and ankyrin repeat domains 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KANK1 mRNA

NCBI chr 1:232,381,720...232,500,834
Ensembl chr 1:232,445,658...232,500,839

G

KAT8 regulatory NSL complex subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KANSL2 mRNA

NCBI chr 7:131,548,062...131,564,876
Ensembl chr 7:131,548,062...131,564,753

G

lysine acetyltransferase 14

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT14 mRNA

NCBI chr 3:152,194,560...152,235,048
Ensembl chr 3:152,194,696...152,235,052

G

lysine acetyltransferase 2B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT2B mRNA

NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616

G

lysine acetyltransferase 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT5 mRNA

NCBI chr 1:212,325,089...212,332,640
Ensembl chr 1:212,325,090...212,332,587

G

lysine acetyltransferase 6B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT6B mRNA

NCBI chr15:2,688,535...2,861,443
Ensembl chr15:2,688,811...2,844,343

G

katanin catalytic subunit A1 like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KATNAL1 mRNA

NCBI chr12:11,130,935...11,192,330
Ensembl chr12:11,139,110...11,194,396

G

katanin regulatory subunit B1 like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KATNBL1 mRNA

NCBI chr 3:119,638,068...119,680,179
Ensembl chr 3:119,638,107...119,680,173

G

katanin interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KATNIP mRNA

NCBI chr 1:189,700,838...189,867,402
Ensembl chr 1:189,700,775...189,867,402

G

kazrin, periplakin interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAZN mRNA

NCBI chr 5:159,675,803...160,666,084
Ensembl chr 5:159,675,803...160,664,154

G

kelch repeat and BTB domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KBTBD2 mRNA

NCBI chr 4:87,358,133...87,380,399
Ensembl chr 4:87,358,133...87,380,399

G

potassium calcium-activated channel subfamily M regulatory beta subunit 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KCNMB4 mRNA

NCBI chr 7:53,952,150...54,005,101
Ensembl chr 7:53,949,881...54,005,281

G

potassium channel tetramerization domain containing 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KCTD10 mRNA

NCBI chr12:47,890,777...47,909,391
Ensembl chr12:47,890,819...47,909,390

G

potassium channel tetramerization domain containing 16

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KCTD16 mRNA

NCBI chr18:32,417,306...32,711,928
Ensembl chr18:32,419,225...32,712,820

G

potassium channel tetramerization domain containing 9

increases expression

ISO

epigallocatechin gallate results in increased expression of KCTD9 protein

NCBI chr15:46,117,211...46,145,258
Ensembl chr15:46,117,874...46,145,266

G

KDEL endoplasmic reticulum protein retention receptor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KDELR3 mRNA

NCBI chr 7:112,959,632...112,969,858
Ensembl chr 7:112,959,718...112,969,858

G

lysine demethylase 4C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KDM4C mRNA

NCBI chr 5:93,146,404...93,353,040
Ensembl chr 5:93,146,969...93,353,040

G

kinase insert domain receptor

decreases expression

ISO

epigallocatechin gallate results in decreased expression of KDR protein; epigallocatechin gallate results in decreased expression of KDR protein modified form

PMID:17992120 PMID:20346928

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

Kelch-like ECH-associated protein 1

multiple interactions
increases expression

ISO

epigallocatechin gallate promotes the reaction [arsenite results in increased expression of KEAP1 mRNA]
epigallocatechin gallate results in increased expression of KEAP1 protein

PMID:29572906 PMID:35218280

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

KH domain containing 4, pre-mRNA splicing factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KHDC4 mRNA

NCBI chr 2:176,446,895...176,475,405
Ensembl chr 2:176,446,910...176,475,392

G

ketohexokinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KHK mRNA

NCBI chr 6:31,165,246...31,175,779
Ensembl chr 6:31,165,248...31,175,481

G

KIAA0586 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA0586 mRNA

NCBI chr 6:95,358,682...95,461,911
Ensembl chr 6:95,358,619...95,462,148

G

KIAA1328 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1328 mRNA

NCBI chr18:16,762,421...17,061,439
Ensembl chr18:16,763,047...17,047,924

G

kinesin family member 13A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF13A mRNA

NCBI chr17:17,972,227...18,154,763
Ensembl chr17:17,972,325...18,154,760

G

kinesin family member 14

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF14 mRNA

NCBI chr13:50,478,646...50,542,256
Ensembl chr13:50,478,721...50,542,248

G

kinesin family member 15

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF15 mRNA

NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:131,479,337...131,550,202

G

kinesin family member 16B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF16B mRNA

NCBI chr 3:150,428,233...150,707,755
Ensembl chr 3:150,366,838...150,707,770

G

kinesin family member 18A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF18A mRNA

NCBI chr 3:116,219,007...116,279,378
Ensembl chr 3:116,219,007...116,279,227

G

kinesin family member 20B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF20B mRNA

NCBI chr 1:241,840,898...241,896,451
Ensembl chr 1:241,840,987...241,896,451

G

kinesin family member 4A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF4A mRNA

NCBI chr X:69,761,803...69,864,335
Ensembl chr X:69,761,883...69,864,335

G

kinesin-associated protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIFAP3 mRNA

NCBI chr13:78,660,849...78,797,821
Ensembl chr13:78,660,871...78,797,820

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIT mRNA

NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812

G

Klotho

decreases expression

ISO

epigallocatechin gallate results in decreased expression of KL mRNA

NCBI chr12:5,326,003...5,367,016
Ensembl chr12:5,325,959...5,367,015

G

KLF transcription factor 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLF10 mRNA

NCBI chr 7:71,352,612...71,358,680
Ensembl chr 7:71,350,573...71,358,948

G

KLF transcription factor 4

multiple interactions
increases response to substance

ISO
EXP

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLF4 mRNA
(-)-epigallocatechin 3-gallate inhibits the reaction [angiotensin II increases expression of KLF4 protein in vascular smooth muscle cells]
KLF4 protein results in increased susceptibility to epigallocatechin gallate
epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of KLF4 mRNA]; epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of KLF4 protein]; KLF4 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]]; KLF4 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]]

CTD
RGD

PMID:22079256 PMID:28478070 PMID:29127880

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592

G

KLF transcription factor 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLF7 mRNA

NCBI chr 9:72,927,485...73,020,167
Ensembl chr 9:72,933,136...73,020,056

G

kelch domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHDC2 mRNA

NCBI chr 6:93,512,981...93,552,809
Ensembl chr 6:93,513,017...93,577,762

G

kelch domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHDC3 mRNA

NCBI chr 9:21,799,870...21,806,337
Ensembl chr 9:21,799,729...21,806,334

G

kelch-like family member 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHL12 mRNA

NCBI chr13:48,451,920...48,485,638
Ensembl chr13:48,455,227...48,485,641

G

kelch-like family member 15

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL15 mRNA

NCBI chr X:62,987,762...63,043,980
Ensembl chr X:62,989,426...63,039,870

G

kelch-like family member 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL18 mRNA

NCBI chr 8:119,279,081...119,337,850
Ensembl chr 8:119,279,081...119,337,719

G

kelch-like family member 20

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHL20 mRNA

NCBI chr13:75,896,802...75,941,724
Ensembl chr13:75,898,410...75,945,061

G

kelch-like family member 21

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL21 mRNA

NCBI chr 5:167,797,621...167,806,276
Ensembl chr 5:167,797,591...167,806,276

G

kelch-like family member 26

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL26 mRNA

NCBI chr16:18,986,095...19,011,297
Ensembl chr16:18,985,865...19,011,297

G

kelch-like family member 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHL9 mRNA

NCBI chr 5:108,449,492...108,453,676
Ensembl chr 5:108,437,583...108,454,140

G

lysine methyltransferase 2C

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of KMT2C mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KMT2C mRNA

NCBI chr 4:10,353,698...10,755,965
Ensembl chr 4:10,353,735...10,568,620

G

kinetochore-localized astrin/SPAG5 binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KNSTRN mRNA

NCBI chr 3:126,254,633...126,274,412
Ensembl chr 3:126,254,663...126,274,418

G

kinetochore associated 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KNTC1 mRNA

NCBI chr12:38,429,925...38,500,564
Ensembl chr12:38,429,925...38,500,457

G

karyopherin subunit beta 1

increases expression

ISO

epigallocatechin gallate results in increased expression of KPNB1 protein

NCBI chr10:82,642,082...82,670,856
Ensembl chr10:82,642,082...82,670,856

G

KRIT1, ankyrin repeat containing

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KRIT1 mRNA

NCBI chr 4:31,253,918...31,288,066
Ensembl chr 4:31,253,918...31,288,073

G

keratin 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of KRT1 protein

NCBI chr 7:134,855,311...134,860,537
Ensembl chr 7:134,855,313...134,860,537

G

keratin 77

increases expression

ISO

epigallocatechin gallate results in increased expression of KRT77 protein

NCBI chr 7:134,868,416...134,880,776
Ensembl chr 7:134,868,416...134,880,776

G

L3MBTL histone methyl-lysine binding protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of L3MBTL3 mRNA

NCBI chr 1:20,807,679...20,908,609
Ensembl chr 1:20,808,973...20,908,608

G

lactamase, beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LACTB mRNA

NCBI chr 8:76,452,679...76,469,986
Ensembl chr 8:76,452,349...76,468,716

G

lactamase, beta 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LACTB2 mRNA

NCBI chr 5:10,352,165...10,374,928
Ensembl chr 5:10,352,154...10,379,255

G

lysosomal-associated membrane protein 1

increases expression

ISO

epigallocatechin gallate results in increased expression of LAMP1 mRNA

NCBI chr16:83,058,131...83,082,843
Ensembl chr16:83,058,385...83,075,159

G

late endosomal/lysosomal adaptor, MAPK and MTOR activator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LAMTOR2 mRNA

NCBI chr 2:176,306,353...176,310,617
Ensembl chr 2:176,306,280...176,310,730

G

large tumor suppressor kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LATS2 mRNA

NCBI chr15:35,940,632...35,992,225
Ensembl chr15:35,940,632...35,980,842

G

lecithin cholesterol acyltransferase

multiple interactions

EXP

epigallocatechin gallate inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein]

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:50,744,601...50,748,081

G

lipid droplet associated hydrolase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LDAH mRNA

NCBI chr 6:36,801,359...36,885,929
Ensembl chr 6:36,801,359...36,885,923

G

low density lipoprotein receptor

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of LDLR mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

low density lipoprotein receptor class A domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LDLRAD3 mRNA

NCBI chr 3:108,694,528...108,936,330
Ensembl chr 3:108,694,528...108,936,368

G

liver enriched antimicrobial peptide 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LEAP2 mRNA

NCBI chr10:38,081,001...38,082,073
Ensembl chr10:38,081,001...38,082,073

G

leukocyte receptor cluster member 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LENG8 mRNA

NCBI chr 1:79,113,038...79,124,868
Ensembl chr 1:79,113,038...79,124,738

G

leptin

multiple interactions

ISO

[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of LEP protein

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

galectin 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of LGALS1 mRNA

NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800

G

galectin 3 binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LGALS3BP mRNA

NCBI chr10:104,118,510...104,127,848
Ensembl chr10:104,118,510...104,127,848

G

leucine-rich repeat-containing G protein-coupled receptor 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LGR4 mRNA

NCBI chr 3:116,901,968...117,004,584
Ensembl chr 3:116,901,968...117,004,153

G

LHFPL tetraspan subfamily member 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LHFPL6 mRNA

NCBI chr 2:139,276,810...139,474,740
Ensembl chr 2:139,276,789...139,474,737

G

DNA ligase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LIG3 mRNA

NCBI chr10:68,215,371...68,238,705
Ensembl chr10:68,215,407...68,238,704

G

LIM domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LIMD1 mRNA

NCBI chr 8:131,998,262...132,045,924
Ensembl chr 8:131,999,770...132,045,922

G

lin-9 DREAM MuvB core complex component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LIN9 mRNA

NCBI chr13:94,906,185...94,951,541
Ensembl chr13:94,906,548...94,951,539

G

lectin, mannose-binding 2-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMAN2L mRNA

NCBI chr 9:46,157,596...46,181,151
Ensembl chr 9:46,157,596...46,181,207

G

limb development membrane protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMBR1 mRNA

NCBI chr 4:6,649,824...6,820,525
Ensembl chr 4:6,649,821...6,822,238

G

LMBR1 domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMBRD1 mRNA

NCBI chr 9:34,592,723...34,674,425
Ensembl chr 9:34,577,616...34,674,428

G

lamin B1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMNB1 mRNA
epigallocatechin gallate results in decreased expression of LMNB1 protein

PMID:22079256 PMID:31195006

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283

G

leucyl and cystinyl aminopeptidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LNPEP mRNA

NCBI chr 1:66,931,712...67,027,610
Ensembl chr 1:66,931,712...67,027,610

G

small ubiquitin-related modifier 2-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SUMO4 mRNA

NCBI chr11:92,667,392...92,668,480

G

uncharacterized LOC130046242

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF57 mRNA

NCBI chr 7:8,663,437...8,669,068
Ensembl chr 7:8,663,217...8,667,271

G

lysyl oxidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LOX mRNA

NCBI chr18:48,162,889...48,175,640
Ensembl chr18:48,165,688...48,239,810

G

lysophosphatidic acid receptor 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LPAR4 mRNA

NCBI chr X:76,106,319...76,119,807
Ensembl chr X:76,106,071...76,119,808

G

lysophosphatidylcholine acyltransferase 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LPCAT4 mRNA

NCBI chr 3:119,499,128...119,507,275
Ensembl chr 3:119,499,128...119,507,362

G

lipin 1

increases expression

ISO

epigallocatechin gallate results in increased expression of LPIN1 mRNA

NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991

G

LPS responsive beige-like anchor protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRBA mRNA

NCBI chr 2:173,919,330...174,500,536
Ensembl chr 2:173,921,747...174,500,527

G

leucine rich repeats and calponin homology domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRCH1 mRNA

NCBI chr15:56,469,403...56,659,201
Ensembl chr15:56,481,395...56,659,100

G

leucine rich repeats and calponin homology domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRCH3 mRNA

NCBI chr11:81,277,581...81,377,339
Ensembl chr11:81,277,581...81,377,337

G

LDL receptor related protein 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRP11 mRNA

NCBI chr 1:3,868,665...3,928,513
Ensembl chr 1:3,899,985...3,928,507

G

leucine rich repeat protein 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of LRR1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRR1 mRNA

NCBI chr 6:93,379,159...93,387,950
Ensembl chr 6:93,379,169...93,387,950

G

leucine rich repeat containing 28

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC28 mRNA

NCBI chr 1:130,526,757...130,655,991
Ensembl chr 1:130,537,930...130,655,949

G

leucine rich repeat containing 40

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC40 mRNA

NCBI chr 2:249,760,354...249,789,897
Ensembl chr 2:249,760,354...249,791,265

G

leucine rich repeat containing 49

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC49 mRNA

NCBI chr 8:69,948,962...70,056,579
Ensembl chr 8:69,948,972...70,079,636

G

leucine rich repeat containing 61

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC61 mRNA

NCBI chr 4:78,834,783...78,854,810
Ensembl chr 4:78,833,857...78,868,931

G

leucine rich repeat containing 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC7 mRNA

NCBI chr 2:249,792,441...250,294,267
Ensembl chr 2:249,805,448...250,293,718

G

leucine rich repeat containing 8 VRAC subunit A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LRRC8A mRNA

NCBI chr 3:33,902,299...33,934,989
Ensembl chr 3:33,908,268...33,933,625

G

leucine rich repeat containing 8 VRAC subunit D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC8D mRNA

NCBI chr14:4,335,114...4,411,549
Ensembl chr14:4,332,130...4,445,639

G

leucine rich repeat and coiled-coil centrosomal protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRCC1 mRNA

NCBI chr 2:88,746,904...88,781,532
Ensembl chr 2:88,746,443...88,781,542

G

leucine-rich repeats and death domain containing 1

increases expression

ISO

epigallocatechin gallate results in increased expression of LRRD1 mRNA

NCBI chr 4:31,219,573...31,247,702
Ensembl chr 4:31,219,477...31,241,491

G

LRR binding FLII interacting protein 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of LRRFIP1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LRRFIP1 mRNA

NCBI chr 9:99,039,590...99,167,805
Ensembl chr 9:99,039,614...99,167,779

G

leucine rich repeat and sterile alpha motif containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRSAM1 mRNA

NCBI chr 3:36,621,042...36,661,932
Ensembl chr 3:36,621,042...36,661,825

G

LSM10, U7 small nuclear RNA associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LSM10 mRNA

NCBI chr 5:143,649,817...143,660,391
Ensembl chr 5:143,615,360...143,663,986

G

LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LSM6 mRNA
epigallocatechin gallate results in decreased expression of LSM6 mRNA

NCBI chr19:46,002,592...46,017,152

G

leucine-rich single-pass membrane protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LSMEM1 mRNA

NCBI chr 6:62,978,880...62,988,750
Ensembl chr 6:62,978,885...62,988,750

G

lipolysis stimulated lipoprotein receptor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LSR mRNA

NCBI chr 1:95,313,830...95,329,471
Ensembl chr 1:95,313,033...95,329,354

G

latexin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LXN mRNA

NCBI chr 2:154,037,604...154,043,473
Ensembl chr 2:154,037,292...154,043,488

G

Ly6/Plaur domain containing 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LYPD6 mRNA

NCBI chr 3:54,896,618...55,041,928
Ensembl chr 3:54,896,575...55,041,929

G

lysosomal trafficking regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LYST mRNA

NCBI chr17:93,225,509...93,427,650
Ensembl chr17:93,225,540...93,427,650

G

leucine zipper like post translational regulator 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LZTR1 mRNA

NCBI chr11:96,991,956...97,008,127
Ensembl chr11:96,991,590...97,007,851

G

meiosis 1 associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of M1AP mRNA

NCBI chr 4:117,003,631...117,094,455
Ensembl chr 4:117,013,069...117,094,455

G

microtubule-actin crosslinking factor 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of MACF1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MACF1 mRNA

NCBI chr 5:140,908,829...141,234,127
Ensembl chr 5:140,908,837...141,233,890

G

macroH2A.2 histone

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MACROH2A2 mRNA

NCBI chr20:30,220,975...30,270,652
Ensembl chr20:30,221,011...30,270,652

G

maelstrom spermatogenic transposon silencer

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MAEL protein

NCBI chr13:80,990,040...81,029,623
Ensembl chr13:80,990,040...81,029,623

G

MAF bZIP transcription factor F

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAFF mRNA

NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:112,791,416...112,804,147

G

MAF bZIP transcription factor G

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAFG mRNA

NCBI chr10:106,401,633...106,410,159

G

membrane associated guanylate kinase, WW and PDZ domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAGI1 mRNA

NCBI chr 4:127,762,590...128,368,228
Ensembl chr 4:127,762,590...128,367,833

G

mal, T-cell differentiation protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAL2 mRNA

NCBI chr 7:87,790,239...87,823,219
Ensembl chr 7:87,790,239...87,850,403

G

MALT1 paracaspase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MALT1 mRNA

NCBI chr18:61,212,290...61,266,272
Ensembl chr18:61,212,317...61,266,272

G

mastermind-like transcriptional coactivator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAML2 mRNA

NCBI chr 8:18,552,480...18,869,923
Ensembl chr 8:18,552,281...18,869,900

G

MEF2 activating motif and SAP domain containing transcriptional regulator

increases expression

ISO

epigallocatechin gallate results in increased expression of MAMSTR protein

NCBI chr 1:105,246,172...105,252,759
Ensembl chr 1:105,246,950...105,252,757

G

mannosidase, alpha, class 2A, member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAN2A2 mRNA

NCBI chr 1:143,712,157...143,736,624
Ensembl chr 1:143,716,072...143,736,562

G

mannosidase, endo-alpha

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MANEA mRNA

NCBI chr 5:44,992,937...45,015,084
Ensembl chr 5:44,992,937...45,015,084

G

microtubule-associated protein 1 light chain 3 alpha

increases expression

ISO

epigallocatechin gallate results in increased expression of MAP1LC3A mRNA

NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:164,243,093...164,244,850

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAP1LC3B mRNA
epigallocatechin gallate results in increased expression of MAP1LC3B protein

PMID:22079256 PMID:32512070

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen-activated protein kinase kinase 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721

G

mitogen-activated protein kinase kinase kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP3K1 mRNA

NCBI chr 2:45,081,889...45,150,555
Ensembl chr 2:45,081,889...45,149,897

G

mitogen-activated protein kinase kinase kinase 14

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MAP3K14 mRNA

NCBI chr10:88,665,417...88,715,669
Ensembl chr10:88,665,417...88,715,592

G

mitogen-activated protein kinase kinase kinase 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP3K8 mRNA

NCBI chr17:58,078,175...58,098,455
Ensembl chr17:58,078,320...58,098,452

G

mitogen-activated protein kinase kinase kinase kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP4K3 mRNA

NCBI chr 6:20,029,246...20,198,583
Ensembl chr 6:20,029,397...20,198,583

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
increases activity
decreases expression

ISO
EXP

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [epigallocatechin gallate results in increased activity of MAPK1 protein]; [epigallocatechin gallate co-treated with Celecoxib] results in increased activity of MAPK1 protein; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of MAPK1 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]]; epigallocatechin gallate results in increased expression of and results in increased phosphorylation of MAPK1 protein
epigallocatechin gallate results in increased phosphorylation of MAPK1 protein
epigallocatechin gallate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of MAPK1 protein]
epigallocatechin gallate results in decreased expression of MAPK1 protein modified form
epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in increased phosphorylation of MAPK1 protein]; epigallocatechin gallate results in increased phosphorylation of and results in increased activity of MAPK1 protein; MFN2 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in increased phosphorylation of MAPK1 protein]]

PMID:15210717 PMID:16463383 PMID:17931610 PMID:19244381 PMID:19557821 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 14

multiple interactions
increases expression

ISO

[epigallocatechin gallate co-treated with Celecoxib] results in increased activity of MAPK14 protein; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAPK14 mRNA
epigallocatechin gallate results in increased expression of MAPK14 mRNA

PMID:16463383 PMID:22079256 PMID:35701726

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
increases activity
decreases expression

ISO
EXP

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [epigallocatechin gallate results in increased activity of MAPK3 protein]; [epigallocatechin gallate co-treated with Celecoxib] results in increased activity of MAPK3 protein; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of MAPK3 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]]; epigallocatechin gallate results in increased expression of and results in increased phosphorylation of MAPK3 protein
epigallocatechin gallate results in increased phosphorylation of MAPK3 protein
epigallocatechin gallate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of MAPK3 protein]
epigallocatechin gallate results in decreased expression of MAPK3 protein modified form
epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in increased phosphorylation of MAPK3 protein]; epigallocatechin gallate results in increased phosphorylation of and results in increased activity of MAPK3 protein; MFN2 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in increased phosphorylation of MAPK3 protein]]

PMID:15210717 PMID:16463383 PMID:17931610 PMID:19244381 PMID:19557821 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

multiple interactions
decreases expression
increases activity

ISO
EXP

epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein]; epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK8 protein]
[Tea results in increased abundance of epigallocatechin gallate] inhibits the reaction [Histamine results in increased expression of MAPK8 mRNA]
epigallocatechin gallate results in decreased expression of MAPK8 protein
epigallocatechin gallate results in increased activity of MAPK8 protein

PMID:15705601 PMID:19944065 PMID:31252129 PMID:35218280 PMID:39322001

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 9

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

MAPK activated protein kinase 5

decreases activity

ISO

epigallocatechin gallate results in decreased activity of MAPKAPK5 protein

NCBI chr12:40,654,220...40,673,740
Ensembl chr12:40,654,423...40,677,170

G

microtubule-associated protein, RP/EB family, member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAPRE3 mRNA

NCBI chr 6:31,233,736...31,278,626
Ensembl chr 6:31,233,736...31,278,775

G

membrane associated ring-CH-type finger 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MARCHF3 mRNA

NCBI chr18:52,435,292...52,587,321
Ensembl chr18:52,435,296...52,587,297

G

methionine adenosyltransferase 2A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAT2A mRNA

NCBI chr 4:106,048,043...106,053,612
Ensembl chr 4:106,038,254...106,053,645

G

methyl-CpG binding domain protein 5

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of MBD5 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MBD5 mRNA

NCBI chr 3:53,742,458...54,147,970
Ensembl chr 3:54,075,084...54,139,389

G

muscleblind-like splicing regulator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MBNL2 mRNA

NCBI chr15:103,792,134...103,949,827
Ensembl chr15:103,792,152...103,949,827

G

membrane bound O-acyltransferase domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MBOAT1 mRNA

NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,540,041...34,653,698

G

melanocortin 1 receptor

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MC1R mRNA

NCBI chr19:68,360,950...68,363,877
Ensembl chr19:68,360,950...68,363,877

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
decreases expression

ISO

[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of MCL1 mRNA alternative form; [Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of MCL1 mRNA alternative form; calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of MCL1 mRNA alternative form]; calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of MCL1 mRNA alternative form]; CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of MCL1 protein]; tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of MCL1 mRNA alternative form]; tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of MCL1 mRNA alternative form]

PMID:16115949 PMID:18348186

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

mucolipin TRP cation channel 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MCOLN2 mRNA

NCBI chr 2:237,714,100...237,762,979
Ensembl chr 2:237,714,084...237,762,978

G

MCTS1, re-initiation and release factor

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MCTS1 mRNA
epigallocatechin gallate results in decreased expression of MCTS1 mRNA

NCBI chr X:122,215,602...122,228,101
Ensembl chr X:122,216,439...122,229,631

G

mitochondrial calcium uniporter

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MCU mRNA

NCBI chr20:27,960,520...28,123,103
Ensembl chr20:27,961,327...28,123,103

G

malate dehydrogenase 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MDH1 protein

NCBI chr14:99,831,934...99,847,227
Ensembl chr14:99,831,615...99,847,232

G

malate dehydrogenase 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MDH2 protein

NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841

G

MDM2 proto-oncogene

multiple interactions

ISO

[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791

G

mediator complex subunit 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED11 mRNA

NCBI chr10:55,662,956...55,664,574
Ensembl chr10:55,663,001...55,664,765

G

mediator complex subunit 12L

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED12L mRNA

NCBI chr 2:145,403,318...145,726,317
Ensembl chr 2:145,404,375...145,723,516

G

mediator complex subunit 13L

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED13L mRNA

NCBI chr12:43,468,556...43,665,819
Ensembl chr12:43,468,556...43,665,819

G

mediator complex subunit 26

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MED26 mRNA

NCBI chr16:17,333,770...17,384,797
Ensembl chr16:17,327,734...17,383,603

G

mediator complex subunit 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED7 mRNA

NCBI chr10:31,343,613...31,359,192
Ensembl chr10:31,343,361...31,361,017

G

mediator complex subunit 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MED9 mRNA

NCBI chr10:45,250,229...45,264,988
Ensembl chr10:45,250,223...45,264,987

G

mesenteric estrogen-dependent adipogenesis

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MEDAG mRNA

NCBI chr12:10,649,526...10,670,913
Ensembl chr12:10,649,526...10,692,756

G

Meis homeobox 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MEIS2 mRNA

NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751

G

maternal embryonic leucine zipper kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MELK mRNA

NCBI chr 5:63,336,151...63,396,254
Ensembl chr 5:63,336,106...63,396,247

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

methyltransferase 15, mitochondrial 12S rRNA N4-cytidine

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL15 mRNA

NCBI chr 3:116,041,480...116,219,011
Ensembl chr 3:116,041,632...116,217,095

G

methyltransferase 18, RPL3 N3(tau)-histidine

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL18 mRNA

NCBI chr13:78,879,053...78,881,226
Ensembl chr13:78,838,447...78,912,730

G

methyltransferase 4, N6-adenosine

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL4 mRNA

NCBI chr 9:118,887,740...118,967,433
Ensembl chr 9:118,887,528...118,911,364

G

methyltransferase 8, tRNA N3-cytidine

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL8 mRNA

NCBI chr 3:76,140,465...76,271,367
Ensembl chr 3:76,144,178...76,271,400

G

mex-3 RNA binding family member C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MEX3C mRNA

NCBI chr18:69,442,850...69,463,843
Ensembl chr18:69,442,152...69,463,846

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MFGE8 mRNA

NCBI chr 1:142,474,027...142,489,431
Ensembl chr 1:142,474,028...142,489,431

G

mitofusin 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of MFN1 protein]; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MFN1 mRNA; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of MFN1 protein]]

PMID:22079256 PMID:29061316

NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190

G

mitofusin 2

increases response to substance
multiple interactions

EXP

MFN2 protein results in increased susceptibility to epigallocatechin gallate
epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]; KLF4 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]]; KLF4 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]]; MFN2 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in increased phosphorylation of MAPK1 protein]]; MFN2 protein promotes the reaction [epigallocatechin gallate inhibits the reaction [Oxygen deficiency results in increased phosphorylation of MAPK3 protein]]

NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495

G

mitochondria-localized glutamic acid-rich protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MGARP mRNA

NCBI chr 2:137,582,152...137,590,294
Ensembl chr 2:137,582,152...137,590,481

G

alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MGAT5 mRNA

NCBI chr13:41,228,327...41,516,462
Ensembl chr13:41,228,360...41,516,461

G

O-6-methylguanine-DNA methyltransferase

decreases methylation
increases expression

ISO

epigallocatechin gallate results in decreased methylation of MGMT promoter
epigallocatechin gallate results in increased expression of MGMT mRNA

PMID:14633667 PMID:15703815

NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482

G

microsomal glutathione S-transferase 1

decreases activity

EXP

epigallocatechin gallate results in decreased activity of MGST1 protein

NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875

G

mitochondrial calcium uptake family, member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MICU3 mRNA

NCBI chr16:58,624,702...58,714,302
Ensembl chr16:58,629,208...58,714,045

G

midline 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of MID1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MID1 mRNA

NCBI chr X:27,678,248...28,053,049
Ensembl chr X:27,681,867...27,906,105

G

mitochondrial elongation factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MIEF1 mRNA

NCBI chr 7:113,666,918...113,679,550
Ensembl chr 7:113,666,901...113,683,977

G

MIER1 transcriptional regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MIER1 mRNA

NCBI chr 5:123,105,114...123,156,653
Ensembl chr 5:123,104,915...123,156,656

G

mirror-image polydactyly 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MIPOL1 mRNA

NCBI chr 6:80,490,330...80,825,413
Ensembl chr 6:80,490,312...80,825,413

G

microRNA 122

affects binding
decreases expression

ISO
EXP

epigallocatechin gallate binds to MIR122 mRNA
epigallocatechin gallate results in decreased expression of MIR122 mRNA

NCBI chr18:61,028,817...61,028,901

G

microRNA 145

multiple interactions

ISO

(-)-epigallocatechin 3-gallate inhibits the reaction [angiotensin II decreases expression of MIR145a RNA in vascular smooth muscle cell]

RGD

NCBI chr18:57,369,983...57,370,070

G

microRNA 33

decreases expression
affects binding

ISO

epigallocatechin gallate results in decreased expression of MIR33A mRNA
epigallocatechin gallate binds to MIR33A mRNA

NCBI chr 7:115,593,952...115,594,020
Ensembl chr 7:115,593,952...115,594,020

G

microRNA 98

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MIR98 mRNA

NCBI chr X:24,460,648...24,460,755
Ensembl chr X:24,460,648...24,460,755

G

MIS18 kinetochore protein A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MIS18A mRNA

NCBI chr11:43,454,129...43,467,157
Ensembl chr11:43,454,161...43,476,264

G

melanocyte inducing transcription factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MITF mRNA

NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790

G

muskelin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MKLN1 mRNA

NCBI chr 4:60,939,239...61,095,214
Ensembl chr 4:60,937,817...61,095,210

G

makorin ring finger protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MKRN1 mRNA

NCBI chr 4:69,142,710...69,170,211
Ensembl chr 4:69,142,723...69,164,020

G

mohawk homeobox

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MKX mRNA

NCBI chr17:59,772,113...59,851,160
Ensembl chr17:59,773,570...59,850,345

G

mutL homolog 1

decreases methylation
multiple interactions
increases expression

ISO

epigallocatechin gallate results in decreased methylation of MLH1 promoter
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MLH1 mRNA
epigallocatechin gallate results in increased expression of MLH1 mRNA; epigallocatechin gallate results in increased expression of MLH1 protein

PMID:14633667 PMID:22079256

NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:120,065,900...120,112,011

G

MLLT10, histone lysine methyltransferase DOT1L cofactor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MLLT10 mRNA

NCBI chr17:85,729,964...85,857,791
Ensembl chr17:85,730,751...85,857,789

G

metabolism of cobalamin associated C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MMACHC mRNA

NCBI chr 5:135,403,094...135,409,285
Ensembl chr 5:135,402,404...135,409,235

G

matrix metallopeptidase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MMP1 mRNA; epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased expression of MMP1 protein]

PMID:22079256 PMID:31252129

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 13

affects activity
multiple interactions

EXP
ISO

epigallocatechin gallate affects the activity of MMP13 protein
epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased expression of MMP13 protein]

PMID:17481882 PMID:31252129

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 2

multiple interactions

EXP
ISO

epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased activity of MMP2 protein]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of MMP2 mRNA]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of MMP2 protein]
epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased expression of MMP2 protein]

PMID:17481882 PMID:20438794 PMID:31252129

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 3

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of MMP3 protein]

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826

G

matrix metallopeptidase 7

multiple interactions
increases expression

ISO

Acetylcysteine inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein]; benzyl isothiocyanate inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein]; Curcumin inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein]; Gallic Acid inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein]

NCBI chr 8:13,133,043...13,140,761
Ensembl chr 8:13,133,043...13,140,755

G

matrix metallopeptidase 8

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased expression of MMP8 protein]

NCBI chr 8:13,008,873...13,018,729
Ensembl chr 8:13,008,890...13,018,729

G

matrix metallopeptidase 9

multiple interactions
decreases activity

ISO

epigallocatechin gallate inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of and results in increased activity of MMP9 protein]; epigallocatechin gallate inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of MMP9 mRNA]
epigallocatechin gallate affects the reaction [Doxorubicin affects the activity of MMP9 protein]; epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased expression of MMP9 protein]
epigallocatechin gallate results in decreased activity of MMP9 protein

PMID:11746506 PMID:16516891 PMID:31252129 PMID:35218280

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

meiosis-specific nuclear structural 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MNS1 mRNA

NCBI chr 8:82,029,587...82,050,276
Ensembl chr 8:82,029,587...82,050,274

G

modulator of apoptosis 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of MOAP1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MOAP1 mRNA

PMID:16084531 PMID:22079256

NCBI chr 6:127,647,389...127,649,324
Ensembl chr 6:127,613,488...127,669,324

G

molybdenum cofactor sulfurase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MOCOS mRNA

NCBI chr18:16,206,402...16,251,928
Ensembl chr18:16,206,402...16,251,928

G

MON2 homolog, regulator of endosome-to-Golgi trafficking

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MON2 mRNA

NCBI chr 7:60,534,772...60,613,467
Ensembl chr 7:60,534,772...60,613,467

G

MOS proto-oncogene, serine/threonine kinase

increases expression

ISO

epigallocatechin gallate results in increased expression of MOS protein

NCBI chr 5:21,657,549...21,658,856
Ensembl chr 5:21,657,431...21,658,987

G

motile sperm domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MOSPD2 mRNA

NCBI chr X:33,052,063...33,105,550
Ensembl chr X:33,052,004...33,107,635

G

Mov10 RNA helicase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MOV10 mRNA

NCBI chr 2:194,982,014...195,003,513
Ensembl chr 2:194,982,014...195,003,442

G

M phase phosphoprotein 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MPHOSPH6 mRNA

NCBI chr19:62,768,909...62,778,874
Ensembl chr19:62,768,909...62,778,950

G

M-phase phosphoprotein 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MPHOSPH9 mRNA

NCBI chr12:37,936,442...38,007,053
Ensembl chr12:37,936,885...38,003,348

G

mannose phosphate isomerase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MPI mRNA

NCBI chr 8:66,843,802...66,852,108
Ensembl chr 8:66,844,116...66,852,016

G

myeloperoxidase

multiple interactions
increases expression

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MPO protein]; epigallocatechin gallate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MPO protein]
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein]
epigallocatechin gallate results in increased expression of MPO protein

PMID:26187476 PMID:35863485 PMID:36056792

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

MRE11 homolog, double strand break repair nuclease

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRE11 mRNA

NCBI chr 8:19,900,211...19,961,906
Ensembl chr 8:19,913,772...19,961,904

G

mitochondrial ribosomal protein L16

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPL16 mRNA

NCBI chr 1:218,058,439...218,063,251
Ensembl chr 1:218,058,433...218,064,898

G

mitochondrial ribosomal protein L33

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of MRPL33 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPL33 mRNA

NCBI chr 6:30,545,794...30,553,987
Ensembl chr 6:30,545,794...30,553,987

G

mitochondrial ribosomal protein L46

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPL46 mRNA

NCBI chr 1:142,108,266...142,117,030
Ensembl chr 1:142,106,531...142,117,030

G

mitochondrial ribosomal protein S11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPS11 mRNA

NCBI chr 1:142,117,045...142,126,644
Ensembl chr 1:142,116,937...142,126,644

G

mitochondrial ribosomal protein S16

affects methylation

EXP

epigallocatechin gallate affects the methylation of MRPS16 gene

NCBI chr15:3,967,809...3,970,211
Ensembl chr15:3,968,054...3,970,185

G

mitochondrial ribosomal protein S18A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPS18A mRNA

NCBI chr 9:22,350,887...22,367,380
Ensembl chr 9:22,344,341...22,367,380

G

mitochondrial ribosomal protein S2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MRPS2 mRNA

NCBI chr 3:32,201,037...32,204,317
Ensembl chr 3:32,198,641...32,204,892

G

myocardin related transcription factor B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRTFB mRNA

NCBI chr10:1,623,887...1,789,658
Ensembl chr10:1,623,940...1,789,658

G

mutS homolog 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MSH2 mRNA

NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:12,567,368...12,626,503

G

male-specific lethal 3-like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MSL3L2 mRNA

NCBI chr20:36,011,381...36,019,529
Ensembl chr20:36,011,380...36,019,530

G

methylsterol monooxygenase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MSMO1 mRNA

NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445

G

mitochondrially encoded cytochrome c oxidase I

increases expression

ISO

epigallocatechin gallate results in increased expression of COX1 mRNA

NCBI chr MT:5,323...6,867
Ensembl chr MT:5,309...6,853

G

mitochondrially encoded cytochrome c oxidase II

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]

NCBI chr MT:7,006...7,689
Ensembl chr MT:6,991...7,674

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND1 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND1 protein]]

NCBI chr MT:2,740...3,694
Ensembl chr MT:2,729...3,685

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ND6 mRNA

NCBI chr MT:13,543...14,061
Ensembl chr MT:13,531...14,049

G

metallothionein 1A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MT1A mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

metallothionein 2

multiple interactions
decreases expression

ISO

epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of MT2A mRNA]; epigallocatechin gallate inhibits the reaction [zinc chloride results in increased expression of MT2A mRNA]
epigallocatechin gallate results in decreased expression of MT2A mRNA

PMID:20471814 PMID:32512070 PMID:35701726

NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709

G

mitochondrial transcription termination factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTERF3 mRNA

NCBI chr 7:65,711,654...65,729,926
Ensembl chr 7:65,711,662...65,729,895

G

mitochondrial methionyl-tRNA formyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTFMT mRNA

NCBI chr 8:74,848,936...74,866,987
Ensembl chr 8:74,848,729...74,867,039

G

mitochondrial fission process 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTFP1 mRNA

NCBI chr14:83,192,013...83,195,853
Ensembl chr14:83,192,021...83,195,927

G

myotubularin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTM1 mRNA

NCBI chr 6:6,234,917...6,252,874
Ensembl chr 6:6,234,922...6,252,961

G

mechanistic target of rapamycin kinase

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased phosphorylation of MTOR protein]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

mitochondrial transcription rescue factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTRES1 mRNA

NCBI chr20:48,604,479...48,622,364
Ensembl chr20:48,604,372...48,622,014

G

mitochondrial translation release factor 1 like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MTRF1L mRNA

NCBI chr 1:44,614,162...44,626,367
Ensembl chr 1:44,615,921...44,626,178

G

metaxin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTX2 mRNA

NCBI chr 3:80,137,556...80,199,547
Ensembl chr 3:80,137,581...80,271,684

G

mevalonate kinase

decreases expression

EXP

epigallocatechin gallate results in decreased expression of MVK mRNA

NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503

G

major vault protein

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MVP mRNA

NCBI chr 1:191,025,259...191,052,866
Ensembl chr 1:191,025,268...191,052,873

G

MX dynamin like GTPase 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of MX1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MX1 mRNA

PMID:22079256 PMID:32512070

NCBI chr11:50,269,056...50,294,699
Ensembl chr11:50,269,057...50,292,904

G

MX dynamin like GTPase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MX2 mRNA

NCBI chr11:50,375,101...50,399,373
Ensembl chr11:50,375,191...50,402,478

G

MYB binding protein 1a

decreases expression

ISO

epigallocatechin gallate results in decreased expression of MYBBP1A protein

NCBI chr10:57,555,458...57,565,819
Ensembl chr10:57,555,452...57,566,041

G

MYB proto-oncogene like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYBL1 mRNA

NCBI chr 5:14,365,768...14,401,012
Ensembl chr 5:14,365,768...14,399,588

G

myosin binding protein C3

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [MYBPC3 gene mutant form results in increased susceptibility to Calcium]

NCBI chr 3:97,550,974...97,569,216
Ensembl chr 3:97,551,061...97,569,216

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression
affects expression

ISO
EXP

epigallocatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of MYC mRNA]; epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA]
epigallocatechin gallate results in decreased expression of MYC protein
epigallocatechin gallate affects the expression of MYC protein

PMID:12663506 PMID:18656336 PMID:22000973 PMID:27058323

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

MYC binding protein 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of MYCBP2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYCBP2 mRNA

NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325

G

MYD88, innate immune signal transduction adaptor

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of MYD88 protein]

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myelin expression factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYEF2 mRNA

NCBI chr 3:132,791,694...132,827,572
Ensembl chr 3:132,791,694...132,827,523

G

myosin heavy chain 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYH10 mRNA

NCBI chr10:53,891,955...54,024,032
Ensembl chr10:53,893,166...54,024,036

G

myosin regulatory light chain interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MYLIP mRNA

NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471

G

myosin X

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO10 mRNA

NCBI chr 2:77,831,532...78,036,137
Ensembl chr 2:77,831,532...78,036,137

G

myosin Ib

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO1B mRNA

NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:57,181,987...57,344,328

G

myosin IE

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO1E mRNA

NCBI chr 8:79,768,828...79,961,048
Ensembl chr 8:79,753,596...79,961,045

G

myosin VI

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO6 mRNA

NCBI chr 8:89,967,351...90,122,219
Ensembl chr 8:89,967,377...90,122,215

G

myosin IXA

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO9A mRNA

NCBI chr 8:69,044,853...69,248,094
Ensembl chr 8:69,044,885...69,245,231

G

myocardin

multiple interactions

ISO

(-)-epigallocatechin 3-gallate inhibits the reaction [angiotensin II decreases expression of MYOCD protein in vascular smooth muscle cell]

RGD

NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819

G

myoferlin

increases expression

ISO

epigallocatechin gallate results in increased expression of MYOF protein

NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768

G

myopalladin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYPN mRNA

NCBI chr20:25,435,554...25,521,149
Ensembl chr20:25,435,554...25,521,149

G

myb-like, SWIRM and MPN domains 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MYSM1 mRNA

NCBI chr 5:114,877,112...114,981,463
Ensembl chr 5:114,889,269...114,942,385

G

N(alpha)-acetyltransferase 15, NatA auxiliary subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAA15 mRNA

NCBI chr 2:137,608,883...137,671,618
Ensembl chr 2:137,608,797...137,671,619

G

NAD kinase 2, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NADK2 mRNA

NCBI chr 2:59,844,854...59,886,989
Ensembl chr 2:59,844,854...59,886,988

G

NEDD8 activating enzyme E1 subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAE1 mRNA

NCBI chr19:452,462...478,591
Ensembl chr19:452,432...478,831

G

N-acetylglucosamine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAGK mRNA

NCBI chr 4:117,838,761...117,846,304
Ensembl chr 4:117,838,826...117,847,836

G

N-acyl phosphatidylethanolamine phospholipase D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAPEPLD mRNA

NCBI chr 4:14,251,591...14,291,010
Ensembl chr 4:14,252,692...14,291,014

G

NSF attachment protein gamma

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAPG mRNA

NCBI chr18:58,710,702...58,729,450
Ensembl chr18:58,708,655...58,729,450

G

asparaginyl-tRNA synthetase 2, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NARS2 mRNA

NCBI chr 1:160,711,680...160,823,311
Ensembl chr 1:160,711,696...160,827,606

G

N-acetyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAT1 mRNA

NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527

G

N-acetyltransferase 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAT10 mRNA

NCBI chr 3:110,566,582...110,604,829
Ensembl chr 3:110,566,582...110,604,836

G

NBAS subunit of NRZ tethering complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NBAS mRNA

NCBI chr 6:41,777,253...42,081,895
Ensembl chr 6:41,755,851...42,081,895

G

neurobeachin-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NBEAL1 mRNA

NCBI chr 9:69,069,326...69,237,932
Ensembl chr 9:69,070,247...69,231,307

G

nibrin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NBN mRNA

NCBI chr 5:34,256,678...34,291,163
Ensembl chr 5:34,256,627...34,291,162

G

NBR1, autophagy cargo receptor

increases expression

ISO

epigallocatechin gallate results in increased expression of NBR1 mRNA

NCBI chr10:86,978,024...87,006,664
Ensembl chr10:86,977,885...87,007,012

G

non-SMC condensin II complex, subunit D3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCAPD3 mRNA

NCBI chr 8:33,696,214...33,765,520
Ensembl chr 8:33,696,270...33,765,518

G

non-SMC condensin I complex, subunit H

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCAPH mRNA

NCBI chr 3:134,825,271...134,852,502
Ensembl chr 3:134,825,271...134,852,502

G

NCK adaptor protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCK1 mRNA

NCBI chr 8:109,897,723...109,958,247
Ensembl chr 8:109,897,724...109,958,247

G

nuclear receptor coactivator 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCOA1 mRNA
epigallocatechin gallate results in increased expression of NCOA1 mRNA

NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924

G

nuclear receptor coactivator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCOA2 mRNA

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776

G

nuclear receptor coactivator 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCOA7 mRNA

NCBI chr 1:28,674,614...28,835,891
Ensembl chr 1:28,675,426...28,835,886

G

NDC80 kinetochore complex component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDC80 mRNA

NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:118,853,806...118,887,568

G

N-myc downstream regulated 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NDRG1 mRNA

NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913

G

N-deacetylase and N-sulfotransferase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDST2 mRNA

NCBI chr15:3,612,775...3,623,061
Ensembl chr15:3,612,775...3,623,061

G

NADH:ubiquinone oxidoreductase complex assembly factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDUFAF1 mRNA

NCBI chr 3:127,089,893...127,104,357
Ensembl chr 3:127,093,659...127,104,020

G

NADH:ubiquinone oxidoreductase core subunit S1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of NDUFS1 mRNA]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of NDUFS1 mRNA]]

NCBI chr 9:72,040,286...72,073,605
Ensembl chr 9:72,040,090...72,073,605

G

NADH:ubiquinone oxidoreductase core subunit S8

decreases expression

ISO

epigallocatechin gallate results in decreased expression of NDUFS8 mRNA

NCBI chr 1:210,569,823...210,573,707
Ensembl chr 1:210,569,824...210,572,971

G

NADH:ubiquinone oxidoreductase core subunit V2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDUFV2 mRNA

NCBI chr 9:113,137,305...113,157,571
Ensembl chr 9:113,137,306...113,157,520

G

NEDD1 gamma-tubulin ring complex targeting factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEDD1 mRNA

NCBI chr 7:29,120,200...29,161,634
Ensembl chr 7:29,120,200...29,161,634

G

NEDD4 E3 ubiquitin protein ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEDD4 mRNA

NCBI chr 8:82,264,751...82,349,642
Ensembl chr 8:82,264,649...82,349,633

G

NEDD4 like E3 ubiquitin protein ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEDD4L mRNA

NCBI chr18:60,663,918...60,996,824
Ensembl chr18:60,663,970...60,996,824

G

neural precursor cell expressed, developmentally down-regulated 9

decreases expression

ISO

epigallocatechin gallate results in decreased expression of NEDD9 mRNA

NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668

G

nei-like DNA glycosylase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEIL3 mRNA

NCBI chr16:45,091,401...45,151,419
Ensembl chr16:45,092,200...45,151,205

G

NIMA-related kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEK1 mRNA

NCBI chr16:34,009,092...34,137,418
Ensembl chr16:34,009,094...34,128,576

G

NIMA-related kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEK3 mRNA

NCBI chr16:76,569,465...76,594,921
Ensembl chr16:76,569,496...76,594,921

G

NIMA-related kinase 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEK6 mRNA

NCBI chr 3:42,693,994...42,766,026
Ensembl chr 3:42,693,971...42,767,773

G

neurofibromin 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NF1 mRNA
epigallocatechin gallate results in increased expression of NF1 mRNA

NCBI chr10:64,803,986...65,037,086
Ensembl chr10:64,804,266...65,034,946

G

NFE2 like bZIP transcription factor 2

increases expression
decreases expression
multiple interactions
affects localization

ISO

epigallocatechin gallate results in increased expression of NFE2L2 mRNA; epigallocatechin gallate results in increased expression of NFE2L2 protein
epigallocatechin gallate results in decreased expression of NFE2L2 protein
[[sodium arsenite results in increased abundance of Arsenic] which co-treated with epigallocatechin gallate] results in increased expression of NFE2L2 mRNA; [Formaldehyde co-treated with epigallocatechin gallate] results in increased expression of NFE2L2 protein; epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NFE2L2 protein]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the localization of NFE2L2 protein; arsenite inhibits the reaction [epigallocatechin gallate results in increased expression of NFE2L2 mRNA]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the localization of NFE2L2 protein]; epigallocatechin gallate inhibits the reaction [arsenite results in increased expression of NFE2L2 mRNA]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of NFE2L2 protein]
epigallocatechin gallate affects the localization of NFE2L2 protein

PMID:16799064 PMID:25585349 PMID:29061316 PMID:29572906 PMID:30395894 More...

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor I/A

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFIA mRNA
epigallocatechin gallate results in increased expression of NFIA mRNA

NCBI chr 5:117,359,006...117,897,391
Ensembl chr 5:117,359,077...117,891,395

G

nuclear factor, interleukin 3 regulated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NFIL3 mRNA

NCBI chr17:12,432,376...12,447,605
Ensembl chr17:12,432,198...12,450,826

G

nuclear factor kappa B subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFKB1 mRNA; epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased expression of NFKB1 protein]

PMID:22079256 PMID:31252129

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

multiple interactions
increases phosphorylation

ISO

epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein]
epigallocatechin gallate results in increased phosphorylation of NFKBIA protein

PMID:19557821 PMID:35863485

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

NFKB inhibitor beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NFKBIB mRNA

NCBI chr 1:93,173,817...93,181,387
Ensembl chr 1:93,173,820...93,326,366

G

NFS1 cysteine desulfurase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFS1 mRNA

NCBI chr 3:165,097,390...165,119,730
Ensembl chr 3:165,097,391...165,119,737

G

nuclear transcription factor, X-box binding 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFX1 mRNA

NCBI chr 5:60,900,140...60,958,889
Ensembl chr 5:60,901,217...60,958,889

G

nuclear transcription factor Y subunit alpha

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NFYA mRNA

NCBI chr 9:20,085,067...20,111,521
Ensembl chr 9:20,085,073...20,111,504

G

nuclear transcription factor Y subunit beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFYB mRNA

NCBI chr 7:22,852,543...22,868,116
Ensembl chr 7:22,852,546...22,882,294

G

N-glycanase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NGLY1 mRNA

NCBI chr15:11,584,475...11,640,977
Ensembl chr15:11,584,475...11,635,328

G

neugrin, neurite outgrowth associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NGRN mRNA

NCBI chr 1:143,622,494...143,628,609
Ensembl chr 1:143,622,731...143,628,609

G

niban apoptosis regulator 1

increases expression

ISO

epigallocatechin gallate results in increased expression of FAM129A mRNA

NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724

G

NGG1 interacting factor 3 like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NIF3L1 mRNA

NCBI chr 9:67,474,286...67,494,350
Ensembl chr 9:67,474,351...67,494,350

G

ninein

increases expression

ISO

epigallocatechin gallate results in increased expression of NIN mRNA

NCBI chr 6:94,261,382...94,363,679
Ensembl chr 6:94,263,206...94,363,610

G

nitrilase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NIT1 mRNA

NCBI chr13:86,302,334...86,305,770
Ensembl chr13:86,298,387...86,305,770

G

nemo like kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NLK mRNA

NCBI chr10:63,965,432...64,089,006

G

NLR family, pyrin domain containing 3

multiple interactions

ISO
EXP

epigallocatechin gallate inhibits the reaction [bisphenol A results in increased expression of NLRP3 mRNA]; epigallocatechin gallate inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]
epigallocatechin gallate inhibits the reaction [ochratoxin A results in increased expression of NLRP3 mRNA]
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]; epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NLRP3 protein]

PMID:35439536 PMID:36056792 PMID:37286014 PMID:39299375

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

NME/NM23 family member 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NME7 mRNA

NCBI chr13:79,190,462...79,319,890
Ensembl chr13:79,190,334...79,319,890

G

N-myc (and STAT) interactor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NMI mRNA

NCBI chr 3:56,824,778...56,848,891
Ensembl chr 3:56,811,314...56,848,717

G

nicotinamide N-methyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NNMT mRNA

NCBI chr 8:57,820,156...57,851,301
Ensembl chr 8:57,825,464...57,843,174

G

NIN1 (RPN12) binding protein 1 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOB1 mRNA

NCBI chr19:52,232,543...52,245,824
Ensembl chr19:52,232,543...52,256,189

G

NOC3-like DNA replication regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NOC3L mRNA

NCBI chr 1:245,969,179...245,997,761
Ensembl chr 1:245,969,179...245,997,708

G

nocturnin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOCT mRNA

NCBI chr 2:137,422,074...137,442,282
Ensembl chr 2:137,422,074...137,442,282

G

nucleolar and coiled-body phosphoprotein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOLC1 mRNA

NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:254,870,319...254,881,069

G

NOP53 ribosome biogenesis factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOP53 mRNA

NCBI chr 1:85,757,271...85,765,089
Ensembl chr 1:85,756,586...85,765,089

G

nitric oxide synthase 2

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; epigallocatechin gallate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; epigallocatechin gallate inhibits the reaction [Formaldehyde results in increased expression of NOS2 protein]
[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein]

PMID:12794164 PMID:20438794 PMID:26187476 PMID:30395894

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nitric oxide synthase 3

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of NOS3 mRNA
epigallocatechin gallate promotes the reaction [Hydrogen Peroxide results in increased expression of NOS3 mRNA]

PMID:20021702 PMID:20706672

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

NADPH oxidase 4

decreases expression

EXP
ISO

epigallocatechin gallate results in decreased expression of NOX4 mRNA

PMID:27659729 PMID:39667565

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

aminopeptidase puromycin sensitive

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NPEPPS mRNA

NCBI chr10:82,687,869...82,770,363
Ensembl chr10:82,687,871...82,770,363

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of NQO1 mRNA
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of NQO1 protein; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] results in increased expression of NQO1 protein]; epigallocatechin gallate inhibits the reaction [arsenite results in increased expression of NQO1 protein]
[Formaldehyde co-treated with epigallocatechin gallate] results in increased expression of NQO1 protein; epigallocatechin gallate results in increased expression of and results in increased activity of NQO1 protein

PMID:25585349 PMID:29061316 PMID:29572906 PMID:30395894

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
decreases expression
increases expression

ISO
EXP

epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of NR0B2 mRNA]
epigallocatechin gallate results in decreased expression of NR0B2 mRNA
NR1H4 protein affects the reaction [epigallocatechin gallate results in increased expression of NR0B2 mRNA]

PMID:22178739 PMID:23146761

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
increases activity

ISO

[epigallocatechin gallate co-treated with gallocatechol] results in increased activity of NR1H4 protein; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; epigallocatechin gallate inhibits the reaction [GW 4064 results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of NR1H4 mRNA]
NR1H4 protein affects the reaction [epigallocatechin gallate results in increased expression of FGF15 mRNA]; NR1H4 protein affects the reaction [epigallocatechin gallate results in increased expression of NR0B2 mRNA]
epigallocatechin gallate results in increased activity of NR1H4 protein

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

nuclear receptor 2C2-associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NR2C2AP mRNA

NCBI chr16:19,322,395...19,324,912
Ensembl chr16:19,322,405...19,324,637

G

nuclear receptor subfamily 3, group C, member 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of NR3C1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NR3C1 mRNA

PMID:16084531 PMID:22079256

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A1 mRNA

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A2 mRNA

NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769

G

nuclear receptor subfamily 4, group A, member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A3 mRNA

NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:67,157,375...67,198,285

G

neuronal regeneration related protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NREP mRNA

NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742

G

neuregulin 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of NRG1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NRG1 mRNA

PMID:20346928 PMID:22079256

NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849

G

nuclear receptor interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NRIP1 mRNA

NCBI chr11:28,382,835...28,466,483
Ensembl chr11:28,378,878...28,467,353

G

N-ethylmaleimide sensitive factor, vesicle fusing ATPase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSF mRNA

NCBI chr10:89,227,937...89,357,383
Ensembl chr10:89,227,937...89,367,621

G

NSL1 component of MIS12 kinetochore complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSL1 mRNA

NCBI chr13:105,176,163...105,205,179
Ensembl chr13:105,180,183...105,196,117

G

NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of NSMCE2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSMCE2 mRNA

NCBI chr 7:92,825,568...93,071,037
Ensembl chr 7:92,825,587...93,054,326

G

NSE4 homolog A, SMC5-SMC6 complex component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSMCE4A mRNA

NCBI chr 1:194,532,364...194,539,456
Ensembl chr 1:194,525,648...194,539,456

G

NOP2/Sun RNA methyltransferase 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSUN6 mRNA

NCBI chr17:82,820,938...82,864,140
Ensembl chr17:82,820,941...82,858,539

G

NUAK family kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUAK1 mRNA

NCBI chr 7:21,217,729...21,289,608
Ensembl chr 7:21,217,681...21,289,354

G

NUBP iron-sulfur cluster assembly factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUBP1 mRNA

NCBI chr10:5,766,157...5,777,648
Ensembl chr10:5,766,157...5,786,422

G

NudC domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUDCD1 mRNA

NCBI chr 7:77,436,035...77,480,651
Ensembl chr 7:77,436,036...77,480,575

G

nudix hydrolase 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUDT12 mRNA

NCBI chr 9:106,188,930...106,202,340
Ensembl chr 9:106,189,661...106,202,340

G

nudix hydrolase 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NUDT4 mRNA

NCBI chr 7:32,074,978...32,091,491
Ensembl chr 7:32,075,002...32,091,491

G

NUF2 component of NDC80 kinetochore complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUF2 mRNA

NCBI chr13:84,226,448...84,290,957
Ensembl chr13:84,226,509...84,255,598

G

NUMB, endocytic adaptor protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUMB mRNA

NCBI chr 6:109,162,499...109,284,527
Ensembl chr 6:109,162,499...109,284,463

G

nucleoporin 107

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP107 mRNA

NCBI chr 7:55,239,610...55,285,050
Ensembl chr 7:55,239,613...55,285,234

G

nucleoporin 133

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP133 mRNA

NCBI chr19:68,789,065...68,838,692
Ensembl chr19:68,789,065...68,838,692

G

nucleoporin 160

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP160 mRNA

NCBI chr 3:97,120,723...97,183,227
Ensembl chr 3:97,121,628...97,180,720

G

nucleoporin 37

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP37 mRNA
epigallocatechin gallate results in decreased expression of NUP37 mRNA

NCBI chr 7:24,443,998...24,497,088
Ensembl chr 7:24,463,301...24,508,741

G

nucleoporin 85

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP85 mRNA

NCBI chr10:101,305,241...101,323,980
Ensembl chr10:101,305,390...101,324,641

G

nucleoporin 98 and 96 precursor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP98 mRNA

NCBI chr 1:165,906,405...166,003,366
Ensembl chr 1:165,906,405...166,003,366

G

nuclear RNA export factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NXF1 mRNA

NCBI chr 1:215,084,563...215,097,756
Ensembl chr 1:215,084,099...215,097,756

G

neurexophilin 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NXPH4 mRNA

NCBI chr 7:65,253,043...65,261,864
Ensembl chr 7:65,252,904...65,261,864

G

2'-5' oligoadenylate synthetase 1A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OAS1 mRNA

NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128

G

2'-5' oligoadenylate synthetase 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of OAS2 mRNA

NCBI chr12:41,464,568...41,492,036
Ensembl chr12:41,467,315...41,495,881

G

2'-5'-oligoadenylate synthetase 3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of OAS3 mRNA

NCBI chr12:41,439,645...41,463,392
Ensembl chr12:41,439,643...41,464,420

G

outer dynein arm docking complex subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ODAD2 mRNA

NCBI chr17:59,910,665...60,104,929
Ensembl chr17:59,910,757...60,103,547

G

ornithine decarboxylase 1

multiple interactions

ISO

epigallocatechin gallate results in decreased expression of and results in decreased activity of ODC1 protein

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146

G

outer dense fiber of sperm tails 2-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ODF2L mRNA

NCBI chr 2:236,696,158...236,733,090
Ensembl chr 2:236,696,389...236,733,086

G

odr-4 GPCR localization factor homolog

increases expression

ISO

epigallocatechin gallate results in increased expression of ODR4 protein

NCBI chr13:64,925,573...64,974,395
Ensembl chr13:64,944,713...64,974,316

G

O-GlcNAcase

decreases expression

ISO

epigallocatechin gallate results in decreased expression of OGA mRNA

NCBI chr 1:254,547,311...254,589,596
Ensembl chr 1:254,547,311...254,582,855

G

oxoglutarate dehydrogenase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OGDH mRNA

NCBI chr14:85,363,949...85,431,405
Ensembl chr14:85,364,014...85,432,271

G

8-oxoguanine DNA glycosylase

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of OGG1 mRNA]

NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604

G

O-linked N-acetylglucosamine (GlcNAc) transferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OGT mRNA

NCBI chr X:70,811,317...70,856,123
Ensembl chr X:70,811,319...70,856,123

G

Opa interacting protein 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OIP5 mRNA

NCBI chr 3:127,047,559...127,057,043
Ensembl chr 3:127,047,559...127,057,043

G

olfactomedin-like 2B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OLFML2B mRNA

NCBI chr13:85,402,151...85,439,342
Ensembl chr13:85,402,169...85,439,342

G

oxidized low density lipoprotein receptor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OLR1 mRNA

NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598

G

one cut homeobox 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ONECUT2 mRNA

NCBI chr18:60,101,967...60,161,095
Ensembl chr18:60,102,126...60,107,668

G

oligophrenin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OPHN1 mRNA

NCBI chr X:67,639,956...68,018,217
Ensembl chr X:67,643,252...68,016,831

G

ORAI calcium release-activated calcium modulator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ORAI2 mRNA

NCBI chr12:26,136,922...26,157,041
Ensembl chr12:26,132,193...26,157,041

G

ORMDL sphingolipid biosynthesis regulator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ORMDL2 mRNA

NCBI chr 7:1,832,368...1,835,501
Ensembl chr 7:1,832,368...1,836,223

G

oxysterol binding protein-like 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OSBPL3 mRNA

NCBI chr 4:80,677,383...80,854,169
Ensembl chr 4:80,677,390...80,854,169

G

oxidative stress responsive serine-rich 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of OSER1 mRNA

NCBI chr 3:172,486,417...172,504,607
Ensembl chr 3:172,486,440...172,504,597

G

O-sialoglycoprotein endopeptidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OSGEP mRNA

NCBI chr15:26,610,694...26,618,113
Ensembl chr15:26,610,698...26,618,113

G

O-sialoglycoprotein endopeptidase-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OSGEPL1 mRNA

NCBI chr 9:55,707,389...55,725,325
Ensembl chr 9:55,707,392...55,721,346

G

osteoclastogenesis associated transmembrane protein 1

increases expression

ISO

epigallocatechin gallate results in increased expression of OSTM1 mRNA

NCBI chr20:47,653,696...47,769,248
Ensembl chr20:47,653,670...47,769,237

G

3-oxoacyl-ACP synthase, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OXSM mRNA

NCBI chr15:11,641,177...11,645,370
Ensembl chr15:11,634,473...11,683,429

G

prolyl 4-hydroxylase subunit beta

increases expression

ISO

epigallocatechin gallate results in increased expression of P4HB protein

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911

G

proliferation-associated 2G4

increases expression

ISO

epigallocatechin gallate results in increased expression of PA2G4 protein

NCBI chr 7:1,569,326...1,576,794
Ensembl chr 7:1,569,327...1,576,802

G

poly(A) binding protein, cytoplasmic 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PABPC1 mRNA
epigallocatechin gallate results in increased expression of PABPC1 protein

PMID:22079256 PMID:31195006

NCBI chr 7:69,662,513...69,674,806
Ensembl chr 7:69,663,068...69,675,050

G

poly(A) binding protein, cytoplasmic 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PABPC4 mRNA

NCBI chr 5:140,847,835...140,864,089
Ensembl chr 5:140,848,225...140,864,087

G

poly(A) binding protein, cytoplasmic 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PABPC3 mRNA

NCBI chr 1:53,592,902...53,595,978
Ensembl chr 1:53,592,884...53,595,973

G

Paxip1-associated glutamate-rich protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PAGR1 mRNA

NCBI chr 1:191,053,228...191,055,554

G

protein associated with LIN7 2, MAGUK p55 family member

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PALS2 mRNA

NCBI chr 4:80,504,298...80,584,951
Ensembl chr 4:80,455,657...80,584,950

G

poly(A) polymerase gamma

increases expression

ISO

epigallocatechin gallate results in increased expression of PAPOLG mRNA

NCBI chr14:102,028,842...102,062,155
Ensembl chr14:102,028,842...102,062,155

G

poly (ADP-ribose) glycohydrolase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARG mRNA

NCBI chr16:7,442,696...7,550,585
Ensembl chr16:7,442,726...7,550,584

G

Parkinsonism associated deglycase

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PARK7 mRNA

NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825

G

poly (ADP-ribose) polymerase 1

increases activity
affects activity
affects cleavage
multiple interactions
increases cleavage

ISO

epigallocatechin gallate results in increased activity of PARP1 protein
epigallocatechin gallate affects the activity of PARP1 protein
epigallocatechin gallate affects the cleavage of PARP1 protein
epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased cleavage of and results in increased activity of PARP1 protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of PARP1 mRNA]
epigallocatechin gallate results in increased cleavage of PARP1 protein

PMID:15657356 PMID:15705601 PMID:15764647 PMID:22079256 PMID:23954321 More...

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

poly (ADP-ribose) polymerase family, member 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP12 mRNA

NCBI chr 4:68,793,411...68,851,214
Ensembl chr 4:68,806,100...68,850,541

G

poly (ADP-ribose) polymerase family, member 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP4 mRNA

NCBI chr15:34,806,203...34,908,492
Ensembl chr15:34,816,701...34,944,433

G

poly (ADP-ribose) polymerase family, member 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PARP6 mRNA

NCBI chr 8:68,912,393...68,944,904
Ensembl chr 8:68,917,388...68,944,898

G

poly (ADP-ribose) polymerase family, member 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP8 mRNA

NCBI chr 2:50,408,404...50,581,513
Ensembl chr 2:50,408,404...50,581,233

G

poly (ADP-ribose) polymerase family, member 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP9 mRNA

NCBI chr11:78,286,282...78,320,409
Ensembl chr11:78,286,287...78,320,608

G

parvin, gamma

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARVG mRNA

NCBI chr 7:117,336,160...117,366,341
Ensembl chr 7:117,336,187...117,362,155

G

polybromo 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PBRM1 mRNA

NCBI chr16:6,219,933...6,319,336
Ensembl chr16:6,219,917...6,319,336

G

PBX homeobox 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PBX2 mRNA

NCBI chr20:4,156,107...4,161,503
Ensembl chr20:4,156,107...4,161,827

G

photoreceptor cilium actin regulator

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PCARE protein

NCBI chr 6:29,469,232...29,478,541
Ensembl chr 6:29,469,817...29,478,541

G

propionyl-CoA carboxylase subunit alpha

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCCA mRNA

NCBI chr15:106,034,586...106,374,908
Ensembl chr15:106,034,610...106,374,908

G

protocadherin 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PCDH10 mRNA

NCBI chr 2:130,553,432...130,619,591
Ensembl chr 2:130,553,425...130,613,407

G

protocadherin 18

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of PCDH18 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCDH18 mRNA

NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:135,983,144...135,996,826

G

PCF11 cleavage and polyadenylation factor subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PCF11 mRNA

NCBI chr 1:156,109,724...156,136,950
Ensembl chr 1:156,109,724...156,136,435

G

polycomb group ring finger 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PCGF2 mRNA

NCBI chr10:83,178,926...83,191,610
Ensembl chr10:83,179,916...83,183,999

G

PCI domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCID2 mRNA

NCBI chr16:83,125,386...83,150,851
Ensembl chr16:83,124,658...83,156,970

G

phosphoenolpyruvate carboxykinase 1

decreases expression

ISO
EXP

epigallocatechin gallate results in decreased expression of PCK1 mRNA

PMID:15549673 PMID:16988119

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

proliferating cell nuclear antigen

multiple interactions

EXP

epigallocatechin gallate promotes the reaction [Sulindac inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein]]

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

proprotein convertase subtilisin/kexin type 9

increases expression

ISO

epigallocatechin gallate results in increased expression of PCSK9 mRNA

NCBI chr 5:126,440,102...126,462,507
Ensembl chr 5:126,440,102...126,462,507

G

programmed cell death 10

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of PDCD10 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDCD10 mRNA

NCBI chr 2:162,602,516...162,644,690
Ensembl chr 2:162,602,516...162,644,612

G

programmed cell death 5

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of PDCD5 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDCD5 mRNA

NCBI chr 1:97,442,755...97,448,084
Ensembl chr 1:97,442,755...97,449,844

G

phosphodiesterase 7B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDE7B mRNA

NCBI chr 1:16,994,072...17,312,828
Ensembl chr 1:17,002,286...17,312,456

G

platelet derived growth factor C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDGFC mRNA

NCBI chr 2:168,613,409...168,791,575
Ensembl chr 2:168,614,353...168,791,573

G

platelet derived growth factor receptor beta

multiple interactions

EXP
ISO

epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB mRNA]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFRB protein]
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDGFRB mRNA

PMID:19646978 PMID:22079256

NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233

G

pyruvate dehydrogenase E1 subunit alpha 1

multiple interactions
decreases expression

ISO

Acetylcysteine inhibits the reaction [epigallocatechin gallate results in decreased expression of PDHA1 mRNA]; Acetylcysteine inhibits the reaction [epigallocatechin gallate results in decreased expression of PDHA1 protein]
epigallocatechin gallate results in decreased expression of PDHA1 mRNA; epigallocatechin gallate results in decreased expression of PDHA1 protein

NCBI chr X:38,509,158...38,522,986
Ensembl chr X:38,509,084...38,522,536

G

pyruvate dehydrogenase E1 subunit beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDHB mRNA

NCBI chr15:19,182,789...19,188,731
Ensembl chr15:19,181,208...19,188,976

G

protein disulfide isomerase family A, member 3

increases expression

ISO

epigallocatechin gallate results in increased expression of PDIA3 protein

NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:128,841,917...128,867,327

G

pyruvate dehydrogenase kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PDK1 mRNA

NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145

G

PDZ and LIM domain 5

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of PDLIM5 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDLIM5 mRNA

PMID:16084531 PMID:22079256

NCBI chr 2:233,625,478...233,793,582
Ensembl chr 2:233,628,503...233,793,528

G

p53 and DNA damage regulated 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PDRG1 mRNA

NCBI chr 3:161,937,812...161,943,981
Ensembl chr 3:161,937,815...161,948,995

G

PDS5 cohesin associated factor B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDS5B mRNA

NCBI chr12:5,038,114...5,181,208
Ensembl chr12:5,038,160...5,181,208

G

pyridoxal phosphatase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PDXP mRNA

NCBI chr 7:112,352,971...112,358,419
Ensembl chr 7:112,352,726...112,358,419

G

PDZ domain containing 2

increases expression

ISO

epigallocatechin gallate results in increased expression of PDZD2 protein

NCBI chr 2:63,111,650...63,497,520
Ensembl chr 2:63,111,650...63,497,478

G

pseudopodium-enriched atypical kinase 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of PEAK1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PEAK1 mRNA

NCBI chr 8:65,501,068...65,715,768
Ensembl chr 8:65,505,043...65,715,111

G

platelet and endothelial cell adhesion molecule 1

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of PECAM1 protein]

NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839

G

pellino E3 ubiquitin protein ligase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PELI1 mRNA

NCBI chr14:99,455,970...99,510,474
Ensembl chr14:99,455,811...99,510,466

G

period circadian regulator 1

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of PER1 mRNA]

NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211

G

period circadian regulator 2

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of PER2 mRNA]; [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PER2 mRNA

PMID:22079256 PMID:29061316

NCBI chr 9:99,454,828...99,497,069
Ensembl chr 9:99,454,830...99,496,993

G

peroxisomal biogenesis factor 11 beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PEX11B mRNA

NCBI chr 2:186,858,222...186,869,814
Ensembl chr 2:186,860,912...186,869,800

G

peroxisomal biogenesis factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PEX2 mRNA

NCBI chr 2:97,957,479...97,973,767
Ensembl chr 2:97,948,443...97,981,092

G

peroxisomal biogenesis factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PEX3 mRNA

NCBI chr 1:9,732,641...9,774,479
Ensembl chr 1:9,732,492...9,774,576

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PFKFB3 mRNA

NCBI chr17:71,893,320...71,974,526
Ensembl chr17:71,893,416...71,975,052

G

phosphofructokinase, liver type

increases expression

EXP

epigallocatechin gallate results in increased expression of PFKL mRNA

NCBI chr20:10,663,907...10,685,967
Ensembl chr20:10,663,955...10,685,966

G

profilin 1

increases expression

ISO

epigallocatechin gallate results in increased expression of PFN1 protein

NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,863,881...55,868,611

G

phosphoglycerate kinase 1

increases expression

ISO

epigallocatechin gallate results in increased expression of PGK1 protein

NCBI chr X:75,336,988...75,352,962
Ensembl chr X:75,336,687...75,352,959

G

phosphoglycerate kinase 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PGK2 protein

NCBI chr 9:27,976,913...27,978,479
Ensembl chr 9:27,973,459...28,079,866

G

progesterone receptor

decreases expression
increases expression

ISO

epigallocatechin gallate results in decreased expression of PGR mRNA
epigallocatechin gallate results in increased expression of PGR protein

PMID:20706672 PMID:35863485

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

phosphatase and actin regulator 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHACTR2 mRNA

NCBI chr 1:9,411,412...9,680,648
Ensembl chr 1:9,418,085...9,680,583

G

phosphatase and actin regulator 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHACTR4 mRNA

NCBI chr 5:149,828,716...149,904,955
Ensembl chr 5:149,833,367...149,905,187

G

phagophore assembly factor 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PHAF1 protein

NCBI chr19:50,011,350...50,050,880
Ensembl chr19:50,011,369...50,053,987

G

PHD finger protein 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHF11 mRNA

NCBI chr15:37,568,090...37,592,490
Ensembl chr15:37,568,090...37,591,016

G

PHD finger protein 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHF19 mRNA

NCBI chr 3:38,572,766...38,604,950
Ensembl chr 3:38,572,766...38,593,854

G

pleckstrin homology domain interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHIP mRNA

NCBI chr 8:92,656,890...92,771,098
Ensembl chr 8:92,656,890...92,771,021

G

phosphorylase kinase catalytic subunit gamma 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PHKG1 mRNA

NCBI chr12:32,474,926...32,490,657
Ensembl chr12:32,474,921...32,490,653

G

pleckstrin homology-like domain, family A, member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PHLDA2 mRNA

NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920

G

pleckstrin homology-like domain, family B, member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHLDB1 mRNA

NCBI chr 8:53,900,338...53,948,325
Ensembl chr 8:53,900,338...53,949,518

G

protein inhibitor of activated STAT, 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIAS1 mRNA

NCBI chr 8:72,233,566...72,347,085
Ensembl chr 8:72,233,566...72,334,315

G

progesterone immunomodulatory binding factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIBF1 mRNA

NCBI chr15:82,258,243...82,427,546
Ensembl chr15:82,258,468...82,427,548

G

phosphatidylinositol binding clathrin assembly protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PICALM mRNA

NCBI chr 1:153,468,982...153,550,086
Ensembl chr 1:153,469,202...153,550,237

G

protein interacting with PRKCA 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PICK1 mRNA

NCBI chr 7:112,676,890...112,697,275
Ensembl chr 7:112,677,322...112,697,257

G

phosphotyrosine interaction domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PID1 mRNA

NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070

G

phosphatidylinositol glycan anchor biosynthesis, class A

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of PIGA mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PIGA mRNA

PMID:16084531 PMID:22079256

NCBI chr X:33,672,832...33,687,747
Ensembl chr X:33,674,923...33,687,636

G

phosphatidylinositol glycan anchor biosynthesis, class F

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIGF mRNA

NCBI chr 6:13,343,134...13,371,237
Ensembl chr 6:13,342,869...13,393,214

G

phosphatidylinositol glycan anchor biosynthesis, class P

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIGP mRNA

NCBI chr11:47,152,601...47,158,766
Ensembl chr11:47,148,465...47,160,082

G

phosphatidylinositol glycan anchor biosynthesis, class V

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIGV mRNA

NCBI chr 5:151,173,486...151,185,748
Ensembl chr 5:151,173,044...151,185,376

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIK3CB mRNA

NCBI chr 8:108,474,017...108,579,140
Ensembl chr 8:108,474,019...108,579,331

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIK3CD mRNA

NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968

G

phosphoinositide-3-kinase regulatory subunit 1

decreases expression
increases methylation

ISO

epigallocatechin gallate results in decreased expression of PIK3R1 mRNA; epigallocatechin gallate results in decreased expression of PIK3R1 protein
epigallocatechin gallate results in increased methylation of PIK3R1 promoter

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

paired immunoglobin-like type 2 receptor alpha like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF37A mRNA

NCBI chr12:23,409,774...23,421,574

G

Pim-2 proto-oncogene, serine/threonine kinase

increases expression

ISO

epigallocatechin gallate results in increased expression of PIM2 mRNA

NCBI chr X:17,289,509...17,294,778
Ensembl chr X:17,289,509...17,294,778

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIP4K2A mRNA

NCBI chr17:86,405,080...86,576,597
Ensembl chr17:86,405,081...86,576,430

G

polycystin 2, transient receptor potential cation channel

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PKD2 mRNA

NCBI chr14:5,541,821...5,585,140
Ensembl chr14:5,495,401...5,587,594

G

protein kinase N2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PKN2 mRNA

NCBI chr 2:234,454,001...234,559,369
Ensembl chr 2:234,454,001...234,594,649

G

plakophilin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PKP2 mRNA

NCBI chr11:98,165,974...98,231,916
Ensembl chr11:98,165,974...98,231,916

G

PLAG1 like zinc finger 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PLAGL1 mRNA

NCBI chr 1:9,297,066...9,337,394
Ensembl chr 1:9,330,204...9,337,394

G

plasminogen activator, tissue type

multiple interactions

ISO

[Sulindac co-treated with epigallocatechin gallate] results in decreased expression of PLAT mRNA

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

plasminogen activator, urokinase

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PLAU mRNA

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030

G

phospholipase C, epsilon 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of PLCE1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLCE1 mRNA

NCBI chr 1:245,655,855...245,964,966
Ensembl chr 1:245,657,080...245,963,828

G

phospholipase D1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLD1 mRNA; PLD1 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]
epigallocatechin gallate results in increased expression of PLD1 mRNA

PMID:15210717 PMID:22079256

NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245

G

phospholipase D2

multiple interactions

ISO

Go 6976 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]]; PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]]

NCBI chr10:55,754,957...55,772,819
Ensembl chr10:55,754,988...55,771,435

G

plectin

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PLEC mRNA

NCBI chr 7:109,768,447...109,829,798
Ensembl chr 7:109,768,447...109,828,089

G

pleckstrin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLEK2 mRNA

NCBI chr 6:103,434,156...103,452,457
Ensembl chr 6:103,434,156...103,452,371

G

pleckstrin homology domain containing A5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLEKHA5 mRNA

NCBI chr 4:175,065,011...175,234,672
Ensembl chr 4:175,065,183...175,234,672

G

pleckstrin homology domain containing A7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLEKHA7 mRNA

NCBI chr 1:179,798,856...179,982,155
Ensembl chr 1:179,799,040...179,982,281

G

plasminogen receptor with a C-terminal lysine

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLGRKT mRNA

NCBI chr 1:236,512,574...236,526,858
Ensembl chr 1:236,512,580...236,524,840

G

perilipin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PLIN2 mRNA

NCBI chr 5:106,202,634...106,258,748
Ensembl chr 5:106,202,634...106,258,878

G

polo-like kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLK2 mRNA

NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296

G

phospholamban

increases expression

EXP

EGCG increases expression of Pln protein after myocardial infarction in rat heart left ventricle

RGD

NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PLOD3 mRNA
epigallocatechin gallate results in increased expression of PLOD3 mRNA

PMID:20706672 PMID:22079256

NCBI chr12:25,313,070...25,323,631
Ensembl chr12:25,313,072...25,323,631

G

phospholipid phosphatase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLPP1 mRNA

NCBI chr 2:46,172,202...46,233,632
Ensembl chr 2:46,172,197...46,234,676

G

phospholipid phosphatase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLPP3 mRNA

NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667

G

phospholipid phosphatase related 2

affects methylation

EXP

epigallocatechin gallate affects the methylation of PLPPR2 gene

NCBI chr 8:28,742,787...28,755,555
Ensembl chr 8:28,745,639...28,755,555

G

plastin 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLS1 mRNA
epigallocatechin gallate results in increased expression of PLS1 protein

PMID:22079256 PMID:31195006

NCBI chr 8:105,196,312...105,306,252
Ensembl chr 8:105,197,455...105,292,447

G

plastin 3

increases expression

ISO

epigallocatechin gallate results in increased expression of PLS3 protein

NCBI chr X:116,401,247...116,495,898
Ensembl chr X:116,401,293...116,495,893

G

plexin A2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLXNA2 mRNA

NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PMAIP1 mRNA

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382

G

peripheral myelin protein 22

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PMP22 mRNA

NCBI chr10:48,294,932...48,324,941
Ensembl chr10:48,297,437...48,324,940

G

PMS1 homolog 1, mismatch repair system component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PMS1 mRNA

NCBI chr 9:55,721,393...55,832,225
Ensembl chr 9:55,745,374...55,832,221

G

pinin, desmosome associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PNN mRNA

NCBI chr 6:82,493,032...82,501,345
Ensembl chr 6:82,492,978...82,501,933

G

purine nucleoside phosphorylase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PNP mRNA

NCBI chr15:26,644,147...26,651,808
Ensembl chr15:26,643,858...26,678,162

G

patatin-like phospholipase domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PNPLA2 mRNA

NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359

G

polyribonucleotide nucleotidyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PNPT1 mRNA

NCBI chr14:107,078,486...107,109,628
Ensembl chr14:107,078,469...107,109,628

G

POC1 centriolar protein A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POC1A mRNA

NCBI chr 8:115,801,335...115,869,812
Ensembl chr 8:115,801,396...115,870,392

G

POC5 centriolar protein

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POC5 mRNA
epigallocatechin gallate results in increased expression of POC5 mRNA

PMID:22079256 PMID:39667565

NCBI chr 2:29,454,392...29,483,468
Ensembl chr 2:29,454,272...29,485,309

G

DNA polymerase alpha 2, accessory subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLA2 mRNA

NCBI chr 1:212,656,500...212,680,667
Ensembl chr 1:212,656,501...212,680,542

G

DNA polymerase epsilon 2, accessory subunit

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of POLE2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLE2 mRNA

NCBI chr 6:93,410,713...93,448,782
Ensembl chr 6:93,410,758...93,435,361

G

DNA polymerase epsilon 3, accessory subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of POLE3 mRNA

NCBI chr 5:80,989,508...80,992,742
Ensembl chr 5:80,989,511...80,992,742
Ensembl chr 7:80,989,511...80,992,742

G

DNA polymerase iota

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLI mRNA

NCBI chr18:66,389,214...66,409,734
Ensembl chr18:66,364,236...66,409,819

G

RNA polymerase I and III subunit D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of POLR1D mRNA

NCBI chr12:13,084,505...13,118,069
Ensembl chr12:13,084,512...13,095,627

G

RNA polymerase I subunit F

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of POLR1F mRNA

NCBI chr 6:55,780,706...55,797,935
Ensembl chr 6:55,780,706...55,797,935

G

RNA polymerase III subunit B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLR3B mRNA

NCBI chr 7:20,926,866...21,030,133
Ensembl chr 7:20,926,866...21,033,654

G

RNA polymerase III subunit H

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLR3H mRNA

NCBI chr 7:115,309,571...115,319,881
Ensembl chr 7:115,309,589...115,319,915

G

proopiomelanocortin

decreases expression

ISO

epigallocatechin gallate results in decreased expression of POMC mRNA

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

POP1 homolog, ribonuclease P/MRP subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POP1 mRNA

NCBI chr 7:67,590,502...67,618,187
Ensembl chr 7:67,590,522...67,618,293

G

POP5 homolog, ribonuclease P/MRP subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POP5 mRNA

NCBI chr12:47,037,451...47,045,778
Ensembl chr12:47,029,403...47,042,032

G

cytochrome p450 oxidoreductase

increases activity

ISO

epigallocatechin gallate results in increased activity of POR protein

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

protection of telomeres 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POT1 mRNA

NCBI chr 4:55,170,821...55,228,588
Ensembl chr 4:55,170,821...55,228,543

G

peroxisome proliferator-activated receptor gamma

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PPARG mRNA

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

multiple interactions
decreases expression

EXP
ISO

[1-Methyl-4-phenylpyridinium co-treated with epigallocatechin gallate] results in increased expression of PPARGC1A mRNA; [1-Methyl-4-phenylpyridinium co-treated with epigallocatechin gallate] results in increased expression of PPARGC1A protein; epigallocatechin gallate analog inhibits the reaction [Dietary Fats results in decreased expression of PPARGC1A protein]
epigallocatechin gallate results in decreased expression of PPARGC1A protein

PMID:22742579 PMID:29175576 PMID:39577827

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

pancreatic progenitor cell differentiation and proliferation factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPDPF mRNA

NCBI chr 3:188,676,821...188,678,599
Ensembl chr 3:188,676,965...188,678,599

G

PPFIA binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPFIBP1 mRNA

NCBI chr 4:181,538,249...181,682,079
Ensembl chr 4:181,539,450...181,682,076

G

peptidylprolyl isomerase A like 4G

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PPIAL4G protein

NCBI chr15:79,601,128...80,424,184
Ensembl chr15:80,423,564...80,424,151

G

peptidylprolyl isomerase like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPIL2 mRNA

NCBI chr11:97,401,944...97,424,581
Ensembl chr11:97,401,963...97,430,769

G

diphosphoinositol pentakisphosphate kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPIP5K2 mRNA

NCBI chr 9:105,727,906...105,838,159
Ensembl chr 9:105,727,911...105,838,157

G

protein phosphatase methylesterase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPME1 mRNA

NCBI chr 1:164,080,242...164,127,261
Ensembl chr 1:164,080,242...164,127,220

G

protein phosphatase 1 catalytic subunit alpha

multiple interactions

ISO

[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of PPP1CA protein

NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:210,914,567...210,918,193

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP1R12A mRNA

NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:45,369,315...45,480,157

G

protein phosphatase 1, regulatory subunit 15A

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of PPP1R15A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPP1R15A mRNA; epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased expression of PPP1R15A mRNA]

PMID:18851785 PMID:22079256

NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774

G

protein phosphatase 1, regulatory subunit 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPP1R18 mRNA

NCBI chr20:2,882,370...2,892,329
Ensembl chr20:2,882,369...2,896,605

G

protein phosphatase 2, regulatory subunit B'', alpha

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of PPP2R3A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP2R3A mRNA

NCBI chr 8:110,582,479...110,720,516
Ensembl chr 8:110,583,743...110,677,482

G

protein phosphatase 2, regulatory subunit B'', gamma

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP2R3C mRNA

NCBI chr 6:78,382,849...78,406,037
Ensembl chr 6:78,382,855...78,406,201

G

protein phosphatase 3 catalytic subunit gamma

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP3CC mRNA

NCBI chr15:51,699,586...51,771,763
Ensembl chr15:51,700,255...51,771,538

G

protein phosphatase 4, regulatory subunit 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP4R4 mRNA

NCBI chr 6:128,427,884...128,518,776
Ensembl chr 6:128,427,893...128,528,039

G

protein phosphatase 6, regulatory subunit 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP6R3 mRNA

NCBI chr 1:210,122,394...210,236,839
Ensembl chr 1:210,122,394...210,236,809

G

PPARG related coactivator 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPRC1 mRNA

NCBI chr 1:254,851,136...254,867,570
Ensembl chr 1:254,851,164...254,867,570

G

peptidylprolyl isomerase domain and WD repeat containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPWD1 mRNA

NCBI chr 2:37,069,744...37,094,252
Ensembl chr 2:37,071,083...37,094,242

G

peroxiredoxin 2

increases expression

ISO

epigallocatechin gallate results in increased expression of PRDX2 protein

NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006

G

prolactin regulatory element binding

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PREB mRNA

NCBI chr 6:31,138,757...31,142,544
Ensembl chr 6:31,138,743...31,142,540

G

PRELI domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRELID2 mRNA

NCBI chr18:34,120,989...34,212,699
Ensembl chr18:34,125,373...34,212,167

G

prickle planar cell polarity protein 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of PRICKLE2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRICKLE2 mRNA

NCBI chr 4:126,426,767...126,771,986
Ensembl chr 4:126,426,771...126,772,008

G

DNA primase subunit 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRIM1 mRNA

NCBI chr 7:1,031,436...1,047,134

G

DNA primase subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRIM2 mRNA

NCBI chr 9:43,188,350...43,400,482
Ensembl chr 9:43,188,350...43,398,990

G

primase and DNA directed polymerase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRIMPOL mRNA

NCBI chr16:52,413,894...52,450,975
Ensembl chr16:52,413,935...52,450,950

G

protein kinase C, delta

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Histamine results in increased phosphorylation of PRKCD protein]; epigallocatechin gallate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of PRKCD protein]

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

protein kinase C, eta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRKCH mRNA

NCBI chr 6:98,027,830...98,226,486
Ensembl chr 6:98,027,646...98,226,477

G

PRKCSH beta subunit of glucosidase II

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PRKCSH mRNA
epigallocatechin gallate results in increased expression of PRKCSH protein

PMID:22079256 PMID:31195006

NCBI chr 8:28,810,836...28,822,503
Ensembl chr 8:28,810,889...28,822,503

G

protein kinase D1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRKD1 mRNA

NCBI chr 6:73,460,640...73,774,433
Ensembl chr 6:73,460,640...73,836,509

G

prolactin receptor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRLR mRNA

NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:60,861,658...61,051,882

G

protein arginine methyltransferase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRMT3 mRNA

NCBI chr 1:108,628,899...108,718,803
Ensembl chr 1:108,626,749...108,718,803

G

protein only RNase P catalytic subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRORP mRNA

NCBI chr 6:78,404,821...78,497,562
Ensembl chr 6:78,405,980...78,497,761

G

pre-mRNA processing factor 38B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PRPF38B mRNA

NCBI chr 2:199,241,312...199,250,342
Ensembl chr 2:199,241,313...199,250,338

G

phosphoribosyl pyrophosphate synthetase-associated protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRPSAP2 mRNA

NCBI chr10:46,910,282...46,945,401
Ensembl chr10:46,910,285...46,945,331

G

serine protease 23

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRSS23 mRNA

NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:152,813,670...152,947,871

G

prune exopolyphosphatase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRUNE1 mRNA

NCBI chr 2:185,519,569...185,548,402
Ensembl chr 2:185,520,781...185,548,402

G

peroxiredoxin like 2C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRXL2C mRNA

NCBI chr17:817,932...849,965
Ensembl chr17:817,949...840,940

G

PC4 and SRSF1 interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PSIP1 mRNA

NCBI chr 5:102,892,929...102,925,191
Ensembl chr 5:102,892,932...102,925,170

G

proteasome 20S subunit alpha 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PSMA2 protein

NCBI chr17:55,250,054...55,260,441
Ensembl chr17:55,247,442...55,339,673

G

proteasome 20S subunit alpha 4

increases expression

ISO

epigallocatechin gallate results in increased expression of PSMA4 protein

NCBI chr 8:64,236,520...64,243,980
Ensembl chr 8:64,236,783...64,243,979

G

proteasome 20S subunit alpha 7

increases expression

ISO

epigallocatechin gallate results in increased expression of PSMA7 protein

NCBI chr 3:187,514,901...187,521,289
Ensembl chr 3:187,513,441...187,521,253

G

proteasome 20S subunit beta 3

increases expression

ISO

epigallocatechin gallate results in increased expression of PSMB3 protein

NCBI chr10:83,193,787...83,200,883
Ensembl chr10:83,193,787...83,200,883

G

proteasome 26S subunit, ATPase 4

increases expression

ISO

epigallocatechin gallate results in increased expression of PSMC4 protein

NCBI chr 1:92,476,690...92,485,268
Ensembl chr 1:92,476,690...92,485,060

G

proteasome activator subunit 3 interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PSME3IP1 mRNA

NCBI chr19:10,407,382...10,436,029
Ensembl chr19:10,407,552...10,436,027

G

proline and serine rich coiled-coil 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PSRC1 mRNA

NCBI chr 2:198,710,427...198,715,001
Ensembl chr 2:198,705,839...198,714,997

G

platelet-activating factor receptor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PTAFR mRNA

NCBI chr 5:150,049,322...150,079,060
Ensembl chr 5:150,049,460...150,079,408

G

phosphatase and tensin homolog

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PTEN mRNA

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

phosphotriesterase related

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTER mRNA

NCBI chr17:80,967,463...81,028,707
Ensembl chr17:80,967,477...81,030,099

G

prostaglandin D2 synthase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PTGDS mRNA

NCBI chr 3:28,680,044...28,682,978
Ensembl chr 3:28,680,044...28,682,978

G

prostaglandin E receptor 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PTGER1 mRNA

NCBI chr19:41,374,983...41,379,593
Ensembl chr19:41,374,471...41,378,284

G

prostaglandin-endoperoxide synthase 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of PTGS1 mRNA

NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
decreases expression

ISO
EXP

1-Butanol inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of PTGS2 protein]; Go 6976 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; Go 6976 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]]; PLD1 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; Propranolol promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]]
[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PTGS2 mRNA]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]
1-Butanol inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; [Tea results in increased abundance of epigallocatechin gallate] inhibits the reaction [Histamine results in increased expression of PTGS2 protein]; epigallocatechin gallate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PTGS2 protein]; epigallocatechin gallate promotes the reaction [Sulindac inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PTGS2 protein]]; Go 6976 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]
epigallocatechin gallate results in decreased expression of PTGS2 mRNA

PMID:15210717 PMID:16084531 PMID:19557821 PMID:20438794 PMID:23717041 More...

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

parathyroid hormone

multiple interactions

ISO

[sodium arsenate co-treated with epigallocatechin gallate] affects the expression of PTH protein

NCBI chr 1:176,942,901...176,946,034
Ensembl chr 1:176,943,102...176,946,034

G

protein tyrosine kinase 2

decreases phosphorylation
multiple interactions

ISO

epigallocatechin gallate results in decreased phosphorylation of PTK2 protein
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTK2 mRNA

PMID:11746506 PMID:22079256

NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091

G

protein tyrosine phosphatase 4A1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PTP4A1 mRNA

NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:40,710,250...40,718,176

G

protein tyrosine phosphatase, non-receptor type 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN12 mRNA

NCBI chr 4:14,913,071...14,985,084
Ensembl chr 4:14,913,218...14,985,284

G

protein tyrosine phosphatase, non-receptor type 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN13 mRNA

NCBI chr14:6,412,841...6,587,238
Ensembl chr14:6,412,841...6,587,171

G

protein tyrosine phosphatase, non-receptor type 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN3 mRNA

NCBI chr 5:76,703,687...76,822,584
Ensembl chr 5:76,703,687...76,860,470

G

protein tyrosine phosphatase, non-receptor type 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN4 mRNA

NCBI chr13:33,324,808...33,504,957
Ensembl chr13:33,324,808...33,504,957

G

protein tyrosine phosphatase, receptor type, E

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPRE mRNA

NCBI chr 1:199,774,195...199,924,646
Ensembl chr 1:199,774,198...199,922,242

G

protein tyrosine phosphatase, receptor type, J

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPRJ mRNA

NCBI chr 3:96,861,785...97,017,702
Ensembl chr 3:96,861,785...97,017,656

G

peptidyl-tRNA hydrolase 1 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTRH1 mRNA

NCBI chr 3:36,462,575...36,475,605
Ensembl chr 3:36,462,575...36,476,139

G

pentraxin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTX3 mRNA

NCBI chr 2:152,797,563...152,803,372
Ensembl chr 2:152,781,955...152,803,372

G

pseudouridine 5'-phosphatase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PUDP mRNA

NCBI chr18:46,064,867...46,067,247
Ensembl chr18:46,063,292...46,067,443

G

pseudouridine synthase 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PUS10 mRNA

NCBI chr14:101,822,525...101,885,187
Ensembl chr14:101,822,458...101,885,190

G

pseudouridine synthase 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PUS7 mRNA

NCBI chr 4:12,252,553...12,293,547
Ensembl chr 4:12,252,545...12,293,539

G

pseudouridine synthase 7 like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PUS7L mRNA

NCBI chr 7:127,538,785...127,561,936
Ensembl chr 7:127,538,558...127,561,798

G

PWP1 homolog, endonuclein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PWP1 mRNA

NCBI chr 7:19,870,465...19,886,463
Ensembl chr 7:19,866,927...19,886,463

G

peroxisomal membrane protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PXMP4 mRNA

NCBI chr 3:163,553,582...163,570,829
Ensembl chr 3:163,553,599...163,570,829

G

PYD and CARD domain containing

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [bisphenol A affects the expression of PYCARD mRNA]
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of PYCARD mRNA]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of PYCARD protein]

PMID:35439536 PMID:36056792

NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419

G

glycogen phosphorylase, muscle associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PYGM mRNA

NCBI chr 1:213,119,805...213,134,622
Ensembl chr 1:213,119,791...213,134,612

G

RAB11B, member RAS oncogene family

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RAB11B mRNA

NCBI chr 7:15,223,613...15,236,754
Ensembl chr 7:15,223,534...15,236,756

G

RAB11 family interacting protein 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAB11FIP5 mRNA

NCBI chr 4:119,428,766...119,466,277
Ensembl chr 4:119,428,766...119,466,213

G

RAB12, member RAS oncogene family

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAB12 mRNA

NCBI chr 9:113,927,119...113,953,722
Ensembl chr 9:113,927,119...113,953,695

G

RAB15, member RAS oncogene family

increases expression

ISO

epigallocatechin gallate results in increased expression of RAB15 protein

NCBI chr 6:101,232,740...101,257,388
Ensembl chr 6:101,232,743...101,257,083

G

RAB1A, member RAS oncogene family

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB1A mRNA

NCBI chr14:98,623,582...98,648,766
Ensembl chr14:98,623,635...98,661,582

G

RAB27B, member RAS oncogene family

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB27B mRNA

NCBI chr18:65,870,230...66,069,597
Ensembl chr18:65,876,342...66,067,700

G

RAB28, member RAS oncogene family

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB28 mRNA

NCBI chr14:73,458,386...73,535,367
Ensembl chr14:73,458,249...73,535,369

G

RAB31, member RAS oncogene family

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB31 mRNA

NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:112,693,597...112,828,092

G

RAB33B, member RAS oncogene family

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAB33B mRNA
epigallocatechin gallate results in increased expression of RAB33B protein

PMID:22079256 PMID:31195006

NCBI chr 2:137,678,953...137,689,581
Ensembl chr 2:137,678,978...137,689,581

G

RAB3D, member RAS oncogene family

increases expression

ISO

epigallocatechin gallate results in increased expression of RAB3D protein

NCBI chr 8:28,714,706...28,725,379
Ensembl chr 8:28,716,241...28,725,317

G

RAB3 GTPase activating non-catalytic protein subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB3GAP2 mRNA

NCBI chr13:99,288,984...99,362,817
Ensembl chr13:99,288,647...99,361,053

G

RAB3A interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB3IP mRNA

NCBI chr 7:54,417,418...54,461,253
Ensembl chr 7:54,418,358...54,447,000

G

RAB5C, member RAS oncogene family

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RAB5C protein

NCBI chr10:86,142,872...86,166,449
Ensembl chr10:86,142,873...86,166,449

G

RAB6A, member RAS oncogene family

increases expression

ISO

epigallocatechin gallate results in increased expression of RAB6A protein

NCBI chr 1:164,370,033...164,422,324
Ensembl chr 1:164,369,861...164,417,763

G

Rab9 effector protein with kelch motifs

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RABEPK mRNA

NCBI chr 3:38,460,205...38,481,077
Ensembl chr 3:38,460,206...38,480,688

G

RAB GTPase activating protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RABGAP1 mRNA

NCBI chr 3:41,617,784...41,735,795
Ensembl chr 3:41,617,793...41,735,791

G

RAB GTPase activating protein 1-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RABGAP1L mRNA

NCBI chr13:74,997,542...75,593,240
Ensembl chr13:74,997,542...75,533,816

G

Rac family small GTPase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAC1 mRNA

NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109

G

Rac family small GTPase 2

increases expression

ISO

epigallocatechin gallate results in increased expression of RAC2 protein

NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:111,996,742...112,009,267

G

RAD23 homolog A, nucleotide excision repair protein

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RAD23A mRNA

NCBI chr19:40,219,235...40,225,543
Ensembl chr19:40,219,636...40,225,543

G

RAD50 double strand break repair protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD50 mRNA

NCBI chr10:38,310,147...38,362,100
Ensembl chr10:38,310,147...38,362,100

G

RAD51 recombinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51 mRNA

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469

G

RAD51 paralog B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51B mRNA

NCBI chr 6:103,829,390...104,373,923
Ensembl chr 6:103,829,554...104,374,509

G

RAD51 paralog C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51C mRNA

NCBI chr10:72,702,299...72,728,980
Ensembl chr10:72,702,299...72,729,143

G

Ral GTPase activating protein catalytic subunit alpha 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RALGAPA2 mRNA

NCBI chr 3:154,112,005...154,392,070
Ensembl chr 3:154,112,014...154,392,138

G

Ral GTPase activating protein non-catalytic subunit beta

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RALGAPB protein

NCBI chr 3:167,482,344...167,571,975
Ensembl chr 3:167,482,343...167,571,815

G

ral guanine nucleotide dissociation stimulator like 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of RGL1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RGL1 mRNA

NCBI chr13:67,184,402...67,454,019
Ensembl chr13:67,184,402...67,454,019

G

Ral GEF with PH domain and SH3 binding motif 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RALGPS2 mRNA

NCBI chr13:71,474,835...71,654,791
Ensembl chr13:71,474,835...71,606,739

G

RAN, member RAS oncogene family

increases expression

ISO

epigallocatechin gallate results in increased expression of RAN protein

NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317

G

Rap guanine nucleotide exchange factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAPGEF2 mRNA

NCBI chr 2:166,505,868...166,728,139
Ensembl chr 2:166,505,868...166,726,698

G

Rap guanine nucleotide exchange factor 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAPGEF6 mRNA

NCBI chr10:39,156,573...39,324,947
Ensembl chr10:39,156,620...39,324,946

G

retinoic acid receptor, alpha

increases expression

ISO

epigallocatechin gallate results in increased expression of RARA mRNA

PMID:12628509 PMID:20706672

NCBI chr10:84,379,780...84,424,371
Ensembl chr10:84,389,622...84,425,160

G

retinoic acid receptor, beta

decreases metabolic processing
increases expression
decreases methylation

ISO

epigallocatechin gallate results in decreased metabolism of RARB promoter
epigallocatechin gallate results in increased expression of RARB mRNA; epigallocatechin gallate results in increased expression of RARB protein
epigallocatechin gallate results in decreased methylation of RARB promoter

PMID:14633667 PMID:16037419

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040

G

retinoic acid receptor responder 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RARRES1 mRNA

NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:154,059,761...154,094,024

G

arginyl-tRNA synthetase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RARS1 mRNA

NCBI chr10:20,774,804...20,799,251
Ensembl chr10:20,774,805...20,799,251

G

RAS protein activator like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RASAL2 mRNA

NCBI chr13:71,808,740...72,102,723
Ensembl chr13:71,813,261...72,102,723

G

RasGEF domain family, member 1B

increases expression

ISO

epigallocatechin gallate results in increased expression of RASGEF1B mRNA

NCBI chr14:10,164,366...10,684,184
Ensembl chr14:10,644,521...10,697,296

G

RAS guanyl releasing protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RASGRP3 mRNA

NCBI chr 6:25,647,386...25,745,952
Ensembl chr 6:25,647,386...25,710,591

G

RAS-like family 11 member A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RASL11A mRNA

NCBI chr12:13,372,023...13,374,784
Ensembl chr12:13,372,023...13,376,451

G

Ras association domain family member 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RASSF8 mRNA

NCBI chr 4:180,447,050...180,528,792
Ensembl chr 4:180,446,846...180,528,790

G

RB transcriptional corepressor 1

multiple interactions
increases expression

ISO

epigallocatechin gallate results in decreased expression of and results in decreased phosphorylation of RB1 protein
epigallocatechin gallate results in increased expression of RB1 mRNA

PMID:15142168 PMID:18851785

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RB binding protein 4, chromatin remodeling factor

increases expression

ISO

epigallocatechin gallate results in increased expression of RBBP4 mRNA

NCBI chr 5:146,940,207...146,959,501
Ensembl chr 5:146,922,611...146,959,501

G

RNA binding fox-1 homolog 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBFOX2 mRNA

NCBI chr 7:110,691,230...110,934,901
Ensembl chr 7:110,691,230...110,934,987

G

RNA binding motif protein 15B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RBM15B mRNA

NCBI chr 8:116,422,309...116,425,374
Ensembl chr 8:116,421,540...116,425,940

G

RNA binding motif protein 45

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBM45 mRNA

NCBI chr 3:81,713,214...81,728,190
Ensembl chr 3:81,713,176...81,728,190

G

RNA binding motif protein 48

increases expression

ISO

epigallocatechin gallate results in increased expression of RBM48 mRNA

NCBI chr 4:31,513,811...31,524,149
Ensembl chr 4:31,513,760...31,524,147

G

RNA binding motif, single stranded interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBMS1 mRNA

NCBI chr 3:65,604,475...65,829,072
Ensembl chr 3:65,606,358...65,829,013

G

RNA binding motif protein, X-linked

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RBMX protein

NCBI chr X:140,342,544...140,352,121
Ensembl chr X:140,345,571...140,352,035

G

RNA binding protein, mRNA processing factor 2

increases expression

ISO

epigallocatechin gallate results in increased expression of RBPMS2 mRNA

NCBI chr 8:75,048,159...75,079,393
Ensembl chr 8:75,048,263...75,079,396

G

ring-box 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of RBX1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBX1 mRNA

NCBI chr 7:114,870,893...114,881,194
Ensembl chr 7:114,870,972...114,881,191

G

RCAN family member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RCAN3 mRNA

NCBI chr 5:152,934,561...152,955,502
Ensembl chr 5:152,938,711...152,955,589

G

RNA terminal phosphate cyclase-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RCL1 mRNA

NCBI chr 1:236,238,078...236,282,597
Ensembl chr 1:236,238,031...236,315,894

G

reversion-inducing-cysteine-rich protein with kazal motifs

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RECK mRNA

NCBI chr 5:62,898,717...62,965,274
Ensembl chr 5:62,898,668...62,965,270

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases phosphorylation
decreases expression

ISO
EXP

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; epigallocatechin gallate inhibits the reaction [Acrylamide results in increased expression of RELA protein]; epigallocatechin gallate inhibits the reaction [Glucose affects the localization of RELA protein]; epigallocatechin gallate inhibits the reaction [Particulate Matter results in increased phosphorylation of RELA protein]; epigallocatechin gallate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]
epigallocatechin gallate results in increased phosphorylation of RELA protein
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased phosphorylation of RELA protein]; epigallocatechin gallate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of RELA protein]; epigallocatechin gallate inhibits the reaction [Gentamicins results in increased phosphorylation of RELA protein]
epigallocatechin gallate results in decreased expression of RELA protein

PMID:19557821 PMID:24508477 PMID:26187476 PMID:27659729 PMID:30368989 More...

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

REV3 like, DNA directed polymerase zeta catalytic subunit

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of REV3L mRNA

NCBI chr20:44,686,482...44,844,668
Ensembl chr20:44,686,940...44,844,668

G

RFT1 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RFT1 mRNA

NCBI chr16:5,833,521...5,867,578
Ensembl chr16:5,833,546...5,880,165

G

regulatory factor X3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RFX3 mRNA

NCBI chr 1:234,863,462...235,122,989
Ensembl chr 1:234,863,462...235,122,536

G

regulatory factor X-associated ankyrin-containing protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RFXANK mRNA

NCBI chr16:19,314,307...19,322,827
Ensembl chr16:19,314,759...19,325,248

G

regulator of cell cycle

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RGCC mRNA
epigallocatechin gallate results in increased expression of RGCC mRNA

PMID:22079256 PMID:35701726

NCBI chr15:61,071,574...61,084,408
Ensembl chr15:61,071,574...61,084,408

G

regulator of G-protein signaling 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RGS2 mRNA

NCBI chr13:58,350,063...58,352,666
Ensembl chr13:58,349,163...58,352,697

G

regulator of G-protein signaling 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RGS4 mRNA

NCBI chr13:84,469,593...84,475,884
Ensembl chr13:84,469,593...84,475,884

G

rhomboid domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RHBDD2 mRNA

NCBI chr12:26,680,206...26,690,926
Ensembl chr12:26,680,969...26,691,080

G

rhomboid like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RHBDL2 mRNA

NCBI chr 5:141,322,246...141,376,702
Ensembl chr 5:141,322,354...141,366,747

G

Rho-related BTB domain containing 1

decreases expression
multiple interactions
increases expression

ISO

epigallocatechin gallate results in decreased expression of RHOBTB1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RHOBTB1 mRNA
epigallocatechin gallate results in increased expression of RHOBTB1 mRNA

PMID:16084531 PMID:22079256

NCBI chr20:19,326,197...19,455,182
Ensembl chr20:19,326,212...19,402,057

G

ras homolog family member D

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RHOD mRNA

NCBI chr 1:211,138,126...211,153,953
Ensembl chr 1:211,138,126...211,152,061

G

RIC1 homolog, RAB6A GEF complex partner 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RIC1 mRNA

NCBI chr 1:236,698,901...236,798,099
Ensembl chr 1:236,698,852...236,798,099

G

reactive intermediate imine deaminase A homolog

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of RIDA mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RIDA mRNA

NCBI chr 7:67,576,586...67,590,493
Ensembl chr 7:67,576,586...67,590,692

G

RNA sensor RIG-1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RIGI mRNA

NCBI chr 5:60,117,398...60,165,995
Ensembl chr 5:60,117,398...60,165,995

G

RIO kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RIOK3 mRNA

NCBI chr18:3,602,535...3,628,108
Ensembl chr18:3,602,535...3,628,108

G

ribosomal oxygenase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RIOX2 mRNA

NCBI chr11:54,327,311...54,353,989
Ensembl chr11:54,330,605...54,353,752

G

RLF zinc finger

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RLF mRNA

NCBI chr 5:139,996,782...140,052,419
Ensembl chr 5:139,996,782...140,052,419

G

regulator of microtubule dynamics 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RMDN1 mRNA

NCBI chr 5:37,867,172...37,890,826
Ensembl chr 5:37,867,263...38,007,420

G

required for meiotic nuclear division 5 homolog A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RMND5A mRNA

NCBI chr 4:104,934,160...104,991,088
Ensembl chr 4:104,934,160...104,991,088

G

required for meiotic nuclear division 5 homolog B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RMND5B mRNA

NCBI chr10:36,382,212...36,394,801
Ensembl chr10:36,382,213...36,393,154

G

ribonuclease H2, subunit A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNASEH2A mRNA

NCBI chr19:40,091,206...40,100,904
Ensembl chr19:40,091,210...40,100,899

G

Rho family GTPase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RND1 mRNA

NCBI chr 7:131,700,321...131,707,392
Ensembl chr 7:131,700,321...131,707,392

G

ring finger protein 115

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF115 mRNA

NCBI chr 2:186,950,959...187,018,673
Ensembl chr 2:186,950,760...187,019,561

G

ring finger protein 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF13 mRNA

NCBI chr 2:144,076,526...144,211,520
Ensembl chr 2:144,077,916...144,211,798

G

ring finger protein 144B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF144B mRNA

NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,639,079...17,769,037

G

ring finger protein 170

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF170 mRNA

NCBI chr16:72,631,638...72,656,893
Ensembl chr16:72,631,638...72,656,469

G

ring finger protein 180

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF180 mRNA

NCBI chr 2:38,064,026...38,244,854
Ensembl chr 2:38,064,031...38,265,358

G

ring finger protein 182

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF182 mRNA

NCBI chr17:21,232,084...21,287,329
Ensembl chr17:21,232,084...21,299,723

G

ring finger protein 19A, RBR E3 ubiquitin protein ligase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF19A mRNA

NCBI chr 7:69,310,947...69,350,567
Ensembl chr 7:69,310,947...69,350,225

G

ring finger protein 213

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF213 mRNA
epigallocatechin gallate results in increased expression of RNF213 mRNA

NCBI chr10:105,154,873...105,254,148
Ensembl chr10:105,157,904...105,254,148

G

ring finger protein 216

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF216 mRNA

NCBI chr12:16,568,327...16,689,868
Ensembl chr12:16,568,347...16,690,989

G

ring finger protein 217

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF217 mRNA

NCBI chr 1:27,835,741...27,927,805
Ensembl chr 1:27,835,148...27,928,044

G

ring finger protein 26

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF26 mRNA

NCBI chr 8:53,351,388...53,353,586
Ensembl chr 8:53,341,487...53,355,777

G

ring finger protein 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RNF6 mRNA

NCBI chr12:13,929,160...13,940,663
Ensembl chr12:13,931,074...13,940,652

G

ring finger protein, transmembrane 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNFT1 mRNA

NCBI chr10:71,807,403...71,821,132
Ensembl chr10:71,807,456...71,821,141

G

RNA guanylyltransferase and 5'-phosphatase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNGTT mRNA

NCBI chr 5:52,503,335...52,709,604
Ensembl chr 5:52,503,313...52,709,597

G

ribonuclease/angiogenin inhibitor 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RNH1 protein

NCBI chr 1:205,698,882...205,711,348
Ensembl chr 1:205,698,882...205,711,582

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ROCK2 mRNA

NCBI chr 6:45,407,823...45,502,773
Ensembl chr 6:45,407,965...45,502,771

G

receptor tyrosine kinase-like orphan receptor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ROR2 mRNA

NCBI chr17:12,124,749...12,300,044
Ensembl chr17:12,124,749...12,300,044

G

RP9, pre-mRNA splicing factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RP9 mRNA

NCBI chr 8:29,218,564...29,281,211
Ensembl chr 8:29,217,346...29,281,150

G

RNA polymerase II associated protein 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RPAP1 protein

NCBI chr 3:127,200,450...127,221,985
Ensembl chr 3:127,110,550...127,221,952

G

Rpgrip1-like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPGRIP1L mRNA

NCBI chr19:31,865,050...31,957,930
Ensembl chr19:31,865,231...31,957,930

G

ribosomal protein L10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL10 mRNA

NCBI chr X:157,205,850...157,208,057
Ensembl chr X:157,205,836...157,208,049

G

ribosomal protein L10A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RPL10A protein

NCBI chr20:6,390,533...6,393,091
Ensembl chr20:6,390,179...6,393,091

G

ribosomal protein L13

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL13 mRNA
epigallocatechin gallate results in decreased expression of RPL13 protein

PMID:22079256 PMID:31195006

NCBI chr19:68,062,442...68,065,065
Ensembl chr19:68,062,493...68,065,059

G

ribosomal protein L14

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL14 mRNA

NCBI chr 8:129,163,620...129,166,745
Ensembl chr 8:129,163,317...129,167,459

G

ribosomal protein L15

increases expression

ISO

epigallocatechin gallate results in increased expression of RPL15 protein

NCBI chr15:9,934,663...9,937,946
Ensembl chr15:9,934,679...9,938,308

G

ribosomal protein L17

increases expression

ISO

epigallocatechin gallate results in increased expression of RPL17 protein

NCBI chr18:70,856,275...70,859,388
Ensembl chr 3:111,722,010...111,722,638
Ensembl chr18:111,722,010...111,722,638

G

ribosomal protein L18A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL18A mRNA

NCBI chr16:18,576,467...18,578,653
Ensembl chr 1:70,166,729...70,167,654
Ensembl chr16:70,166,729...70,167,654

G

ribosomal protein L19

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RPL19 protein

NCBI chr10:83,514,509...83,522,352
Ensembl chr10:83,515,464...83,522,352

G

ribosomal protein L23A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RPL23A protein

NCBI chr10:63,574,732...63,577,511
Ensembl chr10:63,574,732...63,581,606

G

ribosomal protein L27A

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL27A mRNA
epigallocatechin gallate results in increased expression of RPL27A protein

PMID:22079256 PMID:31195006

NCBI chr 1:172,971,957...172,977,591

G

ribosomal protein L28

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL28 mRNA

NCBI chr 1:78,080,945...78,083,532
Ensembl chr 1:78,080,945...78,083,771

G

ribosomal protein L29

increases expression

ISO

epigallocatechin gallate results in increased expression of RPL29 protein

NCBI chr 8:115,056,443...115,949,677
Ensembl chr 8:115,947,394...115,950,565

G

ribosomal protein L34

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL34 mRNA

NCBI chr 2:221,958,551...221,962,309
Ensembl chr17:79,783,869...79,820,922
Ensembl chr 2:79,783,869...79,820,922

G

ribosomal protein L36

increases expression

ISO

epigallocatechin gallate results in increased expression of RPL36 protein

NCBI chr 9:1,529,117...1,534,534
Ensembl chr 1:126,560,003...126,560,369

G

ribosomal protein L36A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RPL36A protein

NCBI chr X:102,058,573...102,062,162
Ensembl chr20:22,034,086...22,034,406

G

ribosomal protein L37

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL37 mRNA

NCBI chr 2:55,942,827...55,944,905
Ensembl chr 2:55,942,945...55,944,900

G

ribosomal protein L37A

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of RPL37A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL37A mRNA

NCBI chr 9:81,748,091...81,750,174
Ensembl chr 9:81,748,103...81,751,975

G

ribosomal protein L39 like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPL39L mRNA

NCBI chr10:5,962,506...5,966,621
Ensembl chr10:5,962,515...5,966,621

G

ribosomal protein L4

increases expression

ISO

epigallocatechin gallate results in increased expression of RPL4 protein

NCBI chr 8:73,566,477...73,571,600
Ensembl chr 8:73,566,466...73,571,788

G

ribosomal protein L5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL5 mRNA

NCBI chr14:1,988,792...1,995,236
Ensembl chr14:1,988,793...1,995,225

G

ribosomal protein L7

increases expression

ISO

epigallocatechin gallate results in increased expression of RPL7 protein

NCBI chr 5:8,000,446...8,003,454
Ensembl chr 5:7,850,630...8,003,451

G

ribosomal protein L7A

increases expression

ISO

epigallocatechin gallate results in increased expression of RPL7A protein

NCBI chr 3:30,637,136...30,639,778
Ensembl chr 3:30,637,059...30,639,791
Ensembl chr18:30,637,059...30,639,791

G

ribonuclease P and MRP subunit p25

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPP25 mRNA

NCBI chr 8:66,803,262...66,804,642
Ensembl chr 8:66,803,212...66,810,550

G

ribosomal protein S13

increases expression

ISO

epigallocatechin gallate results in increased expression of RPS13 protein

NCBI chr 1:180,007,230...180,009,660
Ensembl chr 1:180,002,471...180,009,660

G

ribosomal protein S2

increases expression

ISO

epigallocatechin gallate results in increased expression of RPS2 protein

NCBI chr10:14,251,841...14,253,697
Ensembl chr10:14,251,380...14,253,695

G

ribosomal protein S27

increases expression

ISO

epigallocatechin gallate results in increased expression of RPS27 protein

NCBI chr 2:177,963,499...177,964,708
Ensembl chr 2:177,963,496...177,964,607
Ensembl chr12:177,963,496...177,964,607

G

ribosomal protein S28

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RPS28 protein

NCBI chr 7:15,309,964...15,311,333
Ensembl chr16:72,591,164...72,591,373
Ensembl chr 7:72,591,164...72,591,373
Ensembl chr16:72,591,164...72,591,373

G

ribosomal protein S3a

multiple interactions
increases expression
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPS3A mRNA
epigallocatechin gallate results in increased expression of RPS3A protein
epigallocatechin gallate results in decreased expression of RPS3A mRNA

PMID:22079256 PMID:31195006

NCBI chr 2:173,822,673...173,827,042
Ensembl chr 2:173,822,488...173,827,043

G

ribosomal protein S4, X-linked

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RPS4X protein

NCBI chr X:71,338,478...71,342,921
Ensembl chr X:71,338,479...71,342,921
Ensembl chr 4:71,338,479...71,342,921

G

ribosomal protein S6

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased phosphorylation of RPS6 protein]

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566

G

ribosomal protein S6 kinase A3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA3 mRNA

NCBI chr X:39,325,926...39,432,017
Ensembl chr X:39,325,926...39,433,678

G

ribosomal protein S6 kinase A5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA5 mRNA

NCBI chr 6:125,558,434...125,736,576
Ensembl chr 6:125,558,434...125,735,856

G

ribosomal protein S6 kinase B1

multiple interactions

ISO

epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RPS6KB1 protein]]

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

ribosomal protein S6 kinase C1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KC1 mRNA

NCBI chr13:104,877,296...105,021,490
Ensembl chr13:104,877,296...105,021,435

G

regulatory associated protein of MTOR, complex 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of RPTOR mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPTOR mRNA

NCBI chr10:105,376,943...105,675,416
Ensembl chr10:105,376,943...105,675,413

G

RNA pseudouridine synthase D3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPUSD3 mRNA

NCBI chr 4:148,108,857...148,118,246
Ensembl chr 4:148,109,383...148,118,206

G

RNA pseudouridine synthase D4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPUSD4 mRNA

NCBI chr 8:41,875,217...41,884,702
Ensembl chr 8:41,874,764...41,884,699

G

retinal pigment epithelium derived rhodopsin homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RRH mRNA

NCBI chr 2:221,036,436...221,048,627
Ensembl chr 2:221,036,436...221,048,627

G

ribosomal RNA processing 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RRP8 mRNA

NCBI chr 1:169,489,829...169,500,551
Ensembl chr 1:169,465,397...169,501,164

G

arginine and serine rich coiled-coil 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RSRC2 mRNA

NCBI chr12:38,500,709...38,520,715
Ensembl chr12:38,500,770...38,520,707

G

rhotekin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RTKN2 mRNA

NCBI chr20:20,535,553...20,608,863
Ensembl chr20:20,535,553...20,608,899

G

retrotransposon Gag like 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RTL3 mRNA

NCBI chr X:76,020,183...76,023,848
Ensembl chr X:76,020,183...76,023,848

G

reticulon 4 interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RTN4IP1 mRNA

NCBI chr20:48,964,903...49,004,235
Ensembl chr20:48,964,816...49,006,456

G

rotatin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RTTN mRNA

NCBI chr18:84,495,813...84,673,079
Ensembl chr18:84,482,601...84,700,463

G

RUN and FYVE domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RUFY1 mRNA

NCBI chr10:35,206,801...35,251,696
Ensembl chr10:35,206,801...35,251,696

G

RUNX family transcription factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RUNX2 mRNA

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

RWD domain containing 2A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RWDD2A mRNA

NCBI chr 8:96,416,190...96,419,315
Ensembl chr 8:96,416,190...96,419,315

G

retinoid X receptor alpha

decreases expression

ISO

epigallocatechin gallate results in decreased expression of RXRA mRNA

NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417

G

S100 calcium binding protein A3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of S100A3 mRNA

NCBI chr 2:178,331,856...178,387,280
Ensembl chr 2:178,384,578...178,387,280

G

S100 calcium binding protein A6

decreases expression

ISO

epigallocatechin gallate results in decreased expression of S100A6 protein

NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762

G

S100P binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of S100PBP mRNA

NCBI chr 5:146,778,706...146,820,223
Ensembl chr 5:146,780,061...146,819,822

G

SAC1 like phosphatidylinositide phosphatase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SACM1L mRNA

NCBI chr 8:132,053,465...132,109,857
Ensembl chr 8:132,053,049...132,109,857

G

scaffold attachment factor B2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAFB2 mRNA

NCBI chr 9:1,482,985...1,504,142
Ensembl chr 9:1,479,061...1,504,142

G

sterile alpha motif domain containing 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SAMD9 mRNA

NCBI chr 4:32,119,318...32,139,008
Ensembl chr 4:32,117,137...32,171,759

G

sterile alpha motif domain containing 9 like

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of SAMD9L mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SAMD9L mRNA

NCBI chr 4:32,316,748...32,331,112
Ensembl chr 4:32,222,623...32,331,067

G

SANT and BTB domain regulator of CSR

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SANBR mRNA

NCBI chr14:101,717,619...101,787,092
Ensembl chr14:101,716,868...101,782,480

G

Sin3A associated protein 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAP18 mRNA

NCBI chr15:36,058,784...36,063,089
Ensembl chr10:87,156,914...87,158,257
Ensembl chr15:87,156,914...87,158,257

G

SAM and SH3 domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SASH1 mRNA

NCBI chr 1:4,940,207...5,238,777
Ensembl chr 1:4,940,207...5,238,530

G

SAS-6 centriolar assembly protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SASS6 mRNA

NCBI chr 2:207,231,896...207,263,840
Ensembl chr 2:207,231,333...207,263,851

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAT1 mRNA

NCBI chr X:44,008,089...44,011,376
Ensembl chr X:44,006,781...44,011,374

G

spermidine/spermine N1-acetyltransferase family member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAT2 mRNA

NCBI chr10:54,839,531...54,841,651
Ensembl chr10:54,839,189...54,841,958

G

SAYSVFN motif domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SAYSD1 mRNA

NCBI chr15:4,273,302...4,278,971
Ensembl chr15:4,273,012...4,278,971

G

suppressor of cancer cell invasion

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCAI mRNA

NCBI chr 3:43,222,983...43,335,056
Ensembl chr 3:43,222,983...43,335,025

G

S-phase cyclin A-associated protein in the ER

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCAPER mRNA

NCBI chr 8:64,828,789...65,228,240
Ensembl chr 8:64,828,789...65,228,453

G

stearoyl-CoA desaturase

multiple interactions
decreases expression

ISO
EXP

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SCD mRNA
epigallocatechin gallate results in decreased expression of SCD mRNA; epigallocatechin gallate results in decreased expression of SCD1 mRNA

PMID:16988119 PMID:22079256

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

selenocysteine lyase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCLY mRNA

NCBI chr 9:99,337,796...99,358,487
Ensembl chr 9:99,327,873...99,358,487

G

Scm polycomb group protein like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SCML1 mRNA

NCBI chr X:36,526,068...36,543,336
Ensembl chr X:36,526,068...36,544,450

G

secernin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCRN3 mRNA

NCBI chr 3:78,596,330...78,621,132
Ensembl chr 3:78,596,386...78,621,132

G

scratch family transcriptional repressor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SCRT1 mRNA

NCBI chr 7:110,121,640...110,125,290
Ensembl chr 7:110,121,640...110,125,290

G

SCY1 like pseudokinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCYL3 mRNA

NCBI chr13:78,811,595...78,836,202
Ensembl chr13:78,811,741...78,836,204

G

succinate dehydrogenase complex assembly factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SDHAF2 mRNA

NCBI chr 1:216,564,002...216,592,877
Ensembl chr 1:216,567,861...216,593,540

G

SEC14-like lipid binding 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SEC14L1 mRNA

NCBI chr10:102,818,693...102,865,841
Ensembl chr10:102,818,693...102,865,839

G

SEC22 homolog A, vesicle trafficking protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SEC22A mRNA

NCBI chr11:78,907,552...78,967,575
Ensembl chr11:78,907,470...78,970,447

G

SECIS binding protein 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SECISBP2 mRNA

NCBI chr17:13,690,263...13,721,303
Ensembl chr17:13,690,264...13,721,250

G

selectin E

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SELE mRNA

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903

G

selenoprotein N

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SELENON mRNA

NCBI chr 5:152,032,330...152,046,707
Ensembl chr 5:152,032,330...152,046,707

G

selectin P ligand

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SELPLG mRNA

NCBI chr12:48,457,102...48,470,444
Ensembl chr12:48,456,932...48,473,154

G

semaphorin 6D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SEMA6D mRNA

NCBI chr 3:131,801,680...132,394,578
Ensembl chr 3:132,337,343...132,394,584

G

SUMO specific peptidase 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SENP7 mRNA

NCBI chr11:57,892,801...58,053,213
Ensembl chr11:57,787,914...58,033,766

G

selenophosphate synthetase 2

increases expression

ISO

epigallocatechin gallate results in increased expression of SEPHS2 mRNA

NCBI chr 1:191,323,637...191,325,955
Ensembl chr 1:191,323,641...191,325,955

G

serine active site containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERAC1 mRNA

NCBI chr 1:49,025,845...49,061,853
Ensembl chr 1:49,025,845...49,061,853

G

Serpine1 mRNA binding protein 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SERBP1 protein

NCBI chr 4:97,731,200...97,748,438
Ensembl chr 4:97,731,277...97,751,518

G

serpin family B member 1A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERPINB1 mRNA

NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,799,415...31,808,166

G

serpin family B member 2

increases expression

ISO

epigallocatechin gallate results in increased expression of SERPINB2 protein

NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031

G

serpin family B member 5

increases expression

ISO

epigallocatechin gallate results in increased expression of SERPINB5 mRNA

NCBI chr13:23,500,203...23,520,401
Ensembl chr13:23,500,198...23,520,400

G

serpin family B member 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERPINB9 mRNA

NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974

G

SERTA domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SERTAD1 mRNA

NCBI chr 1:91,903,297...91,906,565
Ensembl chr 1:91,891,814...91,907,001

G

SERTA domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SERTAD2 mRNA

NCBI chr14:98,935,428...99,039,536
Ensembl chr14:98,934,769...99,041,468

G

SERTA domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERTAD3 mRNA

NCBI chr 1:91,891,141...91,894,861
Ensembl chr 1:91,893,616...91,897,110

G

sestrin 3

increases expression

ISO

epigallocatechin gallate results in increased expression of SESN3 mRNA

NCBI chr 8:19,415,307...19,470,943
Ensembl chr 8:19,415,347...19,466,904

G

SEC14 and spectrin domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SESTD1 mRNA

NCBI chr 3:82,530,796...82,627,960
Ensembl chr 3:82,537,092...82,588,078

G

splicing factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SF1 mRNA

NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:213,099,260...213,113,590

G

splicing factor 3B subunit 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SF3B4 mRNA

NCBI chr 2:186,421,667...186,426,419
Ensembl chr 2:186,421,636...186,426,833

G

Scm-like with four mbt domains 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SFMBT1 mRNA

NCBI chr16:5,896,686...6,016,311
Ensembl chr16:5,897,187...6,011,934

G

splicing factor proline and glutamine rich

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SFPQ protein

NCBI chr 5:144,621,678...144,637,930
Ensembl chr 5:144,622,476...144,637,926

G

secreted frizzled-related protein 1

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in decreased expression of SFRP1 mRNA]; epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in decreased expression of SFRP1 protein]

NCBI chr16:75,278,325...75,316,736
Ensembl chr16:75,278,325...75,316,736

G

serum/glucocorticoid regulated kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SGK1 mRNA

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

sphingomyelin synthase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGMS1 mRNA

NCBI chr 1:239,409,991...239,681,195
Ensembl chr 1:239,409,991...239,505,774

G

shugoshin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGO2 mRNA

NCBI chr 9:67,032,083...67,067,439
Ensembl chr 9:67,042,833...67,068,152

G

SH2 domain containing 4A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SH2D4A mRNA

NCBI chr16:26,106,721...26,176,069
Ensembl chr16:26,106,730...26,175,974

G

SH3 and PX domains 2B

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SH3PXD2B mRNA
epigallocatechin gallate results in increased expression of SH3PXD2B mRNA

NCBI chr10:17,422,906...17,538,977
Ensembl chr10:17,422,947...17,512,854

G

shieldin complex subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SHLD2 mRNA

NCBI chr16:9,554,921...9,646,186
Ensembl chr16:9,553,854...9,588,510

G

serine hydroxymethyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SHMT1 mRNA

NCBI chr10:45,968,959...45,990,341
Ensembl chr10:45,960,434...45,997,326

G

SHOC2 leucine-rich repeat scaffold protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SHOC2 mRNA

NCBI chr 1:262,964,345...263,052,898
Ensembl chr 1:262,965,011...263,052,634

G

shootin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SHTN1 mRNA

NCBI chr 1:268,108,095...268,211,947
Ensembl chr 1:268,108,097...268,211,947

G

SID1 transmembrane family, member 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of SIDT2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SIDT2 mRNA

NCBI chr 8:55,129,091...55,146,446
Ensembl chr 8:55,129,091...55,145,408

G

single Ig and TIR domain containing

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIGIRR mRNA

NCBI chr 1:205,625,742...205,637,883
Ensembl chr 1:205,627,708...205,637,802

G

salt-inducible kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SIK1 mRNA

NCBI chr20:9,947,104...9,958,729
Ensembl chr20:9,947,105...9,958,698

G

SIM bHLH transcription factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIM1 mRNA

NCBI chr20:55,409,814...55,489,450
Ensembl chr20:55,410,577...55,489,449

G

signal-induced proliferation-associated 1 like 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIPA1L1 mRNA
epigallocatechin gallate results in increased expression of SIPA1L1 mRNA

NCBI chr 6:107,570,569...107,849,613
Ensembl chr 6:107,737,392...107,848,160

G

signal-induced proliferation-associated 1 like 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIPA1L2 mRNA

NCBI chr19:70,287,134...70,437,810
Ensembl chr19:70,287,147...70,437,773

G

sirtuin 1

multiple interactions

EXP
ISO

[1-Methyl-4-phenylpyridinium co-treated with epigallocatechin gallate] results in increased expression of SIRT1 protein; epigallocatechin gallate analog inhibits the reaction [Dietary Fats results in decreased expression of SIRT1 protein]
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 mRNA]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] affects the reaction [Hydrogen Peroxide affects the expression of SIRT1 protein]

PMID:22742579 PMID:29061316 PMID:36056792 PMID:39577827

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

sirtuin 3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SIRT3 mRNA; epigallocatechin gallate results in decreased expression of SIRT3 protein

NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076

G

sirtuin 7

affects methylation

EXP

epigallocatechin gallate affects the methylation of SIRT7 gene

NCBI chr10:106,394,802...106,401,627
Ensembl chr10:106,394,802...106,401,498

G

SIX homeobox 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SIX4 mRNA

NCBI chr 6:97,538,202...97,551,872
Ensembl chr 6:97,538,202...97,551,872

G

SKI8 subunit of superkiller complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SKIC8 mRNA

NCBI chr 8:63,999,669...64,016,959
Ensembl chr 8:63,999,671...64,016,846

G

S-phase kinase associated protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SKP2 mRNA

NCBI chr 2:59,888,406...59,916,471
Ensembl chr 2:59,888,413...59,916,438

G

solute carrier family 10 member 1

multiple interactions
decreases expression

EXP

epigallocatechin gallate inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 protein]
epigallocatechin gallate results in decreased expression of SLC10A1 mRNA

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 10 member 2

decreases expression
multiple interactions

EXP

epigallocatechin gallate results in decreased expression of SLC10A2 mRNA
epigallocatechin gallate inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A2 mRNA]

NCBI chr16:91,088,089...91,111,025
Ensembl chr16:91,076,423...91,111,025

G

solute carrier family 10, member 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC10A7 mRNA

NCBI chr19:46,087,440...46,311,753
Ensembl chr19:46,049,631...46,311,753

G

solute carrier family 16, member 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC16A13 mRNA

NCBI chr10:55,424,633...55,436,555

G

solute carrier family 16 member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC16A3 mRNA

NCBI chr10:106,712,328...106,756,168
Ensembl chr10:106,714,466...106,720,903

G

solute carrier family 17 member 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC17A5 mRNA

NCBI chr 8:88,274,497...88,309,734
Ensembl chr 8:88,274,721...88,309,664

G

solute carrier family 25 member 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A12 mRNA

NCBI chr 3:76,504,868...76,599,536
Ensembl chr 3:76,504,868...76,599,536

G

solute carrier family 25 member 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A13 mRNA

NCBI chr 4:35,145,721...35,328,403
Ensembl chr 4:35,145,721...35,328,360

G

solute carrier family 25 member 2

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC25A2 mRNA
epigallocatechin gallate results in increased expression of SLC25A2 mRNA

NCBI chr18:29,704,182...29,707,563
Ensembl chr18:29,703,871...29,708,827

G

solute carrier family 25 member 20

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A20 mRNA

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

G

solute carrier family 25 member 36

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC25A36 mRNA

NCBI chr 8:106,539,355...106,573,240

G

solute carrier family 25, member 46

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A46 mRNA

NCBI chr18:23,490,422...23,519,599
Ensembl chr18:23,490,425...23,518,730

G

solute carrier family 26 member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC26A2 mRNA

NCBI chr18:56,918,662...56,937,032
Ensembl chr18:56,923,337...56,937,012

G

solute carrier family 27 member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC27A2 mRNA

NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581

G

solute carrier family 27 member 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC27A4 mRNA

NCBI chr 3:33,472,903...33,485,824
Ensembl chr 3:33,472,903...33,485,824

G

solute carrier family 2 member 1

increases expression
multiple interactions

EXP
ISO

epigallocatechin gallate results in increased expression of SLC2A1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC2A1 mRNA

PMID:16988119 PMID:22079256

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 2 member 10

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SLC2A10 protein

NCBI chr 3:174,659,683...174,671,978
Ensembl chr 3:174,659,656...174,671,978

G

solute carrier family 2 member 3

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC2A3 mRNA; Acetylcysteine inhibits the reaction [epigallocatechin gallate results in increased expression of SLC2A3 mRNA]; Acetylcysteine inhibits the reaction [epigallocatechin gallate results in increased expression of SLC2A3 protein]
epigallocatechin gallate results in increased expression of SLC2A3 mRNA; epigallocatechin gallate results in increased expression of SLC2A3 protein

PMID:22079256 PMID:31857147

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

G

solute carrier family 2 member 4

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein]

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

solute carrier family 2 member 6

increases expression

ISO

epigallocatechin gallate results in increased expression of SLC2A6 mRNA

NCBI chr 3:30,746,472...30,753,287
Ensembl chr 3:30,745,995...30,753,287

G

solute carrier family 30 member 1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SLC30A1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC30A1 mRNA; epigallocatechin gallate inhibits the reaction [zinc chloride results in increased expression of SLC30A1 mRNA]

PMID:20471814 PMID:22079256

NCBI chr13:106,022,019...106,025,892
Ensembl chr13:106,022,019...106,025,892

G

solute carrier family 30 member 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC30A4 mRNA

NCBI chr 3:130,206,852...130,228,888
Ensembl chr 3:130,206,852...130,228,888

G

solute carrier family 31 member 1

multiple interactions
increases expression

ISO

epigallocatechin gallate inhibits the reaction [Cisplatin results in increased degradation of SLC31A1 protein]; epigallocatechin gallate results in increased expression of and affects the localization of SLC31A1 protein
epigallocatechin gallate results in increased expression of SLC31A1 mRNA; epigallocatechin gallate results in increased expression of SLC31A1 protein

PMID:25927922 PMID:27270317

NCBI chr 5:80,830,574...80,859,810
Ensembl chr 5:80,830,389...80,859,809

G

solute carrier family 33 member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC33A1 mRNA

NCBI chr 2:150,565,327...150,587,700
Ensembl chr 2:150,565,328...150,587,416

G

solute carrier family 35 member A1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35A1 mRNA

NCBI chr 5:54,021,896...54,044,677
Ensembl chr 5:54,021,896...54,044,677

G

solute carrier family 35, member A5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35A5 mRNA

NCBI chr11:69,159,435...69,180,503
Ensembl chr11:69,159,384...69,180,502

G

solute carrier family 35 member B2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35B2 mRNA

NCBI chr 9:22,936,031...22,940,114
Ensembl chr 9:22,935,887...22,939,793

G

solute carrier family 35 member D2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35D2 mRNA

NCBI chr17:992,153...1,025,476
Ensembl chr17:993,646...1,025,475

G

solute carrier family 35, member E3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35E3 mRNA

NCBI chr 7:55,222,962...55,236,022
Ensembl chr 7:55,219,998...55,236,035

G

solute carrier family 35, member F5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35F5 mRNA

NCBI chr13:39,544,253...39,581,210
Ensembl chr13:39,544,757...39,581,223

G

solute carrier family 35, member G1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35G1 mRNA

NCBI chr 1:245,576,011...245,584,533
Ensembl chr 1:245,575,996...245,584,529

G

solute carrier family 38, member 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC38A4 mRNA

NCBI chr 7:130,022,039...130,082,169
Ensembl chr 7:130,023,980...130,082,097

G

solute carrier family 38, member 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC38A6 mRNA

NCBI chr 6:97,723,526...97,814,394
Ensembl chr 6:97,723,471...97,785,791

G

solute carrier family 38, member 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC38A9 mRNA

NCBI chr 2:46,024,731...46,102,419
Ensembl chr 2:46,024,947...46,105,983

G

solute carrier family 39 member 1

increases expression

ISO

epigallocatechin gallate results in increased expression of SLC39A1 mRNA

NCBI chr 2:178,001,052...178,006,689
Ensembl chr 2:178,001,119...178,006,689

G

solute carrier family 39 member 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC39A10 mRNA

NCBI chr 9:62,331,281...62,454,754
Ensembl chr 9:62,370,598...62,454,747

G

solute carrier family 39 member 14

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of SLC39A14 mRNA
epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of SLC39A14 mRNA]

PMID:16084531 PMID:20471814

NCBI chr15:51,786,517...51,833,260
Ensembl chr15:51,786,623...51,833,229

G

solute carrier family 39 member 4

increases expression

ISO

epigallocatechin gallate results in increased expression of SLC39A4 mRNA

NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:110,214,017...110,218,202

G

solute carrier family 40 member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC40A1 mRNA

NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460

G

solute carrier family 41 member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC41A2 mRNA

NCBI chr 7:22,271,298...22,378,764
Ensembl chr 7:22,271,313...22,378,764

G

solute carrier family 43, member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC43A3 mRNA

NCBI chr 3:90,414,822...90,450,654
Ensembl chr 3:90,415,977...90,436,976

G

solute carrier family 46, member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC46A3 mRNA

NCBI chr12:12,176,776...12,193,256
Ensembl chr12:12,176,807...12,193,255

G

solute carrier family 4 member 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC4A7 mRNA

NCBI chr15:13,015,854...13,095,485
Ensembl chr15:13,015,854...13,095,292

G

solute carrier family 50 member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC50A1 mRNA

NCBI chr 2:176,975,744...176,978,124
Ensembl chr 2:176,975,744...176,978,622

G

solute carrier family 51 member A

multiple interactions
decreases expression

ISO
EXP

epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of SLC51A mRNA]
epigallocatechin gallate results in decreased expression of SLC51A mRNA
epigallocatechin gallate inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC51A mRNA]

PMID:22178739 PMID:23146761

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

SLC51 subunit beta

multiple interactions

ISO
EXP

epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of SLC51B mRNA]
[epigallocatechin gallate co-treated with Ethinyl Estradiol] results in increased expression of SLC51B mRNA

PMID:22178739 PMID:23146761

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier family 5 member 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC5A3 mRNA

NCBI chr11:44,799,787...44,802,233
Ensembl chr11:44,790,297...44,818,157

G

solute carrier family 5 member 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC5A6 mRNA

NCBI chr 6:31,039,865...31,051,671
Ensembl chr 6:31,040,017...31,051,670

G

solute carrier family 6 member 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC6A13 mRNA

NCBI chr 4:156,211,381...156,248,491
Ensembl chr 4:156,211,462...156,248,489

G

solute carrier family 6 member 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC6A6 mRNA

NCBI chr 4:125,752,340...125,826,033
Ensembl chr 4:125,752,372...125,826,032

G

solute carrier family 6 member 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC6A8 mRNA

NCBI chr X:156,536,017...156,545,321
Ensembl chr X:156,536,017...156,545,321

G

solute carrier family 7, member 6 opposite strand

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC7A6OS mRNA

NCBI chr19:51,011,850...51,020,514
Ensembl chr19:51,011,703...51,020,563

G

solute carrier organic anion transporter family, member 3a1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLCO3A1 mRNA

NCBI chr 1:137,516,037...137,797,836
Ensembl chr 1:137,505,158...137,797,836

G

sarcolemma associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLMAP mRNA

NCBI chr16:1,673,964...1,791,902
Ensembl chr16:1,673,964...1,791,902

G

secretory leukocyte peptidase inhibitor

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of SLPI mRNA
epigallocatechin gallate inhibits the reaction [Ozone results in decreased secretion of SLPI protein]

NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822

G

SLX4 interacting protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLX4IP mRNA

NCBI chr 3:144,672,898...144,849,468
Ensembl chr 3:144,673,857...144,849,465
Ensembl chr 8:144,673,857...144,849,465

G

SLX9 ribosome biogenesis factor

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SLX9 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLX9 mRNA

NCBI chr20:11,114,214...11,147,112
Ensembl chr20:11,114,214...11,147,085

G

SMAD family member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMAD1 mRNA

NCBI chr19:45,417,430...45,477,962
Ensembl chr19:45,417,433...45,477,957

G

SMAD family member 3

multiple interactions
increases expression
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMAD3 mRNA
epigallocatechin gallate results in increased expression of SMAD3 protein
epigallocatechin gallate results in decreased expression of SMAD3 protein

PMID:22079256 PMID:34600025 PMID:35863485

NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324

G

SMAD family member 4

increases methylation
increases expression
decreases expression

ISO

epigallocatechin gallate results in increased methylation of SMAD4 promoter
epigallocatechin gallate results in increased expression of SMAD4 protein
epigallocatechin gallate results in decreased expression of SMAD4 mRNA; epigallocatechin gallate results in decreased expression of SMAD4 protein

PMID:34600025 PMID:35863485

NCBI chr18:69,518,988...69,549,684
Ensembl chr18:69,518,988...69,549,684

G

SMAD family member 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMAD6 mRNA

NCBI chr 8:73,345,457...73,414,985
Ensembl chr 8:73,345,460...73,414,149

G

SNF2 related chromatin remodeling ATPase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCA1 mRNA

NCBI chr X:131,858,148...131,944,639
Ensembl chr X:131,859,088...131,944,282

G

SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCA2 mRNA

NCBI chr 1:233,617,277...233,784,908
Ensembl chr 1:233,617,366...233,784,869

G

SNF2 related chromatin remodeling ATPase with DExD box 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCAD1 mRNA

NCBI chr 4:95,639,722...95,709,055
Ensembl chr 4:95,641,295...95,702,414

G

SNF2 related chromatin remodeling annealing helicase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCAL1 mRNA

NCBI chr 9:81,689,446...81,735,406
Ensembl chr 9:81,689,531...81,735,396

G

SWI/SNF related BAF chromatin remodeling complex subunit B1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCB1 mRNA

NCBI chr20:12,740,105...12,763,054
Ensembl chr20:12,740,943...12,763,055

G

structural maintenance of chromosomes 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMC2 mRNA

NCBI chr 5:71,592,428...71,648,636
Ensembl chr 5:71,602,308...71,648,632

G

structural maintenance of chromosomes 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMC6 mRNA

NCBI chr 6:39,697,810...39,752,275
Ensembl chr 6:39,697,811...39,752,279

G

single-pass membrane protein with coiled-coil domains 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMCO4 mRNA

NCBI chr 8:20,594,633...20,646,916
Ensembl chr 8:20,627,338...20,646,916

G

small integral membrane protein 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMIM8 mRNA

NCBI chr 5:54,132,905...54,141,940
Ensembl chr 5:54,132,905...54,141,729

G

smoothened, frizzled class receptor

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of SMO mRNA]; epigallocatechin gallate inhibits the reaction [Diethylnitrosamine results in increased expression of SMO protein]

NCBI chr 4:59,311,084...59,341,280
Ensembl chr 4:59,311,041...59,341,281

G

spermine oxidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SMOX mRNA

NCBI chr 3:139,184,793...139,220,174
Ensembl chr 3:139,184,798...139,220,170
Ensembl chr X:139,184,798...139,220,170

G

single-strand-selective monofunctional uracil-DNA glycosylase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMUG1 mRNA; epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of SMUG1 mRNA]

NCBI chr 7:136,166,157...136,177,673
Ensembl chr 7:136,167,532...136,170,658

G

snail family transcriptional repressor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNAI1 mRNA

NCBI chr 3:176,667,476...176,671,965

G

synaptosome associated protein 29

increases expression

ISO

epigallocatechin gallate results in increased expression of SNAP29 mRNA

NCBI chr11:97,082,721...97,113,195
Ensembl chr11:97,082,739...97,113,195

G

SNAP-associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNAPIN mRNA

NCBI chr 2:178,269,157...178,271,746
Ensembl chr 2:178,269,166...178,272,041

G

Smad nuclear interacting protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNIP1 mRNA

NCBI chr 5:142,613,028...142,620,502
Ensembl chr 5:142,613,004...142,620,527

G

small nucleolar RNA, H/ACA box 14B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA14B mRNA

NCBI chr19:71,831,457...71,831,590
Ensembl chr19:71,831,457...71,831,590

G

small nucleolar RNA, H/ACA box 28

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SNORA28 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA28 mRNA

NCBI chr 6:136,413,136...136,413,261
Ensembl chr 6:136,413,136...136,413,261

G

small nucleolar RNA, H/ACA box 29

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA29 mRNA

NCBI chr10:40,099,581...40,099,720
Ensembl chr10:40,099,581...40,099,720

G

small nucleolar RNA, H/ACA box 33

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA33 mRNA

NCBI chr10:87,688,990...87,689,121

G

small nucleolar RNA, H/ACA box 3B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA3B mRNA

NCBI chr 1:172,976,556...172,976,686
Ensembl chr 1:172,976,556...172,976,686

G

small nucleolar RNA, H/ACA box 41

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA41 mRNA

NCBI chr 9:72,075,924...72,076,055
Ensembl chr 9:72,075,924...72,076,055

G

small nucleolar RNA, H/ACA box 54

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA54 mRNA

NCBI chr 1:208,156,866...208,156,992
Ensembl chr 1:208,156,866...208,156,992

G

small nucleolar RNA, H/ACA box 55

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA55 mRNA

NCBI chr 5:140,858,463...140,858,595
Ensembl chr 5:140,858,463...140,858,595

G

small nucleolar RNA, H/ACA box 5A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA5A mRNA

NCBI chr14:85,700,633...85,700,761
Ensembl chr14:85,700,633...85,700,761

G

small nucleolar RNA, H/ACA box 5C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA5C mRNA

NCBI chr14:85,701,133...85,701,269
Ensembl chr14:85,701,133...85,701,269

G

small nucleolar RNA, H/ACA box 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA6 mRNA

NCBI chr 8:128,729,844...128,729,999
Ensembl chr 8:128,729,844...128,729,999

G

small nucleolar RNA, H/ACA box 60

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SNORA60 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA60 mRNA

NCBI chr 3:167,455,181...167,455,313
Ensembl chr 3:167,455,181...167,455,313

G

small nucleolar RNA, H/ACA box 69

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA69 mRNA

NCBI chr20:45,164,974...45,165,107
Ensembl chr20:45,164,974...45,165,107

G

small nucleolar RNA, H/ACA box 74A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA74A mRNA

NCBI chr18:27,431,858...27,432,054
Ensembl chr18:27,431,858...27,432,054

G

small nucleolar RNA, H/ACA box 75

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA75 mRNA

NCBI chr 9:94,448,219...94,448,355
Ensembl chr 9:94,448,219...94,448,355

G

small nucleolar RNA, C/D box 12C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD12C mRNA

NCBI chr 3:176,211,560...176,211,651
Ensembl chr 3:176,211,560...176,211,651

G

small nucleolar RNA, C/D box 15A

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SNORD15A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD15A mRNA

NCBI chr 1:163,194,901...163,195,048
Ensembl chr 1:163,194,901...163,195,048

G

small nucleolar RNA, C/D box 20

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD20 mRNA

NCBI chr 9:94,449,039...94,449,118
Ensembl chr 9:94,449,039...94,449,118

G

small nucleolar RNA, C/D box 21

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD21 mRNA
epigallocatechin gallate results in decreased expression of SNORD21 mRNA

NCBI chr14:1,992,069...1,992,162
Ensembl chr14:1,992,069...1,992,162

G

small nucleolar RNA, C/D box 30

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD30 mRNA

NCBI chr 1:215,050,367...215,050,435
Ensembl chr 1:215,050,367...215,050,435

G

small nucleolar RNA, C/D box 38A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD38A mRNA

NCBI chr 5:135,867,648...135,867,715
Ensembl chr 5:135,867,648...135,867,715

G

small nucleolar RNA, C/D box 38B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD38B mRNA

NCBI chr 5:135,867,221...135,867,290
Ensembl chr 5:135,867,221...135,867,290

G

small nucleolar RNA, C/D box 42A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD42A mRNA

NCBI chr10:63,575,102...63,575,166
Ensembl chr10:63,575,102...63,575,166

G

small nucleolar RNA, C/D box 42B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD42B mRNA

NCBI chr10:63,576,897...63,576,965
Ensembl chr10:63,576,897...63,576,965

G

small nucleolar RNA, C/D box 43

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD43 mRNA

NCBI chr 7:113,507,486...113,507,549
Ensembl chr 7:113,507,486...113,507,549

G

small nucleolar RNA, C/D box 45C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD45C mRNA

NCBI chr 2:245,509,952...245,510,031
Ensembl chr 2:245,509,952...245,510,031

G

small nucleolar RNA, C/D box 49A

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SNORD49A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD49A mRNA

NCBI chr10:47,796,770...47,796,841
Ensembl chr10:47,796,770...47,796,841

G

small nucleolar RNA, C/D box 49B

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD49B mRNA
epigallocatechin gallate results in decreased expression of SNORD49B mRNA

NCBI chr10:47,796,228...47,796,298
Ensembl chr10:47,796,228...47,796,298

G

small nucleolar RNA, C/D box 4A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD4A mRNA

NCBI chr10:63,575,491...63,575,561
Ensembl chr10:63,575,491...63,575,561

G

small nucleolar RNA, C/D box 51

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD51 mRNA
epigallocatechin gallate results in decreased expression of SNORD51 mRNA

NCBI chr 9:72,075,585...72,075,662
Ensembl chr 9:72,075,585...72,075,662

G

small nucleolar RNA, C/D box 53

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD53 mRNA

NCBI chr 6:29,581,487...29,581,564
Ensembl chr 6:29,581,487...29,581,564

G

small nucleolar RNA, C/D box 54

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD54 mRNA

NCBI chr 5:21,617,537...21,617,604
Ensembl chr 5:21,617,537...21,617,604

G

small nucleolar RNA, C/D box 55

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SNORD55 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD55 mRNA

NCBI chr 5:135,869,193...135,869,271
Ensembl chr 5:135,869,193...135,869,271

G

small nucleolar RNA, C/D box 58A

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD58A mRNA
epigallocatechin gallate results in decreased expression of SNORD58A mRNA

NCBI chr18:70,857,393...70,857,457
Ensembl chr18:70,857,393...70,857,457

G

small nucleolar RNA, C/D box 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD6 mRNA

NCBI chr 8:20,437,180...20,437,252
Ensembl chr 8:20,437,180...20,437,252

G

small nucleolar RNA, C/D box 63 like1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD63 mRNA

NCBI chr18:26,815,573...26,815,645
Ensembl chr18:26,815,573...26,815,645

G

small nucleolar RNA, C/D box 73A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD73A mRNA

NCBI chr 2:173,823,498...173,823,567
Ensembl chr 2:173,823,498...173,823,567

G

small nucleolar RNA, C/D box 82

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD82 mRNA
epigallocatechin gallate results in decreased expression of SNORD82 mRNA

NCBI chr 9:94,452,486...94,452,557
Ensembl chr 9:94,452,486...94,452,557

G

small nucleolar RNA, C/D box 83B

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of SNORD83B mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD83B mRNA

NCBI chr 7:113,503,235...113,503,328
Ensembl chr 7:113,503,235...113,503,328

G

small nucleolar RNA, C/D box 95

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD95 mRNA

NCBI chr10:33,673,118...33,673,185
Ensembl chr10:33,673,118...33,673,185

G

small nucleolar RNA, C/D box 96A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD96A mRNA

NCBI chr10:33,672,228...33,672,307
Ensembl chr10:33,672,228...33,672,307

G

small nuclear ribonucleoprotein U5 subunit 40

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNRNP40 mRNA

NCBI chr 5:147,984,758...148,017,932
Ensembl chr 5:147,984,656...148,018,725

G

small nuclear ribonucleoprotein D3 polypeptide

increases expression

ISO

epigallocatechin gallate results in increased expression of SNRPD3 mRNA

NCBI chr20:13,129,555...13,145,100
Ensembl chr20:13,109,294...13,145,763

G

snurportin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNUPN mRNA

NCBI chr 8:66,242,940...66,286,651
Ensembl chr 8:66,235,828...66,286,835

G

sorting nexin 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX13 mRNA

NCBI chr 6:57,478,139...57,589,624
Ensembl chr 6:57,434,273...57,589,624

G

sorting nexin 24

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX24 mRNA

NCBI chr18:48,869,804...49,024,352
Ensembl chr18:48,869,882...49,024,350

G

sorting nexin 25

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX25 mRNA

NCBI chr16:52,867,102...52,971,028
Ensembl chr16:52,858,532...52,971,008

G

sorting nexin 29

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX29 mRNA

NCBI chr10:4,391,866...4,805,682
Ensembl chr10:4,394,544...4,813,772

G

sorting nexin 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX4 mRNA

NCBI chr11:80,965,965...81,023,234
Ensembl chr11:80,965,967...81,028,448

G

sorting nexin 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX8 mRNA

NCBI chr12:19,365,746...19,414,333
Ensembl chr12:19,365,755...19,414,332

G

sorting nexin 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX9 mRNA

NCBI chr 1:48,827,061...48,915,215
Ensembl chr 1:48,830,053...48,915,214

G

superoxide dismutase 1

multiple interactions
decreases expression

EXP
ISO

[1-Methyl-4-phenylpyridinium co-treated with epigallocatechin gallate] results in increased expression of SOD1 mRNA; epigallocatechin gallate inhibits the reaction [Acrylamide results in decreased activity of SOD1 protein]
epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of SOD1 protein]
epigallocatechin gallate results in decreased expression of SOD1 protein
epigallocatechin gallate results in decreased expression of SOD1 mRNA

PMID:22742579 PMID:25585349 PMID:28056603 PMID:35218280 PMID:38146662

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

affects activity
multiple interactions
increases expression
decreases expression
increases activity

ISO
EXP

epigallocatechin gallate affects the activity of SOD2 protein
epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in decreased expression of SOD2 mRNA]
epigallocatechin gallate results in increased expression of SOD2 mRNA; epigallocatechin gallate results in increased expression of SOD2 protein
epigallocatechin gallate results in decreased expression of SOD2 mRNA
[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] results in increased activity of SOD2 protein; [epigallocatechin gallate co-treated with leptomycin B] results in increased expression of SOD2 mRNA; SOD2 protein inhibits the reaction [epigallocatechin gallate analog results in increased abundance of Reactive Oxygen Species]
epigallocatechin gallate results in increased activity of SOD2 protein
epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of and affects the activity of SOD2 protein]

PMID:16115949 PMID:20666448 PMID:25922640 PMID:25955525 PMID:26187476 More...

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

superoxide dismutase 3

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SOD3 mRNA

NCBI chr14:62,822,865...62,828,602
Ensembl chr14:62,811,177...62,829,125

G

SOS Ras/Rho guanine nucleotide exchange factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SOS2 mRNA

NCBI chr 6:93,778,971...93,892,161
Ensembl chr 6:93,778,971...93,892,811

G

sosondowah ankyrin repeat domain family member C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SOWAHC mRNA

NCBI chr20:27,738,247...27,742,713
Ensembl chr20:27,736,326...27,752,912

G

Sp1 transcription factor

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [EGF protein results in increased activity of SP1 protein]

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513

G

SP100 nuclear antigen

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SP100 mRNA

NCBI chr 9:93,758,975...93,825,068
Ensembl chr 9:93,759,075...93,825,068

G

sperm associated antigen 16

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPAG16 mRNA

NCBI chr 9:78,782,596...79,702,265
Ensembl chr 9:78,782,614...78,877,630

G

spastin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPAST mRNA

NCBI chr 6:26,807,220...26,858,456
Ensembl chr 6:26,807,220...26,858,446

G

SPATA31 subfamily G member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPATA31G1 mRNA

NCBI chr 5:61,995,800...61,999,889
Ensembl chr 5:61,995,800...61,999,889

G

SPC24 component of NDC80 kinetochore complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPC24 mRNA

NCBI chr 8:28,576,409...28,581,481
Ensembl chr 8:28,576,409...28,581,299

G

signal peptidase complex subunit 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPCS3 mRNA

NCBI chr16:44,038,421...44,043,855
Ensembl chr16:44,038,278...44,046,394

G

SPG11 vesicle trafficking associated, spatacsin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPG11 mRNA

NCBI chr 3:129,453,118...129,526,469
Ensembl chr 3:129,461,477...129,526,742

G

spire-type actin nucleation factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPIRE1 mRNA

NCBI chr18:63,311,800...63,441,545
Ensembl chr18:63,311,800...63,441,534

G

sperm microtubule inner protein 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPMIP6 mRNA

NCBI chr 5:61,462,070...61,474,832
Ensembl chr 5:61,462,070...61,474,774

G

sprouty-related, EVH1 domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPRED2 mRNA

NCBI chr14:98,350,577...98,452,143
Ensembl chr14:98,350,290...98,452,143

G

sprouty RTK signaling antagonist 4

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPRY4 mRNA
epigallocatechin gallate results in decreased expression of SPRY4 mRNA

PMID:22079256 PMID:35701726

NCBI chr18:30,687,633...30,702,546
Ensembl chr18:30,687,039...30,704,173

G

SPRY domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPRYD3 mRNA

NCBI chr 7:135,126,598...135,143,775
Ensembl chr 7:135,126,598...135,143,974

G

serine palmitoyltransferase, long chain base subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPTLC2 mRNA

NCBI chr 6:112,679,623...112,762,470
Ensembl chr 6:112,679,623...112,762,640

G

SPT2 chromatin protein domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPTY2D1 mRNA

NCBI chr 1:106,667,750...106,685,871
Ensembl chr 1:106,667,750...106,685,871

G

squalene epoxidase

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SQLE mRNA
epigallocatechin gallate results in increased expression of SQLE mRNA

PMID:22079256 PMID:32512070

NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:92,757,409...92,773,050

G

sulfide quinone oxidoreductase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SQOR mRNA

NCBI chr 3:130,294,783...130,341,655
Ensembl chr 3:130,292,814...130,340,799

G

sequestosome 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SQSTM1 mRNA
epigallocatechin gallate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of SQSTM1 protein]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased expression of SQSTM1 protein]

PMID:22079256 PMID:34740634

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

S1 RNA binding domain 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRBD1 mRNA

NCBI chr 6:14,226,551...14,417,494
Ensembl chr 6:14,228,461...14,443,047

G

steroid 5 alpha-reductase 2

decreases expression

ISO

epigallocatechin gallate results in decreased expression of SRD5A2 mRNA

NCBI chr 6:27,178,089...27,217,588
Ensembl chr 6:27,178,079...27,217,588

G

sterol regulatory element binding transcription factor 1

decreases expression
multiple interactions
decreases expression

ISO
EXP

epigallocatechin gallate results in decreased expression of SREBF1 mRNA
epigallocatechin gallate analog inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]
(-)-epigallocatechin 3-gallate decreases expression of Srebf1 mRNA in liver
epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF1 mRNA]; epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF1 protein]

CTD
RGD

PMID:20816778 PMID:30092300 PMID:39577827 PMID:29593532

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

sterol regulatory element binding transcription factor 2

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF2 mRNA]; epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF2 protein]

NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:115,543,290...115,600,943

G

SLIT-ROBO Rho GTPase activating protein 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of SRGAP1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRGAP1 mRNA

NCBI chr 7:59,215,007...59,479,600
Ensembl chr 7:59,215,007...59,656,213

G

SLIT-ROBO Rho GTPase activating protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRGAP2 mRNA

NCBI chr13:45,298,192...45,519,330
Ensembl chr13:45,298,192...45,519,330

G

sorcin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRI mRNA

NCBI chr 4:26,928,338...26,952,980
Ensembl chr 4:26,923,662...26,961,361

G

SRSF protein kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRPK2 mRNA

NCBI chr 4:12,356,983...12,548,345
Ensembl chr 4:12,357,053...12,548,342

G

serine and arginine repetitive matrix 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SRRM1 mRNA

NCBI chr 5:152,843,167...152,875,554
Ensembl chr 5:152,843,169...152,875,436

G

serine and arginine rich splicing factor 2

increases expression

ISO

epigallocatechin gallate results in increased expression of SRSF2 protein

NCBI chr10:102,550,962...102,554,200
Ensembl chr10:102,553,072...102,554,141

G

serine and arginine rich splicing factor 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SRSF6 mRNA

NCBI chr 3:172,009,072...172,014,395
Ensembl chr 3:172,009,061...172,014,392

G

single-stranded DNA binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSBP2 mRNA

NCBI chr 2:24,385,494...24,673,768
Ensembl chr 2:24,385,687...24,673,768

G

single stranded DNA binding protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSBP3 mRNA

NCBI chr 5:126,920,145...127,057,968
Ensembl chr 5:126,919,120...127,056,799

G

slingshot protein phosphatase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSH1 mRNA

NCBI chr12:48,281,756...48,343,812
Ensembl chr12:48,281,756...48,343,812

G

slingshot protein phosphatase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSH2 mRNA

NCBI chr10:62,555,388...62,807,457
Ensembl chr10:62,555,460...62,807,453

G

structure specific recognition protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SSRP1 mRNA

NCBI chr 3:90,531,024...90,541,132
Ensembl chr 3:90,530,829...90,541,129

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ST6GALNAC2 mRNA

NCBI chr10:102,409,048...102,427,299
Ensembl chr10:102,409,048...102,427,137

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ST6GALNAC5 mRNA

NCBI chr 2:244,398,604...244,571,100
Ensembl chr 2:244,402,589...244,571,097

G

suppression of tumorigenicity 7

increases expression

ISO

epigallocatechin gallate results in increased expression of ST7 mRNA

NCBI chr 4:47,007,568...47,255,639
Ensembl chr 4:47,008,095...47,255,637

G

STAG1 cohesin complex component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAG1 mRNA

NCBI chr 8:110,057,981...110,443,666
Ensembl chr 8:110,058,056...110,443,665

G

STAG2 cohesin complex component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAG2 mRNA

NCBI chr X:125,839,660...125,971,209
Ensembl chr X:125,840,401...125,971,209

G

signal transducing adaptor molecule 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAM2 mRNA

NCBI chr 3:57,597,557...57,643,915
Ensembl chr 3:57,597,559...57,643,915

G

STAM binding protein-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAMBPL1 mRNA

NCBI chr 1:241,095,695...241,158,225
Ensembl chr 1:241,113,239...241,158,225

G

signal transducing adaptor family member 2

increases expression

ISO

epigallocatechin gallate results in increased expression of STAP2 protein

NCBI chr 9:915,546...924,604
Ensembl chr 9:915,550...924,380

G

StAR-related lipid transfer domain containing 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STARD13 mRNA

NCBI chr12:5,401,878...5,797,937
Ensembl chr12:5,401,995...5,794,967

G

signal transducer and activator of transcription 1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAT1 mRNA
epigallocatechin gallate results in decreased expression of STAT1 mRNA

PMID:22079256 PMID:32512070

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAT2 mRNA

NCBI chr 7:1,287,025...1,302,858
Ensembl chr 7:1,287,024...1,303,459

G

signal transducer and activator of transcription 3

decreases expression
multiple interactions
decreases activity

ISO

epigallocatechin gallate results in decreased expression of STAT3 mRNA; epigallocatechin gallate results in decreased expression of STAT3 protein; epigallocatechin gallate results in decreased expression of STAT3 protein modified form
[docetaxel co-treated with epigallocatechin gallate co-treated with Quercetin] results in decreased expression of and results in decreased phosphorylation of STAT3 protein; [epigallocatechin gallate co-treated with Quercetin] promotes the reaction [docetaxel results in decreased phosphorylation of STAT3 protein]; [epigallocatechin gallate co-treated with Quercetin] results in decreased expression of and results in decreased phosphorylation of STAT3 protein; docetaxel promotes the reaction [[epigallocatechin gallate co-treated with Quercetin] results in decreased phosphorylation of STAT3 protein]
epigallocatechin gallate results in decreased activity of STAT3 protein

PMID:20816778 PMID:22348037 PMID:25655047

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

staufen double-stranded RNA binding protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAU2 mRNA

NCBI chr 5:7,623,528...7,868,206
Ensembl chr 5:7,624,019...7,868,204

G

stanniocalcin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of STC2 mRNA

NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,755,267...16,767,447

G

serine/threonine kinase 10

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK10 mRNA

NCBI chr10:17,622,149...17,716,337
Ensembl chr10:17,622,162...17,716,332

G

serine/threonine kinase 11

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [1,3-dichloro-2-propanol results in decreased expression of STK11 protein]

NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965

G

serine/threonine kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK3 mRNA

NCBI chr 7:67,938,341...68,208,472
Ensembl chr 7:67,938,378...68,208,508

G

serine/threonine kinase 36

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK36 mRNA

NCBI chr 9:83,625,905...83,652,785
Ensembl chr 9:83,626,030...83,653,525

G

serine/threonine kinase 38

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK38 mRNA

NCBI chr20:7,035,923...7,070,657
Ensembl chr20:7,035,933...7,069,711

G

serine/threonine kinase 38 like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK38L mRNA

NCBI chr 4:181,346,969...181,423,844
Ensembl chr 4:181,364,919...181,423,840

G

serine/threonine kinase 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK4 mRNA

NCBI chr 3:173,165,238...173,247,135
Ensembl chr 3:173,165,083...173,247,134

G

serine/threonine kinase 40

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK40 mRNA

NCBI chr 5:143,660,438...143,702,336
Ensembl chr 5:143,665,090...143,702,335

G

stathmin 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of STMN1 protein

NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:151,964,351...151,970,842

G

sperm-tail PG-rich repeat containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STPG1 mRNA

NCBI chr 5:153,000,663...153,053,391
Ensembl chr 5:153,008,958...153,053,387

G

STE20 related adaptor alpha

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STRADA mRNA

NCBI chr10:91,594,648...91,623,710
Ensembl chr10:91,594,419...91,623,691

G

STE20 related adaptor beta

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STRADB mRNA

NCBI chr 9:67,908,277...67,927,224
Ensembl chr 9:67,908,309...67,927,222

G

striatin

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STRN mRNA

NCBI chr 6:22,087,419...22,174,284
Ensembl chr 6:22,087,497...22,193,048

G

syntaxin 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX11 mRNA

NCBI chr 1:9,111,216...9,140,227
Ensembl chr 1:9,107,796...9,178,455

G

syntaxin 17

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX17 mRNA

NCBI chr 5:67,241,673...67,302,228
Ensembl chr 5:67,241,727...67,302,218

G

syntaxin 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX4 mRNA

NCBI chr 1:191,880,549...191,890,333
Ensembl chr 1:191,881,559...191,896,774

G

syntaxin 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX7 mRNA

NCBI chr 1:23,016,330...23,056,579
Ensembl chr 1:23,016,336...23,056,465

G

syntaxin binding protein 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STXBP3 mRNA

NCBI chr 2:199,130,725...199,173,823
Ensembl chr 2:199,130,725...199,173,823

G

syntaxin binding protein 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STXBP5 mRNA

NCBI chr 1:6,002,738...6,155,528
Ensembl chr 1:6,002,738...6,155,528

G

syntaxin binding protein 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STXBP6 mRNA

NCBI chr 6:67,647,721...67,884,369
Ensembl chr 6:67,650,556...67,884,725

G

sulfite oxidase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SUOX mRNA

NCBI chr 7:1,687,666...1,691,759
Ensembl chr 7:1,687,666...1,690,235

G

SPT3 homolog, SAGA and STAGA complex component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SUPT3H mRNA

NCBI chr 9:23,375,889...23,704,229
Ensembl chr 9:23,376,136...23,704,466

G

small vasohibin binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SVBP mRNA

NCBI chr 5:138,091,773...138,099,048
Ensembl chr 5:138,093,456...138,099,068

G

SWT1 RNA endoribonuclease homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SWT1 mRNA

NCBI chr13:66,002,477...66,059,962
Ensembl chr13:66,002,479...66,059,962

G

synaptonemal complex central element protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SYCE2 mRNA

NCBI chr19:40,173,713...40,195,959
Ensembl chr19:40,173,716...40,205,823

G

SYF2 pre-mRNA-splicing factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SYF2 mRNA

NCBI chr 5:152,440,171...152,448,094
Ensembl chr 5:152,440,054...152,448,092

G

syncoilin, intermediate filament protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYNC mRNA

NCBI chr 5:146,915,715...146,940,547
Ensembl chr 5:146,916,361...146,943,191

G

spectrin repeat containing nuclear envelope protein 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of SYNE2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYNE2 mRNA

NCBI chr 6:100,272,729...100,586,364
Ensembl chr 6:100,272,729...100,583,723

G

synaptojanin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYNJ2 mRNA

NCBI chr 1:48,923,742...49,027,153
Ensembl chr 1:48,923,737...49,038,650

G

synaptotagmin 14

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYT14 mRNA

NCBI chr13:106,945,506...107,097,882
Ensembl chr13:106,950,334...107,098,217

G

synaptotagmin-like 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYTL4 mRNA

NCBI chr X:101,428,785...101,479,207
Ensembl chr X:101,428,785...101,479,151

G

translational activator of cytochrome c oxidase I

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TACO1 mRNA

NCBI chr10:91,502,395...91,510,299
Ensembl chr10:91,502,460...91,515,678

G

tumor-associated calcium signal transducer 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TACSTD2 mRNA

NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:98,033,251...98,039,323

G

transcriptional adaptor 2A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TADA2A mRNA

NCBI chr10:69,463,966...69,511,612
Ensembl chr10:69,463,968...69,511,607

G

TATA-box binding protein associated factor, RNA polymerase I subunit B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TAF1B mRNA

NCBI chr 6:46,845,571...46,923,209
Ensembl chr 6:46,846,029...46,923,209

G

TATA-box binding protein associated factor, RNA polymerase I subunit D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TAF1D mRNA

NCBI chr 8:20,427,894...20,438,046
Ensembl chr 8:20,427,954...20,434,556

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TANC1 mRNA

NCBI chr 3:64,508,037...64,741,826
Ensembl chr 3:64,508,085...64,741,825

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of TANC2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TANC2 mRNA

NCBI chr10:91,052,860...91,373,291
Ensembl chr10:91,053,067...91,368,570

G

transport and golgi organization 6 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TANGO6 mRNA

NCBI chr19:51,479,384...51,667,142
Ensembl chr19:51,479,391...51,687,621

G

TRAF family member-associated NFKB activator

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TANK mRNA

NCBI chr 3:66,522,834...66,598,864
Ensembl chr 3:66,537,175...66,598,864

G

TAO kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TAOK3 mRNA

NCBI chr12:44,973,180...45,134,439
Ensembl chr12:44,973,180...45,134,439

G

threonyl-tRNA synthetase 2, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TARS2 mRNA

NCBI chr 2:185,982,042...185,999,155
Ensembl chr 2:185,982,086...185,999,113

G

taste receptor, type 2, member 108

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TAS2R4 mRNA

NCBI chr 4:70,254,367...70,255,281
Ensembl chr 4:70,254,367...70,255,281

G

transcription activation suppressor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TASOR mRNA

NCBI chr16:2,612,942...2,669,870
Ensembl chr16:2,613,505...2,669,867

G

taspase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TASP1 mRNA

NCBI chr 3:147,630,092...147,861,710
Ensembl chr 3:147,630,092...147,861,654

G

TBC1 domain family, member 10a

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D10A mRNA

NCBI chr14:83,278,151...83,307,178
Ensembl chr14:83,278,914...83,307,176

G

TBC1 domain family, member 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D12 mRNA

NCBI chr 1:246,015,985...246,098,241
Ensembl chr 1:246,015,994...246,098,241

G

TBC1 domain family, member 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D19 mRNA

NCBI chr14:61,297,193...61,413,106
Ensembl chr14:61,296,800...61,413,028

G

TBC1 domain family, member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D2 mRNA

NCBI chr 5:65,679,670...65,727,978
Ensembl chr 5:65,679,680...65,726,996

G

TBC1 domain family, member 32

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D32 mRNA

NCBI chr20:35,902,281...36,133,161
Ensembl chr20:35,902,700...36,133,057

G

TBL1X/Y related 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBL1XR1 mRNA

NCBI chr 2:106,718,811...106,857,989
Ensembl chr 2:106,730,665...106,857,989

G

T-box brain transcription factor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TBR1 mRNA

NCBI chr 3:66,758,805...66,769,626
Ensembl chr 3:66,759,803...66,769,626

G

T-box transcription factor 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBX18 mRNA

NCBI chr 8:97,531,960...97,559,988
Ensembl chr 8:97,531,960...97,559,965

G

T-box transcription factor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TBX3 mRNA

NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171

G

TRPM8 channel-associated factor 2

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TCAF2 mRNA
epigallocatechin gallate results in increased expression of TCAF2 protein

PMID:22079256 PMID:31195006

G

transcription elongation factor A like 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCEAL8 mRNA

NCBI chr X:103,962,930...103,965,000
Ensembl chr X:103,961,187...103,965,394

G

transcription elongation factor A N-terminal and central domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCEANC2 mRNA

NCBI chr 5:127,152,776...127,197,405
Ensembl chr 5:127,152,778...127,190,985

G

transcription factor 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCF4 mRNA

NCBI chr18:65,216,840...65,563,186
Ensembl chr18:65,216,849...65,558,401

G

t-complex 11 like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCP11L1 mRNA

NCBI chr 3:111,478,787...111,547,553
Ensembl chr 3:111,453,221...111,546,454

G

t-complex 11 like 2

increases expression

ISO

epigallocatechin gallate results in increased expression of TCP11L2 mRNA

NCBI chr 7:21,037,955...21,072,857
Ensembl chr 7:21,037,958...21,064,681

G

tyrosyl-DNA phosphodiesterase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TDP1 mRNA

NCBI chr 6:124,892,821...124,960,646
Ensembl chr 6:124,881,574...124,960,642

G

tudor domain containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TDRD3 mRNA

NCBI chr15:69,748,754...69,911,605
Ensembl chr15:69,749,217...69,884,656

G

tudor domain containing 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TDRD7 mRNA

NCBI chr 5:65,034,317...65,108,165
Ensembl chr 5:65,034,341...65,108,161

G

TEA domain transcription factor 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEAD4 mRNA

NCBI chr 4:163,180,192...163,258,342
Ensembl chr 4:163,180,192...163,258,479

G

tec protein tyrosine kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEC mRNA

NCBI chr14:35,706,557...35,815,563
Ensembl chr14:35,691,741...35,815,585

G

transcription elongation factor, mitochondrial

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of TEFM mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEFM mRNA

NCBI chr10:65,617,547...65,622,042
Ensembl chr10:65,617,550...65,622,042

G

telomeric repeat binding factor 2

affects expression

EXP

epigallocatechin gallate affects the expression of TERF2 protein

NCBI chr19:51,887,221...51,915,756
Ensembl chr19:51,887,221...51,915,566

G

telomerase reverse transcriptase

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TERT mRNA; epigallocatechin gallate results in decreased expression of TERT protein

PMID:18581255 PMID:20706672

NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111

G

tet methylcytosine dioxygenase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TET2 mRNA

NCBI chr 2:224,662,654...224,746,819
Ensembl chr 2:224,662,654...224,746,186

G

testis expressed 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEX2 mRNA

NCBI chr10:91,936,390...92,046,360
Ensembl chr10:91,936,390...92,045,944

G

testis expressed 30

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEX30 mRNA
epigallocatechin gallate results in decreased expression of TEX30 mRNA

NCBI chr 9:53,735,512...53,744,672
Ensembl chr 9:53,735,512...53,741,042

G

transcription factor A, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TFAM mRNA

NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,355,363...17,369,877

G

transcription factor B1, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TFB1M mRNA

NCBI chr 1:46,520,510...46,567,004
Ensembl chr 1:46,524,435...46,566,948

G

transcription factor CP2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TFCP2 mRNA

NCBI chr 7:133,495,577...133,537,799
Ensembl chr 7:133,495,577...133,537,531

G

transcription factor Dp-2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TFDP2 mRNA

NCBI chr 8:105,640,018...105,781,026
Ensembl chr 8:105,640,033...105,781,001

G

transcription factor EB

multiple interactions
increases expression

ISO

epigallocatechin gallate results in increased expression of and affects the localization of TFEB protein; TFEB protein affects the reaction [epigallocatechin gallate results in decreased expression of CDH2 protein]; TFEB protein affects the reaction [epigallocatechin gallate results in decreased expression of VIM protein]; TFEB protein affects the reaction [epigallocatechin gallate results in increased expression of ATG12 protein]; TFEB protein affects the reaction [epigallocatechin gallate results in increased expression of ATG5 protein]; TFEB protein affects the reaction [epigallocatechin gallate results in increased expression of CDH1 protein]
epigallocatechin gallate results in increased expression of TFEB protein

NCBI chr 9:20,696,440...20,752,265
Ensembl chr 9:20,696,441...20,727,863

G

transforming growth factor, beta 1

multiple interactions
increases expression
increases methylation
decreases expression

ISO
EXP

epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of TGFB1 protein]
epigallocatechin gallate results in increased expression of TGFB1 protein
epigallocatechin gallate results in increased methylation of TGFB1 promoter
epigallocatechin gallate results in decreased expression of TGFB1 mRNA; epigallocatechin gallate results in decreased expression of TGFB1 protein
[Taurine co-treated with epigallocatechin gallate co-treated with Genistein] inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; epigallocatechin gallate inhibits the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]

PMID:20438794 PMID:22101032 PMID:25448286 PMID:34600025 PMID:35863485 More...

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta induced

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TGFBI mRNA

NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471

G

transforming growth factor, beta receptor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TGFBR1 mRNA

NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:66,449,293...66,527,260

G

transforming growth factor beta receptor 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TGFBR3 mRNA

NCBI chr14:2,634,294...2,810,269
Ensembl chr14:2,634,188...2,810,271

G

TGFB-induced factor homeobox 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TGIF1 mRNA

NCBI chr 9:118,194,735...118,204,354
Ensembl chr 9:118,194,444...118,204,442

G

tyrosine hydroxylase

decreases expression

EXP

epigallocatechin gallate results in decreased expression of TH protein

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227

G

THAP domain containing 2

increases expression

ISO

epigallocatechin gallate results in increased expression of THAP2 mRNA

NCBI chr 7:52,879,011...52,893,680
Ensembl chr 7:52,879,011...52,891,932

G

THO complex subunit 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of THOC1 mRNA
epigallocatechin gallate results in increased expression of THOC1 mRNA

PMID:22079256 PMID:35701726

NCBI chr18:1,253,041...1,291,956
Ensembl chr18:1,256,637...1,292,630

G

THO complex subunit 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of THOC2 mRNA

NCBI chr X:125,500,549...125,615,139
Ensembl chr X:125,500,549...125,615,087

G

thymocyte nuclear protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of THYN1 mRNA

NCBI chr 8:33,665,614...33,674,593
Ensembl chr 8:33,665,650...33,675,414

G

TIA1 cytotoxic granule-associated RNA binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TIA1 mRNA

NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:120,410,251...120,440,665

G

TIAM Rac1 associated GEF 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TIAM1 mRNA

NCBI chr11:42,517,527...42,866,280
Ensembl chr11:42,517,528...42,646,075

G

tigger transposable element derived 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TIGD2 mRNA

NCBI chr 4:89,744,516...89,747,608
Ensembl chr 4:89,744,510...89,747,940

G

TIMP metallopeptidase inhibitor 1

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA]

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

TIMP metallopeptidase inhibitor 3

multiple interactions

ISO

[Sulindac co-treated with epigallocatechin gallate] results in decreased expression of TIMP3 mRNA

NCBI chr 7:19,408,539...19,459,558
Ensembl chr 7:19,409,631...19,459,547

G

TERF1 interacting nuclear factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TINF2 mRNA

NCBI chr15:33,140,611...33,146,930
Ensembl chr15:33,140,714...33,146,930

G

tight junction protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TJP2 mRNA

NCBI chr 1:231,136,218...231,264,750
Ensembl chr 1:231,136,243...231,264,750

G

thymidine kinase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TK2 mRNA

NCBI chr19:713,043...737,345
Ensembl chr19:715,318...738,355

G

TLC domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLCD1 mRNA

NCBI chr10:63,572,541...63,574,574
Ensembl chr10:63,572,518...63,574,567

G

TLC domain containing 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLCD4 mRNA

NCBI chr 2:211,969,612...212,044,883
Ensembl chr 2:211,974,471...212,026,081

G

TLE family member 1, transcriptional corepressor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLE1 mRNA

NCBI chr 5:90,898,182...90,982,118
Ensembl chr 5:90,898,182...90,980,928

G

TLE family member 4, transcriptional corepressor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLE4 mRNA

NCBI chr 1:221,086,250...221,222,826
Ensembl chr 1:221,086,253...221,222,826

G

toll-like receptor 2

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of TLR2 protein]

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

toll-like receptor 3

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLR3 mRNA
epigallocatechin gallate results in increased expression of TLR3 mRNA

PMID:22079256 PMID:35701726

NCBI chr16:53,554,916...53,572,321
Ensembl chr16:53,555,131...53,568,385

G

toll-like receptor 4

multiple interactions

ISO

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TLR4 protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of TLR4 protein]

PMID:26187476 PMID:27890776

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

toll-like receptor 9

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of TLR9 protein]

NCBI chr 8:115,743,407...115,747,523
Ensembl chr 8:115,742,889...115,750,148

G

transmembrane 4 L six family member 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TM4SF1 mRNA

NCBI chr 2:143,606,980...143,616,176
Ensembl chr 2:143,603,271...143,616,176

G

transmembrane and coiled-coil domain family 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMCC1 mRNA

NCBI chr 4:150,738,966...150,912,256
Ensembl chr 4:150,738,973...150,912,256

G

transmembrane protein 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TMEM11 mRNA

NCBI chr10:46,042,251...46,057,065
Ensembl chr 6:125,690,543...125,691,404
Ensembl chr10:125,690,543...125,691,404

G

transmembrane protein 117

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM117 mRNA

NCBI chr 7:127,636,862...128,098,944
Ensembl chr 7:127,636,825...128,098,941

G

transmembrane protein 120B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM120B mRNA

NCBI chr12:39,108,280...39,148,090
Ensembl chr12:39,108,280...39,148,090

G

transmembrane 131 like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM131L mRNA

NCBI chr 2:171,555,673...171,689,774
Ensembl chr 2:171,555,673...171,689,733

G

transmembrane protein 135

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM135 mRNA

NCBI chr 1:152,418,929...152,692,405
Ensembl chr 1:152,418,930...152,633,717

G

transmembrane protein 138

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM138 mRNA

NCBI chr 1:216,644,047...216,651,091

G

transmembrane protein 14A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM14A mRNA

NCBI chr 9:31,137,011...31,148,794
Ensembl chr 9:31,136,963...31,148,800

G

transmembrane protein 154

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM154 mRNA

NCBI chr 2:172,313,290...172,352,939
Ensembl chr 2:172,313,240...172,361,723

G

transmembrane protein 164

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM164 mRNA

NCBI chr X:111,084,830...111,245,419
Ensembl chr X:111,085,712...111,245,417

G

transmembrane protein 165

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM165 mRNA

NCBI chr14:32,347,688...32,372,916
Ensembl chr14:32,347,691...32,372,916

G

transmembrane protein 167A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM167 mRNA

NCBI chr 2:22,933,027...22,951,974
Ensembl chr Y:3,291,213...3,291,891
Ensembl chr 2:3,291,213...3,291,891

G

transmembrane protein 171

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM171 mRNA

NCBI chr 2:31,769,486...31,779,358
Ensembl chr 2:31,769,486...31,780,134

G

transmembrane protein 177

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM177 mRNA

NCBI chr13:33,576,704...33,580,129
Ensembl chr13:33,574,281...33,582,159

G

transmembrane protein 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM19 mRNA

NCBI chr 7:52,844,985...52,871,708
Ensembl chr 7:52,844,985...52,872,012

G

transmembrane protein 199

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VMA12 mRNA

NCBI chr10:63,900,543...63,905,115
Ensembl chr10:63,900,545...63,905,139

G

transmembrane protein 241

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35D4 mRNA

NCBI chr18:3,440,866...3,593,099
Ensembl chr18:3,442,212...3,593,218

G

transmembrane protein 267

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM267 mRNA

NCBI chr 2:53,309,857...53,321,466
Ensembl chr 2:53,313,021...53,320,835

G

transmembrane protein 37

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM37 mRNA

NCBI chr13:33,737,096...33,743,602
Ensembl chr13:33,736,308...33,743,747

G

transmembrane protein 60

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of TMEM60 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM60 mRNA

NCBI chr 4:15,102,168...15,107,023
Ensembl chr 4:15,100,348...15,107,139

G

transmembrane protein 62

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM62 mRNA

NCBI chr 3:128,380,366...128,415,583
Ensembl chr 3:128,375,500...128,415,583

G

transmembrane protein 67

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM67 mRNA

NCBI chr 5:30,333,793...30,386,702
Ensembl chr 5:30,333,793...30,386,666

G

transmembrane protein 97

increases expression

ISO

epigallocatechin gallate results in increased expression of TMEM97 mRNA

NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818

G

transmembrane O-mannosyltransferase targeting cadherins 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMTC1 mRNA

NCBI chr 4:182,874,350...183,089,408
Ensembl chr 4:182,878,802...183,102,532

G

thioredoxin-related transmembrane protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TMX4 mRNA

NCBI chr 3:142,309,026...142,352,415
Ensembl chr 3:142,309,033...142,352,415

G

tumor necrosis factor

multiple interactions
decreases expression
affects expression
decreases secretion

ISO
EXP

[epigallocatechin gallate co-treated with gallocatechol co-treated with epicatechin gallate co-treated with Catechin analog] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of TNF mRNA]; epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of TNF protein]
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Gentamicins results in increased expression of TNF protein]
epigallocatechin gallate results in decreased expression of TNF mRNA; epigallocatechin gallate results in decreased expression of TNF protein
epigallocatechin gallate affects the expression of TNF
epigallocatechin gallate results in decreased secretion of TNF protein
epigallocatechin gallate affects the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; epigallocatechin gallate inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Formaldehyde results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of TNF protein]; epigallocatechin gallate inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of TNF protein]

PMID:10757128 PMID:12628509 PMID:16516891 PMID:19557821 PMID:20438794 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFAIP2 mRNA

NCBI chr 6:136,297,388...136,311,106
Ensembl chr 6:136,298,082...136,311,106

G

TNF alpha induced protein 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFAIP8 mRNA

NCBI chr18:45,370,334...45,486,036
Ensembl chr18:45,370,406...45,486,036

G

TNF receptor superfamily member 10b

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TNFRSF10A protein

NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082

G

TNF receptor superfamily member 12A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFRSF12A mRNA

NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704

G

TNF receptor superfamily member 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFRSF19 mRNA

NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438

G

TNF receptor superfamily member 1A

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

TNF receptor superfamily member 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFRSF9 mRNA

NCBI chr 5:166,664,494...166,690,834
Ensembl chr 5:166,664,494...166,690,831

G

TNF superfamily member 10

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of TNFSF10 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFSF10 mRNA

PMID:16084531 PMID:22079256

NCBI chr 2:112,136,550...112,155,903

G

TRAF2 and NCK interacting kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNIK mRNA

NCBI chr 2:113,112,937...113,511,341
Ensembl chr 2:113,112,938...113,511,339

G

trinucleotide repeat containing adaptor 6B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNRC6B mRNA

NCBI chr 7:114,132,574...114,350,010
Ensembl chr 7:114,132,573...114,342,973

G

tensin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNS3 mRNA

NCBI chr14:87,387,441...87,619,457
Ensembl chr14:87,387,441...87,619,712

G

transducer of ErbB-2.1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TOB1 mRNA

NCBI chr10:79,659,993...79,662,031
Ensembl chr10:79,656,433...79,666,601

G

translocase of outer mitochondrial membrane 20

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TOMM20 mRNA

NCBI chr19:71,822,429...71,832,420
Ensembl chr19:71,822,411...71,832,510

G

DNA topoisomerase II alpha

increases expression

ISO

epigallocatechin gallate results in increased expression of TOP2A mRNA

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

DNA topoisomerase II beta

increases expression

ISO

epigallocatechin gallate results in increased expression of TOP2B mRNA

NCBI chr15:11,482,089...11,542,464
Ensembl chr15:11,482,089...11,542,464

G

thymocyte selection-associated high mobility group box

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TOX mRNA

NCBI chr 5:24,672,487...24,968,754
Ensembl chr 5:24,672,487...24,968,754

G

tumor protein p53

multiple interactions
increases expression
increases response to substance
affects response to substance
affects expression

ISO
EXP

epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of TP53 protein]; epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein]; epigallocatechin gallate results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein; epigallocatechin gallate results in increased expression of and results in increased phosphorylation of TP53 protein
[epigallocatechin gallate co-treated with coenzyme Q10] inhibits the reaction [Cisplatin results in increased phosphorylation of TP53 protein]
epigallocatechin gallate results in increased expression of TP53 protein; epigallocatechin gallate results in increased expression of TP53 protein modified form
TP53 protein results in increased susceptibility to epigallocatechin gallate
TP53 mRNA affects the susceptibility to epigallocatechin gallate
epigallocatechin gallate affects the expression of TP53 protein
[epigallocatechin gallate co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA]; epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA]; epigallocatechin gallate promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 mRNA]; epigallocatechin gallate results in increased expression of and results in increased phosphorylation of TRP53 protein

PMID:15657356 PMID:15764647 PMID:15795422 PMID:18656336 PMID:19406223 More...

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tumor protein p53 binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TP53BP1 mRNA

NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:128,620,322...128,696,747

G

TPD52 like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TPD52L1 mRNA

NCBI chr 1:27,991,114...28,109,767
Ensembl chr 1:27,991,131...28,110,158

G

tripeptidyl peptidase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TPP1 mRNA

NCBI chr 1:169,509,816...169,515,939
Ensembl chr 1:169,509,815...169,516,024

G

tyrosylprotein sulfotransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TPST1 mRNA

NCBI chr12:32,180,688...32,247,478
Ensembl chr12:32,180,936...32,241,821

G

tyrosylprotein sulfotransferase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TPST2 mRNA

NCBI chr12:49,982,281...50,024,489
Ensembl chr12:49,982,281...50,023,058

G

Traf3 interacting protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAF3IP2 mRNA

NCBI chr20:44,565,992...44,609,240
Ensembl chr20:44,517,242...44,609,618

G

TNF receptor-associated factor 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAF5 mRNA

NCBI chr13:106,100,921...106,149,724
Ensembl chr13:106,103,291...106,149,707

G

TNF receptor associated factor 6

multiple interactions

ISO

epigallocatechin gallate inhibits the reaction [Paraquat results in increased expression of TRAF6 protein]

NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328

G

translocation associated membrane protein 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAM2 mRNA

NCBI chr 9:30,915,624...30,995,162
Ensembl chr 9:30,915,624...30,995,162

G

tetratricopeptide repeat and ankyrin repeat containing 1

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRANK1 mRNA
epigallocatechin gallate results in increased expression of TRANK1 mRNA; epigallocatechin gallate results in increased expression of TRANK1 protein

PMID:22079256 PMID:31195006

NCBI chr 8:120,153,381...120,233,879
Ensembl chr 8:120,154,362...120,234,087

G

trafficking protein particle complex subunit 11

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAPPC11 mRNA

NCBI chr16:51,465,631...51,512,003
Ensembl chr16:51,465,524...51,512,004

G

trafficking protein particle complex subunit 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAPPC12 mRNA

NCBI chr 6:51,049,878...51,115,343
Ensembl chr 6:51,049,878...51,115,297

G

trafficking protein particle complex subunit 2L

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRAPPC2L mRNA

NCBI chr19:67,570,954...67,574,722

G

trafficking protein particle complex subunit 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAPPC3 mRNA

NCBI chr 5:143,843,612...143,857,347
Ensembl chr 5:143,836,912...143,857,345

G

tRNA aspartic acid methyltransferase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRDMT1 mRNA

NCBI chr17:81,510,740...81,554,036
Ensembl chr17:81,521,200...81,577,639

G

transcriptional regulating factor 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of TRERF1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRERF1 mRNA

NCBI chr 9:21,131,772...21,355,830
Ensembl chr 9:21,131,777...21,176,016

G

tribbles pseudokinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRIB1 mRNA

NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:93,095,973...93,117,480

G

tripartite motif-containing 21

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM21 mRNA

NCBI chr 1:166,376,829...166,399,441
Ensembl chr 1:166,376,829...166,399,449

G

tripartite motif-containing 24

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM24 mRNA

NCBI chr 4:67,534,240...67,659,014
Ensembl chr 4:67,534,335...67,684,226

G

tripartite motif-containing 28

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TRIM28 protein

NCBI chr 1:82,724,842...82,731,566
Ensembl chr 1:82,724,838...82,731,572

G

tripartite motif-containing 37

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM37 mRNA

NCBI chr10:72,440,672...72,572,831
Ensembl chr10:72,440,644...72,572,828

G

tripartite motif-containing 44

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM44 mRNA

NCBI chr 3:109,048,643...109,183,821
Ensembl chr 3:109,048,643...109,183,821

G

tripartite motif-containing 46

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRIM46 mRNA

NCBI chr 2:176,939,253...176,952,285
Ensembl chr 2:176,939,253...176,958,364

G

tripartite motif-containing 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM5 mRNA

NCBI chr 1:168,132,277...168,149,263
Ensembl chr 1:168,132,308...168,141,657

G

tripartite motif-containing 59

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM59 mRNA

NCBI chr 2:155,579,183...155,593,450
Ensembl chr 2:155,567,115...155,598,645

G

TRIO and F-actin binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIOBP mRNA

NCBI chr 7:112,386,371...112,452,130
Ensembl chr 7:112,386,420...112,442,924

G

thyroid hormone receptor interactor 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIP13 mRNA

NCBI chr 1:31,185,700...31,230,638
Ensembl chr 1:31,185,594...31,230,634

G

tRNA methyltransferase 10A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRMT10A mRNA

NCBI chr 2:229,342,853...229,357,573
Ensembl chr 2:229,342,864...229,360,108

G

tRNA methyltransferase 2 homolog B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRMT2B mRNA

NCBI chr X:101,716,656...101,777,105

G

transient receptor potential cation channel, subfamily C, member 4 associated protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRPC4AP mRNA

NCBI chr 3:164,582,146...164,653,123
Ensembl chr 3:164,582,146...164,653,123

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRPV1 mRNA
epigallocatechin gallate results in decreased expression of TRPV1 mRNA

PMID:22079256 PMID:29402411

NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021

G

TSC22 domain family, member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TSC22D2 mRNA

NCBI chr 2:144,796,760...144,847,930
Ensembl chr 2:144,796,841...144,843,559

G

tetraspanin 15

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TSPAN15 mRNA

NCBI chr20:30,673,271...30,717,651
Ensembl chr20:30,673,272...30,717,651

G

tetraspanin 18

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TSPAN18 mRNA

NCBI chr 3:99,615,465...99,755,270
Ensembl chr 3:99,615,466...99,755,270

G

tetraspanin 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TSPAN5 mRNA

NCBI chr 2:229,967,521...230,139,012
Ensembl chr 2:229,967,235...230,142,685

G

tetraspanin 6

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TSPAN6 mRNA

NCBI chr X:101,385,686...101,395,371
Ensembl chr X:101,385,694...101,392,627

G

TSR1, ribosome maturation factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TSR1 mRNA

NCBI chr10:60,258,790...60,270,238
Ensembl chr10:60,258,784...60,274,309

G

TSR2, ribosome maturation factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TSR2 mRNA

NCBI chr X:23,507,141...23,515,711
Ensembl chr X:23,507,142...23,515,659

G

tetratricopeptide repeat domain 27

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTC27 mRNA

NCBI chr 6:26,310,696...26,454,045
Ensembl chr 6:25,781,638...26,454,036

G

tetratricopeptide repeat domain 39B

decreases expression

ISO

(-)-epigallocatechin 3-gallate decreases expression of Ttc39b mRNA and protein in liver

RGD

NCBI chr 5:102,649,259...102,754,092
Ensembl chr 5:102,655,322...102,782,162

G

tetratricopeptide repeat domain 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTC8 mRNA

NCBI chr 6:123,927,657...124,025,354
Ensembl chr 6:123,927,907...123,982,117

G

Ttk protein kinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTK mRNA

NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:93,634,319...93,672,664

G

TTL family tubulin polyglutamylase complex subunit L1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTLL1 mRNA

NCBI chr 7:116,499,536...116,528,833
Ensembl chr 7:116,499,535...116,528,833

G

tubulin, alpha 1C

increases expression

ISO

epigallocatechin gallate results in increased expression of TUBA1C mRNA

NCBI chr 7:131,636,974...132,078,589
Ensembl chr 7:132,070,536...132,079,311

G

tubulin, alpha-like 3

increases expression

ISO

epigallocatechin gallate results in increased expression of TUBAL3 protein

NCBI chr17:71,233,194...71,245,297
Ensembl chr17:71,232,851...71,245,337

G

tubulin, beta 6 class V

increases expression

ISO

epigallocatechin gallate results in increased expression of TUBB6 protein

NCBI chr18:63,213,287...63,222,926
Ensembl chr18:63,213,279...63,224,303

G

tubulin, delta 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TUBD1 mRNA

NCBI chr10:71,865,446...71,888,731
Ensembl chr10:71,864,904...71,888,730

G

tubulin gamma complex component 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TUBGCP5 mRNA

NCBI chr 1:115,772,294...115,807,947
Ensembl chr 1:115,772,384...115,808,438

G

Tu translation elongation factor, mitochondrial

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TUFM mRNA

NCBI chr 1:190,504,373...190,507,980
Ensembl chr 1:190,504,373...190,508,952

G

TUB like protein 4

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of TULP4 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TULP4 mRNA

NCBI chr 1:49,082,492...49,218,262
Ensembl chr 1:49,087,886...49,218,250

G

twinkle mtDNA helicase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TWNK mRNA

NCBI chr 1:253,817,074...253,823,958
Ensembl chr 1:253,817,564...253,824,162

G

thioredoxin 1

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of TXN mRNA
epigallocatechin gallate affects the expression of and affects the activity of TXN protein

PMID:20706672 PMID:25585349

NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307

G

thioredoxin-like 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TXNL1 mRNA

NCBI chr18:59,397,275...59,428,072
Ensembl chr18:59,398,535...59,435,518

G

thioredoxin-like 4B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TXNL4B mRNA

NCBI chr19:54,439,686...54,449,777
Ensembl chr19:54,439,680...54,448,052

G

thioredoxin reductase 1

multiple interactions
increases expression

ISO

epigallocatechin gallate affects the expression of and affects the activity of TXNRD1 protein
epigallocatechin gallate results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

TYRO3 protein tyrosine kinase

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TYRO3 mRNA

NCBI chr 3:127,231,468...127,254,806
Ensembl chr 3:127,231,903...127,250,943

G

tyrosinase-related protein 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of TYRP1 mRNA

NCBI chr 5:100,327,111...100,345,657
Ensembl chr 5:100,327,125...100,345,657

G

uveal autoantigen with coiled-coil domains and ankyrin repeats

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UACA mRNA

NCBI chr 8:70,155,059...70,243,416
Ensembl chr 8:70,155,047...70,243,415

G

ubiquitin-like modifier activating enzyme 1

increases expression

ISO

epigallocatechin gallate results in increased expression of UBA1 protein

NCBI chr X:4,062,216...4,084,192
Ensembl chr X:4,062,182...4,084,246

G

ubiquitin-like modifier activating enzyme 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBA3 mRNA

NCBI chr 4:131,346,219...131,367,378
Ensembl chr 4:131,346,224...131,367,277

G

ubiquitin-like modifier activating enzyme 7

multiple interactions
affects expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBA7 mRNA; epigallocatechin gallate affects the reaction [Acetylcysteine results in increased expression of UBA7 protein]
epigallocatechin gallate affects the expression of UBA7 mRNA; epigallocatechin gallate affects the expression of UBA7 protein

PMID:22079256 PMID:25649257

NCBI chr 8:117,543,902...117,552,709
Ensembl chr 8:117,543,957...117,556,142

G

UBA-like domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBALD2 mRNA

NCBI chr10:102,161,370...102,165,952
Ensembl chr10:102,160,866...102,168,041

G

ubiquitin-conjugating enzyme E2D 2B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBE2D4 mRNA

NCBI chr14:2,060,926...2,062,400
Ensembl chr14:2,048,235...2,063,764

G

ubiquitin-conjugating enzyme E2L 6

decreases expression

ISO

epigallocatechin gallate results in decreased expression of UBE2L6 mRNA

NCBI chr 3:90,279,705...90,294,721
Ensembl chr 3:90,279,668...90,294,717

G

ubiquitin conjugating enzyme E2 Q2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBE2Q2 mRNA

NCBI chr 8:64,414,502...64,474,425
Ensembl chr 8:64,414,301...64,474,418

G

ubiquitin-conjugating enzyme E2Z

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBE2Z mRNA

NCBI chr10:81,494,522...81,513,641
Ensembl chr10:81,494,523...81,513,641

G

ubiquitin family domain containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBFD1 mRNA

NCBI chr 1:186,057,267...186,068,832
Ensembl chr 1:186,057,123...186,066,103

G

ubiquilin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBQLN2 mRNA

NCBI chr X:21,228,809...21,232,228
Ensembl chr X:21,229,197...21,232,268

G

ubiquilin 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBQLN4 mRNA

NCBI chr 2:176,310,524...176,325,724
Ensembl chr 2:176,310,568...176,325,924

G

ubiquitin protein ligase E3 component n-recognin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBR1 mRNA

NCBI chr 3:128,265,160...128,377,830
Ensembl chr 3:128,265,115...128,375,671

G

ubiquitin protein ligase E3 component n-recognin 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBR2 mRNA

NCBI chr 9:21,480,058...21,559,936
Ensembl chr 9:21,480,037...21,559,936

G

ubiquitin protein ligase E3 component n-recognin 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBR3 mRNA

NCBI chr 3:75,057,615...75,214,581
Ensembl chr 3:75,057,615...75,214,568

G

upstream binding transcription factor

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBTF mRNA

NCBI chr10:87,758,346...87,775,377
Ensembl chr10:87,758,346...87,773,088

G

uncoupling protein 1

multiple interactions

EXP

epigallocatechin gallate analog inhibits the reaction [Dietary Fats results in decreased expression of UCP1 protein]

NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420

G

Ufm1-specific ligase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UFL1 mRNA

NCBI chr 5:43,759,271...43,791,682
Ensembl chr 5:43,758,098...43,791,682

G

UDP-glucose ceramide glucosyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UGCG mRNA

NCBI chr 5:78,828,006...78,860,725
Ensembl chr 5:78,828,006...78,860,417

G

UDP-glucose 6-dehydrogenase

increases expression

ISO

epigallocatechin gallate results in increased expression of UGDH mRNA

NCBI chr14:43,202,480...43,226,002
Ensembl chr14:43,202,356...43,226,629

G

unc-51 like kinase 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ULK3 mRNA

NCBI chr 8:66,888,820...66,895,380
Ensembl chr 8:66,888,788...66,895,379

G

unc-13 homolog C

increases expression

ISO

epigallocatechin gallate results in increased expression of UNC13C protein

NCBI chr 8:83,127,650...83,553,822
Ensembl chr 8:83,128,523...83,553,822

G

unc-50 inner nuclear membrane RNA binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UNC50 mRNA

NCBI chr 9:47,160,723...47,169,710
Ensembl chr 9:47,160,796...47,168,688

G

UPF3B, regulator of nonsense mediated mRNA decay

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UPF3B mRNA

NCBI chr X:121,200,993...121,219,059
Ensembl chr X:121,200,993...121,218,921

G

uracil phosphoribosyltransferase homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UPRT mRNA

NCBI chr X:73,582,267...73,612,488
Ensembl chr X:73,582,361...73,612,496

G

ubiquinol-cytochrome c reductase complex assembly factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UQCC2 mRNA

NCBI chr20:5,204,682...5,217,080
Ensembl chr17:12,088,037...12,088,606
Ensembl chr20:12,088,037...12,088,606

G

ubiquinol-cytochrome c reductase binding protein

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UQCRB mRNA

NCBI chr 7:65,700,016...65,705,382
Ensembl chr 7:65,700,029...65,705,558

G

ubiquinol-cytochrome c reductase core protein 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of UQCRC1 mRNA

NCBI chr 8:118,468,223...118,479,968
Ensembl chr 8:118,468,200...118,479,964

G

ubiquinol cytochrome c reductase core protein 2

multiple interactions

ISO

[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of UQCRC2 protein]; BMAL1 protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of UQCRC2 protein]]

NCBI chr 1:184,599,240...184,629,804
Ensembl chr 1:184,599,212...184,630,946

G

ubiquitin specific peptidase 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP13 mRNA

NCBI chr 2:117,502,811...117,617,049
Ensembl chr 2:117,505,122...117,630,161

G

ubiquitin specific peptidase 24

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP24 mRNA

NCBI chr 5:126,309,396...126,439,147
Ensembl chr 5:126,309,597...126,439,135

G

ubiquitin specific peptidase 25

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP25 mRNA

NCBI chr11:29,088,283...29,198,323
Ensembl chr11:29,087,736...29,198,323

G

ubiquitin specific peptidase 32

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP32 mRNA

NCBI chr10:70,353,310...70,538,008
Ensembl chr10:70,353,310...70,538,324

G

ubiquitin specific peptidase 34

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP34 mRNA

NCBI chr14:101,487,110...101,677,519
Ensembl chr14:101,487,153...101,678,632

G

ubiquitin specific peptidase 36

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of USP36 mRNA

NCBI chr10:103,995,970...104,027,492
Ensembl chr10:103,995,970...104,023,450

G

ubiquitin specific peptidase 5

decreases expression

ISO

epigallocatechin gallate results in decreased expression of USP5 mRNA

NCBI chr 4:159,305,927...159,321,345
Ensembl chr 4:159,305,938...159,320,956

G

USP6 N-terminal like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP6NL mRNA

NCBI chr17:76,737,870...76,865,953
Ensembl chr17:76,739,906...76,865,373

G

ubiquitin specific peptidase 9, X-linked

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP9X mRNA

NCBI chr X:12,261,633...12,399,780
Ensembl chr X:12,261,633...12,369,491

G

UTP14A small subunit processome component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UTP14A mRNA

NCBI chr X:132,317,163...132,342,524
Ensembl chr X:132,317,159...132,342,523

G

UTP3, small subunit processome component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UTP3 mRNA

NCBI chr14:19,799,766...19,801,420
Ensembl chr14:19,796,215...19,801,446

G

UTP6 small subunit processome component

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UTP6 mRNA

NCBI chr10:65,395,253...65,425,928
Ensembl chr10:65,395,253...65,425,928

G

utrophin

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of UTRN mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UTRN mRNA

NCBI chr 1:8,541,061...9,044,487
Ensembl chr 1:8,542,798...9,044,487

G

UV radiation resistance associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UVRAG mRNA

NCBI chr 1:162,596,514...162,854,348
Ensembl chr 1:162,596,515...162,854,348

G

vesicle-associated membrane protein 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VAMP8 mRNA

NCBI chr 4:106,000,570...106,011,081
Ensembl chr 4:106,000,570...106,011,073

G

VANGL planar cell polarity protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VANGL1 mRNA

NCBI chr 2:192,277,762...192,326,151
Ensembl chr 2:192,280,422...192,326,186

G

vav guanine nucleotide exchange factor 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VAV2 mRNA

NCBI chr 3:30,982,754...31,152,116
Ensembl chr 3:30,982,754...31,152,116

G

vinculin

increases expression

ISO

epigallocatechin gallate results in increased expression of VCL protein

NCBI chr15:3,315,069...3,404,891
Ensembl chr15:3,315,069...3,405,163

G

valosin containing protein lysine methyltransferase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of VCPKMT mRNA

NCBI chr 6:93,772,558...93,778,400
Ensembl chr 6:93,772,575...93,777,975

G

voltage-dependent anion channel 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of VDAC2 mRNA

NCBI chr15:2,512,214...2,526,105
Ensembl chr15:2,512,216...2,532,229

G

vascular endothelial growth factor A

decreases secretion
multiple interactions
decreases expression

ISO

epigallocatechin gallate results in decreased secretion of VEGFA protein
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of VEGFA mRNA; epigallocatechin gallate inhibits the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA protein]]
epigallocatechin gallate inhibits the reaction [Pyruvaldehyde results in increased expression of VEGFA protein]
epigallocatechin gallate results in decreased expression of VEGFA mRNA

PMID:17992120 PMID:20346928 PMID:22079256 PMID:22101032 PMID:26800359 More...

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vimentin

multiple interactions
decreases expression

ISO

epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of VIM mRNA]; epigallocatechin gallate inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; TFEB protein affects the reaction [epigallocatechin gallate results in decreased expression of VIM protein]

PMID:38146662 PMID:39313106

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

vitamin K epoxide reductase complex, subunit 1-like 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VKORC1L1 mRNA

NCBI chr12:32,354,078...32,404,327

G

vacuolar protein sorting 13 homolog A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13A mRNA

NCBI chr 1:223,328,784...223,555,500
Ensembl chr 1:223,328,784...223,555,331

G

vacuolar protein sorting 13 homolog B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13B mRNA

NCBI chr 7:68,436,996...69,013,574
Ensembl chr 7:68,443,655...69,013,574

G

vacuolar protein sorting 13 homolog C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13C mRNA

NCBI chr 8:77,359,499...77,533,009
Ensembl chr 8:77,359,504...77,531,871

G

vacuolar protein sorting 13 homolog D

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13D mRNA
epigallocatechin gallate results in increased expression of VPS13D mRNA

NCBI chr 5:162,113,732...162,339,121
Ensembl chr 5:162,113,732...162,339,099

G

VPS18 core subunit of CORVET and HOPS complexes

increases expression

ISO

epigallocatechin gallate results in increased expression of VPS18 mRNA

NCBI chr 3:126,733,276...126,744,130
Ensembl chr 3:126,733,232...126,744,129

G

vacuolar protein sorting 25 homolog

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS25 mRNA

NCBI chr10:86,696,330...86,701,871
Ensembl chr10:86,696,157...86,701,871

G

VPS33B, late endosome and lysosome associated

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS33B mRNA

NCBI chr 1:143,633,167...143,656,228
Ensembl chr 1:143,633,197...143,659,552

G

VPS50 subunit of EARP/GARPII complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS50 mRNA

NCBI chr 4:32,439,101...32,540,299
Ensembl chr 4:32,439,138...32,540,538

G

VPS54 subunit of GARP complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS54 mRNA

NCBI chr14:99,580,120...99,657,178
Ensembl chr14:99,580,148...99,657,164

G

VPS8 subunit of CORVET complex

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS8 mRNA

NCBI chr11:92,906,702...93,140,844
Ensembl chr11:92,906,700...93,138,570

G

VRK serine/threonine kinase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VRK1 mRNA

NCBI chr 6:130,679,400...130,746,089
Ensembl chr 6:130,679,515...130,746,752

G

tryptophanyl-tRNA synthetase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of WARS1 mRNA

NCBI chr 6:133,540,463...133,571,645
Ensembl chr 6:133,539,744...133,571,645

G

tryptophanyl tRNA synthetase 2 (mitochondrial)

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WARS2 mRNA

NCBI chr 2:189,150,322...189,233,606
Ensembl chr 2:189,145,371...189,232,970

G

WASP family member 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of WASF2 mRNA

NCBI chr 5:150,620,733...150,685,943
Ensembl chr 5:150,620,733...150,685,943

G

WASH complex subunit 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WASHC4 mRNA

NCBI chr 7:22,075,546...22,127,847
Ensembl chr 7:22,050,098...22,127,828

G

WASH complex subunit 5

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WASHC5 mRNA

NCBI chr 7:92,773,625...92,825,532
Ensembl chr 7:92,773,625...92,825,532

G

WW domain binding protein 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WBP4 mRNA

NCBI chr15:61,271,774...61,299,740
Ensembl chr15:61,271,783...61,299,740

G

WD repeat and FYVE domain containing 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDFY2 mRNA

NCBI chr15:41,259,840...41,385,549
Ensembl chr15:41,259,884...41,385,549

G

WD repeat and FYVE domain containing 3

multiple interactions
increases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDFY3 mRNA
epigallocatechin gallate results in increased expression of WDFY3 mRNA

NCBI chr14:7,873,946...8,115,002
Ensembl chr14:7,911,151...8,114,993

G

WD repeat and HMG-box DNA binding protein 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDHD1 mRNA

NCBI chr15:22,957,492...23,002,820
Ensembl chr15:22,958,069...23,002,820

G

WD repeat domain 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR12 mRNA

NCBI chr 9:68,969,547...68,996,811
Ensembl chr 9:68,969,547...68,996,811

G

WD repeat domain 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR19 mRNA

NCBI chr14:43,396,130...43,460,012
Ensembl chr14:43,397,835...43,459,939

G

WD repeat domain 25

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR25 mRNA

NCBI chr 6:133,571,790...133,704,154
Ensembl chr 6:133,571,804...133,704,145

G

WD repeat domain 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR4 mRNA

NCBI chr20:9,588,532...9,604,718
Ensembl chr20:9,588,532...9,605,007

G

WD repeat domain 44

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR44 mRNA

NCBI chr X:119,286,802...119,392,240
Ensembl chr X:119,287,142...119,392,232

G

WD repeat domain 7

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR7 mRNA

NCBI chr18:59,435,733...59,718,800
Ensembl chr18:59,435,768...59,718,800

G

WD repeat domain 70

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR70 mRNA

NCBI chr 2:58,678,651...58,918,523
Ensembl chr 2:58,678,654...58,918,504

G

Wnt family member 5A

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of WNT5A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WNT5A mRNA

NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860

G

WW domain containing E3 ubiquitin protein ligase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WWP1 mRNA

NCBI chr 5:37,889,280...37,982,743
Ensembl chr 5:37,895,398...37,982,959

G

XIAP associated factor 1

decreases expression

ISO

epigallocatechin gallate results in decreased expression of XAF1 mRNA

NCBI chr10:57,415,935...57,428,348
Ensembl chr10:57,415,658...57,428,349

G

X-linked inhibitor of apoptosis

decreases expression

ISO

epigallocatechin gallate results in decreased expression of XIAP

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

exportin 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XPO1 mRNA

NCBI chr14:101,434,450...101,476,705
Ensembl chr14:101,434,517...101,476,714

G

exportin 6

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XPO6 mRNA

NCBI chr 1:190,102,719...190,192,138
Ensembl chr 1:190,102,724...190,192,138

G

xenotropic and polytropic retrovirus receptor 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XPR1 mRNA

NCBI chr13:69,991,517...70,136,249
Ensembl chr13:69,996,692...70,136,164

G

X-ray repair cross complementing 1

multiple interactions

ISO

[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of XRCC1 mRNA]; epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of XRCC1 mRNA]

NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613

G

X-ray repair cross complementing 3

multiple interactions

ISO

[epigallocatechin gallate co-treated with polylactic acid-polyglycolic acid copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of XRCC3 mRNA]; epigallocatechin gallate inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of XRCC3 mRNA]

NCBI chr 6:136,684,558...136,694,822
Ensembl chr 6:136,684,558...136,694,822

G

X-ray repair cross complementing 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XRCC4 mRNA; epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of XRCC4 mRNA]

NCBI chr 2:22,686,506...22,932,929
Ensembl chr 2:22,686,508...22,933,160

G

X-ray repair cross complementing 5

decreases expression

ISO

epigallocatechin gallate results in decreased expression of XRCC5 protein

NCBI chr 9:81,404,507...81,493,293
Ensembl chr 9:81,375,863...81,493,293

G

xylulokinase

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XYLB mRNA

NCBI chr 8:127,971,194...128,012,511
Ensembl chr 8:127,966,100...128,006,571

G

xylosyltransferase 2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XYLT2 mRNA

NCBI chr10:80,102,776...80,116,346
Ensembl chr10:80,102,873...80,116,257

G

YAE1 maturation factor of ABCE1

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of YAE1 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YAE1 mRNA

NCBI chr17:51,722,582...51,729,098
Ensembl chr17:51,722,570...51,729,095

G

tyrosyl-tRNA synthetase 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YARS1 mRNA

NCBI chr 5:146,820,163...146,848,377
Ensembl chr 5:146,819,358...146,848,377

G

YEATS domain containing 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YEATS4 mRNA

NCBI chr 7:54,744,220...54,751,361
Ensembl chr 7:54,744,221...54,751,361

G

Yip1 domain family, member 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YIPF4 mRNA

NCBI chr 6:26,702,647...26,714,066
Ensembl chr 6:26,682,488...26,714,066

G

yrdC N(6)-threonylcarbamoyltransferase domain containing

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YRDC mRNA

NCBI chr 5:142,394,833...142,399,798
Ensembl chr 5:142,394,938...142,399,795

G

YTH N6-methyladenosine RNA binding protein C1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YTHDC1 mRNA

NCBI chr14:21,540,276...21,570,724
Ensembl chr14:21,540,278...21,570,769

G

YTH N6-methyladenosine RNA binding protein C2

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YTHDC2 mRNA

NCBI chr18:37,517,286...37,582,551
Ensembl chr18:37,517,248...37,582,550

G

YTH N6-methyladenosine RNA binding protein F1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YTHDF1 mRNA

NCBI chr 3:188,402,228...188,417,740
Ensembl chr 3:188,402,231...188,417,740

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YWHAG mRNA

NCBI chr12:26,381,106...26,409,466
Ensembl chr12:26,380,816...26,409,465

G

zinc finger and BTB domain containing 38

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZBTB38 mRNA

NCBI chr 8:106,124,181...106,231,215
Ensembl chr 8:106,157,084...106,230,951

G

zinc finger, C2HC-type containing 1A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZC2HC1A mRNA

NCBI chr 2:96,194,665...96,231,957
Ensembl chr 2:96,194,671...96,232,288

G

zinc finger CCHC-type containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZCCHC3 mRNA

NCBI chr 3:161,332,760...161,335,591
Ensembl chr 3:161,332,559...161,340,290

G

zinc finger CCHC-type containing 9

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZCCHC9 mRNA

NCBI chr 2:24,773,319...24,783,339
Ensembl chr 2:24,773,319...24,781,999

G

zinc finger DHHC-type palmitoyltransferase 13

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZDHHC13 mRNA

NCBI chr 1:107,623,599...107,662,178
Ensembl chr 1:107,623,599...107,662,178

G

zinc finger DHHC-type palmitoyltransferase 16

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZDHHC16 mRNA

NCBI chr 1:250,694,922...250,706,319
Ensembl chr 1:250,694,927...250,706,319

G

zinc finger AN1-type containing 2A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFAND2A mRNA

NCBI chr12:20,275,435...20,286,513
Ensembl chr12:20,275,450...20,286,513

G

zinc finger AN1-type containing 6

multiple interactions
decreases expression

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFAND6 mRNA
epigallocatechin gallate results in decreased expression of ZFAND6 mRNA

NCBI chr 1:147,990,099...148,061,221
Ensembl chr 1:147,990,108...148,061,134

G

zinc finger and AT hook domain containing

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFAT mRNA

NCBI chr 7:101,775,916...101,951,135
Ensembl chr 7:101,775,916...101,943,237

G

zinc finger protein 12

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF12 mRNA

NCBI chr12:16,430,546...16,446,063
Ensembl chr12:16,430,581...16,450,303

G

zinc finger protein 217

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF217 mRNA

NCBI chr 3:179,309,178...179,349,853
Ensembl chr 3:179,310,973...179,321,892

G

zinc finger protein 280C

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF280C mRNA

NCBI chr X:132,594,279...132,685,548
Ensembl chr X:132,594,292...132,685,841

G

zinc finger protein 280D

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF280D mRNA

NCBI chr 8:81,872,108...81,961,194
Ensembl chr 8:81,873,335...81,961,201

G

zinc finger protein 287

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF287 mRNA

NCBI chr10:47,896,517...47,914,860
Ensembl chr10:47,896,517...47,914,950

G

zinc finger protein 296

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF296 mRNA

NCBI chr 1:88,356,653...88,359,841
Ensembl chr 1:88,352,530...88,359,840

G

zinc finger protein 300

increases expression

ISO

epigallocatechin gallate results in increased expression of ZNF567 mRNA

NCBI chr X:3,452,993...3,472,102
Ensembl chr X:3,454,030...3,472,084

G

zinc finger protein 347

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF14 mRNA

NCBI chr 7:8,110,793...8,130,161
Ensembl chr 7:8,111,577...8,130,165

G

zinc finger protein 354A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF354A mRNA

NCBI chr10:35,897,217...35,909,063
Ensembl chr10:35,897,228...35,909,510

G

zinc finger protein 367

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF367 mRNA

NCBI chr17:970,896...990,025
Ensembl chr17:970,741...990,029

G

zinc finger protein 36, C3H type-like 2

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of ZFP36L2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFP36L2 mRNA

PMID:16084531 PMID:22079256

NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:16,242,610...16,246,653

G

zinc finger protein 382

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF382 mRNA

NCBI chr 1:94,504,344...94,528,316
Ensembl chr 1:94,505,067...94,528,334

G

zinc finger protein 438

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF438 mRNA

NCBI chr17:57,121,637...57,242,892
Ensembl chr17:57,121,302...57,245,607

G

zinc finger protein 473

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF473 mRNA

NCBI chr 1:104,358,757...104,379,833
Ensembl chr 1:104,359,709...104,379,775

G

zinc finger protein 512B

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF512B mRNA

NCBI chr 3:189,065,036...189,075,587
Ensembl chr 3:189,065,037...189,075,761

G

zinc finger protein 518A

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF518A mRNA

NCBI chr 1:249,668,815...249,694,401
Ensembl chr 1:249,657,809...249,695,569

G

zinc finger protein 551

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF551 mRNA

NCBI chr 1:81,615,977...81,626,233
Ensembl chr 1:81,617,869...81,626,234

G

zinc finger protein 574

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF574 mRNA

NCBI chr 1:89,798,412...89,805,490
Ensembl chr 1:89,760,956...89,813,198

G

zinc finger protein 58

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF429 mRNA

NCBI chr 1:36,848,858...36,861,605

G

zinc finger protein 583

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF583 mRNA

NCBI chr 1:76,608,730...76,627,570
Ensembl chr 1:76,608,954...76,627,544

G

zinc finger protein 609

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF609 mRNA

NCBI chr 8:75,109,676...75,243,045
Ensembl chr 8:75,109,676...75,213,086

G

zinc finger protein 622

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF622 mRNA

NCBI chr 2:78,205,655...78,224,888
Ensembl chr 2:78,066,031...78,225,356

G

zinc finger protein 623

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF623 mRNA

NCBI chr 7:109,508,046...109,516,965
Ensembl chr 7:109,514,586...109,518,381

G

zinc finger protein 637

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF32 mRNA

NCBI chr 4:152,656,937...152,682,499
Ensembl chr 4:152,656,973...152,685,097

G

zinc finger protein 641

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF641 mRNA

NCBI chr 7:131,313,620...131,324,149
Ensembl chr 7:131,313,624...131,323,691

G

zinc finger protein 691

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF691 mRNA

NCBI chr 5:138,065,576...138,070,269
Ensembl chr 5:138,064,128...138,087,015

G

zinc finger protein 77

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF77 mRNA

NCBI chr 7:7,920,674...7,967,079
Ensembl chr 7:7,920,716...7,937,127

G

zinc finger protein 791

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF791 mRNA

NCBI chr19:39,921,848...39,942,507
Ensembl chr19:39,923,678...39,938,618

G

zinc finger protein 804A

increases expression
multiple interactions

ISO

epigallocatechin gallate results in increased expression of ZNF804A mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF804A mRNA

NCBI chr 3:87,440,496...87,670,872
Ensembl chr 3:87,197,582...87,670,869

G

zinc finger protein 827

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF827 mRNA

NCBI chr19:45,624,849...45,791,739
Ensembl chr19:45,614,604...45,844,430

G

zinc finger protein 830

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF830 mRNA

NCBI chr10:68,198,903...68,200,367
Ensembl chr10:68,198,876...68,217,373

G

zinc finger FYVE-type containing 16

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFYVE16 mRNA

NCBI chr 2:25,448,264...25,495,180
Ensembl chr 2:25,448,829...25,483,295

G

zinc finger FYVE-type containing 19

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFYVE19 mRNA

NCBI chr 3:126,649,625...126,657,812
Ensembl chr 3:126,649,316...126,675,924

G

zinc fingers and homeoboxes 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZHX3 mRNA

NCBI chr 3:169,837,497...169,968,371
Ensembl chr 3:169,837,516...169,935,530

G

zinc finger protein interacting with K protein 1

increases expression

ISO

epigallocatechin gallate results in increased expression of ZIK1 mRNA

NCBI chr 1:73,831,766...73,878,538
Ensembl chr 1:73,833,313...73,840,976

G

zinc finger with KRAB and SCAN domains 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZKSCAN1 mRNA

NCBI chr12:22,080,319...22,101,389
Ensembl chr12:22,080,324...22,101,387

G

zinc finger, MIZ-type containing 1

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMIZ1 mRNA

NCBI chr16:1,033,983...1,239,425
Ensembl chr16:1,034,020...1,239,406

G

zinc finger MYM-type containing 2

decreases expression
multiple interactions

ISO

epigallocatechin gallate results in decreased expression of ZMYM2 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMYM2 mRNA

PMID:16084531 PMID:22079256

NCBI chr15:35,151,356...35,224,528
Ensembl chr15:35,127,994...35,224,941

G

zinc finger MYM-type containing 4

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMYM4 mRNA

NCBI chr 5:144,431,255...144,551,747
Ensembl chr 5:144,431,255...144,548,849

G

zinc finger, MYND-type containing 8

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMYND8 mRNA

NCBI chr 3:174,948,162...175,061,382
Ensembl chr 3:174,948,537...175,061,571

G

zinc finger protein 408

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF408 mRNA

NCBI chr 3:98,071,210...98,077,075
Ensembl chr 3:98,072,568...98,077,196

G

zinc finger protein 624 like

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF624 mRNA

NCBI chr 7:8,504,136...8,550,137
Ensembl chr 7:8,503,571...8,541,778

G

zinc finger RANBP2-type containing 3

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZRANB3 mRNA

NCBI chr13:41,993,110...42,148,298
Ensembl chr13:41,992,922...42,148,274

G

zyg-11 family member B, cell cycle regulator

multiple interactions

ISO

[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZYG11B mRNA

NCBI chr 5:128,214,293...128,271,446
Ensembl chr 5:128,214,293...128,271,446

G

zyxin

increases expression

ISO

epigallocatechin gallate results in increased expression of ZYX protein

NCBI chr 4:72,203,991...72,213,181
Ensembl chr 4:72,204,007...72,213,181

17beta-estradiol 3-benzoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases methylation
multiple interactions

EXP

estradiol 3-benzoate results in increased methylation of A2M promoter
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of A2M mRNA

PMID:27415467 PMID:32741896

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868

G

arylacetamide deacetylase-like 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of AADACL3 mRNA

NCBI chr 5:161,525,452...161,535,485
Ensembl chr 5:161,525,452...161,535,485

G

ATP binding cassette subfamily B member 1A

decreases expression
multiple interactions
increases expression

EXP

estradiol 3-benzoate results in decreased expression of ABCB1A mRNA
fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased expression of ABCB1A mRNA]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP-binding cassette, sub-family B member 1B

decreases expression
multiple interactions

EXP

estradiol 3-benzoate results in decreased expression of ABCB1B mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABCB1B mRNA; Fulvestrant inhibits the reaction [estradiol 3-benzoate results in decreased expression of ABCB1B mRNA]

PMID:23707492 PMID:32741896

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567

G

ATP binding cassette subfamily C member 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of ABCC1 protein

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of ABCC2 promoter

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 4

decreases expression
multiple interactions
increases expression

EXP

estradiol 3-benzoate results in decreased expression of ABCC4 protein
fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased expression of ABCC4 mRNA]
estradiol 3-benzoate results in increased expression of ABCC4 mRNA; estradiol 3-benzoate results in increased expression of ABCC4 protein

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily C member 5

affects expression
multiple interactions
increases expression

EXP

estradiol 3-benzoate affects the expression of ABCC5 protein
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABCC5 mRNA
estradiol 3-benzoate results in increased expression of ABCC5 mRNA; estradiol 3-benzoate results in increased expression of ABCC5 protein

PMID:23707492 PMID:32741896

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

ATP binding cassette subfamily C member 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABCC8 mRNA

NCBI chr 1:105,734,992...105,816,272
Ensembl chr 1:105,734,992...105,815,982

G

ATP binding cassette subfamily C member 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABCC9 mRNA

NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348

G

ATP binding cassette subfamily G member 2

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of ABCG2 mRNA; estradiol 3-benzoate results in decreased expression of ABCG2 protein

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

ATP-binding cassette, subfamily G (WHITE), member 3-like 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABCG3L3 mRNA

NCBI chr14:5,148,826...5,196,890
Ensembl chr14:5,162,358...5,196,884

G

ABI family member 3 binding protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABI3BP mRNA

NCBI chr11:57,381,282...57,597,989
Ensembl chr11:57,381,422...57,598,120

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ACAP1 mRNA

NCBI chr10:55,104,040...55,119,280
Ensembl chr10:55,104,040...55,118,185

G

angiotensin converting enzyme 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

aconitate decarboxylase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ACOD1 mRNA

NCBI chr15:86,286,531...86,295,803
Ensembl chr15:86,286,579...86,295,687

G

acyl-CoA thioesterase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ACOT1 mRNA

NCBI chr 6:109,367,274...109,375,268
Ensembl chr 6:109,367,268...109,380,749

G

acrosin binding protein

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of ACRBP promoter

NCBI chr 4:159,537,395...159,550,454
Ensembl chr 4:159,537,391...159,550,454

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ACSL4 mRNA

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

actin alpha 2, smooth muscle

multiple interactions

EXP

estradiol 3-benzoate promotes the reaction [Thioacetamide results in increased expression of ACTA2 mRNA]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actin, beta

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RASA4 mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

activin A receptor type 2B

decreases expression
affects expression

ISO
EXP

estradiol 3-benzoate results in decreased expression of ACVR2B mRNA
estradiol 3-benzoate affects the expression of SCGB2A2 mRNA

PMID:14994273 PMID:15925091

NCBI chr 8:128,016,589...128,056,193
Ensembl chr 8:128,016,526...128,048,171

G

ADAM metallopeptidase with thrombospondin type 1 motif, 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAMTS12 mRNA

NCBI chr 2:61,759,975...62,054,716
Ensembl chr 2:61,759,987...62,054,716

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAMTS14 mRNA

NCBI chr20:29,685,876...29,762,685
Ensembl chr20:29,685,876...29,762,682

G

ADAM metallopeptidase with thrombospondin type 1 motif, 15

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAMTS15 mRNA

NCBI chr 8:37,566,064...37,589,446
Ensembl chr 8:37,566,065...37,589,446

G

ADAM metallopeptidase with thrombospondin type 1 motif, 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAMTS2 mRNA

NCBI chr10:35,422,030...35,627,483
Ensembl chr10:35,422,030...35,627,483

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAMTS4 mRNA

NCBI chr13:86,203,011...86,212,500
Ensembl chr13:86,202,642...86,212,514

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAMTS5 mRNA

NCBI chr11:38,486,945...38,533,516
Ensembl chr11:38,486,955...38,533,516

G

ADAM metallopeptidase with thrombospondin type 1 motif, 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAMTS6 mRNA

NCBI chr 2:37,155,260...37,367,077
Ensembl chr 2:37,155,288...37,367,070

G

ArfGAP with dual PH domains 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAP2 mRNA

NCBI chr10:65,635,891...65,665,019
Ensembl chr10:65,622,434...65,664,022

G

adenosine deaminase, RNA-specific

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADAR mRNA

NCBI chr 2:177,436,076...177,475,969
Ensembl chr 2:177,436,094...177,475,971

G

adenylate cyclase 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADCY4 mRNA

NCBI chr15:33,236,201...33,252,070
Ensembl chr15:33,236,208...33,252,026

G

adenylate cyclase 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADCY7 mRNA

NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743

G

adhesion G protein-coupled receptor B2

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of ADGRB2 promoter

NCBI chr 5:147,581,573...147,646,726
Ensembl chr 5:147,611,580...147,646,726

G

adhesion G protein-coupled receptor E1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADGRE1 mRNA

NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,329,438...2,484,959

G

adhesion G protein-coupled receptor E4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADGRE4 mRNA

NCBI chr 9:10,085,258...10,240,346
Ensembl chr 9:10,085,352...10,240,229

G

adhesion G protein-coupled receptor G5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADGRG5 mRNA

NCBI chr19:10,080,800...10,104,659
Ensembl chr19:10,085,388...10,103,220

G

adhesion G protein-coupled receptor G7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ADGRG7 mRNA

NCBI chr11:57,282,904...57,345,417
Ensembl chr11:57,282,904...57,345,417

G

adrenomedullin 2

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of ADM2 mRNA

NCBI chr 7:122,272,808...122,274,594
Ensembl chr 7:122,272,808...122,274,594

G

2-aminoethanethiol dioxygenase

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of ADO promoter

NCBI chr20:21,043,694...21,044,862
Ensembl chr20:21,043,317...21,048,483

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AGAP2 mRNA

NCBI chr 7:64,782,618...64,799,624
Ensembl chr 7:64,782,612...64,799,640

G

allograft inflammatory factor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AIF1 mRNA

NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339

G

absent in melanoma 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AIM2 mRNA

NCBI chr13:88,397,516...88,439,325
Ensembl chr13:88,404,048...88,439,318

G

aldo-keto reductase family 1 member B15

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AKR1B8 mRNA

NCBI chr 4:63,964,421...63,976,995
Ensembl chr 4:63,960,880...63,978,349

G

aldo-keto reductase family 1 member C8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AKR1CL mRNA

NCBI chr17:71,091,398...71,117,985
Ensembl chr17:71,083,080...71,117,957

G

aldehyde dehydrogenase 1 family, member A3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ALDH1A3 mRNA

NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777

G

aldehyde dehydrogenase 4 family, member A1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ALDH4A1 mRNA

NCBI chr 5:157,163,189...157,188,673
Ensembl chr 5:157,162,945...157,188,673

G

aldolase, fructose-bisphosphate B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ALDOB mRNA

NCBI chr 5:68,684,541...68,697,582
Ensembl chr 5:68,684,542...68,716,740

G

arachidonate 12-lipoxygenase, epidermal

increases expression

EXP

estradiol 3-benzoate results in increased expression of ALOX12E mRNA

NCBI chr10:55,533,044...55,540,509
Ensembl chr10:55,533,044...55,540,509

G

arachidonate 5-lipoxygenase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ALOX5 mRNA

NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ALOX5AP mRNA

NCBI chr12:10,785,254...10,809,295
Ensembl chr12:10,785,257...10,817,038

G

amylase 2a3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of AMY2A3 mRNA

NCBI chr 2:204,005,840...204,014,412
Ensembl chr 2:204,005,840...204,014,413

G

archaelysin family metallopeptidase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AMZ1 mRNA

NCBI chr12:19,000,448...19,038,625
Ensembl chr12:19,000,448...19,037,925

G

angiopoietin-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ANGPTL1 mRNA

NCBI chr13:71,463,913...71,531,810
Ensembl chr13:71,511,727...71,531,818

G

ankyrin repeat and kinase domain containing 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ANKK1 mRNA

NCBI chr 8:58,676,327...58,685,012
Ensembl chr 8:58,676,327...58,684,489

G

ankyrin repeat domain 66

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ANKRD66 mRNA

NCBI chr 9:24,918,206...24,938,481
Ensembl chr 9:24,912,521...24,938,488

G

annexin A13

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ANXA13 mRNA

NCBI chr 7:91,773,844...91,826,386
Ensembl chr 7:91,770,861...91,826,386

G

acyloxyacyl hydrolase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AOAH mRNA

NCBI chr17:48,503,812...48,745,161
Ensembl chr17:48,503,812...48,745,146

G

adaptor related protein complex 1 subunit mu 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of AP1M2 promoter

NCBI chr 8:28,114,748...28,132,767
Ensembl chr 8:28,114,748...28,132,642

G

adaptor related protein complex 1 subunit sigma 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AP1S2 mRNA

NCBI chr X:34,204,601...34,230,819
Ensembl chr X:34,204,603...34,228,529

G

amyloid beta precursor protein binding family A member 2

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of APBA2 mRNA

NCBI chr 1:127,465,026...127,698,124
Ensembl chr 1:127,465,009...127,698,117

G

apolipoprotein B mRNA editing enzyme catalytic subunit 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of APOBEC1 mRNA

NCBI chr 4:157,472,879...157,500,496
Ensembl chr 4:157,472,868...157,498,909

G

apolipoprotein B receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of APOBR mRNA

NCBI chr 1:190,599,595...190,603,782
Ensembl chr 1:190,597,638...190,616,809

G

apolipoprotein C3

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of APOC3 mRNA

NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:55,428,024...55,458,679

G

apolipoprotein D

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of APOD mRNA

NCBI chr11:82,936,216...82,957,264
Ensembl chr11:82,936,038...82,957,263

G

apolipoprotein L7b, pseudogene 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of APOL7B-PS1 mRNA

NCBI chr 7:111,037,327...111,056,225

G

apolipoprotein L9a

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of APOL9A mRNA

NCBI chr 7:111,021,452...111,030,380
Ensembl chr 7:111,021,453...111,028,213

G

Apol9a-Apol7a readthrough

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of APOL7B mRNA

NCBI chr 7:111,011,645...111,019,326
Ensembl chr 7:111,011,645...111,017,084

G

aquaporin 2

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of AQP2 mRNA

NCBI chr 7:132,590,286...132,595,321
Ensembl chr 7:132,590,225...132,595,319

G

aquaporin 3 (Gill blood group)

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of AQP3 mRNA

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685

G

androgen receptor

multiple interactions
affects expression

EXP

Flutamide inhibits the reaction [estradiol 3-benzoate results in increased expression of AR mRNA]
estradiol 3-benzoate affects the expression of AR mRNA

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

ARF GTPase 6

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of ARF6 promoter

NCBI chr 6:93,589,777...93,590,925
Ensembl chr 6:93,569,234...93,610,536

G

Rho GTPase activating protein 15

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ARHGAP15 mRNA

NCBI chr 3:48,382,945...49,002,213
Ensembl chr 3:48,382,904...49,011,378

G

Rho GTPase activating protein 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ARHGAP4 mRNA

NCBI chr X:156,787,566...156,802,841
Ensembl chr X:156,783,776...156,802,450

G

Rho GTPase activating protein 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ARHGAP9 mRNA

NCBI chr 7:65,034,023...65,042,336
Ensembl chr 7:65,034,144...65,042,336

G

Rho/Rac guanine nucleotide exchange factor 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ARHGEF2 mRNA

NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646

G

ARF like GTPase 5C

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ARL5C mRNA

NCBI chr10:83,481,540...83,492,915
Ensembl chr10:83,481,540...83,488,406

G

aryl hydrocarbon receptor nuclear translocator 2

increases expression
increases expression

EXP

estradiol 3-benzoate results in increased expression of ARNT2 mRNA; estradiol 3-benzoate results in increased expression of ARNT2 protein
Beta-estradiol-3-benzoate increases expression of Arnt2 mRNA and protein in the hypothalamus

CTD
RGD

PMID:12859947 PMID:12859947

NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997

G

arsenite methyltransferase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of AS3MT mRNA

NCBI chr 1:255,536,879...255,569,245
Ensembl chr 1:255,537,109...255,569,249

G

argininosuccinate lyase

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of ASL promoter

NCBI chr12:32,295,779...32,313,257
Ensembl chr12:32,295,633...32,317,261

G

asparaginase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ASPG mRNA

NCBI chr 6:136,997,832...137,017,417
Ensembl chr 6:136,998,023...137,017,417

G

argininosuccinate synthase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ASS1 mRNA

NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ATP12A mRNA

NCBI chr15:34,559,209...34,583,866
Ensembl chr15:34,559,209...34,583,866

G

ATPase 13A5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ATP13A5 mRNA

NCBI chr11:84,881,196...85,020,597
Ensembl chr11:84,881,230...85,020,593

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

EXP

estradiol 3-benzoate results in increased expression of and results in increased activity of ATP1A1 protein

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATPase phospholipid transporting 8A2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ATP8A2 mRNA

NCBI chr15:37,993,507...38,526,408
Ensembl chr15:38,002,305...38,526,212

G

ATPase phospholipid transporting 8B4 (putative)

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ATP8B4 mRNA

NCBI chr 3:134,008,367...134,212,394
Ensembl chr 3:134,009,580...134,210,260

G

RIKEN cDNA B430306N03 gene

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of B430306N03RIKL mRNA

NCBI chr 9:20,179,219...20,188,163
Ensembl chr 9:20,180,117...20,192,148

G

BAALC binder of MAP3K1 and KLF4

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of BAALC promoter

NCBI chr 7:71,803,640...71,877,608
Ensembl chr 7:71,774,898...71,879,261

G

BRCA1 associated RING domain 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BARD1 mRNA

NCBI chr 9:80,069,960...80,144,167
Ensembl chr 9:80,069,960...80,176,873

G

basic leucine zipper ATF-like transcription factor

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of BATF promoter

NCBI chr 6:111,084,717...111,107,052
Ensembl chr 6:111,084,717...111,107,052

G

basic leucine zipper ATF-like transcription factor 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BATF3 mRNA

NCBI chr13:105,220,782...105,232,365
Ensembl chr13:105,220,390...105,232,369

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of BAX mRNA; estradiol 3-benzoate results in increased expression of BAX protein
Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of BAX mRNA]; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions
increases expression

EXP

Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of BCL2 mRNA]; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of BCL2 protein]
estradiol 3-benzoate results in increased expression of BCL2 mRNA; estradiol 3-benzoate results in increased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

affects expression

EXP

estradiol 3-benzoate affects the expression of BCL2L1 mRNA

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

BCL3, transcription coactivator

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BCL3 mRNA

NCBI chr 1:88,599,321...88,613,555
Ensembl chr 1:88,599,321...88,614,368

G

brain-derived neurotrophic factor

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of BDNF mRNA

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

bestrophin 4

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of BEST4 mRNA

NCBI chr 5:135,858,774...135,865,624
Ensembl chr 5:135,860,018...135,863,707

G

brain expressed, X-linked 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of BEX4 mRNA

NCBI chr X:103,923,609...103,925,041
Ensembl chr X:103,923,338...103,925,496

G

basic helix-loop-helix family, member e22

increases expression

EXP

estradiol 3-benzoate results in increased expression of BHLHE22 mRNA

NCBI chr 2:102,402,622...102,405,732
Ensembl chr 2:102,400,164...102,420,508

G

BH3 interacting domain death agonist

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of BID protein
Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of BID protein]

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

baculoviral IAP repeat-containing 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BIRC3 mRNA

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

bMERB domain containing 1

increases expression

EXP

estradiol 3-benzoate results in increased expression of BMERB1 mRNA

NCBI chr10:2,286,999...2,453,890
Ensembl chr10:2,287,000...2,453,728

G

bone morphogenetic protein 7

decreases expression
multiple interactions

EXP

estradiol 3-benzoate results in decreased expression of BMP7 mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of BMP7 mRNA

NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137

G

BMP-binding endothelial regulator

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BMPER mRNA

NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359

G

BMP/retinoic acid inducible neural specific 3

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of BRINP3 mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BRINP3 mRNA

NCBI chr13:60,964,127...61,397,044
Ensembl chr13:60,966,100...61,397,039

G

bone marrow stromal cell antigen 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BST1 mRNA

NCBI chr14:71,466,179...71,482,671
Ensembl chr14:71,466,180...71,482,647

G

BTB domain containing 3

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of BTBD3 promoter

NCBI chr 3:146,044,053...146,074,189
Ensembl chr 3:146,044,096...146,074,635

G

BTG anti-proliferation factor 4

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of BTG4 mRNA

NCBI chr 8:60,307,090...60,322,167
Ensembl chr 8:60,317,121...60,322,167

G

Bruton tyrosine kinase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BTK mRNA

NCBI chr X:102,016,070...102,055,448
Ensembl chr X:102,016,074...102,055,143

G

B and T lymphocyte associated

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BTLA mRNA

NCBI chr11:69,069,734...69,099,331
Ensembl chr11:69,052,644...69,093,224

G

butyrophilin, subfamily 2, member A2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of BTN2A2 mRNA

NCBI chr17:42,048,842...42,060,650
Ensembl chr17:42,048,842...42,060,650

G

butyrophilin-like 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BTNL9 mRNA

NCBI chr10:33,967,098...33,990,304
Ensembl chr10:33,970,675...33,990,354

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

complement C1q A chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C1QA mRNA

NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732

G

complement C1q B chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C1QB mRNA

NCBI chr 5:154,402,276...154,407,827
Ensembl chr 5:154,402,279...154,407,840

G

complement C1q C chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C1QC mRNA

NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468

G

complement C1r

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C1R mRNA

NCBI chr 4:159,099,013...159,109,770
Ensembl chr 4:159,098,918...159,109,714

G

complement C1s

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C1S mRNA

NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736

G

complement C1s, pseudogene 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C1S-PS1 mRNA

NCBI chr 4:158,744,584...158,746,895

G

complement C2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C2 mRNA

NCBI chr20:3,944,722...3,975,006
Ensembl chr20:3,955,776...3,981,740

G

complement C3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C3 mRNA

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

complement C3a receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C3AR1 mRNA

NCBI chr 4:157,747,419...157,756,609
Ensembl chr 4:157,746,089...157,776,323

G

complement C4A (Rodgers blood group)

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C4A mRNA

NCBI chr20:4,010,306...4,024,707

G

complement C4B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C4B mRNA

NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,201,961...4,216,289

G

complement C5a receptor 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C5AR2 mRNA

NCBI chr 1:86,058,557...86,073,583
Ensembl chr 1:86,057,256...86,061,372

G

complement C6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C6 mRNA

NCBI chr 2:55,573,596...55,648,857
Ensembl chr 2:55,573,653...55,649,120

G

complement C7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of C7 mRNA

NCBI chr 2:55,815,687...55,892,605
Ensembl chr 2:55,816,807...55,892,672

G

carbonic anhydrase 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CAR4 mRNA

NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916

G

calcium binding protein 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CABP4 mRNA

NCBI chr 1:210,857,223...210,872,431
Ensembl chr 1:210,858,133...210,862,632

G

calcium voltage-gated channel auxiliary subunit beta 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CACNB2 promoter

NCBI chr17:82,473,097...82,818,564
Ensembl chr17:82,473,129...82,818,564

G

calcium voltage-gated channel auxiliary subunit gamma 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CACNG6 mRNA

NCBI chr 1:74,648,342...74,663,351
Ensembl chr 1:74,648,063...74,662,753

G

calcyclin binding protein

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CACYBP promoter

NCBI chr13:74,970,917...74,981,298
Ensembl chr13:74,970,923...74,981,505

G

calcium homeostasis modulator family member 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FAM26F mRNA

NCBI chr20:26,638,721...26,640,466
Ensembl chr20:26,638,722...26,640,408

G

cathelicidin antimicrobial peptide

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CAMP mRNA

NCBI chr 8:118,720,184...118,721,998
Ensembl chr 8:118,720,184...118,721,998

G

calpain 8

increases expression

EXP

estradiol 3-benzoate results in increased expression of CAPN8 mRNA

NCBI chr13:96,783,640...96,847,825
Ensembl chr13:96,783,667...96,847,820

G

calpain, small subunit 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CAPNS2 promoter

NCBI chr19:30,277,324...30,278,266

G

caspase recruitment domain family, member 11

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CARD11 mRNA

NCBI chr12:18,735,088...18,872,045
Ensembl chr12:18,735,088...18,872,045

G

caspase recruitment domain family, member 14

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CARD14 mRNA

NCBI chr10:105,064,941...105,100,132
Ensembl chr10:105,064,941...105,100,132

G

caspase 1

multiple interactions
increases cleavage
increases expression

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased cleavage of CASP1 protein; [Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of CASP1 mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CASP1 mRNA
estradiol 3-benzoate results in increased cleavage of CASP1 protein
estradiol 3-benzoate results in increased expression of CASP1 mRNA

PMID:32741896 PMID:39368565

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CASP12 mRNA

NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442

G

caspase 3

multiple interactions

EXP

estradiol 3-benzoate results in increased expression of and results in increased activity of CASP3 protein; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of and results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of CASP8 mRNA
estradiol 3-benzoate results in increased expression of and results in increased activity of CASP8 protein; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of and results in increased activity of CASP8 protein]; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of CASP8 mRNA]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions
increases expression

EXP

estradiol 3-benzoate results in increased expression of and results in increased activity of CASP9 protein; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of and results in increased activity of CASP9 protein]; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of CASP9 mRNA]

Ensembl chr 5:159,391,188...159,409,648

G

Cas scaffold protein family member 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CASS4 mRNA

NCBI chr 3:181,580,954...181,620,945
Ensembl chr 3:181,581,902...181,620,945

G

catalase

multiple interactions
decreases expression

EXP

Quercetin inhibits the reaction [estradiol 3-benzoate results in decreased expression of CAT protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

coiled-coil domain containing 162

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CCDC162 mRNA

NCBI chr20:46,627,277...46,820,216
Ensembl chr20:46,627,277...46,818,249

G

coiled-coil domain containing 170

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCDC170 mRNA

NCBI chr 1:43,351,010...43,458,192
Ensembl chr 1:43,345,378...43,644,463

G

coiled-coil domain containing 80

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCDC80 mRNA

NCBI chr11:69,191,188...69,224,844
Ensembl chr11:69,191,189...69,224,844

G

coiled-coil domain containing 82

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCDC82 mRNA

NCBI chr 8:18,509,293...18,665,008
Ensembl chr 8:18,509,382...18,550,529

G

C-C motif chemokine ligand 11

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL11 mRNA

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575

G

C-C motif chemokine ligand 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL12 mRNA

NCBI chr10:67,567,876...67,569,426
Ensembl chr10:67,567,876...67,569,426

G

C-C motif chemokine ligand 19

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL19 mRNA

NCBI chr 5:61,759,220...61,761,164
Ensembl chr 5:61,759,220...61,772,022

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of CCL2 mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL2 mRNA; Dietary Fats inhibits the reaction [estradiol 3-benzoate results in increased expression of CCL2 mRNA]

PMID:32741896 PMID:39368565

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 28

multiple interactions
increases expression

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL28 mRNA
estradiol 3-benzoate results in increased expression of CCL28 mRNA

NCBI chr 2:53,334,071...53,358,709
Ensembl chr 2:53,334,071...53,358,709

G

C-C motif chemokine ligand 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL3 mRNA

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL4 mRNA

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL5 mRNA

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

C-C motif chemokine ligand 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL7 mRNA

NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947

G

C-C motif chemokine ligand 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCL6 mRNA

NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877

G

cellular communication network factor 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cellular communication network factor 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of WISP2 mRNA

NCBI chr 3:172,910,670...172,922,064
Ensembl chr 3:172,910,681...172,922,062

G

cyclin A2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin B2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCNB2 mRNA

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

C-C motif chemokine receptor 10

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CCR10 promoter

NCBI chr10:86,608,836...86,611,273
Ensembl chr10:86,608,836...86,611,273

G

C-C motif chemokine receptor 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCR3 mRNA

NCBI chr 8:132,463,533...132,511,601
Ensembl chr 8:132,463,788...132,511,593

G

C-C motif chemokine receptor 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCR5 mRNA

NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:132,629,683...132,637,594

G

C-C motif chemokine receptor 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCR6 mRNA

NCBI chr 1:55,022,037...55,055,857
Ensembl chr 1:55,021,833...55,046,059

G

C-C motif chemokine receptor like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CCRL2 mRNA

NCBI chr 8:119,912,671...119,915,313
Ensembl chr 8:119,911,288...119,922,380

G

CD163 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD163 mRNA

NCBI chr 4:158,770,751...158,804,146
Ensembl chr 4:158,770,749...158,804,146

G

CD177 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD177 mRNA

NCBI chr 1:89,467,926...89,488,490
Ensembl chr 1:89,467,926...89,488,443

G

CD19 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD19 mRNA

NCBI chr 1:190,417,853...190,424,494
Ensembl chr 1:190,417,853...190,424,355

G

CD200 receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD200R1 mRNA

NCBI chr11:69,392,943...69,427,213
Ensembl chr11:69,392,975...69,427,128

G

CD22 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD22 mRNA

NCBI chr 1:95,243,785...95,270,430
Ensembl chr 1:95,244,868...95,259,730

G

CD226 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD226 mRNA

NCBI chr18:84,723,330...84,819,836
Ensembl chr18:84,725,242...84,819,835

G

CD274 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD274 mRNA

NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951

G

Cd300a molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD300A mRNA

NCBI chr10:100,428,826...100,441,693
Ensembl chr10:100,428,826...100,442,958

G

CD300C molecule 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD300C2 mRNA

NCBI chr10:100,752,301...100,757,549
Ensembl chr10:100,752,621...100,757,332

G

Cd300 molecule-like family member D

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD300LD mRNA

NCBI chr10:100,581,960...100,614,868
Ensembl chr10:100,581,960...100,614,858

G

Cd300 molecule-like family member E

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD300LE mRNA

NCBI chr10:100,770,070...100,779,293
Ensembl chr10:100,770,030...100,779,293

G

Cd300 molecule-like family member F

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD300LF mRNA

NCBI chr10:100,858,924...100,875,111
Ensembl chr10:100,858,924...100,875,022

G

CD36 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142

G

CD3 epsilon subunit of T-cell receptor complex

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD3E mRNA

NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876

G

Cd4 molecule

multiple interactions
increases expression

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of CD4 mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD4 mRNA
estradiol 3-benzoate results in increased expression of CD4 mRNA

PMID:32741896 PMID:39368565

NCBI chr 4:159,355,147...159,381,636
Ensembl chr 4:159,356,337...159,381,461

G

Cd48 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD48 mRNA

NCBI chr13:86,717,960...86,741,540
Ensembl chr13:86,717,961...86,742,942

G

Cd5 molecule

increases expression

EXP

estradiol 3-benzoate results in increased expression of CD5 mRNA

NCBI chr 1:216,790,245...216,811,209
Ensembl chr 1:216,790,245...216,811,209

G

CD52 molecule

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CD52 promoter

NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086

G

Cd53 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD53 mRNA

NCBI chr 2:197,040,369...197,087,925
Ensembl chr 2:197,040,369...197,218,593

G

Cd5 molecule-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD5L mRNA

NCBI chr 2:175,088,915...175,099,928
Ensembl chr 2:175,088,884...175,099,926

G

Cd68 molecule

multiple interactions

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of CD68 mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD68 mRNA

PMID:32741896 PMID:39368565

NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540

G

Cd72 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD72 mRNA

NCBI chr 5:62,493,155...62,500,779
Ensembl chr 5:62,493,161...62,500,519

G

CD74 molecule

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CD74 mRNA

NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410

G

CD8 subunit alpha

multiple interactions

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of CD8A mRNA

NCBI chr 4:104,924,116...104,928,353
Ensembl chr 4:104,900,833...104,928,358

G

cell division cycle associated 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CDCA3 mRNA

NCBI chr 4:159,321,203...159,325,072
Ensembl chr 4:159,321,014...159,325,068

G

cadherin 15

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CDH15 mRNA

NCBI chr19:67,812,169...67,834,986
Ensembl chr19:67,812,164...67,834,985

G

cadherin 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CDH7 mRNA

NCBI chr13:27,186,223...27,336,076
Ensembl chr13:27,187,257...27,336,023

G

cyclin-dependent kinase-like 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CDKL4 mRNA

NCBI chr 6:20,202,047...20,244,821
Ensembl chr 6:20,217,916...20,244,002

G

CDP-diacylglycerol synthase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CDS1 mRNA

NCBI chr14:8,126,678...8,187,243
Ensembl chr14:8,124,838...8,187,218

G

CEA cell adhesion molecule 19

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CEACAM19 mRNA

NCBI chr 1:88,670,054...88,678,900
Ensembl chr 1:88,670,054...88,678,874

G

CCAAT/enhancer binding protein epsilon

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CEBPE mRNA

NCBI chr15:32,139,716...32,141,476
Ensembl chr15:32,139,716...32,141,476

G

CUGBP, Elav-like family member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CELF2 mRNA

NCBI chr17:75,813,928...76,639,300
Ensembl chr17:75,813,704...76,636,362

G

CUGBP, Elav-like family member 4

increases expression

EXP

estradiol 3-benzoate results in increased expression of CELF4 mRNA

NCBI chr18:17,061,284...17,339,747
Ensembl chr18:17,061,293...17,339,571

G

cadherin, EGF LAG seven-pass G-type receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CELSR1 mRNA

NCBI chr 7:118,867,450...119,004,859
Ensembl chr 7:118,867,450...119,004,856

G

centromere protein A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein F

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

centromere protein T

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CENPT mRNA

NCBI chr19:50,644,548...50,651,048
Ensembl chr19:50,634,368...50,651,037

G

centromere protein W

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CENPW mRNA

NCBI chr 1:29,353,939...29,359,109
Ensembl chr 1:29,353,970...29,359,109

G

cilia and flagella associated protein 210

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CFAP210 mRNA

NCBI chr 3:74,928,368...74,962,508
Ensembl chr 3:74,927,880...74,962,497

G

complement factor B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CFB mRNA

NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,955,776...3,981,740

G

cripto, FRL-1, cryptic family 1

increases expression

EXP

estradiol 3-benzoate results in increased expression of CFC1 mRNA

NCBI chr 9:44,234,997...44,247,846
Ensembl chr 9:44,235,020...44,247,845

G

complement factor I

increases methylation
multiple interactions

EXP

estradiol 3-benzoate results in increased methylation of CFI promoter
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CFI mRNA

PMID:27415467 PMID:32741896

NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786

G

complement factor properdin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CFP mRNA

NCBI chr X:3,715,551...3,721,113
Ensembl chr X:3,710,425...3,721,112

G

glycoprotein hormones, alpha polypeptide

decreases expression

ISO

estradiol 3-benzoate results in decreased expression of CGA mRNA

NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:54,235,019...54,295,464

G

chondroadherin

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CHAD promoter

NCBI chr10:80,009,045...80,012,816
Ensembl chr10:80,008,767...80,012,816

G

chromogranin B

increases expression

EXP

estradiol 3-benzoate results in increased expression of CHGB mRNA

NCBI chr 3:140,496,712...140,510,057
Ensembl chr 3:140,495,951...140,510,054

G

chitinase 3 like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CHI3L1 mRNA

NCBI chr13:48,193,839...48,201,822
Ensembl chr13:48,193,800...48,201,825

G

chromatin modifying protein 4B-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CHMP4BL1 mRNA

NCBI chr 4:69,016,565...69,017,614
Ensembl chr 4:69,016,527...69,017,617

G

calcineurin-like EF hand protein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CHP2 mRNA

NCBI chr 1:186,189,090...186,203,663
Ensembl chr 1:186,185,151...186,203,667

G

chordin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CHRD mRNA

NCBI chr11:93,676,400...93,685,584
Ensembl chr11:93,676,400...93,685,278

G

cholinergic receptor nicotinic alpha 3 subunit

increases expression

EXP

estradiol 3-benzoate results in increased expression of CHRNA3 mRNA

NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:64,297,755...64,311,412

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CHRNB4 mRNA

NCBI chr 8:64,312,644...64,333,319
Ensembl chr 8:64,313,669...64,333,248

G

carbohydrate sulfotransferase 14

decreases methylation
increases expression

EXP

estradiol 3-benzoate results in decreased methylation of CHST14 promoter
estradiol 3-benzoate results in increased expression of CHST14 mRNA

NCBI chr 3:126,370,348...126,372,405
Ensembl chr 3:126,370,348...126,372,777

G

class II, major histocompatibility complex, transactivator

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CIITA mRNA

NCBI chr10:5,646,854...5,694,393
Ensembl chr10:5,647,085...5,694,342

G

cytoskeleton associated protein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CKAP2 mRNA

NCBI chr16:76,542,114...76,567,297
Ensembl chr16:76,542,104...76,567,352

G

cytoskeleton associated protein 2-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CKAP2L mRNA

NCBI chr 3:136,950,390...136,977,503
Ensembl chr 3:136,950,381...136,977,565

G

creatine kinase, mitochondrial 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CKMT1 mRNA

NCBI chr 3:128,783,408...128,789,485
Ensembl chr 3:128,783,597...128,789,483

G

chloride channel accessory 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLCA1 mRNA

NCBI chr 2:236,599,022...236,624,714
Ensembl chr 2:236,599,022...236,624,714

G

chloride channel accessory 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLCA2 mRNA

NCBI chr 2:236,655,419...236,682,669
Ensembl chr 2:236,639,545...236,685,129

G

chloride channel calcium activated 4-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLCA4L mRNA

NCBI chr 2:236,486,485...236,506,483
Ensembl chr 2:236,486,485...236,506,483

G

chloride channel accessory 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLCA5 mRNA

NCBI chr 2:236,456,923...236,479,220
Ensembl chr 2:236,456,929...236,479,220

G

chloride channel CLIC-like 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of SPAG11A mRNA

NCBI chr 2:198,984,455...199,015,015
Ensembl chr 2:198,984,495...199,015,014

G

chloride voltage-gated channel Kb

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CLCNKB mRNA

NCBI chr 5:158,993,073...159,005,618
Ensembl chr 5:158,993,074...159,004,900

G

claudin 10

increases expression

EXP

estradiol 3-benzoate results in increased expression of CLDN10 mRNA

NCBI chr15:102,269,858...102,361,589
Ensembl chr15:102,269,858...102,361,589

G

C-type lectin domain containing 10A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC10A mRNA

NCBI chr10:55,374,914...55,379,110
Ensembl chr10:55,374,887...55,379,108

G

C-type lectin domain family 12, member A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC12A mRNA

NCBI chr 4:164,484,162...164,502,793
Ensembl chr 4:164,484,162...164,510,233

G

C-type lectin domain family 4, member A1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC4A1 mRNA

NCBI chr 4:157,845,811...157,857,926
Ensembl chr 4:157,845,752...157,858,273

G

C-type lectin domain family 4, member A2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC4A2 mRNA

NCBI chr 4:157,934,342...157,993,595
Ensembl chr 4:157,934,357...157,993,588

G

C-type lectin domain family 4, member A3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC4A mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC4A3 mRNA

NCBI chr 4:157,885,899...157,896,728
Ensembl chr 4:157,885,895...157,896,727

G

C-type lectin domain family 4, member B2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC4B2 mRNA

NCBI chr 4:158,148,434...158,171,933
Ensembl chr 4:158,148,314...158,172,249

G

C-type lectin domain family 4, member D

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC4D mRNA

NCBI chr 4:158,275,287...158,286,978
Ensembl chr 4:158,275,341...158,287,055

G

C-type lectin domain family 4, member E

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC4E mRNA

NCBI chr 4:158,292,624...158,298,607
Ensembl chr 4:158,293,311...158,298,467

G

C-type lectin domain containing 7A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC7A mRNA

NCBI chr 4:164,588,737...164,599,953
Ensembl chr 4:164,588,754...164,599,919

G

C-type lectin domain containing 9A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLEC9A mRNA

NCBI chr 4:164,546,323...164,561,380
Ensembl chr 4:164,546,311...164,561,380

G

claspin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLSPN mRNA

NCBI chr 5:144,134,619...144,169,531
Ensembl chr 5:144,134,632...144,169,530

G

collectrin, amino acid transport regulator

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CLTRN promoter

NCBI chr X:33,993,825...34,027,124
Ensembl chr X:33,993,825...34,027,181

G

clusterin

affects expression

EXP

estradiol 3-benzoate affects the expression of CLU mRNA

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860

G

calaxin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CLXN mRNA

NCBI chr11:99,410,925...99,500,713
Ensembl chr11:99,487,448...99,500,760

G

carboxymethylenebutenolidase homolog

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CMBL mRNA

NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880

G

chemerin chemokine-like receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CMKLR1 mRNA

NCBI chr12:48,634,929...48,687,833
Ensembl chr12:48,634,003...48,691,458

G

cytidine/uridine monophosphate kinase 2

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of CMPK2 mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CMPK2 mRNA

NCBI chr 6:48,802,150...48,813,652
Ensembl chr 6:48,802,321...48,813,652

G

CKLF-like MARVEL transmembrane domain containing 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CMTM3 mRNA

NCBI chr19:629,000...637,152
Ensembl chr19:628,895...636,225

G

carnosine dipeptidase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CNDP1 mRNA

NCBI chr18:80,254,499...80,305,845
Ensembl chr18:80,255,784...80,282,643

G

cyclic nucleotide gated channel subunit alpha 1

increases expression

EXP

estradiol 3-benzoate results in increased expression of CNGA1 protein

NCBI chr14:35,920,948...35,959,065
Ensembl chr14:35,926,854...35,959,056

G

calponin 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CNN2 mRNA

NCBI chr 7:10,363,141...10,370,312
Ensembl chr 7:10,363,102...10,370,312

G

cannabinoid receptor 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CNR2 mRNA

NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961

G

contactin associated protein 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CNTNAP1 promoter

NCBI chr10:86,610,140...86,625,896
Ensembl chr10:86,611,890...86,631,730

G

Coenzyme A synthase

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of COASY promoter

NCBI chr10:86,514,850...86,519,130
Ensembl chr10:86,514,874...86,519,130

G

collagen type XV alpha 1 chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of COL15A1 mRNA

NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:66,297,461...66,403,170

G

collagen type III alpha 1 chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of COL3A1 mRNA

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type V alpha 1 chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of COL5A1 mRNA

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020

G

collagen type VI alpha 2 chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of COL6A2 mRNA

NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,265...12,057,042

G

collectin sub-family member 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of COLEC12 mRNA

NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297

G

corin, serine peptidase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CORIN mRNA

NCBI chr14:36,034,613...36,264,671
Ensembl chr14:36,034,993...36,264,649

G

cytoplasmic polyadenylation element binding protein 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CPEB3 mRNA

NCBI chr 1:244,161,690...244,343,765
Ensembl chr 1:244,161,690...244,343,561

G

copine 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CPNE7 mRNA

NCBI chr19:68,072,165...68,091,197
Ensembl chr19:68,074,545...68,091,197

G

carboxypeptidase Z

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CPZ mRNA

NCBI chr14:79,448,242...79,471,557
Ensembl chr14:79,448,139...79,471,556

G

cAMP responsive element binding protein 3-like 4

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of CREB3L4 promoter

NCBI chr 2:177,987,981...177,994,568
Ensembl chr 2:177,987,981...177,993,485

G

cAMP responsive element binding protein 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CREB5 mRNA

NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793

G

corticotropin releasing hormone

increases expression

EXP

estradiol 3-benzoate results in increased expression of CRH mRNA

NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386

G

collapsin response mediator protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CRMP1 mRNA

NCBI chr14:77,734,675...77,780,916
Ensembl chr14:77,734,675...77,780,916

G

crystallin, mu

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CRYM mRNA

NCBI chr 1:183,991,752...184,006,923
Ensembl chr 1:183,991,745...184,006,962

G

colony stimulating factor 1 receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CSF1R mRNA

NCBI chr18:56,834,152...56,860,804
Ensembl chr18:56,817,049...56,860,806

G

colony stimulating factor 3 receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CSF3R mRNA

NCBI chr 5:143,583,126...143,604,382
Ensembl chr 5:143,583,213...143,602,411

G

chondroitin sulfate N-acetylgalactosaminyltransferase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CSGALNACT1 mRNA

NCBI chr16:25,761,946...26,097,306
Ensembl chr16:26,002,530...26,096,065

G

cystatin F

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CST7 mRNA

NCBI chr 3:159,857,221...159,865,987
Ensembl chr 3:159,857,052...159,866,919

G

cystatin A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CSTA mRNA

NCBI chr11:78,125,813...78,136,818
Ensembl chr11:78,125,800...78,136,822

G

cystathionine gamma-lyase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CTH mRNA

NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066

G

chymotrypsin C

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CTRC mRNA

NCBI chr 5:159,430,333...159,439,557
Ensembl chr 5:159,430,335...159,439,545

G

cathepsin S

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CTSS mRNA

NCBI chr 2:185,775,316...185,803,440
Ensembl chr 2:185,775,296...185,803,440

G

cathepsin W

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CTSW mRNA

NCBI chr 1:212,201,904...212,208,028
Ensembl chr 1:212,201,904...212,205,292

G

C-X-C motif chemokine ligand 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCL1 mRNA

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 13

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCL13 mRNA

NCBI chr14:13,912,858...13,917,920
Ensembl chr14:13,912,858...13,917,920

G

C-X-C motif chemokine ligand 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCL2 mRNA

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCL3 mRNA

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

C-X-C motif chemokine ligand 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCL9 mRNA

NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299

G

C-X-C motif chemokine receptor 2

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of CXCR2 mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCR2 mRNA

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602

G

C-X-C motif chemokine receptor 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCR4 mRNA

NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459

G

C-X-C motif chemokine receptor 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CXCR6 mRNA

NCBI chr 8:132,311,834...132,317,001
Ensembl chr 8:132,306,600...132,322,498

G

cytochrome b-245 alpha chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYBA mRNA

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214

G

cytochrome b-245 beta chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYBB mRNA

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytoglobin

multiple interactions

EXP

estradiol 3-benzoate promotes the reaction [Thioacetamide results in increased expression of CYGB mRNA]

NCBI chr10:102,376,506...102,386,272
Ensembl chr10:102,376,507...102,386,272

G

chymosin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PGA5 mRNA

NCBI chr 2:197,516,947...197,527,307
Ensembl chr 2:197,516,950...197,527,837

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of CYP17A1 protein

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

affects response to substance

ISO

CYP19A1 protein affects the susceptibility to estradiol 3-benzoate

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases expression
multiple interactions

EXP

estradiol 3-benzoate results in decreased expression of CYP1B1 protein
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP1B1 mRNA

PMID:24752506 PMID:32741896

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CYP26A1 mRNA

NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657

G

cytochrome P450, family 2, subfamily a, polypeptide 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of CYP2A1 protein

NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:91,359,272...91,389,730

G

cytochrome P450, family 2, subfamily c, polypeptide 13

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of CYP2C13 mRNA

NCBI chr 1:248,706,787...248,787,239
Ensembl chr 1:248,706,788...248,787,210

G

cytochrome P450, family 2, subfamily c, polypeptide 22

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of CYP2C22 mRNA

NCBI chr 1:248,941,143...248,980,767
Ensembl chr 1:248,904,062...248,971,182

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP3A9 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytohesin 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYTH4 mRNA

NCBI chr 7:112,032,711...112,057,204
Ensembl chr 7:112,032,775...112,057,204

G

DDB1 and CUL4 associated factor 12-like 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of DCAF12L1 mRNA

NCBI chr X:128,572,969...128,576,588
Ensembl chr X:128,572,811...128,577,222

G

doublecortin-like kinase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DCLK1 mRNA

NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:141,571,983...141,861,090

G

DDAH family member 2, ADMA-independent

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of DDAH2 promoter

NCBI chr20:3,766,115...3,769,161
Ensembl chr20:3,766,120...3,769,183

G

DEXD/H-box helicase 60

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DDX60 mRNA

NCBI chr16:33,087,940...33,208,843
Ensembl chr16:33,087,988...33,208,839

G

defensin alpha 31

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DEFA10 mRNA

NCBI chr16:77,216,346...77,218,685
Ensembl chr16:77,216,346...77,217,475

G

defensin alpha 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DEFA5 mRNA

NCBI chr16:77,044,994...77,047,318
Ensembl chr16:77,044,994...77,047,318

G

defensin beta 37

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of DEFB37 mRNA

NCBI chr16:77,485,949...77,499,215
Ensembl chr16:77,485,949...77,499,215

G

defensin beta 39

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of DEFB39 mRNA

NCBI chr16:77,442,770...77,446,574
Ensembl chr16:77,442,770...77,446,718

G

delta(4)-desaturase, sphingolipid 2

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of DEGS2 mRNA

NCBI chr 6:133,360,449...133,377,677
Ensembl chr 6:133,360,457...133,364,422

G

DEP domain containing 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DEPDC1 mRNA

NCBI chr 2:251,343,250...251,376,709
Ensembl chr 2:251,343,281...251,376,709

G

DEP domain containing 1B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DEPDC1B mRNA

NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:41,624,922...41,697,202

G

derlin 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of DERL3 mRNA

NCBI chr20:12,753,926...12,766,478
Ensembl chr20:12,762,981...12,766,477

G

deuterosome assembly protein 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of DEUP1 promoter

NCBI chr 8:20,661,687...20,724,083
Ensembl chr 8:20,661,689...20,723,585

G

dehydrogenase/reductase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of DHRS2 mRNA

NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588

G

DEXH-box helicase 58

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DHX58 mRNA

NCBI chr10:86,120,677...86,132,095
Ensembl chr10:86,120,677...86,131,844

G

diaphanous-related formin 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DIAPH3 mRNA

NCBI chr15:68,951,992...69,421,623
Ensembl chr15:68,951,989...69,421,552

G

distal-less homeobox 4

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of DLX4 promoter

NCBI chr10:80,581,878...80,587,272
Ensembl chr10:80,582,303...80,587,294

G

deleted in malignant brain tumors 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DMBT1 mRNA

NCBI chr 1:195,047,702...195,126,704
Ensembl chr 1:195,047,713...195,126,704

G

deoxyribonuclease 2 beta

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of DNASE2B promoter

NCBI chr 2:238,131,182...238,168,041
Ensembl chr 2:238,131,185...238,146,558

G

deoxynucleotidyltransferase, terminal, interacting protein 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of DNTTIP1 promoter

NCBI chr 3:173,901,070...173,924,742
Ensembl chr 3:173,900,945...173,925,098

G

dedicator of cytokinesis 11

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DOCK11 mRNA

NCBI chr X:119,997,523...120,180,643
Ensembl chr X:119,997,552...120,180,634

G

dedicator of cytokinesis 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DOCK2 mRNA

NCBI chr10:19,331,412...19,748,987
Ensembl chr10:19,331,412...19,748,969

G

dedicator of cytokinesis 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DOCK4 mRNA

NCBI chr 6:63,240,050...63,629,772
Ensembl chr 6:63,240,136...63,629,772

G

docking protein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DOK2 mRNA

NCBI chr15:52,237,046...52,251,091
Ensembl chr15:52,236,900...52,251,074

G

docking protein 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DOK3 mRNA

NCBI chr17:9,114,763...9,121,781
Ensembl chr17:9,114,762...9,120,335

G

dipeptidase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DPEP2 mRNA

NCBI chr19:50,795,322...50,806,320
Ensembl chr19:50,795,327...50,801,757
Ensembl chr19:50,795,327...50,801,757

G

dipeptidylpeptidase 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DPP4 mRNA

NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422

G

dopamine receptor D2

multiple interactions

EXP

estradiol 3-benzoate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]

NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339

G

desmocollin 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of DSC1 mRNA

NCBI chr18:11,774,711...11,831,868
Ensembl chr18:11,775,010...11,803,522

G

desmocollin 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of DSC2 promoter

NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,725,466...11,757,466

G

desmocollin 3

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of DSC3 promoter

NCBI chr18:11,654,833...11,688,871
Ensembl chr18:11,653,832...11,688,871

G

deltex E3 ubiquitin ligase 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DTX4 mRNA

NCBI chr 1:218,882,391...218,969,837
Ensembl chr 1:218,832,284...218,917,130

G

dual oxidase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DUOX1 mRNA

NCBI chr 3:129,714,125...129,749,186
Ensembl chr 3:129,714,149...129,749,187

G

dual oxidase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DUOX2 mRNA

NCBI chr 3:129,680,543...129,698,886
Ensembl chr 3:129,680,546...129,699,203

G

dual oxidase maturation factor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DUOXA1 mRNA

NCBI chr 3:129,703,416...129,714,110
Ensembl chr 3:129,703,416...129,706,829

G

dual oxidase maturation factor 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DUOXA2 mRNA

NCBI chr 3:129,698,938...129,702,656
Ensembl chr 3:129,698,092...129,702,656

G

dual specificity phosphatase 18

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of DUSP18 mRNA

NCBI chr14:83,013,850...83,035,168
Ensembl chr14:83,011,014...83,056,929

G

E2F transcription factor 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of E2F7 mRNA

NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055

G

E2F transcription factor 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of E2F8 mRNA

NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009

G

EBF transcription factor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EBF1 mRNA

NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702

G

EBF transcription factor 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EBF3 mRNA

NCBI chr 1:201,426,446...201,544,444
Ensembl chr 1:201,426,450...201,544,305

G

Epstein-Barr virus induced 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EBI3 mRNA

NCBI chr 9:861,441...874,731
Ensembl chr 9:870,792...874,973

G

epithelial cell transforming 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ECT2 mRNA

NCBI chr 2:111,904,522...111,966,786
Ensembl chr 2:111,904,522...111,966,626

G

EF-hand calcium binding domain 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of EFCAB12 mRNA

NCBI chr 4:150,541,983...150,563,973
Ensembl chr 4:150,541,982...150,563,286

G

ephrin B2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EFNB2 mRNA

NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208

G

epidermal growth factor

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of EGF mRNA

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

increases expression

EXP

estradiol 3-benzoate results in increased expression of EGFR protein

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EGR2 mRNA

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of EHHADH mRNA

NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662

G

eukaryotic translation initiation factor 4E family member 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EIF4E3 mRNA

NCBI chr 4:133,709,802...133,858,398
Ensembl chr 4:133,625,768...133,885,647

G

endosome-lysosome associated apoptosis and autophagy regulator family member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ELAPOR2 mRNA

NCBI chr 4:25,565,298...25,760,684
Ensembl chr 4:25,568,122...25,760,684

G

ELAV like RNA binding protein 2

increases expression

EXP

estradiol 3-benzoate results in increased expression of ELAVL2 mRNA

NCBI chr 5:111,076,705...111,202,341
Ensembl chr 5:111,076,705...111,224,918

G

E74 like ETS transcription factor 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ELF5 mRNA

NCBI chr 3:110,264,460...110,291,926
Ensembl chr 3:110,252,797...110,291,926

G

ELMO domain containing 1

decreases expression
multiple interactions

EXP

estradiol 3-benzoate results in decreased expression of ELMOD1 mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ELMOD1 mRNA

NCBI chr 8:63,194,539...63,251,526
Ensembl chr 8:63,137,295...63,251,322

G

ectonucleoside triphosphate diphosphohydrolase 3

increases expression

EXP

estradiol 3-benzoate results in increased expression of ENTPD3 mRNA

NCBI chr 8:129,124,540...129,155,528
Ensembl chr 8:129,124,709...129,156,252

G

ectonucleoside triphosphate diphosphohydrolase 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ENTPD8 mRNA

NCBI chr 3:28,283,392...28,295,686
Ensembl chr 3:28,285,777...28,293,686

G

eomesodermin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EOMES mRNA

NCBI chr 8:127,059,215...127,067,070
Ensembl chr 8:127,059,215...127,067,070

G

EPH receptor A5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EPHA5 mRNA

NCBI chr14:24,007,400...24,374,854
Ensembl chr14:24,008,122...24,374,848

G

epoxide hydrolase 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of EPHX1 protein

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

epithelial stromal interaction 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EPSTI1 mRNA

NCBI chr15:59,692,712...59,791,376
Ensembl chr15:59,693,142...59,791,380

G

glutamate-rich 5

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of ERICH5 mRNA

NCBI chr 7:67,538,154...67,569,433
Ensembl chr 7:67,536,588...67,563,989

G

endoplasmic reticulum protein 27

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ERP27 mRNA

NCBI chr 4:171,535,845...171,552,848
Ensembl chr 4:171,535,847...171,553,072

G

estrogen receptor 1

affects binding
multiple interactions
increases expression
decreases expression
increases methylation
affects expression

ISO
EXP

estradiol 3-benzoate binds to ESR1 protein
methyl palmitate inhibits the reaction [estradiol 3-benzoate results in increased expression of ESR1 protein]
estradiol 3-benzoate results in increased expression of ESR1 mRNA; estradiol 3-benzoate results in increased expression of ESR1 protein
estradiol 3-benzoate results in decreased expression of ESR1; estradiol 3-benzoate results in decreased expression of ESR1 protein
estradiol 3-benzoate results in increased methylation of ESR1 exon; estradiol 3-benzoate results in increased methylation of ESR1 intron
estradiol 3-benzoate affects the expression of ESR1 mRNA

PMID:11162928 PMID:15375486 PMID:15716488 PMID:15778002 PMID:15925091 More...

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

affects expression
increases expression
decreases expression

EXP

estradiol 3-benzoate affects the expression of ESR2 mRNA
estradiol 3-benzoate results in increased expression of ESR2 mRNA
estradiol 3-benzoate results in decreased expression of ESR2; estradiol 3-benzoate results in decreased expression of ESR2 mRNA

PMID:15375486 PMID:19350480 PMID:24352099 PMID:27830003

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

ETS proto-oncogene 1, transcription factor

multiple interactions
increases expression

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of ETS1 mRNA; [Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of ETS1 protein; Dietary Fats promotes the reaction [estradiol 3-benzoate results in increased expression of ETS1 protein]
estradiol 3-benzoate results in increased expression of ETS1 mRNA; estradiol 3-benzoate results in increased expression of ETS1 protein

NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021

G

ecotropic viral integration site 2A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EVI2A mRNA

NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516

G

ecotropic viral integration site 2B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EVI2B mRNA

NCBI chr10:64,970,659...64,972,277
Ensembl chr10:64,964,719...64,979,417

G

exocyst complex component 3-like 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of EXOC3L4 mRNA

NCBI chr 6:136,273,857...136,287,877
Ensembl chr 6:136,273,854...136,287,881

G

coagulation factor X

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of F10 mRNA

NCBI chr16:83,170,973...83,190,280
Ensembl chr16:83,170,977...83,190,280

G

F11 receptor

multiple interactions
increases expression

ISO

fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased expression of F11R mRNA]; fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased expression of F11R protein]
estradiol 3-benzoate results in increased expression of F11R mRNA; estradiol 3-benzoate results in increased expression of F11R protein

NCBI chr13:86,406,229...86,429,819
Ensembl chr13:86,406,218...86,429,816

G

Fas apoptotic inhibitory molecule 2

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of FAIM2 promoter

NCBI chr 7:132,512,095...132,539,192
Ensembl chr 7:132,512,210...132,538,026

G

family with sequence similarity 163, member B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FAM163B mRNA

NCBI chr 3:30,834,145...30,865,802
Ensembl chr 3:30,834,146...30,864,530

G

family with sequence similarity 171, member B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FAM171B mRNA

NCBI chr 3:89,337,566...89,392,973
Ensembl chr 3:89,337,661...89,392,971

G

family with sequence similarity 229, member B

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of FAM229B promoter

NCBI chr20:44,093,492...44,106,871
Ensembl chr20:44,093,493...44,106,871

G

FAM3 metabolism regulating signaling molecule B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FAM3B mRNA

NCBI chr11:50,300,926...50,333,296
Ensembl chr11:50,300,926...50,347,339

G

family with sequence similarity 83, member D

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of FAM83D mRNA

NCBI chr 3:167,841,748...167,861,062
Ensembl chr 3:167,841,791...167,861,061

G

family with sequence similarity 89, member A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FAM89A mRNA

NCBI chr19:69,607,391...69,620,019
Ensembl chr19:69,607,391...69,620,019

G

Fas cell surface death receptor

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of FAS mRNA; estradiol 3-benzoate results in increased expression of FAS protein
Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of FAS mRNA]; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of FAS protein]

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of FASLG mRNA; estradiol 3-benzoate results in increased expression of FASLG protein
Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of FASLG mRNA]; Quercetin inhibits the reaction [estradiol 3-benzoate results in increased expression of FASLG protein]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fibulin 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FBLN1 mRNA

NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965

G

F-box protein 16

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of FBXO16 mRNA

NCBI chr15:43,667,207...43,717,096
Ensembl chr15:43,667,855...43,734,346

G

F-box protein 6

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of FBXO6 promoter

NCBI chr 5:163,859,909...163,865,693
Ensembl chr 5:163,859,916...163,865,574

G

Fc epsilon receptor Ig

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCER1G mRNA

NCBI chr13:86,181,908...86,186,766
Ensembl chr13:86,181,908...86,186,859

G

Fc epsilon receptor II

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCER2 mRNA

NCBI chr12:6,540,697...6,552,364
Ensembl chr12:6,540,703...6,549,374

G

Fc fragment of IgG binding protein-like 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of FCGBPL1 mRNA

NCBI chr 1:92,552,363...92,590,377
Ensembl chr 1:92,552,363...92,590,374

G

Fc gamma receptor 1A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCGR1A mRNA

NCBI chr 2:186,539,941...186,548,941
Ensembl chr 2:186,539,942...186,548,858

G

Fc gamma receptor 2A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCGR2A mRNA

NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394
Ensembl chr13:85,855,437...85,864,394

G

Fc gamma receptor 2B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCGR2B mRNA

NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517

G

ficolin B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCNB mRNA

NCBI chr 3:31,791,750...31,800,188
Ensembl chr 3:31,791,750...31,800,188

G

Fc receptor-like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCRL2 mRNA

NCBI chr 2:174,992,226...175,005,177
Ensembl chr 2:174,992,226...175,004,967

G

Fc receptor-like 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FCRL5 mRNA

NCBI chr 2:175,179,630...175,211,180
Ensembl chr 2:175,179,690...175,211,039

G

FERM domain containing kindlin 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FERMT3 mRNA

NCBI chr 1:213,618,691...213,636,889
Ensembl chr 1:213,618,208...213,636,273

G

free fatty acid receptor 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FFAR4 mRNA

NCBI chr 1:245,286,009...245,304,029
Ensembl chr 1:245,285,883...245,304,031

G

FYVE, RhoGEF and PH domain containing 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FGD2 mRNA

NCBI chr20:7,426,407...7,443,207
Ensembl chr20:7,426,414...7,443,207

G

fibrinogen gamma chain

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FGG mRNA

NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:170,652,234...170,661,170

G

fibronectin leucine rich transmembrane protein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FLRT2 mRNA

NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004

G

Fms related receptor tyrosine kinase 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FLT3 mRNA

NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581

G

fibronectin 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FN1 mRNA

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

fibronectin type III domain containing 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FNDC1 mRNA

NCBI chr 1:49,686,856...49,769,263
Ensembl chr 1:49,686,856...49,769,263

G

fibronectin type III domain containing 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of FNDC5 mRNA

NCBI chr 5:146,765,951...146,775,611
Ensembl chr 5:146,751,416...146,778,540

G

fibronectin type III domain containing 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FNDC9 mRNA

NCBI chr10:31,166,051...31,170,964
Ensembl chr10:31,154,346...31,179,698

G

folate receptor beta

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FOLR2 mRNA

NCBI chr 1:165,612,047...165,630,382
Ensembl chr 1:165,612,063...165,617,731

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression
multiple interactions

EXP
ISO

estradiol 3-benzoate results in decreased expression of FOS protein
[estradiol 3-benzoate co-treated with Progesterone] results in increased abundance of FOS protein

PMID:21190954 PMID:22577852

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FOS like 2, AP-1 transcription factor subunit

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FOSL2 mRNA

NCBI chr 6:30,017,952...30,039,269
Ensembl chr 6:30,021,916...30,039,406

G

forkhead box Q1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FOXQ1 mRNA

NCBI chr17:33,121,454...33,124,087
Ensembl chr17:33,121,545...33,123,720

G

fibrinogen silencer binding protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of FSBP mRNA

NCBI chr 5:29,855,340...29,861,613
Ensembl chr 5:29,855,304...29,901,964

G

fascin actin-bundling protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FSCN1 mRNA

NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734

G

follicle stimulating hormone subunit beta

decreases expression
decreases secretion
multiple interactions

ISO
EXP

estradiol 3-benzoate results in decreased expression of FSHB mRNA
estradiol 3-benzoate results in decreased secretion of FSHB protein
Quercetin inhibits the reaction [estradiol 3-benzoate results in decreased secretion of FSHB protein]

PMID:15223135 PMID:24316378

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

FXYD domain-containing ion transport regulator 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FXYD3 mRNA

NCBI chr 1:95,432,918...95,440,129
Ensembl chr 1:95,432,919...95,439,702

G

FYN binding protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FYB1 mRNA

NCBI chr 2:57,360,084...57,508,609
Ensembl chr 2:57,360,096...57,508,608

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FYN mRNA

NCBI chr20:44,322,635...44,514,498
Ensembl chr20:44,322,361...44,515,479

G

G0/G1switch 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of G0S2 mRNA

NCBI chr13:107,335,036...107,335,948
Ensembl chr13:107,335,036...107,336,293

G

gamma-aminobutyric acid type B receptor subunit 1

increases expression

EXP

estradiol 3-benzoate results in increased expression of GABBR1 mRNA

NCBI chr20:1,469,779...1,499,352
Ensembl chr20:1,469,779...1,498,607

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GABRA1 mRNA

NCBI chr10:27,096,731...27,152,563
Ensembl chr10:27,096,740...27,152,442

G

gamma-aminobutyric acid type A receptor subunit alpha 4

multiple interactions

EXP

[Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of GABRA4 mRNA

NCBI chr14:36,944,747...37,021,652
Ensembl chr14:36,944,388...37,021,648

G

polypeptide N-acetylgalactosaminyltransferase 13

increases expression

EXP

estradiol 3-benzoate results in increased expression of GALNT13 mRNA

NCBI chr 3:59,312,628...59,969,633
Ensembl chr 3:59,383,516...59,965,379

G

polypeptide N-acetylgalactosaminyltransferase 14

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GALNT14 mRNA

NCBI chr 6:27,507,878...27,724,033
Ensembl chr 6:27,507,627...27,724,031

G

galanin receptor 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GALR3 mRNA

NCBI chr 7:112,483,183...112,496,359
Ensembl chr 7:112,485,672...112,488,136

G

growth arrest specific 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GAS7 mRNA

NCBI chr10:52,651,690...52,882,244
Ensembl chr10:52,651,690...52,882,244

G

golgi associated kinase 1A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of FAM198A mRNA

NCBI chr 8:130,488,279...130,521,242
Ensembl chr 8:130,488,354...130,521,242

G

guanylate binding protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GBP1 mRNA

NCBI chr 2:234,071,366...234,106,012
Ensembl chr 2:234,190,708...234,206,802
Ensembl chr 2:234,190,708...234,206,802

G

guanylate binding protein 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GBP4 mRNA

NCBI chr 2:233,978,163...233,992,124
Ensembl chr 2:233,978,486...233,992,120

G

guanylate binding protein family member 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GBP6 mRNA

NCBI chr14:5,034,999...5,062,023
Ensembl chr14:4,968,325...4,983,692
Ensembl chr14:4,968,325...4,983,692

G

GTP cyclohydrolase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GCH1 mRNA

NCBI chr15:22,884,006...22,917,412
Ensembl chr15:22,884,006...22,917,412

G

glucosaminyl (N-acetyl) transferase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GCNT1 mRNA

NCBI chr 1:224,145,104...224,182,496
Ensembl chr 1:224,141,108...224,185,741

G

germinal center-associated, signaling and motility

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GCSAM mRNA

NCBI chr11:68,658,350...68,669,598
Ensembl chr11:68,660,438...68,669,584

G

guanine deaminase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GDA mRNA

NCBI chr 1:228,333,401...228,408,901
Ensembl chr 1:228,333,364...228,409,348

G

growth factor independent 1 transcriptional repressor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GFI1 mRNA

NCBI chr14:2,185,489...2,204,191
Ensembl chr14:2,187,286...2,196,730

G

GTPase, IMAP family member 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GIMAP6 mRNA

NCBI chr 4:78,984,597...78,990,006
Ensembl chr 4:78,983,504...78,990,010

G

GTPase, IMAP family member 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GIMAP7 mRNA

NCBI chr 4:79,001,416...79,005,586
Ensembl chr 4:78,999,384...79,006,756

G

gap junction protein, beta 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GJB2 mRNA

NCBI chr15:35,375,977...35,393,817
Ensembl chr15:35,375,692...35,393,877

G

gap junction protein, beta 6

increases expression

EXP

estradiol 3-benzoate results in increased expression of GJB6 mRNA

NCBI chr15:35,400,147...35,410,649
Ensembl chr15:35,398,770...35,410,849

G

glycerol kinase 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of GK5 mRNA

NCBI chr 8:105,562,018...105,630,975
Ensembl chr 8:105,562,050...105,631,978

G

galactosidase, beta 1-like 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of GLB1L3 mRNA

NCBI chr 8:33,454,914...33,496,641
Ensembl chr 8:33,454,914...33,496,641

G

GLI family zinc finger 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GLI2 mRNA

NCBI chr13:32,499,678...32,716,418
Ensembl chr13:32,499,678...32,716,418

G

GLI pathogenesis-related 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GLIPR1 mRNA

NCBI chr 7:49,373,579...49,399,190
Ensembl chr 7:49,373,581...49,384,640

G

glutaredoxin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GLRX mRNA

NCBI chr 2:7,073,737...7,083,548
Ensembl chr 2:7,073,759...7,083,543

G

glycosyltransferase 1 domain containing 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of GLT1D1 mRNA

NCBI chr12:34,611,942...34,685,591
Ensembl chr12:34,612,643...34,685,468

G

glia maturation factor, gamma

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GMFG mRNA

NCBI chr 1:92,856,154...92,866,722
Ensembl chr 1:92,854,995...92,866,723

G

G protein subunit alpha 15

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GNA15 mRNA

NCBI chr 7:8,835,396...8,856,269
Ensembl chr 7:8,835,357...8,856,268

G

G protein subunit alpha transducin 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of GNAT2 mRNA

NCBI chr 2:198,414,568...198,431,532
Ensembl chr 2:198,414,920...198,424,022

G

G protein subunit gamma transducin 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GNGT2 mRNA

NCBI chr10:81,271,916...81,280,980
Ensembl chr10:81,277,423...81,280,970

G

gonadotropin releasing hormone 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with GNRH1 protein] results in increased secretion of LH protein

NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977
Ensembl chr15:46,148,301...46,148,977

G

gonadotropin releasing hormone receptor

decreases expression

ISO

estradiol 3-benzoate results in decreased expression of GNRHR mRNA

NCBI chr14:22,211,666...22,229,654

G

glycoprotein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GP2 mRNA

NCBI chr 1:183,228,395...183,243,954
Ensembl chr 1:183,228,395...183,243,954

G

glycoprotein 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GP6 mRNA

NCBI chr 1:78,471,900...78,535,374
Ensembl chr 1:78,508,468...78,535,374

G

glycerol-3-phosphate acyltransferase 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPAT3 mRNA

NCBI chr14:9,018,762...9,072,552

G

glypican 5

multiple interactions
decreases expression

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of GPC5 mRNA
estradiol 3-benzoate results in decreased expression of GPC5 mRNA

NCBI chr15:98,614,499...100,051,285
Ensembl chr15:98,646,340...100,051,514

G

G protein-coupled receptor 176

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPR176 mRNA

NCBI chr 3:125,690,750...125,791,172
Ensembl chr 3:125,690,751...125,791,172

G

G protein-coupled receptor 31

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPR31 mRNA

NCBI chr 1:55,474,484...55,475,443
Ensembl chr 1:55,474,484...55,475,443

G

G protein-coupled receptor 34

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPR34 mRNA

NCBI chr X:11,777,667...11,786,640
Ensembl chr X:11,776,371...11,843,240

G

G protein-coupled receptor 35

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPR35 mRNA

NCBI chr 9:100,974,580...100,995,330
Ensembl chr 9:100,962,538...100,986,985

G

G protein-coupled receptor 68

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPR68 mRNA

NCBI chr 6:125,865,205...125,895,674
Ensembl chr 6:125,864,942...125,895,674

G

G protein-coupled receptor 84

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPR84 mRNA

NCBI chr 7:136,322,374...136,324,648
Ensembl chr 7:136,322,191...136,324,703

G

G protein-coupled receptor 87

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPR87 mRNA

NCBI chr 2:145,589,630...145,608,094
Ensembl chr 2:145,589,569...145,604,442

G

G protein-coupled receptor, class C, group 5, member A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPRC5A mRNA

NCBI chr 4:169,634,896...169,653,627
Ensembl chr 4:169,634,748...169,653,625

G

glutathione peroxidase 1

multiple interactions
decreases expression

EXP

Quercetin inhibits the reaction [estradiol 3-benzoate results in decreased expression of GPX1 mRNA]

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione peroxidase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GPX2 mRNA

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862

G

glutathione peroxidase 7

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of GPX7 promoter

NCBI chr 5:128,373,881...128,381,866
Ensembl chr 5:128,372,875...128,381,725

G

GRB2-related adaptor protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GRAP mRNA

NCBI chr10:46,798,423...46,851,524
Ensembl chr10:46,832,390...46,851,523

G

growth regulating estrogen receptor binding 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GREB1 mRNA

NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126

G

glutamate ionotropic receptor NMDA type subunit 1

increases phosphorylation
multiple interactions

EXP

estradiol 3-benzoate results in increased phosphorylation of GRIN1 protein
fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased phosphorylation of GRIN1 protein]; U 0126 inhibits the reaction [estradiol 3-benzoate results in increased phosphorylation of GRIN1 protein]

NCBI chr 3:28,501,836...28,528,754
Ensembl chr 3:28,501,836...28,528,754

G

glutamate ionotropic receptor NMDA type subunit 2B

increases expression
increases phosphorylation
multiple interactions
decreases expression

EXP

estradiol 3-benzoate results in increased expression of GRIN2B mRNA
estradiol 3-benzoate results in increased phosphorylation of GRIN2B protein
fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased phosphorylation of GRIN2B protein]; U 0126 inhibits the reaction [estradiol 3-benzoate results in increased phosphorylation of GRIN2B protein]
estradiol 3-benzoate results in decreased expression of GRIN2B mRNA

PMID:21190954 PMID:21277884 PMID:21763338

NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570

G

glutamate ionotropic receptor NMDA type subunit 2C

increases expression

EXP

estradiol 3-benzoate results in increased expression of GRIN2C mRNA

NCBI chr10:100,987,410...101,006,064
Ensembl chr10:100,987,513...101,005,409

G

G protein-coupled receptor kinase 3

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of GRK3 promoter

NCBI chr12:49,285,228...49,395,803
Ensembl chr12:49,285,263...49,395,802

G

granulin precursor

increases expression

EXP

estradiol 3-benzoate results in increased expression of GRN mRNA

NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,886,122...87,893,936

G

gamma-secretase activating protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GSAP mRNA

NCBI chr 4:14,705,237...14,800,057
Ensembl chr 4:14,705,237...14,800,005

G

goosecoid homeobox

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GSC mRNA

NCBI chr 6:129,152,836...129,154,875
Ensembl chr 6:129,152,836...129,154,875

G

glutathione S-transferase alpha 3 like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of GSTA3L1 mRNA

NCBI chr 9:31,115,727...31,128,997
Ensembl chr 9:31,036,978...31,129,006

G

guanylate cyclase 2C

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of GUCY2C promoter

NCBI chr 4:171,299,715...171,380,296
Ensembl chr 4:171,299,740...171,380,296

G

glucoside xylosyltransferase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GXYLT2 mRNA

NCBI chr 4:134,903,595...135,006,066
Ensembl chr 4:134,903,859...134,987,956

G

granzyme B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GZMB mRNA

NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469

G

granzyme M

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of GZMM mRNA

NCBI chr 7:10,661,683...10,667,448
Ensembl chr 7:10,661,684...10,667,504

G

hyaluronan binding protein 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of HABP2 promoter

NCBI chr 1:265,321,084...265,355,375
Ensembl chr 1:265,303,172...265,355,374

G

hepatitis A virus cellular receptor 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of HAVCR1 mRNA

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

HCK proto-oncogene, Src family tyrosine kinase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HCK mRNA

NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935

G

hematopoietic cell signal transducer

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HCST mRNA

NCBI chr 1:94,804,429...94,806,661
Ensembl chr 1:94,804,430...94,806,641

G

histone deacetylase 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HDAC9 mRNA

NCBI chr 6:56,489,472...57,351,654
Ensembl chr 6:56,490,988...57,351,835

G

helicase with zinc finger 2

multiple interactions
increases expression

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HELZ2 mRNA
estradiol 3-benzoate results in increased expression of HELZ2 mRNA

NCBI chr 3:188,716,370...188,730,776
Ensembl chr 3:188,716,370...188,730,716

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HERC6 mRNA

NCBI chr 4:88,854,612...88,897,043
Ensembl chr 4:88,854,640...88,896,993

G

hes-related family bHLH transcription factor with YRPW motif-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HEYL mRNA

NCBI chr 5:140,793,271...140,810,262
Ensembl chr 5:140,793,271...140,810,262

G

huntingtin interacting protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HIP1 mRNA

NCBI chr12:26,769,868...26,904,367
Ensembl chr12:26,769,961...26,904,296

G

hexokinase 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HK3 mRNA

NCBI chr17:9,602,119...9,620,038
Ensembl chr17:9,605,016...9,620,037

G

high mobility group box 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of HMGB1 mRNA

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

heme oxygenase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

homeo box C5

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of HOXC5 promoter

NCBI chr 7:136,029,454...136,032,876
Ensembl chr 7:136,029,454...136,032,876

G

homologous recombination factor with OB-fold

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HROB mRNA

NCBI chr10:87,705,846...87,722,635
Ensembl chr10:87,706,194...87,722,635

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HSD11B2 mRNA

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

hematopoietic SH2 domain containing

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HSH2D mRNA

NCBI chr16:17,664,548...17,686,976
Ensembl chr16:17,669,345...17,682,013

G

heat shock protein family A (Hsp70) member 2

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of HSPA2 promoter

NCBI chr 6:100,864,172...100,866,946
Ensembl chr 6:100,864,553...100,867,133

G

heat shock protein family A (Hsp70) member 8

multiple interactions
increases expression

EXP

[estradiol 3-benzoate co-treated with Progesterone] results in increased expression of HSPA8 mRNA; Progesterone promotes the reaction [estradiol 3-benzoate results in increased expression of HSPA8 mRNA]

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372

G

5-hydroxytryptamine receptor 2A

multiple interactions
increases expression

EXP

Raloxifene Hydrochloride inhibits the reaction [estradiol 3-benzoate results in increased expression of HTR2A mRNA]; Raloxifene Hydrochloride inhibits the reaction [estradiol 3-benzoate results in increased expression of HTR2A protein]
estradiol 3-benzoate results in increased expression of HTR2A mRNA; estradiol 3-benzoate results in increased expression of HTR2A protein

NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619

G

5-hydroxytryptamine receptor 2C

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of HTR2C mRNA

NCBI chr X:115,453,190...115,682,325
Ensembl chr X:115,452,842...115,682,324

G

hydrogen voltage-gated channel 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of HVCN1 mRNA

NCBI chr12:40,001,205...40,030,671
Ensembl chr12:40,001,498...40,042,020

G

hyaluronidase 3

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of HYAL3 promoter

NCBI chr 8:117,133,028...117,138,663
Ensembl chr 8:117,132,649...117,139,289

G

intercellular adhesion molecule 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ICAM2 mRNA

NCBI chr10:91,808,449...91,819,319
Ensembl chr10:91,808,316...91,815,072

G

intercellular adhesion molecule 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ICAM5 mRNA

NCBI chr 8:27,843,563...27,851,767
Ensembl chr 8:27,844,780...27,857,104

G

inducible T-cell co-stimulator

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ICOS mRNA

NCBI chr 9:69,862,042...69,900,864
Ensembl chr 9:69,877,785...69,900,960

G

immediate early response 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IER5 mRNA

NCBI chr13:69,820,450...69,822,542
Ensembl chr13:69,820,451...69,822,543

G

interferon activated gene 214

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFI214 mRNA

NCBI chr13:88,472,400...88,483,335
Ensembl chr13:88,472,409...88,483,335

G

interferon, alpha-inducible protein 27 like 2A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFI27L2B mRNA

NCBI chr 6:128,363,658...128,365,144
Ensembl chr 6:128,363,658...128,365,146

G

interferon-induced protein 44

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFI44 mRNA

NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:243,286,052...243,306,877

G

interferon-induced protein 44-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFI44L mRNA

NCBI chr 2:243,328,629...243,366,404
Ensembl chr 2:243,328,723...243,366,404

G

interferon gamma inducible protein 47

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFI47 mRNA

NCBI chr10:33,798,744...33,806,374
Ensembl chr10:33,776,399...33,806,372

G

interferon-induced protein with tetratricopeptide repeats 1B-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFIT1BL mRNA

NCBI chr 1:241,535,776...241,580,476
Ensembl chr 1:241,535,145...241,580,516

G

interferon-induced protein with tetratricopeptide repeats 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFIT3 mRNA

NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521

G

interferon induced transmembrane protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IFITM1 mRNA

NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776

G

insulin-like growth factor 1

affects expression
decreases expression

EXP

estradiol 3-benzoate affects the expression of IGF1 mRNA
estradiol 3-benzoate results in decreased expression of IGF1 mRNA

PMID:15925091 PMID:19350480 PMID:21190954

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor binding protein 3

increases expression

EXP

estradiol 3-benzoate results in increased expression of IGFBP3 mRNA

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

immunoglobulin heavy chain 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGH-6 mRNA

G

immunoglobulin kappa variable 2-112 like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGKV2-112L2 mRNA

NCBI chr 4:103,444,658...103,445,307
Ensembl chr 4:103,766,891...103,767,229

G

immunoglobulin kappa chain variable 28

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGKV28 mRNA

NCBI chr 4:102,852,907...102,853,451

G

immunoglobulin kappa variable like 15

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGKVL15 mRNA

NCBI chr19:3,099,541...3,100,174
Ensembl chr 4:101,944,224...101,944,538
Ensembl chr19:101,944,224...101,944,538

G

immunoglobulin lambda constant 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGLL1 mRNA

NCBI chr11:95,452,233...95,454,185
Ensembl chr11:95,452,341...95,454,353

G

immunoglobulin superfamily, member 10

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGSF10 mRNA

NCBI chr 2:145,725,868...145,754,850
Ensembl chr 2:145,725,878...145,754,579

G

immunoglobulin superfamily, member 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGSF6 mRNA

NCBI chr 1:185,041,462...185,051,956
Ensembl chr 1:185,041,462...185,052,245

G

immunoglobulin superfamily, member 7 like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGSF7L1 mRNA

NCBI chr10:100,673,958...100,681,704
Ensembl chr10:100,655,705...100,682,549

G

immunoglobulin superfamily, member 9

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of IGSF9 promoter

NCBI chr13:87,480,979...87,497,974
Ensembl chr13:87,481,279...87,497,974

G

interferon gamma induced GTPase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IGTP mRNA

NCBI chr10:42,875,047...42,882,866
Ensembl chr10:42,876,790...42,882,858

G

IKAROS family zinc finger 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IKZF1 mRNA

NCBI chr14:90,468,696...90,556,522
Ensembl chr14:90,469,172...90,557,574

G

interleukin 10

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL10 mRNA

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 10 receptor subunit alpha

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL10RA mRNA

NCBI chr 8:54,459,754...54,474,786
Ensembl chr 8:54,459,882...54,475,028

G

interleukin 18

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of IL18 mRNA
[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of IL18 mRNA

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 alpha

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions
increases expression

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of IL1B mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL1B mRNA; methyl palmitate inhibits the reaction [estradiol 3-benzoate results in increased expression of IL1B protein]

PMID:32741896 PMID:32967526 PMID:39368565

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL1R2 mRNA

NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:49,877,266...49,920,374

G

interleukin 1 receptor antagonist

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL1RN mRNA

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 21 receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL21R mRNA

NCBI chr 1:189,598,682...189,626,340
Ensembl chr 1:189,598,558...189,626,342

G

interleukin 27 receptor subunit alpha

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL27RA mRNA

NCBI chr19:41,014,730...41,026,740
Ensembl chr19:41,014,730...41,026,760

G

interleukin 2 receptor subunit alpha

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL2RA mRNA

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin 36, beta

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL36B mRNA

NCBI chr 3:27,422,980...27,521,344
Ensembl chr 3:27,423,171...27,428,678

G

interleukin 6

multiple interactions

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of IL6 mRNA

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 7 receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IL7R mRNA

NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027

G

inhibin subunit beta B

decreases expression
multiple interactions

EXP

estradiol 3-benzoate results in decreased expression of INHBB mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of INHBB mRNA

NCBI chr13:33,083,671...33,089,373
Ensembl chr13:33,083,671...33,089,609

G

inositol polyphosphate-5-phosphatase D

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of INPP5D mRNA

NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589

G

inositol hexakisphosphate kinase 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of IP6K1 promoter

NCBI chr 8:117,594,177...117,613,266
Ensembl chr 8:117,594,317...117,613,274

G

inositol 1,4,5-triphosphate receptor associated 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IRAG2 mRNA

NCBI chr 4:179,819,526...179,874,408
Ensembl chr 4:179,820,188...179,874,406

G

interleukin-1 receptor-associated kinase 1 binding protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of IRAK1BP1 mRNA

NCBI chr 8:92,608,468...92,628,377
Ensembl chr 8:92,611,843...92,628,377

G

interleukin-1 receptor-associated kinase 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IRAK3 mRNA

NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706

G

interferon regulatory factor 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IRF4 mRNA

NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,930,471...33,948,730

G

interferon regulatory factor 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IRF7 mRNA

NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:205,796,959...205,800,023

G

immunity-related GTPase M

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IRGM mRNA

NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,732,961...33,743,228

G

immunity-related GTPase family M member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IRGM2 mRNA

NCBI chr10:42,889,919...42,900,060

G

ISG15 ubiquitin-like modifier

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ISG15 mRNA

NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:172,066,369...172,067,656

G

integrin subunit alpha 4

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of ITGA4 mRNA
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ITGA4 mRNA

NCBI chr 3:84,569,487...84,646,276
Ensembl chr 3:84,560,369...84,641,039

G

integrin subunit alpha 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ITGA8 mRNA

NCBI chr17:80,213,139...80,410,633
Ensembl chr17:80,213,143...80,410,633

G

integrin subunit alpha M

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ITGAM mRNA

NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943

G

integrin subunit alpha X

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ITGAX mRNA

NCBI chr 1:192,140,089...192,171,151
Ensembl chr 1:192,149,905...192,171,151

G

integrin subunit beta 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ITGB2 mRNA

NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,058,492...11,097,182

G

integrin subunit beta 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ITGB7 mRNA

NCBI chr 7:135,225,962...135,243,522
Ensembl chr 7:135,226,555...135,243,597

G

IZUMO1 receptor, JUNO

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of IZUMO1R mRNA

NCBI chr 8:20,025,830...20,030,829
Ensembl chr 8:20,025,831...20,029,578

G

joining chain of multimeric IgA and IgM

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of JCHAIN mRNA

NCBI chr14:19,822,976...19,831,072
Ensembl chr14:19,822,976...19,838,307

G

junctophilin 3

increases expression

EXP

estradiol 3-benzoate results in increased expression of JPH3 mRNA

NCBI chr19:66,702,497...66,763,948
Ensembl chr19:66,702,680...66,763,937

G

katanin catalytic subunit A1 like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of KATNAL2 mRNA

NCBI chr18:72,806,967...72,883,091
Ensembl chr18:72,806,900...72,883,256

G

katanin regulatory subunit B1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of KATNB1 promoter

NCBI chr19:9,927,249...9,946,750
Ensembl chr19:9,927,249...9,946,738

G

potassium voltage-gated channel subfamily D member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KCND1 mRNA

NCBI chr X:17,333,612...17,349,255
Ensembl chr X:17,333,612...17,347,799

G

potassium two pore domain channel subfamily K member 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of KCNK2 promoter

NCBI chr13:103,297,387...103,494,686
Ensembl chr13:103,297,393...103,494,686

G

potassium two pore domain channel subfamily K member 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KCNK7 mRNA

NCBI chr 1:212,419,555...212,422,173
Ensembl chr 1:212,419,555...212,422,566

G

potassium voltage-gated channel subfamily Q member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KCNQ1 mRNA

NCBI chr 1:207,721,134...208,054,073
Ensembl chr 1:207,721,131...208,054,072

G

potassium sodium-activated channel subfamily T member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KCNT1 mRNA

NCBI chr 3:29,081,071...29,136,902
Ensembl chr 3:29,081,321...29,134,768

G

kinesin family member 18B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KIF18B mRNA

NCBI chr10:88,370,520...88,392,388
Ensembl chr10:88,370,524...88,389,691

G

kinesin family member 20A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KIF20A mRNA

NCBI chr18:26,504,422...26,512,908
Ensembl chr18:26,504,072...26,512,909

G

kinesin family member 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of KIF6 mRNA

NCBI chr 9:18,573,925...18,870,789
Ensembl chr 9:18,573,789...18,870,729

G

KiSS-1 metastasis-suppressor

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of KISS1 mRNA; estradiol 3-benzoate results in decreased expression of KISS1 protein

PMID:19106226 PMID:19442818 PMID:20951797 PMID:21190954 PMID:22016562

NCBI chr13:47,327,159...47,332,759
Ensembl chr13:47,327,004...47,332,906

G

KISS1 receptor

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of KISS1R mRNA

NCBI chr 7:10,435,766...10,439,424
Ensembl chr 7:10,435,766...10,439,424

G

kelch-like family member 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of KLHL12 mRNA

NCBI chr13:48,451,920...48,485,638
Ensembl chr13:48,455,227...48,485,641

G

kelch-like family member 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLHL3 mRNA

NCBI chr17:6,528,114...6,651,338
Ensembl chr17:6,528,487...6,651,338

G

kelch-like family member 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLHL6 mRNA

NCBI chr11:94,475,262...94,514,653
Ensembl chr11:94,475,262...94,514,623

G

killer cell lectin-like receptor, subfamily A, member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRA1 mRNA

NCBI chr 4:166,291,838...166,313,615
Ensembl chr 4:166,291,841...166,313,615

G

killer cell lectin-like receptor, subfamily A, member 17

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRA17 mRNA

NCBI chr 4:165,522,631...165,550,502
Ensembl chr 4:165,375,355...165,550,451

G

killer cell lectin-like receptor, subfamily A, member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRA2 mRNA

NCBI chr 4:166,604,723...166,717,294
Ensembl chr 4:166,598,713...166,717,344

G

killer cell lectin-like receptor subfamily A, member 22

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRA22 mRNA

NCBI chr 4:165,721,602...165,743,025
Ensembl chr 4:165,721,602...165,751,546

G

killer cell lectin like receptor C1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRC1 mRNA

NCBI chr 4:164,828,163...164,838,446
Ensembl chr 4:164,828,163...164,838,464

G

killer cell lectin like receptor C2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRC2 mRNA

NCBI chr 4:164,808,722...164,819,865
Ensembl chr 4:164,808,722...164,819,865

G

killer cell lectin like receptor C3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRC3 mRNA

NCBI chr 4:164,791,102...164,798,758
Ensembl chr 4:164,791,128...164,798,758

G

killer cell lectin like receptor D1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRD1 mRNA

NCBI chr 4:164,730,833...164,742,539
Ensembl chr 4:164,730,856...164,742,538

G

killer cell lectin like receptor E1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRE1 mRNA

NCBI chr 4:164,719,307...164,727,664
Ensembl chr 4:164,719,604...164,727,664

G

killer cell lectin-like receptor family I member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRI1 mRNA

NCBI chr 4:164,869,695...164,904,924
Ensembl chr 4:164,869,689...164,904,889

G

killer cell lectin-like receptor family I member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KLRI2 mRNA

NCBI chr 4:164,938,862...164,947,504
Ensembl chr 4:164,938,862...164,947,504

G

kynurenine 3-monooxygenase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KMO mRNA

NCBI chr13:90,089,340...90,121,108
Ensembl chr13:90,089,463...90,125,151

G

kininogen 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KNG1 mRNA

NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148

G

kininogen 2-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KNG2L1 mRNA

NCBI chr11:91,483,419...91,507,564
Ensembl chr11:91,483,402...91,506,159

G

kinetochore scaffold 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KNL1 mRNA

NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:126,483,544...126,545,774

G

kinetochore-localized astrin/SPAG5 binding protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KNSTRN mRNA

NCBI chr 3:126,254,633...126,274,412
Ensembl chr 3:126,254,663...126,274,418

G

keratin 20

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KRT20 mRNA

NCBI chr10:84,880,952...84,890,285
Ensembl chr10:84,880,952...84,890,285

G

keratin 25

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of KRT25 promoter

NCBI chr10:84,763,567...84,772,390
Ensembl chr10:84,763,573...84,771,197

G

keratin 36

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KRT36 mRNA

NCBI chr10:85,536,779...85,540,403
Ensembl chr10:85,536,779...85,540,403

G

keratin 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KRT7 mRNA

NCBI chr 7:134,407,626...134,423,787
Ensembl chr 7:134,407,584...134,423,786

G

keratin 8

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of KRT8 promoter

NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403

G

keratin 87

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of KRT83 promoter

NCBI chr 7:134,426,567...134,433,740
Ensembl chr 7:134,426,567...134,433,740

G

keratin associated protein 16-5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of KRTAP16-5 mRNA

NCBI chr11:41,735,430...41,736,014
Ensembl chr11:41,735,430...41,736,014

G

laccase domain containing 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LACC1 mRNA

NCBI chr15:58,799,477...58,816,840
Ensembl chr15:58,786,637...58,816,840

G

lymphocyte activating 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LAG3 mRNA

NCBI chr 4:159,398,930...159,407,001
Ensembl chr 4:159,398,932...159,406,669

G

laminin subunit beta 1

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of LAMB1 mRNA

NCBI chr 6:53,562,849...53,630,118
Ensembl chr 6:53,563,073...53,630,760

G

lysosomal protein transmembrane 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LAPTM5 mRNA

NCBI chr 5:148,371,880...148,393,927
Ensembl chr 5:148,339,435...148,393,927

G

linker for activation of T cells family, member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LAT2 mRNA

NCBI chr12:27,740,647...27,754,760
Ensembl chr12:27,740,654...27,755,843

G

lipopolysaccharide binding protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LBP mRNA

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:167,373,924...167,401,518

G

lipocalin 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LCN2 mRNA

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842

G

lymphocyte cytosolic protein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LCP2 mRNA

NCBI chr10:19,146,846...19,193,750
Ensembl chr10:19,146,554...19,193,744

G

low density lipoprotein receptor class A domain containing 2

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of LDLRAD2 mRNA

NCBI chr 5:155,062,172...155,070,752
Ensembl chr 5:155,062,208...155,070,715

G

leptin receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of LEPR mRNA

NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215

G

galectin 3 binding protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LGALS3BP mRNA

NCBI chr10:104,118,510...104,127,848
Ensembl chr10:104,118,510...104,127,848

G

galectin 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LGALS9 mRNA

NCBI chr10:64,405,044...64,428,249
Ensembl chr10:64,405,044...64,428,070

G

leucine-rich repeat LGI family, member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LGI2 mRNA

NCBI chr14:62,628,746...62,656,231
Ensembl chr14:62,596,150...62,656,188

G

luteinizing hormone subunit beta

decreases expression
decreases secretion
multiple interactions
increases secretion

ISO
EXP

estradiol 3-benzoate results in decreased expression of LHB mRNA
estradiol 3-benzoate results in decreased secretion of LHB protein
Atrazine inhibits the reaction [[estradiol 3-benzoate co-treated with Progesterone] results in increased secretion of LHB protein]; Atrazine inhibits the reaction [estradiol 3-benzoate results in increased secretion of LHB protein]; Quercetin inhibits the reaction [estradiol 3-benzoate results in decreased secretion of LHB protein]; Raloxifene Hydrochloride inhibits the reaction [estradiol 3-benzoate results in increased secretion of LHB protein]
[estradiol 3-benzoate co-treated with Progesterone] results in increased abundance of LHB protein

PMID:10696778 PMID:15056801 PMID:15223135 PMID:16614383 PMID:17398000 More...

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

luteinizing hormone/choriogonadotropin receptor

increases expression

ISO

estradiol 3-benzoate results in increased expression of LHCGR mRNA

NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:11,415,415...11,478,061

G

LIM homeobox 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LHX8 mRNA

NCBI chr 2:245,904,712...245,929,376
Ensembl chr 2:245,904,712...245,929,376

G

leukocyte immunoglobulin like receptor A5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LILRA5 mRNA

NCBI chr 1:79,011,865...79,073,860
Ensembl chr 1:79,045,546...79,050,111

G

leukocyte immunoglobulin like receptor B4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LILRB4 mRNA

NCBI chr 1:78,847,685...78,853,294
Ensembl chr 1:78,847,685...78,853,326

G

leukocyte immunoglobulin-like receptor, subfamily C, member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LILRC2 mRNA

NCBI chr 1:74,187,623...74,192,646
Ensembl chr 1:74,188,164...74,192,719

G

lin-7 homolog A, crumbs cell polarity complex component

increases expression

EXP

estradiol 3-benzoate results in increased expression of LIN7A mRNA

NCBI chr 7:44,473,568...44,629,074
Ensembl chr 7:44,473,347...44,625,208

G

lipase G, endothelial type

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of LIPG mRNA

NCBI chr18:70,790,077...70,811,259
Ensembl chr18:70,790,077...70,812,260

G

limb and CNS expressed 1

increases expression

EXP

estradiol 3-benzoate results in increased expression of LIX1 mRNA

NCBI chr 1:66,802,044...66,859,040
Ensembl chr 1:66,802,272...66,860,627

G

lysyl oxidase-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LOXL1 mRNA

NCBI chr 8:67,587,636...67,612,224
Ensembl chr 8:67,587,636...67,612,224

G

leucine rich colipase-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of LRCOL1 mRNA

NCBI chr12:51,985,786...51,999,282
Ensembl chr12:51,985,814...51,997,688

G

leucine-rich alpha-2-glycoprotein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LRG1 mRNA

NCBI chr 9:1,034,691...1,036,937
Ensembl chr 9:1,034,679...1,037,337

G

leucine rich repeat containing 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of LRRC1 mRNA

NCBI chr 8:87,120,281...87,289,748
Ensembl chr 8:87,119,975...87,286,853

G

leucine rich repeat containing 15

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of LRRC15 promoter

NCBI chr11:83,974,708...83,989,157
Ensembl chr11:83,974,695...83,989,146

G

leucine rich repeat containing 17

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LRRC17 mRNA

NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048

G

leucine rich repeat containing 18

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of LRRC18 promoter

NCBI chr16:8,259,083...8,283,722
Ensembl chr16:8,260,666...8,284,802

G

leucine rich repeat containing 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LRRC4 mRNA

NCBI chr 4:58,398,942...58,402,538
Ensembl chr 4:58,397,302...58,402,808

G

leucine rich repeat containing 73

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of LRRC73 mRNA

NCBI chr 9:22,223,735...22,227,867
Ensembl chr 9:22,223,152...22,226,736

G

leucine rich repeat containing 74A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LRRC74A mRNA

NCBI chr 6:112,117,226...112,147,152
Ensembl chr 6:112,117,241...112,148,068

G

LRRN4 C-terminal like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LRRN4CL mRNA

NCBI chr 1:215,172,689...215,192,627
Ensembl chr 1:215,174,216...215,198,343

G

leucine rich repeat transmembrane neuronal 1

increases expression

EXP

estradiol 3-benzoate results in increased expression of LRRTM1 mRNA

NCBI chr 4:111,246,213...111,295,638
Ensembl chr 4:111,235,054...111,276,818

G

lymphocyte-specific protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LSP1 mRNA

NCBI chr 1:207,044,157...207,077,891
Ensembl chr 1:207,044,159...207,077,893

G

leukocyte specific transcript 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LST1 mRNA

NCBI chr20:3,639,353...3,644,399
Ensembl chr20:3,639,341...3,642,669

G

latent transforming growth factor beta binding protein 2

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of LTBP2 promoter

NCBI chr 6:110,161,029...110,261,586
Ensembl chr 6:110,161,029...110,257,298

G

leukocyte receptor tyrosine kinase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LTK mRNA

NCBI chr 3:127,188,479...127,195,356
Ensembl chr 3:127,188,480...127,197,402

G

Ly49 inhibitory receptor 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY49I7 mRNA

NCBI chr 4:166,584,725...166,604,575
Ensembl chr 4:166,585,010...166,598,801

G

Ly49 inhibitory receptor 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY49I9 mRNA

G

Ly-49 stimulatory receptor 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY49S3 mRNA

G

Ly49 stimulatory receptor 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY49S6 mRNA

NCBI chr 4:165,765,947...165,790,123
Ensembl chr 4:165,765,947...165,790,121
Ensembl chr 4:165,765,947...165,790,121

G

immunoreceptor Ly49si1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY49SI1 mRNA

NCBI chr 4:165,272,974...165,286,574

G

immunoreceptor Ly49si2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY49SI2 mRNA

NCBI chr 4:165,358,092...165,410,591

G

lymphocyte antigen 6 family member A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6AL mRNA

NCBI chr 7:109,064,222...109,067,757

G

Ly6-C antigen

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6C mRNA

NCBI chr 7:108,840,263...108,844,082
Ensembl chr 7:108,840,263...108,878,007

G

Ly6-C antigen like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6CL1 mRNA

NCBI chr 7:109,002,958...109,097,841
Ensembl chr 7:109,003,347...109,008,841

G

lymphocyte antigen 6 family member E

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6E mRNA

NCBI chr 7:108,815,970...108,820,444
Ensembl chr 7:108,816,887...108,820,443

G

lymphocyte antigen 6 family member L

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY6L mRNA

NCBI chr 7:109,101,360...109,103,440
Ensembl chr 7:109,101,044...109,103,440

G

lymphocyte antigen 86

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LY86 mRNA

NCBI chr17:27,621,313...27,705,336
Ensembl chr17:27,621,313...27,692,743

G

LYL1, basic helix-loop-helix family member

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LYL1 mRNA

NCBI chr19:40,356,967...40,359,834
Ensembl chr19:40,354,819...40,359,834

G

Ly6/neurotoxin 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LYNX1 mRNA

NCBI chr 7:108,521,783...108,527,012
Ensembl chr 7:108,521,780...108,527,130

G

Ly6/Plaur domain containing 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LYPD8 mRNA

NCBI chr10:43,062,261...43,073,108
Ensembl chr10:43,065,186...43,073,105

G

lysozyme 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LYZ2 mRNA

NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011

G

mono-ADP ribosylhydrolase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MACROD2 mRNA

NCBI chr 3:148,173,821...150,191,077
Ensembl chr 3:148,173,829...150,188,058

G

MAF bZIP transcription factor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MAF mRNA

NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378

G

mal, T-cell differentiation protein-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MALL mRNA

NCBI chr 3:135,381,180...135,404,136
Ensembl chr 3:135,377,410...135,404,066

G

mannosidase, alpha, class 1C, member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MAN1C1 mRNA

NCBI chr 5:152,057,839...152,197,737
Ensembl chr 5:152,057,967...152,197,138

G

mitogen activated protein kinase kinase 1

decreases phosphorylation

EXP

estradiol 3-benzoate results in decreased phosphorylation of MAP2K1 protein

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen activated protein kinase kinase 2

decreases phosphorylation

EXP

estradiol 3-benzoate results in decreased phosphorylation of MAP2K2 protein

NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940

G

N6-Methyl-AMP deaminase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of ADAL mRNA

NCBI chr 3:128,555,604...128,583,809
Ensembl chr 3:128,555,604...128,575,708
Ensembl chr 3:128,555,604...128,575,708

G

mitogen activated protein kinase 1

decreases phosphorylation

EXP

estradiol 3-benzoate results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation

EXP

estradiol 3-benzoate results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

membrane associated ring-CH-type finger 10

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of MARCHF10 promoter

NCBI chr10:90,832,647...90,975,700
Ensembl chr10:90,832,648...90,922,722

G

MARCKS-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MARCKSL1 mRNA

NCBI chr 5:147,135,827...147,138,150
Ensembl chr 5:147,134,514...147,138,417

G

mast cell-expressed membrane protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MCEMP1 mRNA

NCBI chr12:6,519,709...6,523,880
Ensembl chr12:6,517,854...6,523,880

G

minichromosome maintenance complex component 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MCM3 mRNA

NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746

G

mucolipin TRP cation channel 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MCOLN2 mRNA

NCBI chr 2:237,714,100...237,762,979
Ensembl chr 2:237,714,084...237,762,978

G

mucolipin TRP cation channel 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MCOLN3 mRNA

NCBI chr 2:237,596,544...237,705,770
Ensembl chr 2:237,626,302...237,705,769

G

microfibril associated protein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MFAP2 mRNA

NCBI chr 5:158,595,121...158,603,283
Ensembl chr 5:158,597,512...158,610,656

G

maltase-glucoamylase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MGAM mRNA

NCBI chr 4:70,408,263...70,568,752
Ensembl chr 4:70,408,263...70,568,752

G

mast cell immunoglobulin-like receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MILR1 mRNA

NCBI chr10:92,184,002...92,205,001
Ensembl chr10:92,187,479...92,205,003

G

microRNA 615

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of MIR615 promoter

NCBI chr 7:136,030,353...136,030,444
Ensembl chr 7:136,030,353...136,030,444

G

marker of proliferation Ki-67

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MKI67 mRNA

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

matrix metallopeptidase 16

increases expression

EXP

estradiol 3-benzoate results in increased expression of MMP16 mRNA

NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:36,109,265...36,353,252

G

matrix metallopeptidase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MMP2 mRNA

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 28

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MMP28 mRNA

NCBI chr10:68,738,651...68,762,377
Ensembl chr10:68,738,651...68,824,884

G

matrix metallopeptidase 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MMP8 mRNA

NCBI chr 8:13,008,873...13,018,729
Ensembl chr 8:13,008,890...13,018,729

G

myeloid cell nuclear differentiation antigen

multiple interactions
increases expression

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MNDA mRNA
estradiol 3-benzoate results in increased expression of MNDA mRNA

NCBI chr13:88,550,224...88,567,892
Ensembl chr13:88,550,228...88,566,537

G

macrophage expressed 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MPEG1 mRNA

NCBI chr 1:218,876,848...218,881,364
Ensembl chr 1:218,876,069...218,908,715

G

myeloperoxidase

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [estradiol 3-benzoate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MPO protein]]; estradiol 3-benzoate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

myelin protein zero

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MPZ mRNA

NCBI chr13:86,103,290...86,109,156
Ensembl chr13:86,103,290...86,109,155

G

mannose receptor, C type 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MRC1 mRNA

NCBI chr17:82,157,725...82,239,411
Ensembl chr17:82,157,705...82,239,410

G

MAS related GPR family member X3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MRGPRX3 mRNA

NCBI chr 1:106,857,685...106,883,199
Ensembl chr 1:106,857,687...106,883,145

G

membrane spanning 4-domains A1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A1 mRNA

NCBI chr 1:217,331,274...217,351,934
Ensembl chr 1:217,331,274...217,343,447

G

membrane spanning 4-domains A10

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A10 mRNA

NCBI chr 1:217,034,156...217,049,369
Ensembl chr 1:217,036,206...217,049,346

G

membrane spanning 4-domains A12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A12 mRNA

NCBI chr 1:217,307,238...217,318,785
Ensembl chr 1:217,307,238...217,318,785

G

membrane spanning 4-domains A18

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A18 mRNA

NCBI chr 1:217,069,752...217,090,869
Ensembl chr 1:217,069,884...217,090,754

G

membrane spanning 4-domains A4A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A4E mRNA

NCBI chr 1:217,495,704...217,510,019
Ensembl chr 1:217,487,996...217,510,503

G

membrane spanning 4-domains A6A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A6A mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A6E mRNA

NCBI chr 1:217,826,261...217,839,606
Ensembl chr 1:217,826,261...217,850,013

G

membrane-spanning 4-domains, subfamily A, member 6B-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A6BL1 mRNA

NCBI chr 1:217,668,326...217,680,151
Ensembl chr 1:217,670,168...217,682,105

G

membrane spanning 4-domains A7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MS4A7 mRNA

NCBI chr 1:217,394,019...217,409,643
Ensembl chr 1:217,394,019...217,409,643

G

musculin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MSC mRNA

NCBI chr 5:9,330,522...9,336,391
Ensembl chr 5:9,330,544...9,336,857

G

mesothelin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MSLN mRNA

NCBI chr10:15,276,489...15,285,921
Ensembl chr10:15,275,659...15,282,153

G

myostatin

multiple interactions
decreases expression

EXP

estradiol 3-benzoate promotes the reaction [Progesterone results in decreased expression of MSTN mRNA]
estradiol 3-benzoate results in decreased expression of MSTN mRNA

NCBI chr 9:55,944,513...55,950,913
Ensembl chr 9:55,944,513...55,950,913

G

metallothionein 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MT3 mRNA

NCBI chr19:10,854,676...10,856,080
Ensembl chr19:10,854,677...10,856,080

G

metallothionein 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MT4 mRNA

NCBI chr19:10,869,735...10,871,831
Ensembl chr19:10,869,735...10,871,831

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MTHFD2L mRNA

NCBI chr14:17,374,139...17,455,508
Ensembl chr14:17,374,144...17,454,322

G

MX dynamin like GTPase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MX1 mRNA

NCBI chr11:50,269,056...50,294,699
Ensembl chr11:50,269,057...50,292,904

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MYCN mRNA

NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508

G

myosin, heavy chain 9

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of MYH9 promoter

NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963

G

myosin light chain kinase 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MYLK3 mRNA

NCBI chr19:37,858,298...37,916,805
Ensembl chr19:37,865,141...37,915,827

G

myosin IF

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MYO1F mRNA

NCBI chr 7:15,065,530...15,116,087
Ensembl chr 7:15,065,530...15,116,087

G

myosin VIIA

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MYO7A mRNA

NCBI chr 1:161,755,110...161,825,397
Ensembl chr 1:161,755,110...161,825,365

G

marginal zone B and B1 cell-specific protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of MZB1 mRNA

NCBI chr18:27,513,087...27,515,148
Ensembl chr18:27,513,089...27,515,182

G

NEDD4 binding protein 2-like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of N4BP2L2 mRNA

NCBI chr12:4,972,967...5,038,027
Ensembl chr12:4,972,990...5,033,405

G

N-acylethanolamine acid amidase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NAAA mRNA

NCBI chr14:16,061,599...16,080,703
Ensembl chr14:16,061,583...16,080,702

G

N-acyl phosphatidylethanolamine phospholipase D

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NAPEPLD mRNA

NCBI chr 4:14,251,591...14,291,010
Ensembl chr 4:14,252,692...14,291,014

G

napsin A aspartic peptidase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NAPSA mRNA

NCBI chr 1:104,200,967...104,213,603
Ensembl chr 1:104,200,960...104,213,608

G

neuron navigator 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NAV3 mRNA

NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893

G

neural cell adhesion molecule 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of NCAM1 mRNA

NCBI chr 8:58,762,088...59,062,131
Ensembl chr 8:58,762,116...59,061,971

G

neutrophil cytosolic factor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NCF1 mRNA

NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079

G

neutrophil cytosolic factor 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NCF4 mRNA

NCBI chr 7:111,705,926...111,723,893
Ensembl chr 7:111,706,520...111,723,898

G

NCK associated protein 1 like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NCKAP1L mRNA

NCBI chr 7:136,455,900...136,501,384
Ensembl chr 7:136,455,897...136,501,384

G

NDC80 kinetochore complex component

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NDC80 mRNA

NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:118,853,806...118,887,568

G

Nedd4 family interacting protein 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of NDFIP2 mRNA

NCBI chr15:88,394,548...88,500,881
Ensembl chr15:88,395,032...88,503,600

G

N-terminal EF-hand calcium binding protein 2

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of NECAB2 promoter

NCBI chr19:64,409,627...64,436,371
Ensembl chr19:64,409,751...64,436,369

G

NIMA-related kinase 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NEK6 mRNA

NCBI chr 3:42,693,994...42,766,026
Ensembl chr 3:42,693,971...42,767,773

G

neural EGFL like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NELL2 mRNA

NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917

G

neuralized E3 ubiquitin protein ligase 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NEURL3 mRNA

NCBI chr 9:45,990,373...45,998,470
Ensembl chr 9:45,990,375...45,998,535

G

NFAT activating protein with ITAM motif 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NFAM1 mRNA

NCBI chr 7:116,019,383...116,055,628
Ensembl chr 7:116,020,311...116,055,378

G

nuclear factor, erythroid 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NFE2 mRNA

NCBI chr 7:136,261,234...136,273,850
Ensembl chr 7:136,261,236...136,268,585

G

nuclear factor I/A

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of NFIA promoter

NCBI chr 5:117,359,006...117,897,391
Ensembl chr 5:117,359,077...117,891,395

G

NFKB inhibitor delta

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NFKBID mRNA

NCBI chr 1:94,808,459...94,824,726
Ensembl chr 1:94,808,453...94,817,861

G

Sodium/potassium transporting ATPase interacting 3

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of NKAIN3 gene

NCBI chr 5:38,410,576...39,106,910
Ensembl chr 5:38,386,841...39,106,385

G

NKD inhibitor of WNT signaling pathway 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of NKD1 mRNA

NCBI chr19:34,649,803...34,722,846

G

natural killer cell granule protein 7

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NKG7 mRNA

NCBI chr 1:102,981,497...102,982,564
Ensembl chr 1:102,981,450...102,982,562

G

NK1 homeobox 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of NKX1-2 mRNA

NCBI chr 1:196,816,491...196,821,371
Ensembl chr 1:196,816,491...196,821,371

G

NLR family, CARD domain containing 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NLRC3 mRNA

NCBI chr10:12,055,809...12,093,449
Ensembl chr10:12,057,738...12,091,393

G

NLR family, CARD domain containing 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NLRC5 mRNA

NCBI chr19:10,483,601...10,587,223
Ensembl chr19:10,483,755...10,555,786

G

NLR family, pyrin domain containing 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NLRP12 mRNA

NCBI chr 1:74,848,020...74,885,945
Ensembl chr 1:74,848,063...74,876,341

G

NLR family, pyrin domain containing 1A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NLRP1A mRNA

NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880

G

NLR family, pyrin domain containing 3

multiple interactions
increases expression

EXP

[Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of NLRP3 mRNA; [Dietary Fats co-treated with estradiol 3-benzoate] results in increased expression of NLRP3 protein; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NLRP3 mRNA
estradiol 3-benzoate results in increased expression of NLRP3 mRNA

PMID:32741896 PMID:39368565

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

nucleolar protein 10

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of NOL10 mRNA

NCBI chr 6:45,861,773...45,954,067
Ensembl chr 6:45,872,960...45,954,066

G

nitric oxide synthase 1

multiple interactions

EXP

[Progesterone co-treated with estradiol 3-benzoate] results in increased expression of NOS1 protein

NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837

G

NADPH oxidase 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NOX4 mRNA

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

NADPH oxidase organizer 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NOXO1 mRNA

NCBI chr10:14,226,473...14,230,541
Ensembl chr10:14,228,205...14,230,541

G

defensin NP-4 precursor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NP4 mRNA

NCBI chr16:77,197,061...77,199,713
Ensembl chr16:77,121,639...77,122,502
Ensembl chr16:77,121,639...77,122,502

G

natriuretic peptide receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NPR1 mRNA

NCBI chr 2:178,231,766...178,247,591
Ensembl chr 2:178,231,766...178,247,088

G

neuropeptide Y receptor Y4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NPY4R mRNA

NCBI chr16:9,474,051...9,475,307
Ensembl chr16:9,472,011...9,482,405

G

nuclear receptor subfamily 2, group E, member 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of NR2E3 mRNA

NCBI chr 8:69,261,343...69,269,081
Ensembl chr 8:69,261,343...69,269,081

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NR5A2 mRNA

NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938

G

neurogranin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NRGN mRNA

NCBI chr 8:45,444,223...45,452,417
Ensembl chr 8:45,444,223...45,452,417

G

neuropilin 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of NRP1 mRNA

NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702

G

neurturin

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of NRTN promoter

NCBI chr 9:1,669,099...1,674,957
Ensembl chr 9:1,641,618...1,675,133

G

NMDA receptor synaptonuclear signaling and neuronal migration factor

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of NSMF mRNA

NCBI chr 3:28,260,018...28,268,790
Ensembl chr 3:28,260,004...28,268,789

G

nuclear GTPase, germinal center associated

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of NUGGC mRNA

NCBI chr15:43,997,446...44,041,716
Ensembl chr15:43,997,438...44,041,643

G

neurexophilin and PC-esterase domain family, member 5 like 3

increases expression

EXP

estradiol 3-benzoate results in increased expression of NXPE5L3 mRNA

NCBI chr12:22,351,917...22,367,016
Ensembl chr12:22,300,388...22,366,108

G

neurexophilin 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of NXPH3 mRNA

NCBI chr10:80,953,080...80,956,746
Ensembl chr10:80,952,227...80,956,668

G

2'-5' oligoadenylate synthetase 1A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OAS1A mRNA

NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128

G

2-5 oligoadenylate synthetase 1B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OAS1B mRNA

NCBI chr12:41,385,184...41,395,891
Ensembl chr12:41,384,678...41,395,914

G

2 ' -5 ' oligoadenylate synthetase 1I

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OAS1I mRNA

NCBI chr12:41,285,201...41,297,242

G

2 ' -5 ' oligoadenylate synthetase 1K

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OAS1K mRNA

NCBI chr12:41,423,100...41,432,330
Ensembl chr12:41,422,937...41,432,330

G

2'-5' oligoadenylate synthetase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OAS2 mRNA

NCBI chr12:41,464,568...41,492,036
Ensembl chr12:41,467,315...41,495,881

G

2'-5'-oligoadenylate synthetase-like

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OASL mRNA

NCBI chr12:47,343,551...47,356,509
Ensembl chr12:47,343,551...47,356,483

G

2'-5' oligoadenylate synthetase-like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OASL2 mRNA

NCBI chr12:47,369,829...47,383,337
Ensembl chr12:47,370,028...47,383,185

G

odorant binding protein I f

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of OBP1F mRNA

NCBI chr X:45,833,861...45,839,070

G

odorant binding protein 2A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OBP2A mRNA

NCBI chr 3:28,904,024...28,907,391
Ensembl chr 3:28,902,876...28,907,389

G

obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OBSCN mRNA

NCBI chr10:44,273,686...44,419,275
Ensembl chr10:44,288,866...44,419,297

G

occludin

increases expression
multiple interactions

ISO
EXP

estradiol 3-benzoate results in increased expression of OCLN mRNA; estradiol 3-benzoate results in increased expression of OCLN protein
fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased expression of OCLN mRNA]
fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased expression of OCLN mRNA]; fulvestrant inhibits the reaction [estradiol 3-benzoate results in increased expression of OCLN protein]

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

ornithine decarboxylase 1

affects expression

EXP

estradiol 3-benzoate affects the expression of ODC1 mRNA

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146

G

oxidized low density lipoprotein receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OLR1 mRNA

NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598

G

olfactory receptor family 10 subfamily AA member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OR10AA1 mRNA

NCBI chr13:88,579,823...88,580,767
Ensembl chr13:88,579,823...88,580,767

G

olfactory receptor family 2 subfamily B member 11

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OR2B11 mRNA

NCBI chr10:44,857,952...44,858,908
Ensembl chr10:44,856,938...44,860,595

G

olfactory receptor family 56 subfamily B member 6

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of OR56B6 promoter

NCBI chr 1:169,031,148...169,032,113
Ensembl chr 1:169,031,148...169,032,113

G

olfactory receptor family 7 subfamily R member 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of OR7R1 promoter

NCBI chr X:157,436,003...157,436,941
Ensembl chr X:157,436,003...157,436,941

G

oxysterol binding protein-like 6

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of OSBPL6 promoter

NCBI chr 3:81,751,020...81,948,186
Ensembl chr 3:81,750,982...81,946,615

G

oncostatin M

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of OSM mRNA

NCBI chr14:83,327,202...83,332,073
Ensembl chr14:83,327,554...83,331,827

G

odd-skipped related transcription factor 2

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of OSR2 promoter

NCBI chr 7:68,372,500...68,380,195
Ensembl chr 7:68,373,049...68,380,805

G

ovo like transcriptional repressor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of OVOL1 mRNA

NCBI chr 1:212,284,601...212,296,106
Ensembl chr 1:212,284,605...212,296,106

G

oxoglutarate receptor 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of OXGR1 promoter

NCBI chr15:103,551,338...103,573,611
Ensembl chr15:103,552,861...103,553,874

G

purinergic receptor P2X 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of P2RX3 mRNA

NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:90,487,506...90,531,794

G

purinergic receptor P2Y12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of P2RY12 mRNA

NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:145,629,967...145,633,410

G

purinergic receptor P2Y13

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of P2RY13 mRNA

NCBI chr 2:145,620,321...145,624,730
Ensembl chr 2:145,619,655...145,622,787

G

peptidyl arginine deiminase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PADI2 mRNA

NCBI chr 5:158,492,087...158,534,662
Ensembl chr 5:158,492,066...158,534,662

G

pantothenate kinase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PANK1 mRNA

NCBI chr 1:241,737,371...241,808,126
Ensembl chr 1:241,741,083...241,807,824

G

progestin and adipoQ receptor family member 4

decreases methylation
multiple interactions
increases expression

EXP

estradiol 3-benzoate results in decreased methylation of PAQR4 promoter
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PAQR4 mRNA
estradiol 3-benzoate results in increased expression of PAQR4 mRNA

PMID:27415467 PMID:28728135 PMID:32741896

NCBI chr10:13,263,559...13,267,237
Ensembl chr10:13,263,559...13,267,173

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

EXP

estradiol 3-benzoate results in increased cleavage of PARP1 protein
Quercetin inhibits the reaction [estradiol 3-benzoate results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

poly (ADP-ribose) polymerase family, member 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PARP12 mRNA

NCBI chr 4:68,793,411...68,851,214
Ensembl chr 4:68,806,100...68,850,541

G

poly (ADP-ribose) polymerase family, member 14

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PARP14 mRNA

NCBI chr11:78,408,134...78,440,201
Ensembl chr11:78,408,058...78,440,195

G

PARP1 binding protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PARPBP mRNA

NCBI chr 7:24,398,897...24,468,330
Ensembl chr 7:24,398,897...24,464,744

G

parvin, gamma

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PARVG mRNA

NCBI chr 7:117,336,160...117,366,341
Ensembl chr 7:117,336,187...117,362,155

G

paired box 9

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of PAX9 promoter

NCBI chr 6:79,917,466...79,938,551
Ensembl chr 6:79,921,801...79,938,549

G

protocadherin 17

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PCDH17 mRNA

NCBI chr15:66,631,549...66,725,007
Ensembl chr15:66,633,142...66,722,105

G

protocadherin alpha 13

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PCDHA13 promoter

G

proliferating cell nuclear antigen

increases expression

EXP

estradiol 3-benzoate results in increased expression of PCNA mRNA; estradiol 3-benzoate results in increased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

programmed cell death 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PDCD1 mRNA

NCBI chr 9:101,866,124...101,879,278
Ensembl chr 9:101,866,126...101,879,270

G

phosphodiesterase 3A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PDE3A mRNA

NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:175,904,077...176,169,270

G

phosphodiesterase 7A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PDE7A mRNA

NCBI chr 2:103,631,655...103,723,057
Ensembl chr 2:103,634,594...103,722,890

G

platelet derived growth factor receptor alpha

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PDGFRA mRNA

NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,360,028...33,408,516

G

peptidoglycan recognition protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PGLYRP1 mRNA

NCBI chr 1:87,659,863...87,665,048
Ensembl chr 1:87,651,271...87,665,048

G

progesterone receptor

increases expression

EXP

estradiol 3-benzoate results in increased expression of PGR mRNA; estradiol 3-benzoate results in increased expression of PGR protein; estradiol 3-benzoate results in increased expression of PGR protein alternative form

PMID:15456929 PMID:15778002 PMID:19574278

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

phosphatase and actin regulator 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PHACTR1 promoter

NCBI chr17:21,769,006...22,246,227
Ensembl chr17:21,768,662...22,244,586

G

proline, histidine and glycine rich 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PHGR1 mRNA

NCBI chr 3:126,211,495...126,214,749
Ensembl chr 3:126,211,495...126,214,746

G

phosphoethanolamine/phosphocholine phosphatase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PHOSPHO1 mRNA

NCBI chr10:81,258,810...81,266,345
Ensembl chr10:81,257,427...81,268,481

G

phosphohistidine phosphatase 1

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of PHPT1 promoter

NCBI chr 3:28,791,062...28,792,905

G

phosphatidylinositol glycan anchor biosynthesis, class U

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PIGU mRNA

NCBI chr 3:164,245,011...164,341,444
Ensembl chr 3:164,245,011...164,341,912

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PIK3C2G promoter

NCBI chr 4:174,215,527...174,583,378
Ensembl chr 4:174,215,527...174,581,705

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PIK3CD mRNA

NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968

G

phosphoinositide-3-kinase regulatory subunit 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PIK3R1 promoter

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

paired immunoglobin-like type 2 receptor beta, pseudogene 6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PILRB-PS6 mRNA

NCBI chr12:24,305,306...24,335,088

G

paired immunoglobin like type 2 receptor beta 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PILRB2 mRNA

NCBI chr12:23,438,506...23,445,088

G

paired immunoglobin like type 2 receptor beta 2 like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PILRB2L1 mRNA

NCBI chr12:23,386,004...23,398,133

G

paired immunoglobin like type 2 receptor beta 2 like 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PILRB2L3 mRNA

NCBI chr12:23,125,397...23,132,038
Ensembl chr12:23,126,020...23,131,936

G

phospholipase A2 inhibitor and Ly6/Plaur domain containing

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PINLYP mRNA

NCBI chr 1:89,262,559...89,268,402
Ensembl chr 1:89,262,560...89,267,913

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PIP4K2A mRNA

NCBI chr17:86,405,080...86,576,597
Ensembl chr17:86,405,081...86,576,430

G

paired-Ig-like receptor A12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PIRA12 mRNA

NCBI chr 1:74,219,771...74,228,458

G

paired-Ig-like receptor A2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PIRA2 mRNA

NCBI chr 1:74,283,713...74,338,208

G

paired Ig-like receptor B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of LILRB3 mRNA; [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PIRB mRNA

NCBI chr 1:74,414,556...74,433,015
Ensembl chr 1:74,331,291...74,422,116

G

paired-like homeodomain 3

decreases methylation
increases expression

EXP

estradiol 3-benzoate results in decreased methylation of PITX3 promoter
estradiol 3-benzoate results in increased expression of PITX3 mRNA

NCBI chr 1:254,942,550...254,955,325
Ensembl chr 1:254,942,608...254,955,336

G

cAMP-dependent protein kinase inhibitor beta

increases expression

EXP

estradiol 3-benzoate results in increased expression of PKIB mRNA

NCBI chr20:37,511,564...37,608,607
Ensembl chr20:37,512,822...37,608,401

G

phospholipase A2 group IIA

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLA2G2A mRNA

NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:156,359,725...156,362,297

G

phospholipase A2, group IID

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLA2G2D mRNA

NCBI chr 5:156,299,374...156,305,816
Ensembl chr 5:156,297,777...156,305,812

G

phospholipase A2, group V

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLA2G5 mRNA

NCBI chr 5:156,324,628...156,393,065
Ensembl chr 5:156,324,629...156,381,926

G

phospholipase A2 group VII

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLA2G7 mRNA

NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:24,859,502...24,901,747

G

placenta associated 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLAC8 mRNA

NCBI chr14:9,356,950...9,378,586
Ensembl chr14:9,356,972...9,378,572

G

plasminogen activator, tissue type

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLAT mRNA

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

plasminogen activator, urokinase receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLAUR mRNA

NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130

G

phospholipase B domain containing 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLBD1 mRNA

NCBI chr 4:171,204,198...171,260,488
Ensembl chr 4:171,204,198...171,260,488

G

phospholipase C, beta 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLCB2 mRNA

NCBI chr 3:126,134,925...126,158,303
Ensembl chr 3:126,138,736...126,158,221

G

phospholipase C-like 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLCL2 mRNA

NCBI chr 9:3,529,117...3,713,712
Ensembl chr 9:3,529,841...3,713,712

G

phospholipase C, zeta 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PLCZ1 mRNA

NCBI chr 4:174,604,281...174,660,368
Ensembl chr 4:174,604,281...174,660,290

G

phospholipase D2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLD2 mRNA

NCBI chr10:55,754,957...55,772,819
Ensembl chr10:55,754,988...55,771,435

G

phospholipase D family, member 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLD4 mRNA

NCBI chr 6:137,639,948...137,647,462
Ensembl chr 6:137,639,945...137,649,024

G

pleckstrin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLEK mRNA

NCBI chr14:95,598,650...95,631,326
Ensembl chr14:95,598,654...95,655,721

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLOD2 mRNA

NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022

G

plastin 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLS1 mRNA

NCBI chr 8:105,196,312...105,306,252
Ensembl chr 8:105,197,455...105,292,447

G

phospholipid transfer protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLTP mRNA

NCBI chr 3:173,994,162...174,011,982
Ensembl chr 3:173,994,162...174,012,505

G

plexin domain containing 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLXDC2 mRNA

NCBI chr17:84,077,793...84,502,831
Ensembl chr17:84,104,864...84,497,999

G

plexin B3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PLXNB3 mRNA

NCBI chr X:156,645,505...156,660,011
Ensembl chr X:156,645,182...156,660,003

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PMAIP1 mRNA

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382

G

peripheral myelin protein 22

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PMP22 mRNA

NCBI chr10:48,294,932...48,324,941
Ensembl chr10:48,297,437...48,324,940

G

PNMA family member 8B

multiple interactions
increases expression

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PNMA8B mRNA
estradiol 3-benzoate results in increased expression of PNMA8B mRNA

NCBI chr 1:86,749,840...86,754,605
Ensembl chr 1:86,748,610...86,767,756

G

podocan-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PODNL1 mRNA

NCBI chr19:40,932,026...40,938,760
Ensembl chr19:40,932,026...40,938,631

G

cytochrome p450 oxidoreductase

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of POR protein

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

periostin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of POSTN mRNA

NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:140,677,754...140,709,300

G

POU class 2 homeobox associating factor 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of POU2AF3 mRNA

NCBI chr 8:60,484,596...60,493,475
Ensembl chr 8:60,484,596...60,493,821

G

POU class 2 homeobox 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of POU2F2 mRNA

NCBI chr 1:89,810,153...89,897,560
Ensembl chr 1:89,812,093...89,897,564

G

protein phosphatase, Mg2+/Mn2+ dependent 1N

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PPM1N mRNA

NCBI chr 1:88,057,365...88,062,912
Ensembl chr 1:88,058,624...88,060,700

G

protein phosphatase 1, regulatory subunit 16B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PPP1R16B mRNA

NCBI chr 3:167,743,518...167,839,511
Ensembl chr 3:167,743,952...167,839,242

G

protein phosphatase 4, regulatory subunit 4

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of PPP4R4 mRNA

NCBI chr 6:128,427,884...128,518,776
Ensembl chr 6:128,427,893...128,528,039

G

PML-RARA regulated adaptor molecule 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRAM1 mRNA

NCBI chr 7:15,125,813...15,142,494

G

protein regulator of cytokinesis 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRC1 mRNA

NCBI chr 1:143,659,312...143,681,019
Ensembl chr 1:143,659,481...143,681,012

G

PR/SET domain 10

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRDM10 mRNA

NCBI chr 8:37,982,210...38,085,907
Ensembl chr 8:37,982,403...38,085,907

G

perforin 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRF1 mRNA

NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124

G

proteoglycan 2, pro eosinophil major basic protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRG2 mRNA

NCBI chr 3:90,469,192...90,472,759
Ensembl chr 3:90,469,176...90,472,752

G

protein kinase cAMP-dependent type I regulatory subunit alpha

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PRKAR1A promoter

NCBI chr10:95,120,537...95,139,028
Ensembl chr10:95,120,487...95,139,025

G

protein kinase cGMP-dependent 2

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PRKG2 promoter

NCBI chr14:10,864,020...10,972,617
Ensembl chr14:10,864,186...10,972,614

G

prolactin

multiple interactions
increases secretion

EXP

Atrazine inhibits the reaction [estradiol 3-benzoate results in increased secretion of PRL protein]; estradiol 3-benzoate results in increased expression of and results in increased secretion of PRL protein; Mifepristone promotes the reaction [estradiol 3-benzoate results in increased secretion of PRL protein]

PMID:2159045 PMID:10696778 PMID:27830003

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

protein arginine methyltransferase 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PRMT8 mRNA

NCBI chr 4:162,221,986...162,304,036
Ensembl chr 4:162,221,986...162,307,310

G

proline rich 16

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRR16 mRNA

NCBI chr18:46,622,816...46,963,251
Ensembl chr18:46,623,058...46,830,385

G

proline rich 7 (synaptic)

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRR7 mRNA

NCBI chr17:9,170,405...9,178,814
Ensembl chr17:9,170,411...9,179,361

G

proline-rich coiled-coil 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PRRC1 promoter

NCBI chr18:53,010,606...53,047,601
Ensembl chr18:53,010,600...53,045,015

G

proline-rich coiled-coil 2A

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PRRC2A promoter

NCBI chr20:3,660,981...3,686,715
Ensembl chr20:3,663,400...3,678,778

G

serine protease 12

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PRSS12 mRNA

NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:214,308,774...214,369,941

G

prosaposin-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PSAPL1 mRNA

NCBI chr14:78,769,304...78,771,864
Ensembl chr14:78,755,276...78,772,220

G

phosphoserine aminotransferase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PSAT1 mRNA

NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:222,623,556...222,655,693

G

proteasome 20S subunit alpha 6, pseudogene 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of PSMA6-PS1 promoter

NCBI chr20:16,822,879...16,823,827

G

proteasome 20S subunit beta 8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PSMB8 mRNA

NCBI chr20:4,654,068...4,657,049
Ensembl chr20:4,654,068...4,657,031

G

proline-serine-threonine phosphatase-interacting protein 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PSTPIP1 mRNA

NCBI chr 8:65,395,328...65,434,616
Ensembl chr 8:65,395,358...65,434,627

G

platelet-activating factor receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTAFR mRNA

NCBI chr 5:150,049,322...150,079,060
Ensembl chr 5:150,049,460...150,079,408

G

prostaglandin D2 receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTGDR mRNA

NCBI chr15:19,790,499...19,797,873
Ensembl chr15:19,790,499...19,797,873

G

prostaglandin E receptor 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTGER2 mRNA

NCBI chr15:20,694,765...20,708,475
Ensembl chr15:20,696,013...20,708,950

G

prostaglandin-endoperoxide synthase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTGS2 mRNA

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

protein tyrosine phosphatase, non-receptor type 13

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PTPN13 mRNA

NCBI chr14:6,412,841...6,587,238
Ensembl chr14:6,412,841...6,587,171

G

protein tyrosine phosphatase, non-receptor type 22

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTPN22 mRNA

NCBI chr 2:194,055,165...194,103,209
Ensembl chr 2:194,045,746...194,103,209

G

protein tyrosine phosphatase, receptor type, C

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTPRC mRNA

NCBI chr13:52,147,717...52,259,810
Ensembl chr13:52,147,717...52,259,746

G

protein tyrosine phosphatase, receptor type, E

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTPRE mRNA

NCBI chr 1:199,774,195...199,924,646
Ensembl chr 1:199,774,198...199,922,242

G

protein tyrosine phosphatase, receptor type, O

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTPRO mRNA

NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903

G

PTTG1 regulator of sister chromatid separation, securin

increases expression
multiple interactions

EXP

estradiol 3-benzoate results in increased expression of PTTG1 mRNA; estradiol 3-benzoate results in increased expression of PTTG1 protein
[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PTTG1 mRNA

PMID:27830003 PMID:32741896

NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309

G

pentraxin 3

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of PTX3 promoter

NCBI chr 2:152,797,563...152,803,372
Ensembl chr 2:152,781,955...152,803,372

G

PVR related immunoglobulin domain containing

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PVRIG mRNA

NCBI chr12:22,474,441...22,479,191
Ensembl chr12:22,477,694...22,478,894

G

PWWP domain containing 3B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of MUM1L1 mRNA

NCBI chr X:107,593,062...107,627,215
Ensembl chr X:107,582,676...107,627,803

G

peroxidasin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of PXDN mRNA

NCBI chr 6:52,308,347...52,385,943
Ensembl chr 6:52,308,364...52,385,942

G

PYM homolog 1, exon junction complex associated factor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of PYM1 mRNA

NCBI chr 7:1,761,556...1,785,318
Ensembl chr 7:1,759,110...1,783,948

G

quinolinate phosphoribosyltransferase

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of QPRT mRNA

NCBI chr 1:191,148,715...191,164,006
Ensembl chr 1:191,148,713...191,194,162

G

RAB32, member RAS oncogene family

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RAB32 mRNA

NCBI chr 1:6,766,448...6,781,258
Ensembl chr 1:6,766,455...6,781,258

G

RAB37, member RAS oncogene family

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RAB37 mRNA

NCBI chr10:100,833,240...100,900,950
Ensembl chr10:100,833,397...100,900,944

G

RAB42, member RAS oncogene family

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RAB42 mRNA

NCBI chr 5:149,781,181...149,782,851
Ensembl chr 5:149,781,181...149,782,851

G

Rac family small GTPase 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RAC2 mRNA

NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:111,996,742...112,009,267

G

RAD54 homolog B

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of RAD54B mRNA

NCBI chr 5:29,829,465...29,901,967
Ensembl chr 5:29,855,304...29,901,964

G

Raf-1 proto-oncogene, serine/threonine kinase

decreases phosphorylation

EXP

estradiol 3-benzoate results in decreased phosphorylation of RAF1 protein

NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813

G

receptor activity modifying protein 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RAMP3 mRNA

NCBI chr14:85,741,314...85,758,813
Ensembl chr14:85,755,211...85,758,818

G

retinoic acid receptor responder 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RARRES1 mRNA

NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:154,059,761...154,094,024

G

RAS p21 protein activator 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RASA3 mRNA

NCBI chr16:82,557,556...82,671,527
Ensembl chr16:82,557,428...82,672,984

G

ras related dexamethasone induced 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RASD1 mRNA

NCBI chr10:45,265,975...45,275,279
Ensembl chr10:45,265,979...45,267,710

G

RAS guanyl releasing protein 4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RASGRP4 mRNA

NCBI chr 1:93,560,513...93,580,321
Ensembl chr 1:93,560,513...93,580,323

G

defensin rat NP-3 precursor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RATNP-3B mRNA

NCBI chr16:77,246,811...77,248,977
Ensembl chr16:77,216,342...77,248,966

G

recombination signal binding protein for immunoglobulin kappa J region-like

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of RBPJL promoter

NCBI chr 3:173,553,389...173,565,869
Ensembl chr 3:173,553,498...173,565,869

G

RCAN family member 3

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of RCAN3 promoter

NCBI chr 5:152,934,561...152,955,502
Ensembl chr 5:152,938,711...152,955,589

G

regenerating family member 3 gamma

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of REG3G mRNA

NCBI chr 4:112,482,183...112,484,738
Ensembl chr 4:112,482,183...112,484,738

G

RELT, TNF receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RELT mRNA

NCBI chr 1:164,619,059...164,636,707
Ensembl chr 1:164,619,059...164,636,670

G

resistin-like gamma

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RETNLG mRNA

NCBI chr11:65,393,907...65,395,639
Ensembl chr11:65,393,907...65,395,419

G

refilin A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RFLNA mRNA

NCBI chr12:37,294,643...37,323,373
Ensembl chr12:37,294,643...37,303,535

G

raftlin lipid raft linker 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RFTN1 mRNA

NCBI chr 9:18,302,143...18,499,819
Ensembl chr 9:18,285,934...18,499,819

G

similar to vitellogenin-like 1 precursor

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of RGD1559536 mRNA

NCBI chr18:36,739,164...36,742,536
Ensembl chr18:36,739,164...36,742,536

G

similar to novel protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RGD1559575 mRNA

NCBI chr10:33,752,208...33,777,536
Ensembl chr10:33,753,267...33,776,789

G

similar to killer cell lectin-like receptor subfamily B member 1A

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RGD2301395 mRNA

G

regulator of G-protein signaling 10

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RGS10 mRNA

NCBI chr 1:192,376,772...192,422,640
Ensembl chr 1:192,376,774...192,418,904

G

regulator of G-protein signaling 13

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RGS13 mRNA

NCBI chr13:58,472,604...58,505,922
Ensembl chr13:58,472,604...58,505,922

G

regulator of G-protein signaling 14

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RGS14 mRNA

NCBI chr17:9,254,112...9,268,233
Ensembl chr17:9,254,149...9,268,233

G

regulator of G-protein signaling 18

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RGS18 mRNA

NCBI chr13:59,043,431...59,066,342
Ensembl chr13:59,043,431...59,066,342

G

regulator of G-protein signaling 20

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of RGS20 promoter

NCBI chr 5:19,282,249...19,412,122
Ensembl chr 5:19,282,153...19,413,286

G

Rhox homeobox family member 5

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RHOX5 mRNA

NCBI chr X:121,401,888...121,407,643

G

reproductive homeobox like

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of RHOXL promoter

NCBI chr X:121,308,351...121,309,782
Ensembl chr X:121,308,353...121,309,661

G

RNA sensor RIG-1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RIGI mRNA

NCBI chr 5:60,117,398...60,165,995
Ensembl chr 5:60,117,398...60,165,995

G

receptor-interacting serine-threonine kinase 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RIPK3 mRNA

NCBI chr15:33,253,071...33,262,025
Ensembl chr15:33,253,071...33,262,025

G

RHO family interacting cell polarization regulator 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RIPOR2 mRNA

NCBI chr17:40,751,771...40,975,611
Ensembl chr17:40,751,771...40,975,337

G

ribonuclease A family member 1, pancreatic

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RNASE1 mRNA

NCBI chr15:26,835,436...26,837,145
Ensembl chr15:26,835,463...26,837,248

G

ribonuclease, RNase A family, 1-like 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RNASE1L1 mRNA

NCBI chr15:26,811,738...26,813,456
Ensembl chr15:26,811,549...26,821,582

G

ring finger protein 180

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of RNF180 mRNA

NCBI chr 2:38,064,026...38,244,854
Ensembl chr 2:38,064,031...38,265,358

G

ring finger protein 186

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of RNF186 promoter

NCBI chr 5:156,493,750...156,494,974
Ensembl chr 5:156,493,752...156,494,978

G

ribosomal protein S4, X-linked, pseudogene 1

increases expression

EXP

estradiol 3-benzoate results in increased expression of RPS4X-PS1 mRNA

NCBI chr 1:240,623,498...240,624,785

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

radial spoke head component 1

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of RSPH1 promoter

NCBI chr20:9,343,258...9,361,988
Ensembl chr20:9,343,261...9,361,988

G

RT1 class II, locus Bb

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-BB mRNA

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,598,475...4,604,118

G

RT1 class I, locus CE10

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-CE10 mRNA

NCBI chr20:3,381,377...3,385,052

G

RT1 class I, locus CE11

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in decreased expression of RT1-CE11 mRNA

NCBI chr20:3,355,422...3,385,063

G

RT1 class I, locus CE6

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-CE6 mRNA

NCBI chr20:3,465,652...3,466,602

G

RT1 class II, locus Da

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-DA mRNA

NCBI chr20:4,515,393...4,520,387
Ensembl chr20:4,513,908...4,520,383

G

RT1 class II, locus Db1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-DB1 mRNA

NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,550,596...4,560,165

G

RT1 class II, locus Db2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-DB2 mRNA

NCBI chr20:4,521,929...4,541,654
Ensembl chr20:4,522,792...4,541,595

G

RT1 class II, locus DOb

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-DOB mRNA

NCBI chr20:4,621,336...4,627,537
Ensembl chr20:4,619,694...4,627,523

G

RT1 class Ib, locus M2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-M2 mRNA

NCBI chr20:984,174...986,762
Ensembl chr20:984,174...986,762

G

RT1 class Ib, locus N3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-N3 mRNA

NCBI chr20:2,666,469...2,670,355
Ensembl chr20:2,666,464...2,670,348

G

RT1 class I, locus T24, gene 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-T24-1 mRNA

NCBI chr20:2,766,304...2,779,680
Ensembl chr20:2,766,319...2,780,951

G

RT1 class I, locus T24, gene 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RT1-T24-3 mRNA

NCBI chr20:2,723,043...2,752,691
Ensembl chr20:2,723,049...2,730,857

G

receptor (chemosensory) transporter protein 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RTP3 mRNA

NCBI chr 8:119,847,947...119,853,549
Ensembl chr 8:119,848,556...119,853,095

G

RUNX family transcription factor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RUNX1 mRNA

NCBI chr11:45,325,778...45,560,300
Ensembl chr11:45,329,044...45,564,925

G

RUNX family transcription factor 3

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of RUNX3 promoter

NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:152,644,270...152,702,835

G

RWD domain containing 2A

decreases expression

EXP

estradiol 3-benzoate results in decreased expression of RWDD2A mRNA

NCBI chr 8:96,416,190...96,419,315
Ensembl chr 8:96,416,190...96,419,315

G

relaxin family peptide receptor 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RXFP1 mRNA

NCBI chr 2:167,070,414...167,191,616
Ensembl chr 2:167,070,417...167,191,556

G

retinoid X receptor gamma

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of RXRG mRNA

NCBI chr13:82,276,330...82,318,097
Ensembl chr13:82,276,291...82,318,095

G

S100 calcium binding protein A14

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of S100A14 mRNA

NCBI chr 2:178,305,976...178,308,004
Ensembl chr 2:178,306,025...178,307,999

G

S100 calcium-binding protein A4

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of S100A4 mRNA

NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837

G

S100 calcium binding protein A8

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of S100A8 mRNA

NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:178,464,702...178,465,221

G

S100 calcium binding protein A9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of S100A9 mRNA

NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870

G

sterile alpha motif domain containing 9

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SAMD9 mRNA

NCBI chr 4:32,119,318...32,139,008
Ensembl chr 4:32,117,137...32,171,759

G

SAM domain, SH3 domain and nuclear localization signals, 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SAMSN1 mRNA

NCBI chr11:27,971,565...28,021,944
Ensembl chr11:27,970,564...28,021,944

G

suppressor APC domain containing 2

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SAPCD2 mRNA

NCBI chr 3:28,583,615...28,590,694
Ensembl chr 3:28,585,416...28,591,389

G

scavenger receptor class A, member 3

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SCARA3 mRNA

NCBI chr15:44,315,422...44,348,416
Ensembl chr15:44,315,422...44,348,551

G

scavenger receptor family member expressed on T-cells 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SCART1 mRNA

NCBI chr 1:204,450,386...204,462,094
Ensembl chr 1:204,450,386...204,461,441

G

sciellin

increases methylation

EXP

estradiol 3-benzoate results in increased methylation of SCEL promoter

NCBI chr15:86,754,595...86,871,200
Ensembl chr15:86,754,373...86,871,195

G

secretoglobin family 1A member 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SCGB1A1 mRNA

NCBI chr 1:215,406,138...215,409,686
Ensembl chr 1:215,406,138...215,409,686

G

SLP adaptor and CSK interacting membrane protein

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SCIMP mRNA

NCBI chr10:56,006,243...56,026,357
Ensembl chr10:56,006,243...56,026,357

G

serine carboxypeptidase 1

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SCPEP1 mRNA

NCBI chr10:74,200,491...74,230,107
Ensembl chr10:74,200,491...74,230,241

G

secretin

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SCT mRNA

NCBI chr 1:205,812,435...205,813,246
Ensembl chr 1:205,812,435...205,813,246

G

secretin receptor

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SCTR mRNA

NCBI chr13:33,680,562...33,744,049
Ensembl chr13:33,680,627...33,733,709

G

SEC14-like lipid binding 2

decreases methylation

EXP

estradiol 3-benzoate results in decreased methylation of SEC14L2 promoter

NCBI chr14:83,197,384...83,222,059
Ensembl chr14:83,197,387...83,217,317

G

selectin E

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SELE mRNA

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903

G

selenoprotein P

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SELENOP mRNA

NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:54,225,152...54,236,019

G

selectin L

multiple interactions

EXP

[estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SELL mRNA

NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600

G